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ABSTRACT 
 
Extra-welfarist measures are recommended, by decision-makers, for use in economic 
evaluations. Hence they are commonly used to value outcomes in chronic conditions with 
episodic symptoms, such as menorrhagia. In menorrhagia, a woman’s perceived change in 
quality-of-life (QoL) is the measure of treatment success and consequently, the primary 
clinical and economic outcome is change in QoL. This thesis presents findings of a 
comparison between welfarist and extra-welfarist approaches to valuing outcomes in 
menorrhagia, and aims to determine the value of levonorgestrel-releasing intrauterine system 
(LNG-IUS) compared to usual medical treatment for menorrhagia.  
Findings from the systematic review demonstrated concerns that extra-welfarist measures 
may be unsuitable in menorrhagia due to their narrow health-related focus and that results 
depend on the timing of assessment, given the condition’s episodic nature. The economic 
evaluation alongside the ECLIPSE trial showed that the extra-welfarist measures, EQ-5D and 
SF-6D, provide contrasting cost-effectiveness decisions. The welfarist willingness-to-pay 
(WTP) was shown to capture important aspects of wellbeing that are not captured by these 
extra-welfarist measures. Similar to SF-6D, the economic evaluation using WTP presented 
evidence against the use of the decision-maker recommended EQ-5D. It is argued that each 
measure provides information that should be considered by decision-makers when allocating 
healthcare resources. 
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CHAPTER 1.  INTRODUCTION 
 
1.1 Economic Evaluation and Outcome Measures  
Economic evaluations are carried out to determine the opportunity cost of using resources to 
provide a service or intervention to one group over another. As healthcare resources are 
scarce, it is important to assess the relative costs and benefits of interventions to enable 
decision-makers to allocate such scarce resources. Interventions are not recommended to be 
implemented in clinical practice without evidence on both the effectiveness and the cost-
effectiveness relative to usual practice (NICE, 2008). To conduct an economic evaluation, 
information on the costs and benefits of competing interventions are considered.  
In health economics there are two main alternative frameworks to conducting economic 
evaluations. These are welfarism and extra-welfarism. Each framework has a different 
theoretical and methodological basis for carrying out economic evaluations. Briefly, 
welfarists believe that the output of healthcare should be judged according to the extent to 
which it contributes to overall welfare, hence the aim of welfarism is to maximise social 
welfare (wellbeing). Whilst the aim of the extra-welfarist framework, on the other hand, has 
typically been to maximise health. Extra-welfarists tend to value the output of healthcare in 
terms of the contribution to health itself, not in terms of preferences for health compared to 
other goods. Consequently, the approach to conducting economic evaluations differs 
markedly in terms of the measures of costs and benefits used.  
Currently, decision-makers, such as the National Institute for Health and Care Excellence 
(NICE), recommend the use of the extra-welfarist approaches to economic evaluations, 
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specifically the cost-utility analysis (CUA) (NICE, 2008). In a CUA, the costs are measured 
in monetary terms and the benefits are measured as a quality adjusted life year (QALY). The 
QALY incorporates length and quality of life (QoL) in a single metric. The QALY is 
recommended to be generated using EQ-5D, which is a health-related QoL measure. 
However, when EQ-5D is not considered to be suitable for a condition, decision-makers will 
accept the QALY outcome derived from another health-related QoL measure, SF-6D (NICE, 
2008).  
When costs are measured in monetary terms and outcomes are expressed in natural units, 
which are specific to the condition under analysis (i.e. symptom avoided), the economic 
evaluation is termed a cost-effectiveness analysis (CEA). Whilst a CEA is an extra-welfarist 
evaluation, it is not recommended by decision-makers because the findings from these 
economic evaluations cannot be compared across conditions, due to the disease-specific 
nature of the outcome measure used. It should be noted that beyond the UK, the term CEA 
and CUA are typically used interchangeably, to mean a CUA.  
An alternative economic evaluation, which is less commonly used in health, is known as a 
cost-benefit analysis (CBA). The CBA is a welfarist approach to economic evaluation. In this 
economic evaluation, both the benefits and costs are measured in monetary terms. The 
outcome measure typically used is willingness-to-pay (WTP). WTP provides a broad 
assessment of wellbeing and therefore encompasses benefits beyond health. The CBA is 
widely used in all other sectors, including transport, environment and education (Gafni, 
2006). However, its application in healthcare is much more limited due to the perception of 
decision-makers that results are based on ability to pay, amongst other methodological issues 
(NICE, 2004).  
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Finally, when the outcomes and costs are presented in a disaggregated manner the economic 
evaluation is called a cost-consequence analysis. This analysis can be used when data from 
multiple outcome measures are available and when it is thought that each measure provides 
additional information that the decision-maker should take into consideration when allocating 
resources. For example, both extra-welfarist and welfarist costs and outcomes could be 
presented to decision-makers in a cost-consequence analysis.  
For economic evaluation the value that individuals place on healthcare is typically assessed 
using measures that assess preferences for possible outcomes (preference based measures), 
rather than measures that assess health status (non-preference based measures) (Brazier et al, 
1999). The welfarist approaches to valuing outcomes, such as WTP, are based on preferences, 
and this basis for valuing outcomes has been used in the case of the extra-welfarist CUA 
measures, EQ-5D and SF-6D. This issue is discussed further in section 3.3.  
 
1.2 Valuing Outcomes in Menorrhagia  
Menorrhagia is defined as “excessive menstrual blood loss which interferes with the woman’s 
social, emotional, physical and material quality of life” (NICE, 2007). It is a chronic condition 
but has symptoms that occur in episodes, which typically present for one week out of every 
month until menopause. Menorrhagia places a considerable burden on healthcare resources, 
with around 6% of women per year consulting their general practitioner (GP) in England and 
Wales (Office of Population Census and Surveys, 1995). Treatment is prompted 
predominantly by a woman’s subjective assessment of interference in her QoL, rather than 
solely by clinical assessment of volume of blood loss (Shapley et al., 2002). Women may 
change or cease treatment, according to their perception of effectiveness and relative to their 
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contraceptive needs. The primary clinical and economic outcome measure used to assess 
treatment success is improvement in QoL. 
Historically, women often progressed quickly to a surgical solution; either hysterectomy, 
resulting in the permanent cessation of bleeding and sterility, or since the 1990s, endometrial 
ablation, which uses electrical or thermal energy to destroy the endometrium, causing 
cessation of bleeding in 34% of women (Daniels et al., 2012). Non-hormonal and hormonal 
medical treatments are now available as first line therapy for women presenting with 
menorrhagia in primary care.   
In 2007, NICE introduced guidelines for the levonorgestrel-releasing Intrauterine System 
(LNG-IUS) to be used to treat menorrhagia (NICE, 2007). It is shown in Chapter 4 that there 
is currently no reliable evidence on the cost-effectiveness of LNG-IUS compared to usual 
medical treatment and that the NICE recommendations for its use in clinical practice are 
based on limited evidence on cost-effectiveness (Stewart et al., 2001). The importance of 
using an outcome measure that accurately reflects women’s concerns and experiences is 
explored throughout this thesis.  
 
1.3 Aim and Objectives 
The aim of this research is to (1) determine the value of LNG-IUS compared to usual medical 
treatment in menorrhagia, and (2) consider the suitability of current measures available for 
assessing the value of outcomes and interventions in menorrhagia. 
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The research has the following objectives; 
 Systematically review the literature to; identify the current evidence from economic 
evaluations that have assessed LNG-IUS or usual medical treatment in menorrhagia, 
and to determine which economic outcome measures have been used and assessed in 
menorrhagia. 
 Conduct an economic evaluation for the ECLIPSE trial using the currently 
recommended EQ-5D measure, and re-estimate this evaluation using SF-6D to draw a 
comparison between the cost-effectiveness findings of these extra-welfarist measures. 
 Elicit WTP for LNG-IUS and usual medical treatment, from the theoretically preferred 
ex-ante perspective and the most commonly practiced ex-post perspective, followed 
by interviews to assess respondents’ understanding of the WTP exercise.  
 Conduct a CBA comparing LNG-IUS and usual medical treatment, and compare the 
cost-effectiveness decisions between the welfarist CBA and the extra-welfarist CUAs. 
 
1.4 Structure of Thesis:  
Following on from this introductory chapter, the remaining 9 chapters are structured 
accordingly. 
In Chapter 2 the background of the clinical condition, menorrhagia, is outlined. This chapter 
describes the condition and its treatments, highlights the importance of assessing outcome 
measures particularly in menorrhagia, and describes the ECLIPSE trial, within which this 
PhD is nested.  
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Chapter 3 introduces the concepts of welfarism and extra-welfarism. The chapter outlines the 
theoretical underpinnings behind the two frameworks for conducting economic evaluations. 
The theoretical foundations, the methodological considerations associated with each of these 
frameworks and their use in economic evaluations are described. 
In Chapter 4 a systematic review of economic evaluations using LNG-IUS or usual medical 
treatment is described. This review was carried out to identify the available evidence within 
the area. That is, which intervention has been shown to be cost-effective in previous studies 
and to identify which outcome measures and decision models were used to determine these 
cost-effectiveness decisions. 
Chapter 5 follows on from Chapter 4 by systematically reviewing the evidence on the 
outcome measures used in menorrhagia. The type of economic outcome measure used is 
identified, and the current evidence on the psychometric properties and the feasibility of the 
use of these measures in menorrhagia is presented.  
The use of the extra-welfarist measures EQ-5D and SF-6D are explored in Chapter 6. In this 
chapter the model-based economic evaluation for the ECLIPSE trial is reported using EQ-5D. 
The economic evaluation is then re-estimated using SF-6D and the findings from the two 
extra-welfarist measures are compared and discussed.  
The use of the welfarist WTP measure in menorrhagia is investigated in Chapters 7, 8 and 9; 
In Chapter 7 the methodology for the empirical welfarist WTP study is reported. The method 
for eliciting WTP from the ex-ante and the ex-post perspective is described, in addition to the 
methods used for the interviews. The chapter is concluded with a discussion related to the 
methodology used. 
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In Chapter 8 the results of the WTP study are presented. The chapter is separated into three 
parts. In Part 1, the results from the ex-ante perspective are reported. In Part 2, the results 
from the ex-post perspective are outlined, and Part 3, refers to the findings from the 
interviews. Each part is concluded with a discussion and an overall discussion on the WTP 
findings is reported at the end of the chapter.  
The findings from the ex-ante WTP study are then incorporated into a CBA which is reported 
in Chapter 9. The economic evaluation is carried out similar to the extra-welfarist economic 
evaluation to enable comparisons to be drawn.  
In Chapter 10 a comprehensive discussion on the key findings of the thesis that relate to the 
initial aim is reported. The main findings in relation to other research are presented along with 
reflections on the use of the welfarist and extra-welfarist measures in menorrhagia. The 
chapter is concluded with implications for policy-makers and further research 
recommendations.  
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CHAPTER 2.  BACKGROUND OF CONDITION 
 
2.1 Introduction 
In this chapter the background to the condition of menorrhagia is reported. Since the objective 
of this thesis is to assess the suitability of outcome measures used in menorrhagia, the reasons 
for the focus on this condition are outlined. The chapter is structured as follows; first the 
nature of the condition is discussed, followed by the prevalence, types of treatments available 
and the clinical findings from the ECLIPSE trial. 
 
2.2 Nature of the Condition 
Menorrhagia is defined as “excessive menstrual blood loss which interferes with the woman’s 
social, emotional, physical and material quality of life” (NICE, 2007). Menstrual bleeding 
typically begins at 12 years of age and ceases when menopause occurs, around 45-55 years 
old (NHS Choices, 2012). Menorrhagia occurs for a ‘period’ of the month, each month. The 
duration of menstruation typically lasts up to 7 days, but varies across women. Therefore, 
menorrhagia can be considered as a chronic condition that occurs in episodes.  
Similar to the duration of bleeding, the volume of blood loss also varies across women but the 
‘average’ volume of blood loss for a woman at reproductive age is 35ml per menstrual cycle 
however, the volume of blood loss is known to increase with age (O’Flynn & Britten, 2000). 
Previous attempts have been made to clinically define menorrhagia according to an objective 
volume of blood loss. The exact volume that the definition should be set to has been disputed 
over the years by researchers, but a definition of blood loss in excess of 80ml per cycle 
9 
 
remained for many years (Fraser et al., 1984; Hallberg et al., 1966; Janssen, 1998; O’Flynn & 
Britten, 2000). 
In theory, defining menorrhagia according to an objective volume of blood loss for clinical 
use to diagnose menorrhagia seems reasonable. However in practice, objective measurements 
of volume of blood loss are rarely taken and women are treated according to their subjective 
complaint (Sambrook & Cooper, 2005). Treatment was shown to be prompted predominantly 
by a woman’s subjective assessment of interference in her quality of life (QoL), rather than 
solely by traditional clinical assessments of volume of blood loss (Shapley et al., 2002). Thus, 
women who complain of menorrhagia, but do not bleed in excess of 80ml per cycle, are still 
offered the same medical treatment as women that do bleed in excess of 80 ml per cycle.  
Moreover, women’s complaints of blood loss have been determined to be secondary to those 
of pain, physical sensation of blood loss, and tiredness (O’Flynn & Britten, 2000). 
Menorrhagia was also shown to impact on physical and psychological health, limiting work 
productivity, hindering social life and affecting family life and relationships (Bunkheila & 
Powell, 2008; Shaw et al., 1998). Further, Shaw et al (1998) also showed that impact on 
family life/ relationships was more important than physical wellbeing (Grant et al., 2000; 
Shaw et al., 1998). Following these findings and the difficulties in objectively identifying 
menorrhagia, in 2007 the National Institute of Health and Care Excellence (NICE) in the UK 
formally recognised that a clinical definition of menorrhagia based on volume of menstrual 
blood loss was inappropriate. The medical definition was changed to ensure that a woman’s 
subjective assessment of her ability to cope with the blood loss and the impact of bleeding on 
her QoL are the key prompts for medical intervention. Therefore, the primary indicator of 
treatment success is now improvement in QoL (NICE, 2007).  
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2.3 Prevalence 
Menorrhagia is one of the most common gynaecological conditions presenting in primary care 
(Protheroe, 2004). The condition places a considerable strain on healthcare resources as it 
affects 1.5 million women in England and Wales annually, resulting in 1 in 20 women, aged 
between 30-49, per year, consulting their GP with this problem (Effective Healthcare Bulletin, 
1995; Office of Population Census and Surveys, 1995; Rees, 1991); with slightly fewer 
women of a younger age consulting their GP. Between 10-12% of all gynaecological referrals 
had been shown to be comprised of menorrhagia (Coulter et al., 1995; Grant et al., 2000). 
Approximately 50% of women referred to secondary care had a hysterectomy (Coulter et al., 
1991; Grant et al., 2000), with 1 in 5 women expected to have a hysterectomy prior to turning 
60 years old as a result of the condition (Bulmer, 2008). However, with the introduction of 
guidelines to promote pharmaceutical treatments as first line treatment, the number of 
hysterectomies carried out is reducing (Bulmer, 2008; RCOG, 1998). The relative impact on 
resources may be particularly great in menorrhagia, because an objective assessment and 
clinical criteria is not required to be met in order to obtain treatment, as women can demand 
treatment based on their perception of interference on their lives and not necessarily a clinical 
assessment.   
 
2.4 Treatment 
Menorrhagia can occur as a direct result of another condition, such as an infection, fibroids, or 
a coagulation (blood clotting) disorder (Woman’s Health Medicine, 2005). In these cases, 
because menorrhagia is the secondary complaint, treatment is generally directed towards the 
underlying condition, which in turn eliminates menorrhagia. Menorrhagia can also occur 
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when an underlying pathology does not exist. In these cases, as the cause of heavy bleeding is 
unknown, non-surgical treatments are used to help women manage the bleeding, rather than 
provide a cure for the bleeding. The second type of menorrhagia, with no underlying cause, is 
the main focus of this research as menorrhagia is the primary complaint from the women. 
Historically, women usually progressed quickly to one of two surgical solutions to treat 
menorrhagia (Daniels et al., 2012). The first is hysterectomy, which is an expensive major 
operation resulting in the permanent cessation of bleeding and sterility. The second option, 
available since the 1990s, is endometrial ablation, which is a minor operation that uses 
electrical or thermal energy to destroy the endometrium, causing cessation of bleeding in 34% 
of women (Daniels et al., 2012). If not fully effective the first time, endometrial ablation may 
need to be repeated. 
In 2007, the UK NICE guidelines (NCCWCH, 2007) for menorrhagia were published and 
recommended that, due to their invasive nature and expense, surgical intervention be the last 
course of treatment for menorrhagia. Surgical interventions are now only considered when 
pharmaceutical interventions are either unsuccessful, poorly tolerated, or the patient has a 
strong preference for surgery (Protheroe, 2004). As an alternative to surgical intervention, 
patients can manage their bleeding by taking pharmaceutical treatments. These include a 
range of alternative medications which can be taken orally, via injection, or inserted in the 
uterus, as is the case for the newly licenced levonorgestrel-releasing intrauterine system 
(LNG-IUS). As changes to the provision of treatment has been made, the clinical and cost-
effectiveness of pharmaceutical treatments has become the primary focus of clinicians and 
decision-makers alike.  
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In this thesis a comparison of the alternative economic theoretical frameworks for valuing 
outcomes in menorrhagia will, in part, be assessed by measuring changes in outcomes 
associated with usual medical treatment or LNG-IUS. This is because, first, the research 
reported within this thesis is nested within the ECLIPSE trial and the comparator treatments 
of the trial include ‘usual medical treatment’ and ‘LNG-IUS’ and, second, because evidence 
on the clinical and cost-effectiveness of these competing treatment strategies is required to 
determine the first line treatment strategy in menorrhagia. These treatment strategies will be 
explained next. 
 
2.4.1  Usual Medical Treatment 
In this context, and according to the ECLIPSE trial definition, usual medical treatment 
includes either one of, or a combination of, five alternative treatments (NICE, 2007; RCOG, 
1998). The alternative treatments are either non-hormonal which do not provide 
contraception; or hormonal treatments which do provide contraception. 
 
i) Non-Hormonal Treatment 
Non-hormonal treatments include tranexamic acid and mefenamic acid. In some cases a 
combination of these treatments are offered to patients to help alleviate symptoms. These non-
hormonal treatments can also be combined with hormonal treatments. Non-hormonal 
treatments are not provided free of charge by the UK National Health Service (NHS), but the 
prescriptions for the medication are heavily subsidised by the government. These treatments 
are provided at the primary care level by a GP and are reviewed for effectiveness at 3 months.  
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Both mefenamic acid and tranexamic acid are oral tablets that are not taken continuously. 
Thus they are only taken during menstruation. Whilst both treatments reduce menstrual blood 
loss, mefenamic acid is claimed to be the least effective of the two treatments as blood loss is 
reduced by approximately 30% in comparison to the reduction of 50% observed when 
tranexamic acid is used (Zachariah & Fender, 2005). However, in addition to reducing blood 
loss, mefenamic acid also alleviates pain associated with menstrual cramps, which tranexamic 
acid does not (NICE, 2007; Protheroe, 2004). Potential side effects of both of these non-
hormonal treatments include gastrointestinal side effects which are minor and uncommon. 
 
ii) Hormonal Treatments 
Hormonal treatments include combined oral contraceptives, injectable progestogen (depo-
provera), and high dose progestogen (norethisterone). As each of the hormonal treatments 
provide contraceptive benefits they are provided free of charge to patients. Each of these 
treatments provide reversible contraceptive protection in addition to a reduction in menstrual 
blood loss. Similar to non-hormonal treatments, these hormonal treatments are prescribed at 
the primary care level by a GP. Combined oral contraceptives are reviewed at 3 months, 
whilst norethisterone and depo-provera are reviewed at 6 months.  
A large range of these combined oral contraceptives are offered to patients with menorrhagia 
(Kadir, 2009). They are able to reduce blood loss by 50% and help to regulate the cycle 
(Zacchariah & Fender, 2005). Unlike the non-hormonal treatments, combined oral 
contraceptive tablets must be taken daily at approximately the same period of time, and in 
some cases, a seven day break from medication is required. Norethisterone should be taken 
orally from day 5 to day 25 of the menstrual cycle. Norethisterone reduces the volume of 
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bleeding by up to 85% (NICE, 2007). However, the evidence on the effectiveness of 
norethisterone is poor and widely disputed (Protheroe, 2004). Due to the high dose required to 
reduce bleeding, norethisterone is commonly associated with side effects, which has led to 
reduced compliance (Kadir, 2009). Depo-provera is administered to the patient by the GP via 
injection every 6 months. This injected medication has been shown to cause complete 
cessation of blood loss in up to 85% of women (Bulmer, 2008). However, similar to 
norethisterone, the side effects of depo-provera, which can include irregular bleeding, lead to 
low compliance as patients discontinue treatment. Common side effects for all hormonal 
treatments include headaches, acne, nausea and weight gain, which typically subside over 
time. 
 
2.4.2  Levonorgestrel-releasing Intrauterine System (LNG-IUS) 
LNG-IUS is a hormone releasing intrauterine device which is inserted into the uterus by a 
healthcare provider, normally a GP (Figure 2.1). The LNG-IUS was originally licensed for 
contraception only, but its notable reduction in blood loss was identified and its potential use 
in menorrhagia was realised. The LNG-IUS is free of charge to patients, the insertion of the 
LNG-IUS typically takes a few minutes and the device remains active for up to 5 years. After 
5 years the device can be replaced.  
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Figure 2.1 Image of intrauterine device (IUD) in uterus (Gralapp, 2006)  
  
LNG-IUS is claimed to be the most effective alternative treatment to hysterectomy, as it 
minimises blood loss and has the ability to eliminate menstrual pain (Kadir, 2009). The 
reduction in blood loss ranges from 71% to 96% (NICE, 2007). However, the LNG-IUS has 
an extensive side effect profile which is extremely common within the first 6 months of 
fitting. These side effects are thought to be a large reason for patients seeking alternative 
treatment. Side effects include increased bleeding, increased irregular bleeding, bleeding 
between menstruation, bleeding following intercourse and device expulsion. If women are 
able to withstand these side effects, after 6-9 months 90% of women have been shown to be 
pleased with the treatment (Bulmer, 2008). 
In all of the above cases, when administration of these non-surgical treatments is stopped, the 
beneficial effects are also no longer seen. Hence, unlike surgical treatments, these 
pharmaceutical treatments are not curative. For this reason, women often seek to change, or 
cease treatment, according to their perception of effectiveness, and relative to their 
contraceptive needs or their reproductive life stage.  
Uterus IUD 
Strings 
16 
 
2.5  The ECLIPSE Trial  
To identify evidence on the clinical and cost-effectiveness of the two treatments LNG-IUS 
and usual treatment, the largest randomised controlled trial in menorrhagia and the first in the 
UK to compare these treatments is currently underway. The acronym ECLIPSE stands for 
The Effectiveness and Cost-Effectiveness of Levonorgestrel-Containing Intrauterine System 
in Primary Care against Standard Treatment for Menorrhagia (ECLIPSE). The (ECLIPSE) 
trial is a National Institute of Health Research Health Technology Assessment (NIHR HTA) 
funded randomised controlled trial. 
Clinical trials are used to gather data on the effectiveness of new interventions. There are 
several types of clinical studies, but randomised controlled trials are currently considered the 
gold standard (Sibbald & Roland, 1998). Randomised controlled trials typically provide 
unbiased evidence on the treatment-effect relationship because they are carried out in 
controlled conditions which ensure that there are no systematic differences between the 
compared treatment groups (Sibbald & Roland, 1998). Randomised controlled trials are 
known to provide the most rigorous method of establishing whether a relationship exists 
between the treatment and outcome, which in turn means that the findings of economic 
evaluations, alongside these trials, are amongst the most robust (Sibbald & Roland, 1998). 
Hence economic evaluations are commonly conducted alongside randomised controlled trials 
to identify the cost-effectiveness of a ‘new’ intervention, relative to treatment as usual. 
Evidence on cost-effectiveness alongside evidence on effectiveness is required by decision-
makers when making decisions about resource allocation. 
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2.5.1 Study Design 
Full details of the trial are reported in Gupta et al (2013). Briefly, 571 women with 
menorrhagia from 63 UK centres were randomised between February 2005 and July 2009. 
Women between 25 and 50 years of age presenting to their GP with menorrhagia, occurring 
over at least three consecutive cycles, provided written informed consent to participate. 
Women were randomised to having a LNG-IUS fitted, or usual medical treatment, chosen by 
the GP and the woman based on contraceptive needs or desire to avoid hormonal treatment. 
Usual medical treatment options included mefenamic acid, tranexamic acid, norethisterone, a 
combined oestrogen/progestogen or a progestogen only oral contraceptive pill (any 
formulation), or methoxyprogesterone acetate injection (NCCWCH, 2007; RCOG, 1998). The 
particular medical treatment was specified prior to randomisation. Treatments were reviewed 
by a GP at 6 weeks and 3 months. Subsequently, treatments could be changed or discontinued 
due to perceived lack of benefit, side effects, change in contraception need, referral for 
endometrial ablation or hysterectomy as per usual practice (NCCWCH, 2007; RCOG, 1998). 
Treatment changes reported by patients were confirmed with the GP. 
The primary outcome measure used in the clinical analysis was a disease-specific QoL 
measure named Menorrhagia Multi-Attribute Scale (MMAS). Briefly, the MMAS 
questionnaire is comprised of six attributes including ‘practical difficulties’, ‘social life’, 
‘psychological health’, ‘physical health’, ‘work and daily routine’, and ‘family 
life/relationships’ (Shaw et al., 1998). Each attribute has been weighted according to patient 
preferences using counters, which are considered to be ‘importance points’. The patients 
disease-specific QoL is captured on a 0-100 scale (Shaw et al., 1998). Zero represents the 
worst severity of the condition and 100 represents the best state for the condition. The 
methods for scoring and weighting measures are discussed further in section 3.3.2 in Chapter 
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3. Secondary outcomes such as EQ-5D and SF-36 (described in more detail in the next 
chapter), impact on sexual activity and number of surgical interventions were also recorded. 
Data were collected at baseline, 6 months, 1 year and 2 years. 
Currently the 2 year interim analysis on the clinical effectiveness has been carried out and 
published (Gupta et al., 2013). A 5 year analysis and potential 10 year analysis are planned for 
the future. In this section, the clinical findings from the trial so far will be summarised.  
 
2.5.2 Trial Results 
The trial had an (478/571) 84% response rate at the 2 year time point but in 9% of these cases, 
the MMAS was not completed (Gupta et al., 2013). The number of women in each treatment 
arm, at each time point, is detailed in Figure 2.2.  
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Figure 2.2 Follow up of ECLIPSE patients (reproduced from Gupta et al 2013) 
 
 
According to Gupta et al (2013) at the 2 year time point, the chance of women remaining in 
the LNG-IUS arm was approximately twice as likely as those randomised to usual medical 
treatment remaining in that arm. A significant improvement in the primary outcome, MMAS, 
was observed in both treatment arms at all time points compared to baseline (Gupta et al., 
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2013). However, when compared to usual medical treatment, the degree of improvement was 
significantly greater in the LNG-IUS arm at every time point of assessment. The average 
difference was 13.4 points [95% CI 9.9 -16.9] p<0.001, which suggests an improvement in 
two or three of the MMAS domains indicating a change from being greatly affected to 
minimally affected or minimally affected to unaffected (Gupta et al, 2013). 22% of women 
underwent surgery, either hysterectomy or endometrial ablation, at the 2 year time point and 
there was no statistically significant difference in the rate of surgery between the two 
treatment arms (Gupta et al., 2013). In the trial based analysis the secondary outcomes for 
general QoL revealed the following: EQ-5D scores increased significantly from baseline in 
both treatment groups; a significant difference in scores between treatments was not detected 
(p=0.38); the scores from SF-36 were reported according to the instrument attributes and 
similar to EQ-5D showed a significant improvement from baseline; for SF-36 in all but one 
domain, ‘mental health’, the score for LNG-IUS was significantly greater than the score for 
usual medical treatment.   
Consequently, the clinical results of the ECLIPSE trial showed that LNG-IUS produces a 
significantly greater improvement in disease-specific QoL compared to usual medical 
treatment. The results of the cost-utility analysis alongside the ECLIPSE trial are reported in 
Chapter 5.  
 
2.6 Conclusion 
Menorrhagia is a common condition that has a considerable impact on healthcare resources. 
Objective assessments of volume of blood loss are not deemed to be suitable for the 
condition. The medical definition of menorrhagia has been changed to ensure that a woman’s 
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perception of blood loss and the impact of bleeding on her QoL are the primary prompts for 
medical intervention. Therefore, the patients’ subjective assessment of their ability to cope 
with the bleeding is important, rather than an objective assessment of volume of blood loss. 
As surgical interventions are no longer considered as first line treatment for menorrhagia, the 
clinical and cost-effectiveness of non-surgical treatment strategies, LNG-IUS and usual 
medical treatment, must be explored. Given that LNG-IUS is a relatively newly licensed 
treatment for menorrhagia, and very little evidence is currently available, the ECLIPSE trial 
aimed to explore this very issue and found that at the 2 year time point LNG-IUS is most 
effective when a clinical outcome measure is used. 
As the primary indicator of treatment success is improvement in QoL it is deemed important 
to identify which QoL measures have been used, and to determine whether current measures 
accurately capture women’s concerns and experiences. This assessment of outcome measures 
will ensure that robust recommendations of economic evidence are provided to decision-
makers. As part of the empirical work, the economic evaluation for the ECLIPSE trial 
comparing LNG-IUS and usual medical treatment is presented in Chapter 6. The use of 
economic evaluations, and outcome measures, from the alternative frameworks within 
menorrhagia will then be explored in subsequent chapters. 
In the next chapter, a background to economic evaluation is provided. The theoretical 
foundations behind economic evaluations and the outcome measures, described. 
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CHAPTER 3.  THEORETICAL FOUNDATIONS AND APPLICATION 
OF ECONOMIC EVALUATION 
 
3.1 Introduction 
In this chapter a discussion on some of the theoretical and methodological principles of 
economic evaluation is provided. As mentioned in Chapter 1, healthcare resources are scarce 
and economic evaluations are used by decision-making bodies such as the UK National 
Institute for Health and Care Excellence (NICE) to aid decisions about resource allocation. 
Economic evaluations represent a framework used to compare the costs and benefits, or 
outcomes, of alternative options for resource use (Drummond et al., 2005). In a normal 
market the value of a good is determined directly by observing how an individual responds to 
changes in price and quantity (McIntosh et al, 2010). For example, whether the individual is 
willing to pay £40 but not £50 reveals how much they value that good. Therefore, whether the 
individual consumes the good is related to their willingness and ability to pay (Morris et al, 
2007). However in healthcare, the conditions that define a normal market are not met and 
market failure is said to occur. Consequently, in the UK, the government intervenes to ensure 
an efficient allocation of resources and provides healthcare free at the point of consumption 
(Morris et al, 2007). Hence, it is not possible to measure individual’s preferences or value for 
healthcare by assessing their response to changes in price. It is then necessary to use other 
measures to assess the benefits of a treatment or programme, which can be measured directly 
or indirectly and are discussed in section 3.3. Economic evaluation provides values for 
healthcare services (McIntosh et al, 2010). The type of economic evaluation used is driven by 
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the theoretical underpinnings of the approach. The most suitable method to use is widely 
debated.   
The aim of the thesis is to assess the valuations of the outcomes used in economic evaluations 
of interventions for menorrhagia. In this chapter, a comprehensive discussion of the two main 
theoretical frameworks for conducting economic evaluations is first presented. The 
methodological considerations associated with the application of these frameworks to 
economic evaluations are then reported. The reporting is deliberately concise as a wealth of 
literature has already been written within the area (Birch & Donaldson, 2003; Brouwer et al., 
2008; Drummond et al., 2005; Morris et al., 2007).   
 
3.2 Theoretical Foundations  
Normative economics is a type of analysis to assess the most desirable resource allocation 
according to a set of assumptions or value judgements. The assumptions provide a basis for 
ordering different states of resource allocation according to desirability, enabling an 
assessment of the value of providing the resources to one group and not another (Boadway & 
Bruce, 1984). The investigation into determining (ranking) which states are most desirable is 
traditionally known as welfare economics. Further, some researchers do now differentiate 
normative economics into welfarism and non-welfarism to allow for the additional methods 
developed for ranking alternative states (Morris et al., 2007; Tsuchiya & Williams, 2003).  
Broadly, within health economics, there are two frameworks from which economic 
evaluations can be conducted. These include ‘welfarism’ and ‘extra-welfarism’. Extra-
welfarism is considered to be a type of non-welfarism and is the most widely accepted 
alternative to welfarism. Other such non-welfarism frameworks, or the decision-maker 
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approach, have also been suggested but all of these approaches have the same objective as 
extra-welfarism (discussed in 3.2.2). The welfarist and extra-welfarist framework differ in the 
methodological basis for conducting economic evaluations, as the value judgements used for 
ranking different states of resource allocation differ. In the next sections each framework will 
be discussed in turn. 
 
3.2.1 Welfarism 
Welfare generally refers to well-being and the key value judgment behind welfare economics 
is to maximise social welfare (wellbeing), by maximising utility (McIntosh et al., 2010). The 
definition of ‘utility’ or ‘utilities’ varies widely, but in welfarism it is typically considered a 
measure of strength of preference which is related to desirability (Coast, 2009). The impact of 
a change in resource allocation is judged by the value that individuals place on the alternative 
states of the world and this value for the change is captured in terms of changes in utilities. In 
other words, value judgements about the desirability of different options of resource 
allocation are judged by how the changes affect individual utility. This approach, where the 
evaluative space is confined to impact on utilities, was first termed ‘the welfarist approach’ by 
Sen in 1977 (Sen, 1977). 
Welfare economics is grounded in consumer choice (preference) theory, which assumes that 
individuals will have preferences and will therefore be able to rank alternative states of the 
world with the aim of maximising their own utility, within the restraints of their income 
(McIntosh et al., 2010). Thus the welfarist decision rule of maximising utility is rooted in 
theory. The utility change that occurs as a result of alternative states of resource allocation 
(the welfare change) is dependent on the individuals’ preference for the alternative states. The 
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strength of preference for the welfare change determines the amount the individual values the 
change (i.e. how it changes their utility). Following a change in welfare (resource allocation) 
individuals’ utilities are aggregated to determine whether that change in resource allocation 
results in an improvement in social welfare (McIntosh et al., 2010). As utility cannot be 
measured directly, money is used as a proxy for the change in utility.  
The key value judgement, of maximising utility (social welfare), was presented as the Pareto 
principle. The principle asserts that a state of the world is better than another if an individual 
is made better off without making another individual worse off (Mitchell & Carson, 1989). 
This state of the world is considered to be an improvement in social welfare, hence there is a 
Pareto improvement; ergo a policy that can achieve this should be implemented. The Pareto 
principle provides a method for drawing comparisons between different states of the world 
according to whether a Pareto improvement is observed. However, it has been widely argued 
that in reality it is unlikely that a change in resource allocation could make one person better 
off without making another worse-off (Coast, 2004; Mitchell & Carson, 1989). Due to these 
limitations and the lack of translation to real life, a compensation principle was introduced to 
operationalise the approach. The compensation principle by Kaldor and Hicks states that there 
is a potential Pareto improvement if the gainers, from the change in resource allocation, could 
hypothetically compensate the losers (Hicks, 1939).  
Hicks then described two key methods to use to measure the impact of a change in welfare, 
which are (i) equivalent variation and (ii) compensating variation (Hicks, 1939). The aim of 
these methods is to identify the level of compensation that ensures utility levels are 
unchanged. A third method known as consumer surplus which is the difference between what 
an individual is willing to pay and what they actually pay (Jonnesson & Jonsson, 1991), is 
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less widely used as it is thought to be less appropriate in a policy decision-making context 
(McIntosh et al., 2010).  
Equivalent variation measures the amount of money required to keep the individual at the 
utility level post change (O’Brien & Gafni, 1996). Hence the change has already occurred and 
the measurement is from an ex-post perspective. The compensating variation measures the 
amount of money required to keep the individual at the initial (before change) utility level. 
Thus it is measured prior to the change occurring, from an ex-ante perspective, to obtain the 
expected change in utility following the provision of resources (O’Brien & Gafni, 1996). 
The Kaldor criterion of the Kaldor-Hicks compensation principle states that a programme 
results in an increase in efficiency and should be implemented if the gainers can compensate 
the losers sufficiently so that everyone would be better off following the change (Kaldor, 
1939). Hence the criteria of the compensation principle (whether a programme would be 
implemented) is equivalent to whether the sum of the values derived from the compensating 
variation is greater than zero, as explained by McIntosh et al (2010). The compensating 
variation relates to the gainers being able to compensate the losers and still maintain the initial 
utility level. If this is the case, the programme should be implemented. The (compensating 
variation and Kaldor criterion) values are relative to the initial utility level and therefore the 
compensating variation (ex-ante) is the theoretically preferred approach (McIntosh et al., 
2010). The equivalent variation is related to the amount of money that the losers must give to 
the gainers to compensate them for the forgone utility gain from the lack of intervention. In 
this case everyone would be better off without the change and therefore the programme 
should not be implemented. The compensation principle is operationalised in economic 
evaluations through the use of the cost-benefit analysis (CBA) (Mishan, 1972). The Kaldor-
(Hicks) criterion is implemented in a CBA using methods associated with the compensating 
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variation. Although the compensation principle is widely accepted, it is argued that as the 
compensation is hypothetical, the change would involve a redistribution of health in favour of 
the gainers at the expense of the losers (Little, 1949; Morris et al., 2007).  
In welfarist theory, an improvement in social welfare is measured as an improvement in utility 
alone. The effect that the consumption of healthcare has on individual utility is valued in the 
utility function but the provision of healthcare itself is not (Brouwer & Koopmanschap, 
2000). Health itself does not enter the utility function but the consequence of health, what the 
consumption of healthcare and subsequent improved health enables an individual to do, is 
reflected in the utility function, in the form of the ability to, for example, go back to work, to 
continue with daily routine, feeling better and so on. Thus welfarism considers overall 
wellbeing and enables the individual to incorporate both health and non-health benefits into 
their decision in so far as the effect on their utility (Donaldson et al., 1997a). Culyer (1991) 
argued that a downfall of the welfarist approach is that benefits associated with non-goods 
characteristics, such as the process of care, cannot be incorporated into the analysis but Birch 
and Donaldson (2003) explain that characteristics of non-goods can and have been 
incorporated into welfarist studies, in terms of process utility which is the utility associated 
with the process of care, in so far as its consequence on utility.  
Some researchers have intimated that welfarism requires value judgments of alternative states 
of the world to be based on the individuals who are affected by the change in resource 
allocation only, as individuals are thought to be the best judge of their own welfare (Brouwer 
et al., 2008; Coast, 2004). This notion has been criticised for not accounting for individuals 
who are willing to sacrifice their own utility, in order to improve the utility of another. 
However, Birch and Donaldson (2003) outline that this is not a strict criterion of welfarism. It 
should be noted that caring externalities and option externalities have been incorporated into 
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studies, so the values of individuals who are not directly affected by the change in resource 
allocation, can be taken into consideration (Birch & Donaldson, 2003). Further, the way in 
which healthcare is funded determines who the affected individuals are, following a resource 
change. From a UK perspective, as healthcare provision is primarily publicly financed 
through taxation, all citizens contribute to the National Health Service. It is therefore argued 
that all citizens would be affected as they either incur the losses or benefits associated with a 
change in resource allocation (NICE, 2008). Brazier et al (2005) explains that the welfarist 
approach is unclear in this respect and that to use a welfarist framework does not necessarily 
mean to use patient values in a publicly financed system, as they are not the only affected 
individuals. O’Brien and Gafni (1996) state that in a publicly financed system the entire 
population makes up the affected individuals. Shackley and Donaldson (2000) outline whose 
values should be used according to each context. This notion of whose values should be 
incorporated is discussed further in section 3.3.1. 
The welfarist approach addresses issues with allocative efficiency (Currie et al., 1999). That 
is, as the outcome measure is expressed in monetary terms, comparisons of resource use can 
be made across industry sectors and comparisons are not confined to healthcare. Thus, 
information can be used to determine how resources should be allocated to the healthcare, 
transport, environment and education sectors. However, as issues of distribution and 
efficiency are separated in the welfarist approach, it is argued that welfarism rarely takes into 
account equity and distribution concerns (Morris et al., 2007; Olsen & Smith, 2001). The 
Kaldor-Hicks compensation principle presents the most efficient allocation of resources and 
the redistribution of utilities, or compensation, can be researched by others and applied by 
decision-makers (Coast, 2009; Kaldor, 1939). The issue of ‘ethical’ or equitable distribution 
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can be solved by decision-makers. Work has been undertaken to apply distributional weights, 
but these are rarely used in practice (Donaldson, 1999). 
Despite the extensive use of the welfarist framework in transport and environmental 
economics and its strong theoretical underpinnings in consumer choice theory, the use of the 
welfarist approach in health economics is widely debated (Brouwer et al., 2008). It is often 
argued to be too narrow due to its focus on utility alone. Sen has argued that utility alone is 
not sufficient to capture wellbeing, and that healthcare and health should be valued as an end 
in itself, not for the benefits that health can derive (Sen, 1980). The quality of the utility 
derived and the individual’s capability to convert the healthcare received into wellbeing were 
argued to be necessary to take into consideration. Further, an individual may have adapted to 
their current situation and therefore adjusted their expectations of utility, which would 
subsequently alter their ability to value and desire goods (Brouwer et al., 2008; Cohen, 1993).  
It is also often argued that as judgements on different states of allocation are based on an 
individual’s strength of preference for a state, which is measured in monetary terms, it is 
ultimately based on ability to pay, therefore the allocation of resources are argued to be 
skewed towards the rich (Coast, 2004; Gold et al., 1996). This is one of the key arguments 
against the use of welfarism in healthcare. It is argued that healthcare should be distributed in 
a fair manner, i.e. based on need, not on strength of preference (Brouwer et al., 2008). 
Healthcare is considered to be a merit good that should be provided to society based on need 
(Musgrave, 1959). Despite the distributional weights available, this argument of not basing 
allocation on anything other than need is backed by decision-makers. Hence, the claimed 
discomfort of the public and decision-makers of valuing health in monetary terms is argued to 
be one of the main reasons that have led to the reduced focus of welfarism in healthcare and 
30 
 
the development of other methods for valuing different states of resource allocation (Brouwer 
et al., 2008, Coast et al., 2008b).   
Brouwer et al (2008) described a final ‘seed’ that led researchers to consider other approaches 
for valuing different states of resource allocation, that of allowing decision-makers to be the 
sources of values in public decision-making. One such approach, which was developed out of 
the perceived problems associated with welfarism, was extra-welfarism.  
 
3.2.2 Extra-welfarism 
The exact definition of extra-welfarism is unclear. Other prior approaches such as the ‘non-
welfarist’, or the ‘decision-maker approach’ all differ in their exact application but the key 
value judgement behind all three of these approaches, as applied in health economics, is the 
same. 
In 1991, Culyer (1991) wrote about an approach, now known as extra-welfarism, which 
attempted to overcome the perceived problems associated with the welfarist approach and 
incorporate Sen’s writings. The approach aimed to consider non-utility information, such as 
capabilities and functioning, in the evaluative space. Health would be valued in its own right 
and not for how it makes the individual feel. Other information in addition to utilities would 
be taken into consideration when comparing states of the world. Therefore the initial aim of 
extra-welfarism was to broaden the valuation scope, enabling more than utility to be taken 
into account. Brouwer et al (2008) also differentiate extra-welfarism from welfarism because 
outcomes do not necessarily need to be weighted according to preferences. Indeed, more than 
solely the individual’s views are said to be considered in extra-welfarism and comparisons 
between individuals on a range of wellbeing measures can be made. Birch and Donaldson 
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(2003) are among many researchers who have reported the flaws in extra-welfarism and have 
attempted to refute some of these differences in their paper which set out to identify what is 
‘extra’ in extra-welfarism.  
Culyer (1991) deemed health to be one of the most relevant characteristics to take into 
consideration when valuing healthcare, as an individual’s endowment of health (health 
characteristic) could be directly taken into consideration when comparing resource allocation 
for healthcare. Therefore outcomes were not solely weighted based on preferences. Although 
originally aiming to broaden the evaluative scope, in practice the extra-welfarist framework 
tends to focus only on health and has led to changes in health being considered instead of 
changes in utility (Hurley, 1998). The key value judgement behind extra-welfarism is to 
maximise health. Capabilities are not considered, but only the functionings, i.e. being in good 
health or being mobile, are considered rather than what the individual is capable of doing as a 
result of healthcare (Coast et al., 2008b). The extra-welfarist approach is argued to have an 
even narrower evaluative space than welfarism and is considered to be a partial 
implementation of Sen’s capability approach (Coast et al., 2008a). The extra-welfarist 
approach is operationalised through cost-utility analysis (CUA) (discussed in section 3.2.2). 
As outcomes are based on health, the evaluations cannot assess efficiency in terms of how 
much should be allocated to healthcare over other sectors, as in welfarism, but instead these 
evaluations can assess technical efficiency in terms of determining which resource allocation 
produces the greatest benefit at the same cost, or the same benefit at the lowest cost (Morris et 
al., 2007). In summary, the aim of extra-welfarism is to maximise health, by using community 
values to assess the impact of the change in resource allocation on health status.   
The extra-welfarist approach is widely implemented in health economics and is recommended 
by decision-makers (NICE, 2004). Although extra-welfarism is routinely implemented in 
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practice, it has been criticised to lack any substantial theoretical underpinnings (Birch & 
Donaldson, 2003; Coast, 2004; Tsuchiya & Williams, 2001). Health alone is argued not to be 
appropriate by many researchers in the field (Birch & Donaldson, 2003; Coast et al., 2008b; 
Ryan, 1999). Several interventions have benefits that either lie outside of health or are not 
confined to health, and current health related measures are likely to underestimate the 
benefits, which will have a negative impact on decision-making (Coast et al., 2008b). Further, 
the primary value judgement behind extra-welfarism of maximising health has been 
questioned (Anand & Wailoo, 2000; Coast, 2009). It has been argued that as the aim of 
healthcare is to improve health, then resources should be allocated in a manner that maximises 
health (Brouwer et al., 2008). However, this principle of maximising health, in particular, 
does not coincide with any theory and it has been widely reported that society does not agree 
with such a stance (Dolan et al., 2005). The actual criteria for distributing healthcare in 
practice is unclear. Coast (2009) explains that currently, distribution is not based on need 
because once health is produced it cannot be redistributed to ensure a fair allocation, as in 
welfarism. Instead, once health is produced, it is simultaneously consumed. She states that the 
extra-welfarists are “endorsing the ethical position that the total sum of health produced 
within the healthcare system is what matters, no matter how that health is distributed” (Coast, 
2009 pp 789). For these reasons Birch and Donaldson (2003) also state that the same 
criticisms of welfarism, which are related to the hypothetical compensation and decisions 
based on potential compensation, apply to extra-welfarism. Coast suggests an alternative, 
possibly more appropriate, rule for the distribution of healthcare based on providing a 
“threshold level of health […], rather than maximising the total level of health…” (Coast 
2009 pp 791). 
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These ‘limitations’ of welfarism, and extra-welfarism, led to the development of the 
capability approach which aims to more fully implement Sen’s work in health economics. 
This work is currently in the development stages. Specifically the capability approach focuses 
on what interventions enable the individual to do in terms of their capabilities, whether they 
choose to or not, aiming to ensure an ethical and equitable distribution of healthcare (Coast, 
2008b). As the capability approach is not the focus of this thesis its theoretical underpinnings 
or the suggested outcomes will not be discussed any further. A summary of the differences 
between welfarism and extra-welfarism are presented in Table 3.1. 
 
Table 3.1 Summary of welfarism and extra-welfarism 
Welfarism Extra-welfarism 
Maximise social welfare (utility) Maximise health 
Affected individuals values should be considered Societal values should be considered  
Consequence of health and healthcare on utility is the 
most important outcome 
Health itself is valued and is the most important 
outcome 
Distribution and equity are considered to be separate Distribution and equity are not separable 
Allocative efficiency Technical efficiency  
Incorporates benefits wider than health*  Incorporates only health benefits 
*But has been argued to be narrow due to the impact of change in resource only being incorporated in so far as 
its consequences on utility 
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3.3 Methodological Considerations 
As the theoretical background to welfarism and extra-welfarism has now been described the 
methodological considerations associated with the application of these approaches through 
economic evaluation will be discussed next.  
 
3.3.1 Welfarist Cost-Benefit Analysis and Willingness-to-Pay 
CBAs are found in abundance in environmental economics, and other sectors but are less 
commonly conducted within health economics (Gafni, 2006). The more widespread use in 
environmental economics is likely to be attributable to the contingent valuation approach 
being primarily developed in environmental economics, and the National Oceanographic and 
Atmospheric Administration (NOAA) providing recommendations and guidelines for its use. 
Furthermore, contingent valuation is one of the only methods that can account for existence 
value which is particularly relevant to environmental economics, and is related to the benefit 
derived from knowing an environmental resource exists regardless of whether you want to 
visit (Mitchell & Carson, 1989). The less frequent use in healthcare is partly due to UK 
decision-makers, such as NICE, rejecting the welfarist approach in health arguing that 
decisions should not be based on ability to pay but on need, as mentioned previously, and 
recommending the use of the alternative extra-welfarist type of economic evaluation, namely 
CUA (discussed in 3.3.2). It is also likely to be related to the empirical limitations of getting 
people to attach a monetary value to health. Furthermore, not only are there issues with the 
use of the theoretical underpinnings of the welfarist approach, there are also methodological 
concerns with the application of the approach. 
35 
 
The welfarist principles are applied to decision-making through the CBA type of economic 
evaluation. Like all economic evaluations the CBA assesses the costs and outcomes related to 
a change in resource allocation, which could for example be the provision of a healthcare 
intervention. As mentioned previously, in welfarism, money is used as a proxy for measuring 
changes in the utility (outcome) following a welfare change. Thus in CBA both costs and 
outcomes are expressed as monetary values. A CBA aids policy-makers’ decisions about 
whether an intervention is worth implementing. This would be the case if the benefits 
outweighed the cost, resulting in a positive net social benefit, producing a welfare gain.  
As mentioned in section 3.1 the healthcare market does not resemble a normal market and 
therefore individual’s preferences for healthcare cannot be measured by assessing their 
response to changes in price. Other measures such as stated preferences and revealed 
preferences can be used. The welfare change observed from the provision of an intervention 
can be measured directly through the contingent valuation stated preference technique. 
Alternative methods for eliciting preferences include the stated preference discrete choice 
experiment. These choice experiments present the individual with a scenario of various 
attributes and attribute levels of healthcare (i.e. the comparison of two treatments) and 
measure the amount an individual is willing to pay for a change in the level of an attribute of 
healthcare (McIntosh et al., 2010). The use of stated preference discrete choice experiments is 
growing in the literature and is at the development stages for eliciting preferences in health. 
Indirect methods, such as revealed preferences, are methods of eliciting the value for 
healthcare by assessing the influence the improved health has on another good (McIntosh et 
al., 2010). Revealed preferences are rarely used in health economics. As the welfarist 
contingent valuation method is the focus of this thesis, it will be discussed in more detail.   
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Direct and indirect elicitation methods 
In the contingent valuation technique, an individual’s utility is measured directly in terms of 
the amount of money they would be willing to give up (receive), to (not) receive an 
intervention, in order to compensate those individuals that lose out following the welfare 
change (O’Brien & Gafni, 1996). Hence, this compensation would restore social welfare to 
the original utility level prior to the change in resource allocation. The outcome measure 
typically used is known as willingness-to-pay (‘WTP’), which is a measure of the amount of 
money the gainers are willing to give up for the treatment (Johannesson & Jonsson, 1991; 
Olsen & Smith, 2001). An alternative, less commonly used outcome is called willingness-to-
accept (‘WTA’) where the amount of money the losers would be willing to receive to incur 
the welfare loss and forgo the intervention is assessed (Olsen & Smith, 2001; Johannesson & 
Jonsson, 1991). WTP is measured rather than WTA because a welfare gain from the treatment 
is more often assessed (Sach et al., 2007). In practice, healthcare decisions are related to the 
addition of a new programme and tend to measure welfare gain (WTP). WTP is also 
associated with more conservative answers as the responses are constrained to the 
respondents’ income (Arrow et al., 1993; Diener et al., 1998). Hence outcomes of CBAs in 
terms of WTP will be discussed. 
 
Elicitation perspective 
The changes in utility, as captured by WTP, following a change in provision of healthcare can 
be measured by either the equivalent variation or the compensating variation. The ‘correct’ 
perspective to use is dependent on whether there is any uncertainty in the outcome (O’Brien 
& Gafni, 1996). That is, if uncertainty exists the ex-ante perspective should be used and 
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where the values are given under conditions of certainty the ex-post perspective is said to be 
most appropriate. However, what is considered to be ex-ante and ex-post varies in the 
literature. It was initially stated that where there is uncertainty, the approach to be considered 
should be ex-ante (Klose, 1999). This can be taken to mean that those at risk of becoming ill 
and those at risk of requiring treatment are ex-ante (Mcintosh et al., 2010, O’Brien & Gafni, 
1996). Therefore some argue that even if patients are considered but have yet to have 
treatment, they are ex-ante as there is uncertainty around the effect of treatment on their utility 
function (McIntosh et al., 2010; O’Brien & Gafni, 1996). Shackley and Donaldson (2000) 
define the ex-post perspective as patients that are diseased, in the process of waiting for 
treatment or currently having treatment.  
 
Whose values? 
As mentioned previously, whose values should be used to value healthcare has also been 
debated. O’Brien and Gafni (1996) state that use value (patients alone) is not consistent with 
theory as the entire population is affected not just patients. Thus both use and non-use (non-
patients) values should be used to account for option value and caring externalities. Smith 
(2003) and Sach et al (2007) determined that use value is most commonly used as patients’ 
values are used, in spite of use and non-use being theoretically preferred in CBAs.   
 
Elicitation techniques 
Several methods for eliciting WTP have evolved. Table 3.2 outlines the main methods and 
provides details of the issues associated with each elicitation method.  
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Table 3.2 WTP elicitation formats 
Elicitation format Elicitation method Methodological issues 
Open-ended questions 
the respondent is asked their maximum 
WTP for treatment 
Questionnaire/ 
interview 
 Large sample required 
 Requires a-priori information on 
distribution of WTP 
A bidding game 
the respondent is asked whether they would 
WTP a certain amount for treatment and this 
amount is varied until the maximum WTP is 
identified 
Interview  Provides value cues – starting point 
bias 
 Large sample 
Closed-ended question 
where the respondent is presented with a 
value and asked if they would be WTP 
Questionnaire/ 
interview 
 Provides value cues – starting point 
bias and yea saying 
 Requires a-priori information on 
distribution of WTP 
Payment scale 
where a vertical list of monetary values are 
presented to the respondents and they are 
asked to circle their maximum WTP 
Questionnaire/ 
interview 
 Provides value cues – range bias 
 Possibly Requires a-priori 
information on distribution of WTP 
WTP; willingness-to-pay 
There are a range of variations to these elicitation methods which are outlined in McIntosh et 
al (2010). Each elicitation method has advantages and disadvantages: some are related to 
introducing bias by providing value cues to patients (all but open-ended), others are related to 
requiring very large sample sizes to obtain an appropriate distribution of WTP (bidding game/ 
closed-ended), or requiring a-priori information on the distribution of WTP to be able to ask 
the questions (bidding game, closed-ended, in some cases payment scale) (Johannesson & 
Jonsson, 1991; McIntosh et al., 2010). The introduction of bias through the provision of value 
cues is an issue in WTP studies because the respondent’s final WTP values are said to be 
influenced by the values presented, and therefore the final WTP value may not reflect their 
true WTP (Whynes et al, 2004). Instead the values elicited are related to the elicitation 
method used. However methods to overcome or limit the potential for bias are suggested in 
McIntosh et al (2010). A disadvantage of the open-ended question format is that it results in a 
large number of protest answers or non-response due to the way in which the question is 
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asked as it provides little guidance (Arrow et al., 1993; Donaldson, 1997b). Protest answers 
relate to the respondent misunderstanding the exercise and refusing to provide a WTP value. 
The payment scale has been shown to have a higher completion rate than the open-ended 
format (Whynes et al., 2003). The payment scale (card) and bidding game are the most 
commonly used elicitation formats (Sach et al., 2007).  
It has also been found that the maximum average WTP differs depending on the elicitation 
method (Frew et al., 2003) and a consensus has not been reached on which elicitation method 
is most suitable. This is one of the obstacles to implementing WTP. Another obstacle is the 
lack of agreement on whether an interview or questionnaire format is most suitable. The use 
of interviews is thought to introduce interviewer bias, whereby individuals may not provide 
their real WTP values and may be influenced by the interviewing situation (Johannesson & 
Jonsson, 1991; McIntosh et al., 2010). Recommendations from environmental economics are 
often used as a basis to suggest that interviews are the most suitable format. However, it can 
be argued that interviews are not required for the following reasons: healthcare goods are not 
as alien to respondents as goods in environmental economics and therefore do not need such a 
rich context of the programme or the market to elicit meaningful WTP values and also 
because private payment is also taken for some interventions (Smith, 2003; Smith, 2006).  
Whether WTP should be elicited as a one off, yearly or monthly payment or in terms of out of 
pocket cost or taxation is another issue of debate. There appears to be no consensus on which 
payment vehicle should be used but it has been found that taxation leads to a greater number 
of protest responses (Donaldson, 1997a; Klose, 1999). The out of pocket payment is the most 
commonly used type when comparing pharmaceutical interventions (Sach et al., 2007). The 
type of payment vehicle used is dependent on whether healthcare is privately or publicly 
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financed, and whether option value, that is providing a valuation to be able to have the 
intervention if the respondent should need it, is elicited.  
As outlined in McIntosh et al (2010) other more general issues that apply to all applications of 
WTP are related to individuals providing inconsistent responses which can be related to: 
 Strategic bias where a respondent values a treatment but provides a protest answer or 
very low value because they think they will have to pay, or the respondent provides a 
high WTP value to ensure the intervention is implemented (Johannesson & Jonsson, 
1991) 
  The embedding effect has been observed where individuals are unable to differentiate 
between two treatments and instead provide a value for any treatment (Kahnemann & 
Knetsch, 1992) 
 The warm glow effect can also occur where true preferences are not elicited but the 
respondent provides WTP values for a good cause and receives moral satisfaction 
from the act (Kahnemann & Knetsch, 1992).  
 
Approach to Costing 
According to welfare (CBA) theory as the benefits are broad and can include both health and 
non-health in so far as they impact on utility, broad costs impacted on healthcare and society 
are also argued to be important to take into consideration in the analysis (McIntosh et al., 
2010). Societal costs include costs to employers which are related to patient time off work due 
to illness (productivity costs) and patient costs associated with travel for healthcare, amongst 
others (Gray et al., 2010). Very few studies have carried out a full CBA in healthcare which 
41 
 
includes costs associated with healthcare and society. A recent (partial) CBA has been carried 
out by Haefaeli et al (2008) in healthcare as part of their feasibility study. The use of societal 
costs is widely debated and the most appropriate method of handling certain societal costs, 
such as productivity costs is not entirely clear. The reason for such a debate is related to 
decision-makers recommending that as healthcare resources are allocated within a fixed 
healthcare budget, costs beyond healthcare are not of primary importance to decision-makers 
(NICE, 2008). However, these costs are important in other countries, such as the Netherlands, 
and are a part of the reference case. It should be noted that productivity costs are more 
commonly and more readily incorporated into CBAs, relative to CUAs, as both costs and 
outcomes are reported in monetary units. As the collection of productivity costs includes an 
additional burden on patients, and decision-makers do not recommend societal costs, they are 
likely to be rarely collected which will mean that they will not be readily available to analysts. 
Further, it should be noted that the incorporation of societal costs is likely to be more 
important for certain conditions, such as those which require carers because societal costs are 
likely to be more prominent in these cases (McIntosh et al., 2010). 
Finally it is widely reported that CBAs lack any reporting guidelines (McIntosh et al., 2010). 
The development of formal guidelines may lead to an increase in CBAs in healthcare. 
 
3.3.2 Extra-welfarist Cost-Effectiveness Analysis and Quality-Adjusted Life Years 
Similar to approaches of WTP and CBA, which comprise the welfarist framework, there are 
also methodological issues with the application of the extra-welfarist approach. Whilst within 
the extra-welfarist framework utility is substituted for health as a measure of assessment of 
welfare change, the notion of utility does still exist as (health) utility-based measures can be 
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used to obtain the measure of change in health following a change in resource allocation. A 
broad range of measures are available to assess change in health-related quality of life (QoL), 
including those specific to particular conditions, and those that are generic. NICE explicitly 
recommend the use of generic outcomes to achieve a level of consistency when making 
resource allocation decisions across healthcare conditions. Specifically, NICE recommend the 
use of the quality-adjusted life year (QALY) as the unit of outcome (NICE, 2008). 
The extra-welfarist framework is applied to the decision-making process through the use of 
economic evaluation either by using the cost-effectiveness analysis (CEA) or the CUA. 
Internationally these terms are used interchangeably, but in the UK a CUA assesses costs and 
outcomes, where the outcome measure used is a QALY. The QALY is a measure that 
incorporates both quality and quantity of life. The patient’s QoL is measured on a (utility) 
scale where 1 represents full health, 0 death and values below zero reflect states worse than 
death (Drummond et al., 2005). The utility value is then combined with information on length 
of life to estimate QALYs. Unlike the CBA, in CUAs only costs are measured in monetary 
terms as outcomes are measured in QALYs. Data on costs and QALYs are combined to 
compare the associated costs and outcomes of the new intervention against standard practice. 
Interventions that lie within an arbitrary threshold of £20,000 to £30,000 per QALY are 
considered to be cost-effective and should be implemented in clinical practice (NICE, 2008). 
The advantages of the QALY are related to health utilities being derived using the same 0 
(death) to 1 (full health) anchors, so the QALYs gained across a range of conditions can be 
compared (Gold et al., 1996). Further, the length of time spent in a state is assessed in 
combination with the health related utility associated with the state. However, further to 
concerns discussed in the theoretical section about using health alone in the evaluative space, 
Tsuchiya and Dolan (2005) identified issues specific to the use of QALYs. These include 
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concerns with the assumption that the value of a health state is constant irrespective of time 
spent in the health state and that the value of the health state is independent of subsequent or 
prior health states. 
Possible methods for eliciting utilities and generating QALYs are outlined in Figure 3.1 and 
are discussed next. 
 
Direct elicitation methods 
The utility value for different health states is derived through the use of preference-based 
measures. This valuation or weighting of health states is related to utility theory and therefore 
produces (health) utilities. Individuals are provided with a description of a health state and 
then directly or indirectly express their preferences for that health state. The recommended 
measures used to elicit these preferences are those that are choice based including time trade 
off (TTO) and standard gamble (SG), with standard gamble being the most in line with the 
von- Neumann-Morgenstern utility theory (Drummond et al., 2005; von Neumann-
Morgenstern, 1944). A third measure, which will not be discussed in detail, is the rating scale 
Method of obtaining health utilities 
Standard 
gamble/ 
Time trade off 
Generic 
preference 
based measures 
Condition specific 
preference based 
measures 
 
Mapping 
Figure 3.1 Summary of key methods to derive utilities in extra-welfarism 
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and the most common is the visual analogue scale (VAS) (Parkin & Devlin, 2006). The VAS 
is not choice based and is thought to provide weaker evidence than the other measures 
(Brazier & Rowen, 2011). Choice based measures such as SG and TTO are the preferred 
methods and are recommended by NICE because they incorporate opportunity cost into the 
assessment, with SG also taking into account risk attitudes. 
Standard gamble uses risk and probability to assign weights. The technique presents an 
individual with a choice between two alternative health states. As shown in Figure 3.2, a poor 
health state is presented to the individual; they can either remain in this state or have an 
intervention that has a probability of returning to a health state in full health, and a probability 
of immediate death. Utility values are assigned to the described poor health state by 
identifying the probability at which the individual is indifferent between the alternative 
options (Drummond et al., 2005).  
 
 
 
 
 
 
 
 
Option 1 
Death 
Full health 
(p) 
1-(p) 
Option 2 
Current (poor) 
state 
Figure 3.2 Illustration of SG (based on Drummond et al., 2005) 
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Time trade-off differs to SG in that uncertainty and probability is not used (Torrance, 1976). 
As shown in Figure 3.3, an individual is presented with a poor health state for a certain 
amount of time, and a health state in full health for a shorter period of time. The time in full 
health is varied to identify the point at which the individual is not willing to trade off any 
more years of life in full health to move out of the poor health state. The utility value is then 
obtained by calculating the amount of time at which the individual is indifferent and the 
utility for the poor health state is estimated by the amount of time in full health state divided 
by the amount of time in the poor health state (Drummond et al., 2005). For example, 20 
years in full health is equivalent to 40 years in poor health (20/40=) 0.5 utility value.  
  
 
 
 
 
 
 
In the UK, preferences are elicited using values derived from the community, as NICE states, 
utilities should be based on the general public preferences and not the condition-specific 
patient’s preferences alone (NICE, 2008). 
When both SG and TTO are used, the respondent is asked to imagine they are in the health 
states and provide their own values, similar to use values for WTP. Similar to the welfarist 
Full health 
Death 
Poor health 
state 
1.0 
0 
Time T1 T2 
Option 1 
Option 2 
Figure 3.3 Illustration of TTO (based on Drummond et al., 2005) 
0.5 
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WTP, the elicitation of preferences using SG and TTO have also been found to produce 
different results (Tsuchiya et al., 2006). The way in which the SG and TTO are presented also 
lead to different results not only between the methods but also within the same choice based 
technique. This effect is also observed with WTP (Dolan, 1997).  
 
Indirect elicitation methods – generic measures 
Typically, utility values are not derived for every possible health state associated with all 
diseases and conditions using these direct methods. Instead multi-attribute utility instruments 
(MAUI) such as the EuroQol-5 Dimension (EQ-5D) are used. Currently EQ-5D is 
recommended by decision-makers (NICE, 2013). Generally, these multi-attribute systems are 
generic and therefore present descriptions of health states that can be used and compared 
across conditions. Thus, weights, based on preferences, are assigned to alternative 
characteristics of health states and are then used to optimally allocate resources in order to 
maximise health (Coast et al., 2008b).  
A questionnaire is constructed with a set of health related domains or attributes (i.e. mobility, 
pain, self-care, as in EQ-5D) and each domain has a set of levels (3 or 5 for EQ-5D) to 
describe the extent of the problem associated with each domain. Information from patients 
was then used to generate a set of descriptions for a range of health states. The general 
population then valued a sub-set of these health states using either SG or TTO (EQ-5D uses 
TTO) and an algorithm was applied to generate values for the remaining health states. Thus, 
each possible health state associated with the questionnaire has a utility value assigned to it. 
The patient with the condition under investigation is then able to complete the questionnaire 
and an analyst can attach a utility value for the patient’s health state by using the appropriate 
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algorithm, which accounts for public preferences, to obtain an overall EQ-5D utility index 
score for the patient (Dolan et al., 1995). This overall utility score is then multiplied by the 
length of time the patient spends in the health state in order to produce a QALY.  
Currently, there is a range of generic health related utility-based QoL instruments (multi-
attribute systems) available that can be used in all conditions. These measures are used in 
CUAs and include, EQ-5D (5L and 3L); Short Form 6 dimension (SF-6D), Health Utility 
Instrument (HUI2 &3); the Assessment of QoL (AQOL), and 15D (Drummond et al., 2005).  
Unlike the other preference based measures discussed previously, SF-6D was not originally 
designed as a preference based measure. That is, SF-6D was developed from a non-preference 
based measure (SF-36). SF-6D was developed by obtaining preference weights, using SG 
from the general population, for the various attributes to assess the strength of preference for 
the different health states (Brazier et al., 1998). Hence, SF-6D is generated by mapping 
(explained later) the non-utility based Short Form-36 (SF-36) or SF-12 on to SF-6D. Table 
3.3 describes the measures that have UK value sets for the adult population. 
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Table 3.3 Generic preference based measures with adult UK value sets 
Instrument Attribute Recall period Preferences Scoring 
EQ-5D 
(hrQoL) 
1. Mobility 
2. Self care 
3. Usual activities 
4. Pain/ Discomfort 
5. Anxiety/Depression 
 Health today TTO  Each item rated on a 3 or 
5 point scale depending 
on measure used: 
1. No problems 
2. Some problems 
3. Unable 
Or 
1. No pain/anxiety 
2. Moderate pain/anxiety 
3. Extreme pain/anxiety 
5L 
1. No problems 
2. Slight problems 
3. Moderate problems 
4. Severe problems 
5. Unable 
 
SF-36/ SF-
12 (hr QoL) 
1. Physical functioning 
2. Role physical 
3. Bodily pain 
4. General health 
5. Vitality 
6. Social functioning 
7. Role – emotional 
8. Mental health 
 In general 
 Past 4 weeks 
N/A Must first be mapped onto 
SF-6D in order to be used 
in a cost-utility analysis 
Can be summarised into; 
1. Mental health (MCS) 
2. Physical Health (PCS) 
SF-36 has 36 questions, 
whilst SF-12 covers the 
same attributes but has 
only 12 questions 
SF-6D 
(hrQoL) 
1. Physical functioning 
2. Role limitations 
3. Social functioning 
4. Pain 
5. Mental health 
6. Vitality  
N/A – mapped from 
SF-36/SF-12 
SG Each item rated on a 4-6 
point scale 
Algorithm provided by 
John Brazier 
HUI2 
(hrQoL) 
1. Sensory 
2. Mobility 
3. Emotion 
4. Cognition 
5. Self-care 
6. Pain 
 Current – 
specific recall 
period or 
 Usual health 
VAS mapped 
onto to SG 
Each item rated on a 4-5 
point scale 
 
Hrqol; health related quality of life, N/A; not applicable, TTO; time trade off, SG; standard gamble, VAS; Visual 
analogue scale. (Adapted from Brazier & Rowen, 2011) 
 
Despite NICE recommending EQ-5D to generate QALYs as a reference case, it is recognised 
that EQ-5D may not be appropriate in all cases (NICE, 2008). When EQ-5D is not appropriate 
NICE recommend that a choice based method be used (Brazier & Rowen, 2011; NICE, 2008). 
EQ-5D may not be suitable because it may not be sufficiently sensitive or relevant for all 
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conditions. Brazier et al (2004) have shown that ceiling effects have been observed, where 
many respondents have scored the highest level of EQ-5D. It is also recognised that some 
researchers and clinicians do not consider EQ-5D to be a suitable measure, as clinicians are 
typically interested in condition specific outcomes (Brazier & Rowen, 2011). It has been 
found that the two most commonly used preference based measures SF-6D and EQ-5D do not 
generate the same results. The utility values for the same patient have been shown to differ 
and the reasons for this are likely to be related to the measures capturing different aspects of 
QoL and the valuations for the utilities being derived by different methods i.e. SG for SF-6D 
and TTO for EQ-5D (Brazier et al., 2004, Whitehurst & Bryan, 2011). Whitehurst et al (2011) 
also showed that at a group level, the mean values differ which provides warnings against 
drawing comparisons between studies that have used SF-6D and those that have used EQ-5D. 
Furthermore, the degree of the cost-effectiveness of competing interventions has also been 
shown to differ across the two measures (Davis et al., 2012; Sach et al., 2009). 
 
Indirect elicitation methods – disease-specific measures 
When a generic utility based measure is not considered to be suitable for a condition, disease-
specific utility based measures are increasingly developed (Drummond et al., 2005). Due to 
their nature, disease-specific measures are more sensitive to changes than generic measures. 
There is a range of condition specific preference based measures available. For NICE to use 
the condition specific measure it must: 
1. Focus on condition-specific health related QoL, not just on symptoms of the condition 
2.  The valuations of the states must be provided from the UK general population 
3.  Choices should be based on SG or TTO  
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4.  The measures must be anchored by (0) death and (1) full health as generic measures, 
to be able to generate QALYs (Brazier & Rowen, 2011). 
However, condition-specific utility-based measures are typically anchored by full health (1) 
and the worst possible state for the condition (0), rather than full health (1) and death (0) as in 
generic measures. The disease-specific Menorrhagia Multi-attribute Scale (MMAS), 
discussed in Chapter 2, falls into this category (Shaw et al., 1998). These types of measures 
cannot be used to generate QALYs, which are currently recommended by decision-makers, as 
mortality has not been taken into consideration when the preference based technique was 
conducted. Further, patient values, rather than the general population values are typically 
used, despite NICE’s recommendations for UK general population values. A specific obstacle 
for the wide use of MMAS is that the choice based method used was not based on SG or 
TTO. Currently economic evaluations which use measures such as MMAS, which cannot 
generate QALYs, are considered to be sophisticated CEAs (Drummond et al., 2005). At the 
very least, as preferences for the different health states have been identified, incremental 
changes on the disease-specific scale can be considered to be more meaningful than changes 
on non-preference based disease-specific measures. An increase in score does mean a 
preferable change to a ‘better’ state than previously, enabling scores across respondents to be 
more readily compared (Brazier, 2005).  
Preference based condition specific measures for cancer and asthma that do meet NICE’s 
criteria have been developed (Brazier & Rowen, 2011; Yang et al., 2011). Recent studies have 
placed valuations for health states on the typical 0 (death) to 1 (full health) scale using the UK 
general population values, enabling the generation of QALYs (Brazier & Rowen, 2011). In 
these cases the disease-specific utility based measures provide the benefits of utility measures, 
enabling comparisons to be made across conditions, and the sensitivity required for the 
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specific condition (Drummond et al., 2005). However, much research has yet to be carried out 
within this area before it can become a viable alternative to generic utility-based measures. 
Concerns with condition specific preference based measures typically include their limited 
ability to incorporate co-morbidities and side effects and some measures can also be criticised 
for overly focussing on domains that are specific to the condition and not on domains that are 
unaffected by the condition, which could lead respondents to overstate values (Brazier & 
Rowen, 2011).  
 
Mapping  
Mapping is typically considered to be the process of obtaining values for a utility based 
instrument from a non-utility based measure (Brazier et al., 2010). In cases where generic 
preference based measures are not appropriate for a particular condition and condition 
specific preference based measures are not available, non-utility based measures can be used 
to generate utilities by mapping. This can be carried out by either mapping, also known as 
‘cross-walking’, the results of the condition-specific measures or indicators onto preference 
based measures, such as EQ-5D. A robust mapping method requires the collection of both the 
utility based measure (i.e. EQ-5D) and the condition specific measures, or indicators, (i.e. 
MMAS) to generate an algorithm that predicts the relationship between the measures, for 
example, enabling MMAS to be mapped onto EQ-5D. This algorithm can then be applied to 
any study where a condition-specific measure or indicator has been used and a utility based 
measure has not. As utilities are not directly elicited and mapping relies on the robustness of 
the algorithm, it is recognised to be the ‘second-best’ approach to generating utilities 
(Longworth & Rowen, 2013). A further limitation of mapping is that a prior sample study 
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must be available to establish the relationship between the measures before a condition 
specific measure can be mapped onto a utility based instrument. Further, in some cases it is 
not possible to carry out mapping where there is insufficient overlap in the descriptive content 
of the measures (Longworth & Rowen, 2013).  
Box 1 outlines the key recommendations provided by NICE for valuing health states and 
generating QALYs. 
  
Box 1. NICE recommendations (adapted from Brazier & Rowen, 2011) 
MAUI; multi-attribute utility instrument, SG; standard gamble, TTO; time trade off. 
 
It is clear from the discussion presented here on extra-welfarist measures, that more applied 
research has been carried out and reported in extra-welfarism than in welfarism, as 
prescriptive guidelines have been produced on how to report and conduct CUAs. Many CUAs 
have been carried out in the vast majority of disease areas to value interventions for decision-
makers. These evaluations are primarily taken from a healthcare perspective and not a societal 
perspective, for reasons mentioned previously, despite some researchers advocating the use of 
the societal perspective for a CUA to ensure decision-makers are presented with all available 
information (Brouwer et al., 1997; Sculpher, 2001).   
Key NICE recommendations for valuing outcomes: 
1. Choice based method using either SG or TTO and UK general population values in a generic 
MAUI to generate QALYs 
 Specifically EQ-5D to enable comparability (the use of any other technique must be 
justified including SF-6D)  
 Condition specific MAUI (valued using SG/TTO) using UK general population values 
 Mapping based on empirical data, not opinion 
 Additional analyses using condition-specific measures and patients values can be used where 
justification is provided.  
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Table 3.4 presents a summary of the outcomes and economic evaluations associated with the 
welfarist and extra-welfarist framework. 
 
Table 3.4 Summary of application of welfarist and extra-welfarist approaches 
Framework Economic 
evaluation 
Efficiency Outcome Method of obtaining preferences 
Directly Indirectly 
Extra-welfarism CUA:  productive 
efficiency 
QALY*  TTO 
 SG 
 EQ-5D* 
 SF-6D 
 Preference based 
condition specific 
 Mapping 
Welfarism CBA:  allocative 
efficiency 
Monetary 
amount 
 CV 
 DCE 
 
 
 Revealed preferences 
*recommended by decision-makers. CV; contingent valuation, QALY; quality adjusted life year, CUA; cost-
utility analysis, CBA; cost-benefit analysis; DCE, discrete choice experiment 
 
3.3.3 Vehicles for Economic Evaluation 
Decision-modelling can also be used as a vehicle to carry out an economic evaluation. The 
costs and outcomes are entered into the model, and it is used to determine the cost-
effectiveness of alternative interventions. The use of decision-models can be thought of as 
‘providing a framework for decision-making under conditions of uncertainty’ (Drummond et 
al., 2005 pp 276). Decision-modelling is increasingly applied to healthcare decisions due to 
the advantages which are outlined by Buxton et al (1997). For example, when economic 
evaluations of competing interventions are required and economic data are not collected 
alongside a trial, decision-models can be used to synthesise data on costs and effects from 
multiple sources (Buxton et al., 1997). Further, when trial data are available but the trial time 
horizon does not reflect the full disease process, decision models can be used to project costs 
and outcomes beyond the trial time horizon (Buxton et al., 1997). Hence they can be used to 
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determine the long-term cost-effectiveness of interventions. Drummond et al (2005) also 
noted that decision-models can be used to identify gaps in current evidence by assessing 
uncertainty, therefore informing further research. It is stated by Briggs et al (2006) that 
decision-models can be used in both CBAs and CUAs, however the current evidence would 
suggest that decision-models have primarily been used in an extra-welfarist framework. 
Hence Brennan et al (2006) state that the model-based economic evaluation output typically 
includes the costs of the competing treatments and the QALYs accrued by each intervention.  
Decision-makers have recognised the benefits of decision-models and have incorporated their 
use into the guidelines for economic evaluations (NICE, 2004). NICE state that decision-
models can be used to inform decision-making where appropriate. The assumptions of the 
model and its justification must be presented in the report along with an assessment of the 
structural uncertainty of the model and the uncertainty associated with the model input. 
Guidelines of good practice in modelling have been developed by Philips et al (2004) and are 
expected to be followed. However the structure of the model is dependent on the ability of the 
analyst to reflect the disease pathway adequately and the availability of data (Brennan et al., 
2006).   
There are several types of models, which include those that model cohorts of patients, such as 
decision trees and Markov models where the average values for all patients is obtained and 
those that model at the individual patient level, such as individual sampling models (Brennan 
et al., 2006; Briggs et al., 2006). Each type of model has its own properties and assumptions. 
Each will be discussed in turn next: 
1) The decision tree is one of the most commonly used decision models and is also one 
of the most simplistic. The alternative treatment options for the disease are first 
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presented and from there on the subsequent pathways or events associated with that 
treatment, such as improvement in health or death, are presented with the associated 
probabilities of each occurring (Briggs et al., 2006). The decision tree then presents 
the subsequent pathway associated with each event, i.e. improved health or death. 
Hence the probability of subsequent events occurring is dependent on previous 
events. The mean value is then calculated by multiplying the probabilities for each 
event by the costs and outcomes for each treatment (Brennan et al., 2006). However, 
there are limitations associated with the decision-tree as it does not allow for 
recurrent events. The amount of time spent in each state is also not taken into account 
and the decision-tree does not readily allow for complex disease pathways, with 
multiple consequences, that occur over a long time horizon (Briggs et al., 2006).  
 
2) A Markov model reflects several health states or consequences of treatment, where 
the probability of transitioning between health states occurs according to the time 
cycle of the model (Briggs et al., 2006). The time cycle reflects a set period of time 
in which transitions between health states can occur i.e. on a monthly basis. Each 
state is then given an average cost and outcome, which is summed and multiplied by 
the proportion of people in each state. Markov models are therefore used for more 
complex disease pathways and when recurrent events are required to be modelled. 
However, the limitation of these models is the Markov assumption that patient 
history is not taken into consideration, as the prior health states and the amount of 
time since transitioning to the subsequent states are not taken into account (Briggs et 
al., 2006). These assumptions can be overcome, but the analysis becomes complex 
and the limitations are outlined by Briggs et al (2006). 
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3) Individual sampling models are the most complex of the three key models 
discussed here and build upon the limitations of the previous models. As mentioned 
previously, individual sampling models are used to model patients at the individual 
level. Hence, future transitions to health states can be dependent on the patient’s 
history, which in turn will have an effect on costs and QoL (Briggs et al., 2006). 
However, these models do require a vast amount of data, are computationally 
complex and it has been suggested that they do not easily allow for a comprehensive 
assessment of uncertainty in the parameters to be carried out through sensitivity 
analysis (Briggs et al., 2006).  
 
The uncertainty of results obtained from decision-models can be assessed in sensitivity 
analyses. These can be either deterministic or probabilistic. In a deterministic sensitivity 
analysis, model parameters are changed individually. Hence one parameter is changed and the 
others are not (Andronis et al., 2009). In probabilistic sensitivity analyses, model parameters 
are altered simultaneously according to a given distribution. Each parameter is assigned a 
distribution and a value for each parameter is randomly drawn from the distribution and the 
effect on the cost-effectiveness of varying multiple model parameters can then be assessed 
(Briggs, 2000). 
 
3.4 Conclusion 
In this chapter the two main theoretical foundations behind economic evaluations and their 
methodological considerations have been discussed. The concerns related to applying both 
welfarist and extra-welfarist theoretical frameworks in practice outlined and the similarities in 
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the issues associated with the application of the frameworks, described. It is explained that 
due to the perceived reliance of the welfarist framework on ability to pay, amongst other 
things, the extra-welfarist approach is recommended in the UK. 
As the condition of menorrhagia has been described in Chapter 1 and the potential outcome 
measures that can be used to assess changes in QoL for economic evaluation outlined here, in 
the next chapter a systematic review on the economic evaluations conducted in menorrhagia 
using utility-based measures is provided.  
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CHAPTER 4. SYSTEMATIC REVIEW: ECONOMIC EVALUATIONS 
IN MENORRHAGIA 
 
4.1 Introduction 
This chapter presents a systematic review of pharmaceutical interventions for menorrhagia. 
The objective of the review is to assess the evidence on cost-effectiveness for the different 
pharmaceutical interventions for menorrhagia, including levonorgestrel-releasing intrauterine 
system (LNG-IUS). The focus is on pharmaceutical interventions because surgical 
interventions are no longer recommended as first line treatment for menorrhagia. It is 
necessary to conduct this systematic review in order to collate the existing evidence on cost-
effectiveness, identify any limitations of studies, conflicting results or methodologies, and 
areas of uncertainty that should be investigated prior to conducting the economic evaluation 
alongside the ECLIPSE trial. It is intended that the evaluations or model structures identified 
in this review could then be used to inform the economic evaluation for the ECLIPSE trial. 
The National Institute of Health and Care Excellence (NICE) issued clinical guidelines on 
heavy menstrual bleeding in 2007. As an economic evaluation is reported in the NICE 
guidelines, it is critiqued along with the other studies identified, but first the main 
recommendations from the NICE guidelines are briefly described in section 4.1.1. Following 
the summary of the NICE guidelines, the methods of the review are described including 
eligibility criteria, search strategy and data extraction criteria. The results are then reported as 
a critique of the studies, followed by the discussion and conclusion. 
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4.1.1 NICE Guidelines 
It is important to summarise and critique the NICE guidelines for menorrhagia because they 
are developed to provide recommendations on which treatments should be used in clinical 
practice. To provide these recommendations, NICE commissioned a systematic review of the 
literature on treatment effects and cost-effectiveness in menorrhagia to be carried out. 
Typically, in areas where there is little evidence available on cost-effectiveness, an economic 
evaluation is conducted and reported as part of the NICE guidelines. The NICE review 
identified one study that considered the cost-effectiveness of LNG-IUS compared to a 
hysterectomy (Hurskainen et al., 2004). No studies considering the cost-effectiveness of the 
other pharmaceutical treatments (combined oral contraceptives, oral progestogens, tranexamic 
acid, mefenamic acid and norethisterone) in menorrhagia were found. An economic 
evaluation was therefore conducted to determine the cost-effectiveness of all the currently 
available treatments for menorrhagia (NICE, 2007).   
The results in the NICE guidelines showed that when the need for contraception is not taken 
into account and all of the pharmaceutical treatments (LNG-IUS, mefenamic acid, tranexamic 
acid and combined oral contraceptives) are compared against watchful waiting, LNG-IUS is 
most cost-effective (NICE, 2007). When hormonal treatment (LNG-IUS and combined oral 
contraceptives) is compared to surgical treatment (hysterectomy and endometrial ablation), 
LNG-IUS is the most cost-effective. When contraception is not sought and non-hormonal 
treatment (mefenamic acid and tranexamic acid) is compared to watchful waiting, tranexamic 
acid is found to be the most cost-effective intervention. The results of the sensitivity analysis 
showed that the policy decision did not change in any case. A summary of the NICE 
recommendations is presented in Box 4.1. 
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Box 4.1 Summary of NICE recommendations (NICE, 2007) 
LNG-IUS; levonorgestrel-releasing intrauterine system, QoL; quality of life 
 
4.2 Methods 
The guidelines by the Centre for Review and Dissemination and Cochrane Collaboration for 
Reviews were followed in the review reported in this chapter (CRD, 2009; Higgins & Green, 
2009).   
The literature is updated using June 2006 as a starting point. Reasons for updating the 
literature are explained in section 4.5.2. In the process of updating the review in June 2013, 
two other systematic reviews within the area were identified (Blumenthal et al., 2011; 
Gemzell-Danielsson et al., 2013). After reading these reviews it was still deemed necessary to 
carry out the systematic review reported in this chapter as neither had assessed the quality of 
the available evidence. Further details of these published reviews are discussed in section 
4.5.2 of the discussion.  
Summary of NICE Recommendations 
 
1. LNG-IUS as first line treatment; 
2. Second line treatment is either tranexamic acid, mefenamic acid or combined 
oral contraceptives; 
3. Third line is oral progestogens (norethisterone), or injected progestogen;   
4. Where pharmaceutical treatments are unsuccessful, the woman does not want to 
conceive and QoL is severely impaired, surgical interventions should be 
considered.  
a. First line surgical treatment is endometrial ablation  
b. A hysterectomy should only be considered as a final option.   
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4.2.1 Eligibility Criteria 
Since the objective of the review was to assess the evidence on cost-effectiveness for 
pharmaceutical treatments in menorrhagia, studies were included in the review if they met the 
following criteria:  
i. Report an economic evaluation, such as a cost-utility analysis (CUA) (termed cost-
effectiveness analysis in international studies), cost-benefit analysis or effectiveness 
studies that assess costs and include a measure of quality of life (QoL), willingness-to-
pay (‘WTP’) 
ii. The interventions compared must include either LNG-IUS, combined oral 
contraceptives, tranexamic acid, mefenamic acid, norethisterone or long-acting 
progestogens for menorrhagia. Therefore, if a pharmaceutical intervention is compared 
to a surgical intervention the study is eligible for inclusion in the review.    
 The population of interest was women with menorrhagia 
 Studies that focused on adolescents (less than 15 years old) were not included. If 
menorrhagia is experienced in adolescents, it is likely that it will subside after puberty and 
the typical population of sufferers are predominantly women approaching menopause 
(Duckitt & Shaw, 1998) 
 Studies involving patients with adenomyosis and endometriosis were excluded because 
menorrhagia is typically secondary to another symptom  
 Studies including women with bleeding disorders such as Von Willebrand disease were 
excluded because the relationship between the impact of this on QoL compared to the 
impact of menorrhagia alone on QoL has yet to be established and treatment for the 
condition differs (James et al., 2004; Kujovich, 2005).  
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In all other cases, studies were included if menorrhagia was the presenting complaint.  
 
4.2.2 Databases and Search Terms 
In November 2010, the following databases were searched from 2006 onwards; Medline 
(1946 onwards), EMBASE (1947 onwards), PsycINFO (1967 onwards), Social Science 
Index, SSCI, Database of Abstracts of Reviews of Effects and NHS EED. Reference lists 
from eligible studies that were selected were also reviewed. The review was updated in June 
2013.  
The search terms used were heavy menstrual bleeding or menorrhagia or HMB and cost or 
economic and levonorgesterel releasing intrauterine system or LNG-IUS or levonorgesterel 
intrauterine system or oral contraceptive or tranexamic acid or mefenamic acid or 
progestogen or norethisterone. Both index terms and free text terms were used. Search terms 
used for each database including Boolean operators are presented in Appendix 1.1. The results 
were managed using Reference Manager Software (version 12). 
 
4.2.3 Selection of Papers for Review 
The review of the papers followed a two-stage method used by Mugford (1996) which has 
subsequently been established and described elsewhere (Bricker et al., 2000; Roberts et al., 
2002). Firstly each study was categorised based on the title and abstract using the eligibility 
criteria. Then the full paper was obtained if the title and abstract was deemed relevant. Where 
no abstract was available, the full paper was obtained. All studies were reviewed in both 
stages by this author. To validate this process, 20% of the titles and abstracts were 
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independently reviewed by two other researchers (Tracy Roberts and Emma Frew). All of the 
investigators were blind to the categorisation decisions.  
 
Stage 1 – Initial Categorisation of studies 
The following criteria were used to assess the relevance of each study in the first stage of the 
review: 
A) Primary research is reported and includes an economic evaluation 
B) The study discusses the economic aspects of care and contains useful primary or 
secondary cost or utilisation data  
C) The study may have useful information but does not obviously fall into (A) or (B) 
D) The study has no relevance 
Studies in category (A) and (B) were considered relevant to the systematic review. 10% of the 
studies in category (C) were reviewed for relevance and those studies in category (D) were 
not reviewed any further.  
 
Stage 2 – Further categorisation 
The studies categorised in (A), (B), and (C) were further categorised after reading the entire 
article into the following categories: 
1. Economic Evaluation  
2. Cost study which reports QoL 
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3. Review article, describes results of previously published economic data 
4. Not relevant 
Studies classified into A(1), A(2), B(1) and B(2) were carried forward and assessed according 
to their quality.  
 
4.2.4 Data Extraction and Management 
The quality of the economic evaluations was assessed according to the recommended criteria 
presented in Drummond et al (2005) as it is more comprehensive than other available 
checklists. Where a decision model was used, the study was assessed according to the 
recommended criteria outlined in the checklist by Philips et al (2004). Data were then 
extracted from all of the studies with an indication of the quality of the study. The data 
extraction criteria based on the key areas of the checklists is presented in Table 4.1. In 
addition to the key criteria in the checklists, the country of the study, funding source and 
whether the mean or median values were used as data sources in the model were also 
assessed, though the country of study and funding source were not used to assess the quality 
of the studies but were extracted for discussion purposes. Data extraction was managed in 
Microsoft Excel (v2010).  
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Table 4.1 Data extraction criteria 
Criteria Justification 
Country  
It is important to determine generalisability and 
whether the data sources are appropriate for the 
country of the study. 
Currency  
 
Was the currency reported suitable based on the 
data source used? Are the findings generalisable to 
other settings? 
Primary or secondary study? 
 
The findings from primary data can be considered 
to be more robust, provided the study is carried out 
appropriately. 
Data source 
Where is data taken from for costs, outcomes and 
transition probabilities? Was the source suitable in 
terms of country? The validity of the study is 
limited if evidence is taken from unsuitable sources 
and extrapolated.  
Costs 
Was the most current cost year for the study used? 
Were all data inflated to the same price year? Were 
discount rates applied as is widely recommended? 
Perspective of the analysis 
Healthcare service or societal perspective? Are the 
data used consistent with perspective? 
Outcome measures 
 
Are QALYs or WTP the main outcome measure? 
How were QALYs derived, was the same valuation 
method used for all utility inputs? There is 
evidence to show that the results of the different 
valuation methods are not comparable. 
Mean or Median values used   
Are utility data based on medians or mean values? 
Is justification provided for the value used? 
Model type 
 
The use of the most suitable model type will ensure 
a valid economic evaluation. 
Model structure 
How was the model structure determined? Theory? 
Prior models? Expert opinion? 
Model time horizon 
 
Is the model time horizon suitable for the theory of 
the treatments and menorrhagia? 
Model cycle 
 
Does the model time cycle allow for costs and 
outcomes to be captured accurately?  
Key model assumptions Are they suitable? Determines validity of findings. 
Uncertainty analysis 
Has a comprehensive sensitivity analysis been 
carried out using one-way and probabilistic 
sensitivity analysis?. Were appropriate sampling 
distributions used? 
Funding source 
Was the study funded by the manufacturer of the 
pharmaceutical interventions or was it 
independent? 
Interventions 
 
Which pharmaceutical interventions have been 
assessed in the evaluation? 
Study size 
In primary data studies was the sample sufficient to 
provide robust results? 
Most cost-effective intervention 
Which intervention was shown to be most cost-
effective? 
QALY; quality adjusted life year, WTP; willingness-to-pay 
 
66 
 
4.3 Results 
The literature search identified 180 articles. 114 articles were screened and 17 of these were 
considered to be potentially relevant. Figure 4.1 illustrates the flow of papers from the initial 
electronic search to the number included in the review. Seven studies were assessed according 
to the quality criteria. Six of these studies were economic evaluations and used secondary data 
(Clegg et al., 2007; Ganz et al., 2013; Lete et al., 2011; NICE, 2007; Roberts et al., 2011; You 
et al., 2006). The one remaining study used primary data on costs and QoL but did not 
combine this information (Brown et al., 2006). All studies used decision-model based 
economic evaluations. The most robust study was carried out by Roberts et al (2011). This 
was an academic study that used secondary data and was carried out from a UK health service 
perspective. Roberts et al (2011) found hysterectomy to be the most cost-effective 
intervention, compared to endometrial ablation and LNG-IUS. They did not consider other 
non-surgical interventions. However, the utility values used in the model were combined from 
studies in different countries (Finland and the UK) and included values from EQ-5D and a 
direct TTO valuation method. These limitations will be discussed in section 4.4. 
Of all the studies that reached the quality assessment stage of the review, it can be seen that 
only one study has used primary data to inform the model (Brown et al., 2006). However, the 
outcomes were not presented in terms of quality adjusted life years (QALYs) as the SF-36 
values were not mapped onto SF-6D. Three studies were carried out in the UK, including the 
NICE guidelines (Clegg et al., 2007; NICE, 2007; Roberts et al., 2011) and all of the studies 
used a decision model. Two studies found hysterectomy to be most cost-effective (You et al., 
2006; Roberts et al., 2011) whilst the remaining studies found LNG-IUS to be most cost-
effective. 
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The seven studies that reached the quality assessment stage will be assessed in this section. 
Details of the seven studies can be found in Tables 4.2 and 4.3. The discussion of the articles 
will be divided into the following areas: model features, model inputs, study perspective, 
effectiveness measure, mean/median, sensitivity analysis and funding source. It is necessary 
to discuss the key issues that arose in each of the studies that reached the quality assessment 
stage of the systematic review, thereby ensuring these issues are not repeated in subsequent 
economic evaluations. Further details of the issues related to the quality of the studies are 
presented in Appendix 1.2. The more specific concerns with the NICE guidelines will then be 
discussed separately as the findings reported in the guidelines carry a considerable weight 
when informing clinical practice. 
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*Both the HTA report and the publication relating to the same cost-effectiveness study were identified. 
Articles identified from 
electronic searches 
(n=177) 
Duplicate studies (n=66) 
 HTA report* (n=1) 
  
Excluded studies following 
screening of title and abstracts 
(n=97) 
Not relevant (n=91) 
Maybe useful (n=6) 
Potentially relevant full text articles retrieved for 
more detailed evaluation 
(n=17) 
Studies excluded following detailed 
evaluation 
Not relevant (n=10) 
Studies included in the review 
(n=7) 
Articles identified from other 
sources 
(n=3) 
Articles screened  
(n=114) 
Figure 4.1 Flow of papers through study 
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Table 4.2 Data extracted from relevant studies 
Study Year Final 
Classification 
Country Currency Data 
Source 
Perspective Effectiveness 
Measure 
Mean/ 
Median 
Model 
Type 
Uncertainty 
Analysis 
Funding 
Source 
            
Clegg et al 2007 A1 UK UK £ Secondary 
data 
Healthcare 
provider 
QALYs: EQ-
5D & TTO 
Mean 
& 
Median 
Markov One-way & 
PSA 
Manufacturer 
of LNG-IUS 
NICE 2007 A1 UK UK £ Secondary 
data 
Healthcare 
provider 
QALYs: EQ-
5D & 
RAND36 
Mean Markov One-way  
Roberts et 
al 
2011 A1 UK UK £ Secondary 
data 
Healthcare 
provider 
QALYs: EQ-
5D & TTO 
Mean Markov One-way & 
PSA 
Academic 
You et al 2006 A1 Hong 
Kong 
US $ Secondary 
data 
Healthcare 
provider 
QALYs: 
TTO 
(Sculpher) 
Median Markov One-way & 
PSA 
Academic 
Brown et al 2006 A2 New 
Zealand 
NZ $ Primary 
data 
Direct & 
Indirect 
SF-36 Mean Decision 
tree 
One-way Academic 
Ganz et al  2013 A2 US US $ Secondary 
data 
US payer 
perspective 
QALYs: EQ-
5D 
Mean Individual 
sampling  
One-way & 
PSA 
Manufacturer 
of LNG-IUS 
Lete et al 2011 A2 Spain ESP € Secondary 
data 
Healthcare 
provider 
QALM: TTO 
(claimed EQ-
5D); SFM 
Mean Markov One-way & 
PSA 
Manufacturer 
of LNG-IUS 
LNG-IUS; levonorgestrel-releasing intrauterine system, PSA; probabilistic sensitivity analysis, QALY; quality adjusted life year, QALM; quality adjusted life month; 
SFM; symptom free months, TTO; time trade off 
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Table 4.3 Data extracted from relevant studies continued 
Study  Interventions Model cycle  Model time horizon Study size Most cost-effective 
Clegg et al LNG-IUS/ Hysterectomy/ EA 1 month 5 years n/a LNG-IUS 
NICE LNG-IUS/Surgery/ Oral 3 months 5 years n/a LNG-IUS 
Roberts et al Hysterectomy/ EA/ LNG-IUS 1 month 10 years n/a Hysterectomy 
You et al Hysterectomy/EA/LNG-IUS/ 
Oral 
1 year 5  years n/a Hysterectomy 
Brown et al LNG-IUS Vs TBEA  n/a 2 years 70 LNG-IUS 
Ganz et al LNG-IUS/surgery/non-surgical 3 months 5 years n/a LNG-IUS 
Lete et al LNG-IUS/combined oral 
contraceptive/progestogens 
6 months 5 years n/a LNG-IUS 
EA; endometrial ablation, LNG-IUS; levonorgestrel-releasing intrauterine system, TBEA; thermal balloon endometrial ablation 
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4.3.1 Model Features 
A Markov model was used in five of the studies identified, except Brown et al (2006) and 
Ganz et al (2013). Brown et al (2006) used a decision tree which is not entirely appropriate as 
the condition and the treatments under assessment are continuous. Hence LNG-IUS is not a 
cure for menorrhagia and if a decision tree is used the changes in QoL that occur and the 
associated recurring resource use is not captured. Therefore the treatments and the monthly 
condition cannot be accurately modelled by a decision tree as it does not allow for recurrent 
events and is far too simplistic. Ganz et al (2013) used the individual sampling model. The 
Markov model or, the more complex, individual sampling models are more appropriate for 
menorrhagia as they enable the recurrent events to be captured and can more accurately 
model the pathways. 
 
There is a notable heterogeneity in time horizons used across the studies. The NICE 
guidelines and four of the other studies used a 5 year time horizon, whilst Brown et al (2006) 
adopt a 2 year time horizon and Roberts et al (2011), a 10 year time horizon. It is reasonable 
to expect that given the condition is chronic and continues until menopause, a longer time 
horizon would be most suitable. However there are advantages and disadvantages associated 
with each time horizon used. The 5 year time horizon commonly used seems to be reasonable 
given that the LNG-IUS is effective and licenced for 5 years. However as the condition 
continues until menopause and the LNG-IUS can be replaced and used for another 5 years, 
this time horizon may not capture all impact on resources. In contrast, the 2 year time horizon 
used by Brown et al (2006) is based on primary data and could therefore be considered to be 
more reliable but relatively short since future changes in resource use and QoL would not be 
captured. If this latter study was to be on-going and the analysis reported the first of many 
analyses to be carried out at various intervals, this interim analysis could be deemed 
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acceptable. However, a subsequent evaluation is not mentioned in the paper. The evaluation 
by Brown et al (2006) could be considered to be more reliable in terms of data but the results 
are limited due to the short time horizon used. Roberts et al (2011) use a 10 year time horizon 
based on secondary data and use various assumptions to allow extrapolation of data to such a 
time horizon. The findings may prove to be more insightful when robust primary data are 
available because uncertainties associated with such broad assumptions need not arise. For 
example, the contraceptive needs and preferences for treatment are not likely to remain 
constant as they may change over such a long length of time. The length of the time horizon, 
then, of 10 years, is most suitable given the chronic nature of the condition. However, a clear 
trade-off, between the use, and availability, of more robust primary data in a short time 
horizon versus the less reliable, but more suitable, long-term analysis based on secondary 
data taken from several different sources is evident.  
The time cycle used in the Markov model varies across all studies. Roberts et al (2011) and 
Clegg et al (2007) use a monthly time cycle. NICE (2007) and Ganz et al (2013) use a 3 
month cycle. You et al (2006) use a yearly cycle and Lete et al (2011) use a 6 month cycle. 
The suitability of a time cycle of 3 months or more for the model is questionable. A cycle of 
3 months or greater assumes that a patient does not change health states for the given time 
period. The NICE guidelines state that a 3 month cycle was chosen due to available evidence 
(NICE, 2007). It is also presumed that a 3 month cycle was chosen because treatment of both 
tranexamic acid and mefenamic acid should cease if no improvement is observed after 3 
months of administration. However, if there is no improvement after 1 or 2 months, or if the 
treatment is associated with side effects, it is unlikely that a patient will continue to 
administer the treatment. This point is particularly pertinent in the case of LNG-IUS, as it is 
associated with numerous side effects within the first 6 months, such as inter-menstrual 
bleeding, post-coital bleeding or device expulsion. Such effects will more than likely result in 
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changes in health states and treatment and would impact on QoL and resource use each 
month. By using a time cycle of more than a month, the monthly changes and impact on 
resource associated with a change of treatment, repeat prescriptions and follow-up 
appointments will not be captured resulting in an inaccurate economic evaluation. Hence, the 
6 month and 1 year time cycles used by You et al (2006) and Lete et al (2011) will not 
capture important changes in QoL or effects on resource use leading to a poor economic 
evaluation. Whilst the studies using 3 month cycles will be slightly more accurate than these 
two studies with longer time cycles, they will still not be entirely accurate and capture all 
important changes (Ganz et al 2013; NICE 2007). The monthly time cycle used by Roberts et 
al (2011) and Clegg et al (2007), is most appropriate because menstruation occurs monthly 
and data on effectiveness and costs will be modelled according to the cyclical nature of the 
disease.  
 
4.3.2 Model Inputs –Data Sources 
Six of the seven studies were based on limited data as data on costs and utilities were taken 
from small trials in different countries. Furthermore, in some cases data from trials with 
different population characteristics were synthesised and in other cases data sources were 
unclear. As mentioned previously, Brown et al (2006) used primary data as they conducted a 
clinical trial within New Zealand but a sample size of 70 women was used. It is unlikely that 
the results of this study could be generalisable as it could be argued that the sample size used 
may not accurately reflect the population of menorrhagia sufferers. Further, three of the 
studies (Lete et al., 2011; Roberts et al., 2011; You et al., 2006) used utility values for the 
health states ‘well’ and ‘recurrent menorrhagia’ based on a study by Sculpher (1998). These 
utilities are based on patients who are referred to surgery. This point will be discussed in 
detail later but it is important to note that the QoL of these sufferers may be worse than a 
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sufferer who had not been referred to surgery. Furthermore, some of these studies made 
assumptions to adjust the utility values from the secondary data to obtain values for the LNG-
IUS, convalescence and other new health states that were more relevant for the newer 
treatments (Clegg et al., 2007; Roberts et al., 2011; You et al., 2006). Two studies estimated 
utility values from secondary data but provided a limited explanation of how the estimated 
values were derived, meaning that the results were not reproducible (Clegg et al., 2007; Lete 
et al., 2011). It is presumed that assumptions were made due to limited data on these 
alternative health states being available. Whilst fairly robust assumptions can be made on the 
process of care and associated resource use, it is unclear whether assumptions regarding the 
actual utility values for several health states of the model that have not been valued 
previously would be suitable. In some cases where assumptions were made, justifications for 
these values were not provided. It would be beneficial to elaborate on these methods to 
improve the transparency of the study.  
Being a primary study, the study by Brown et al (2006) was the only one to use values from 
the country of interest. Four studies used utility values from a Finnish study, despite the 
country under analysis not being Finland (Clegg et al., 2007; Ganz et al., 2013; NICE, 2007; 
Roberts et al., 2011). Lete et al (2011) was a Spanish study and used UK values from 
Sculpher (1998) due to a value set not being available for Spain. There is evidence to suggest 
that different countries have different value sets which are not transferable, and therefore only 
values obtained from the country under analysis should be used where possible to ensure an 
appropriate evaluation is carried out (Knies et al., 2009). This issue will be discussed further 
in section 4.6.  
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Effectiveness Measure 
A range of instruments have been used to assess the QoL of a woman for menorrhagia and a 
woman treated with menorrhagia. In some studies combinations of different measures have 
been used in the same analysis. The SF-36 instrument was used in the only study with 
primary data by Brown et al (2006). Sculpher (1998) was referenced for some utility values 
in the studies by NICE (2007), You et al (2006), Clegg et al (2007), Lete et al (2011) and 
Roberts et al (2011). Sculpher (1998) used the direct time trade-off (TTO) method to value 
QoL in menorrhagia sufferers. In addition, Clegg et al (2007), NICE (2007) and Roberts et al 
(2011) also used utility values from an earlier Finnish clinical trial by Hurskainen et al (2004) 
which used the EQ-5D instrument. There are concerns with using utility values from different 
valuation methods. Despite both Sculpher’s values and EQ-5D being based on TTO, the way 
in which the values were elicited are entirely different. The TTO used by Sculpher (1998) 
uses patient values to directly elicit utility values for health states that are specific to 
menorrhagia, whilst the utility values in EQ-5D are valued indirectly by TTO using values 
from the general population for general health states. Therefore, the utility values obtained 
from the two methods are not comparable and should not be used together in the same 
analysis. Data then, from a variety of instruments should not be used, in the same way that 
data from different countries should not be employed in a study that only considers the effect 
on one country.  
 
Mean/Median Values 
Data on utilities or costs are commonly summarised as either the mean and median values. 
The arithmetic mean, or average, is defined as “the sum of all scores in a distribution divided 
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by the total number of cases” (Argyrous, 2000 pp 126). The median is defined as the middle 
score of a set of data that is rank-ordered from lowest to highest (Argyrous, 2000).  
In the articles identified in the systematic review, various summary measures have been used. 
Clegg et al (2007) have combined both mean and median utility values in the same analysis, 
that is from one source they use mean values and from another, median values. You et al 
(2006) and Lete et al (2011) both employ median values and the remaining studies, mean 
values. Roberts et al (2011) use mean values for their primary outcome and use median 
values in the sensitivity analysis to demonstrate the extent to which the results of an 
economic evaluation can change depending on the summary measure used. There appears to 
be some confusion about which summary measure should be used. It is therefore important to 
provide a discussion on why this issue occurs and which summary measure should be used. 
It has been argued that the type of summary statistic used should be dependent on the 
distribution (or spread) of the data (Altman, 1990). In many cases datasets have a 
symmetrical distribution which is a bell shape, where the majority of scores lie in the centre 
of the distribution and fewer and fewer scores are seen as the scores move away from the 
centre. In symmetrical distributions, the mean and median values are identical. However, in 
certain cases, the distribution can be skewed, particularly in the case of resource use. The 
majority of people will lie within a certain range of resource use, but there will be some 
people that utilise many more resources causing the distribution to be skewed towards one 
end of the scale. In this case, the mean and median values would differ drastically. When data 
are right skewed, the median would be greater than the mean, and vice versa, as the mean is 
greatly influenced by outliers (extreme results). It has therefore been described as a 
“misleading notion of the average” (Argyrous, 2000 pp128). As the median is simply the 
middle value in the dataset and not the sum of all the values, it is not affected by the outliers. 
Many statisticians argue that the median should be used when the data are skewed as it is a 
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more representative summary of the data. This issue has led to some confusion when 
conducting economic evaluations, as some health economists have used the median value 
when the distribution of data are skewed and others have used the mean. In the NICE 
guidelines, when determining the mean length of menstruation, NICE state that “the use of 
the mean is questionable, given the skewed distribution” and therefore the median is used to 
define the summary value (NICE, 2007 pp21). However, this statement is not related to 
utility values and it is possible that the opinion may differ when data from an economic 
evaluation are under consideration. 
Numerous authors including Thompson and Barber (2000), Torrance (1986) and Roberts et al 
(2011) argue that the mean should be used to summarise any dataset that is used for an 
economic evaluation, regardless of the shape of the distribution. It is argued that each 
person’s utility value should be valued equally, giving equal weight to each person (Torrance, 
1986). If every individual person’s utility was not given equal weight and the median was 
used as a summary measure, it could be argued that a representative estimate of the 
population’s utility value has not been obtained. Hence, it is argued that those people that 
belong to this population and have extremely high or extremely low utility values will not be 
taken into account. A recent article by Roberts et al (2011) highlighted that numerous studies 
that have conducted economic evaluations of surgical interventions for menorrhagia have 
used median values. They highlight that the articles do not justify the use of the median over 
the mean, and explain that the only possible justification could be due to inconsistencies 
when mean values are reported in the literature. For example, in the article by Sculpher 
(1998) ‘well post ablation’ had a lower mean value than ‘convalescence following ablation’, 
which is unexpected. However, the median value for ‘well post ablation’ was greater than 
‘convalescence post ablation’. As mentioned previously, Roberts et al (2011) re-calculated 
their evaluation and used median utility values to demonstrate that the result of the most cost-
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effective intervention differs depending on the summary statistic employed. Thompson and 
Barber (2000) also argue that the arithmetic mean is the most “informative measure” as the 
other summary measures do not provide information on the overall cost or utility value that 
will be derived by treating all patients. Instead, the median value provides data on the 
‘typical’ value for an individual.  
Conversely, Dolan (2000) argue that neither the mean nor median is appropriate. They 
initially state that if the majority of data are found within a certain range of values and very 
few lie outside of this range, it would be much more intuitive to use the median value, as the 
mean will be ‘pulled’ up or down much more than is representative of the population. They 
then discuss the notable differences that using each summary statistic will have when 
determining resource allocation, stating that the less severe states would be negatively 
skewed and the more severe states positively skewed. Therefore, the benefits of moving 
between states, i.e. from more severe to less severe, will be less if the mean was used than if 
the median was used. It is then concluded that neither measure is an accurate representation 
of the population (Dolan, 2000). 
Although it seems that neither of the measures, mean or median, are particularly appropriate 
for summarising datasets, it is clear that one set method must be agreed upon to improve the 
consistency of economic evaluations. A key argument for using the mean is that all 
individuals’ utility values should be treated equally. It would not be appropriate to ignore 
certain individual’s values, as the results would be unrepresentative of the population. 
Therefore, it is argued that the most appropriate method to use would be the mean to 
summarise the data, but the median value could also be presented. 
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4.3.3 Perspective of Economic Evaluation 
Although the perspective of the economic evaluation is not used as criterion to pass or fail a 
study, it is worth discussing the perspective used in each study. All the studies identified 
except Brown et al (2006), considered direct costs borne by the healthcare provider. In the 
UK, the decision-makers, NICE, recommend that a healthcare provider perspective be used 
as they are primarily interested in trying to allocate healthcare resources within the healthcare 
budget. Therefore, only costs borne by the healthcare provider are recommended when the 
economic evaluation is conducted. Hence all UK studies used a healthcare provider 
perspective (Clegg et al., 2007; NICE, 2007; Roberts et al., 2011). However, as discussed in 
Chapter 3, there is also a debate around whether the societal perspective should be taken into 
consideration. The societal perspective includes impact on the healthcare provider and society 
through changes in productivity and out of pocket costs incurred by the patient, such as travel 
to appointments, amongst other things. The study by Brown et al (2006) carried out in New 
Zealand, incorporated societal costs such as lost income. As menorrhagia is known to 
significantly impact the QoL of sufferers on a continuous cyclical basis, it is likely that the 
condition would impact on productivity (work) every month. Also, some women will be 
expected to pay for their prescribed pharmaceutical medication which will add to the costs 
that should be taken into consideration from the societal perspective. Therefore, in this sense, 
Brown et al (2006) have conducted a more comprehensive economic evaluation than the 
other studies as they have considered both the healthcare provider and societal costs. 
However, the likelihood of studies carrying out the societal perspective will be dependent on 
the decision-makers recommendations. 
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4.3.4 Sensitivity Analysis 
All studies conducted a one-way sensitivity analysis to assess the uncertainty of the findings. 
In a one-way sensitivity analysis, model parameters are altered individually and the effect of 
this change on the overall cost-effectiveness result is determined. To conduct a robust 
sensitivity analysis and provide a more accurate assessment of the uncertainty of the findings, 
it is necessary to conduct a probabilistic sensitivity analysis (‘PSA’) where model parameters 
are changed simultaneously. Five out of the seven studies conducted this additional PSA 
(Clegg et al., 2007; Ganz et al., 2013; Lete et al., 2011; Roberts et al., 2011; You et al., 2006). 
You et al (2006) conducted the PSA and specified the triangular distribution for the cost and 
utility parameters but did not justify the use of the triangular distribution over the traditional 
gamma distribution for costs and beta distribution for utility values. A PSA was not 
conducted in the NICE guidelines (2007). It is particularly important to assess the uncertainty 
associated with the results of the NICE guidelines for two reasons. First because poor data 
were available and, second, because these recommendations from the guidelines inform 
clinical practice, emphasising the importance of ensuring the results are robust. 
  
4.3.5 Funding Source 
Finally, although the source of funding was not used to pass or fail a study, funding sources 
for each of the studies must be mentioned. The manufacturer of LNG-IUS is the funding 
source for three out of the seven studies (Clegg et al., 2007; Ganz et al., 2013; Lete et al., 
2011). LNG-IUS was shown to be the most cost-effective intervention in all three of these 
studies. In these cases there is a conflict of interest, which the authors acknowledge, as the 
funders of the study have a vested interest in the outcome of the study. An outcome of LNG-
IUS being most cost-effective, as was shown in all of these studies, would lead to an increase 
in company profits. While the cost-effectiveness findings from the academic study conducted 
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by Brown et al (2006) and the NICE guidelines (2007) concurred with these industry funded 
studies, by finding LNG-IUS to be most cost-effective, two of the other academic studies 
determined that hysterectomy was the most cost-effective (Roberts et al., 2011; You et al., 
2006). The mixed results indicate the need for further investigation into the most cost-
effective intervention for treating menorrhagia.   
 
4.4 Discussion Related to NICE Guidelines 
In this section a summary and critique of the NICE guidelines is reported. It is deemed 
necessary to lend a whole section to appraising the NICE guidelines because, as mentioned, 
recommendations that arise from these guidelines are used to inform clinical practice. Hence 
an assessment of the quality of the guidelines is particularly important. In addition to the 
issues mentioned previously, several issues specific to the NICE guidelines will be discussed 
in this section to highlight the importance of ensuring that the guidelines are as accurate as 
possible. 
 
4.4.1 Analyses 
In the NICE guidelines two of the three analyses conducted were not deemed to be entirely 
appropriate. When ‘all pharmaceutical treatment’ or ‘non-hormonal treatment’ is compared to 
watchful waiting, each intervention is compared to no treatment. For example, mefenamic 
acid is compared to no treatment, and tranexamic acid is compared to no treatment and so on. 
Indirect comparisons of the cost-effectiveness results of each intervention against no 
treatment are then made to determine the order of cost-effectiveness of each treatment. Rather 
than indirectly comparing the cost-effectiveness of each intervention, it would be more 
meaningful to obtain the decision model results from a direct comparison by comparing 
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tranexamic acid against mefenamic acid. NICE stated that a direct comparison between 
treatment groups is not conducted, because a rank order of treatment did not previously exist. 
However, in order to overcome this obstacle, several different analyses comparing a range of 
different interventions could have been conducted.  
Furthermore, a literature search was carried out by the NICE guideline team and they found 
that no economic evidence supporting or opposing the case for cost-effectiveness of the oral 
progestogen, norethisterone, and injected progestogen was available. However, neither 
norethisterone nor injected progestogens were considered in the decision model as possible 
interventions for treating menorrhagia and therefore no results on their cost-effectiveness 
were obtained. Despite this, NICE do recommend that oral progestogen and injected 
progestogen should be used as a third line treatment for menorrhagia. This recommendation 
has no economic merit and could lead to a situation where clinicians are more inclined, than 
previously, to prescribe these treatments even though their cost-effectiveness has not been 
determined.  
 
4.4.2 ECLIPSE Committee Points 
Many of the key limitations of the evaluation reported in the NICE guidelines were identified 
by the ECLIPSE trial team in their trial protocol, where the methods for assessing the 
effectiveness and cost-effectiveness of LNG-IUS against usual medical treatment in primary 
care is reported, as detailed in Chapter 1. It should be noted that the rationale for the 
ECLIPSE study was largely based on the limited findings of the NICE guidelines which 
highlighted the lack of direct data available on non-surgical interventions for menorrhagia. 
The objective of the ECLIPSE trial therefore was to provide the first opportunity to capture 
primary data on utilities and resource use on menorrhagia within the UK.  
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It is argued by the ECLIPSE team that the source of data used to populate the model reported 
in the NICE guidelines for the LNG-IUS intervention is particularly poor. One study 
conducted in Finland by Hurskainen et al (2004) with a small number of participants is 
heavily drawn upon to provide data for the model for LNG-IUS. It is recognised that at the 
time, this was the only study that provided information on cost-effectiveness for LNG-IUS in 
relation to menorrhagia, yet the small sample size and the country of the study limits the 
generalisability to the population of women with menorrhagia within the UK. As the 
perspective of the NICE guidelines is the UK, National Health Service (NHS), the use of data 
from a Finnish clinical trial to estimate utility values to populate the model would not be 
consistent with the UK perspective, as clinical practice and utilities derived from patients in 
Finland may not translate to UK clinical practice. There is emerging literature suggesting that 
the transferability of the EQ-5D instrument across countries is limited (Knies et al., 2009). 
This is because the EQ-5D and similarly SF-6D have national value sets, and results from 
international studies should be adjusted to the appropriate value set for the country. It was 
found that a difference between national value sets can be perceived in the preferences for the 
attributes and that these differences were due to methodological and cultural differences 
(Knies et al., 2009).  
Secondly, as the study by Hurskainen et al (2004) is set in secondary care, rather than 
primary care, each of the women in the study had been referred by their general practitioner 
(GP) or clinic to a hospital. It must be questioned whether it would be appropriate to 
extrapolate this information into the primary care setting. One could argue that the very fact 
that these women have been referred to hospital is because the women believe that their 
condition is particularly severe and that it cannot be managed by pharmaceutical treatment 
alone, assuming it was offered beforehand. Furthermore, as the women recruited into the trial 
were on the waiting list to have a hysterectomy, the utility values can be considered to be 
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biased towards surgery and the women themselves may have already have been resolved to 
the idea of a permanent solution, or cure. Consequently, using a value from this Finnish trial 
for the NICE model parameter ‘proportion of women who have surgical treatment following 
failed pharmaceutical treatment’ for LNG-IUS in the guidelines is inappropriate because 
these cases may be unrepresentative of all sufferers of menorrhagia, and would result in an 
overestimation of cost-effectiveness. However, it should be noted that NICE did recognise 
that using a utility value from Sculpher (1998), derived from women who had been referred 
to surgery, may overestimate the extent of the problem in primary care because these may be 
severe cases. But, the one-way sensitivity analysis undertaken by NICE to test this 
assumption showed that even if the utility decrement associated with menorrhagia is low, i.e. 
it is considered a serious problem for the woman, the relative results of the model were 
unchanged. However, a significant point highlighted by the ECLIPSE team is that only a one-
way sensitivity analysis and threshold analysis was conducted. A thorough analysis of 
uncertainty using PSA was not carried out. Thus, even though NICE recognised that there 
were very little data available to inform the guidelines, a full analysis of the uncertainty of 
results was not attempted. 
 
4.5 Discussion 
This review has highlighted the lack of data available on the cost-effectiveness of alternative 
interventions for menorrhagia. The findings from the NICE guidelines demonstrate the need 
for a large pragmatic clinical trial, as the recommendations were based largely on one 
primary study, argued to be of poor quality, which was carried out in Finland. Overall, the 
NICE guidelines highlight the sheer lack of effectiveness and cost-effectiveness data within 
this area. This is especially emphasised by the value for treatment success rate for the 
combined oral contraceptive treatment, being estimated by “taking high and low estimates of 
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the effectiveness value obtained for other therapies and using a triangular distribution” 
(NICE, 2007 pp 111). It seems that, from a decision-makers perspective, to provide truly 
useful and accurate clinical guidelines for menorrhagia, it would have been much more 
beneficial to emphasise the importance of conducting a large UK based randomised 
controlled trial which considered the range of interventions under consideration, rather than 
providing clinical guidelines based on poor data.  
Six subsequent publications following the NICE guidelines were identified. Only one of these 
studies was a primary study but the costs and outcomes, in terms of QoL, were reported 
separately and not presented as a CUA (Brown et al., 2006). This systematic review also 
demonstrates that the available cost-effectiveness results conflict with each other as five out 
of the seven studies identified in the review found LNG-IUS to be the most cost-effective 
intervention for treating menorrhagia and two did not. However, three of these studies that 
found LNG-IUS to be cost-effective were funded by the manufacturers of LNG-IUS. The 
shortage of UK based studies is also revealed as only two studies, in addition to the NICE 
guidelines, were conducted in the UK and neither of these used primary data. 
One study was considered to be more robust and more relevant for the UK, than the others 
(Roberts et al., 2011). This study was a UK based economic evaluation conducted using 
secondary data to populate a decision model. This study found hysterectomy to be the most 
cost-effective intervention, when compared to LNG-IUS and endometrial ablation. This 
finding contrasts with those reported in the NICE guidelines. LNG-IUS was deemed the most 
cost-effective intervention in the NICE guidelines and it was also recommended that 
endometrial ablation should be conducted prior to a hysterectomy as it was the least cost-
effective treatment. The study by Roberts et al (2011) was much more robust than the NICE 
study because individual patient level data from numerous clinical trials were used in the 
meta-analysis when synthesising evidence. Hence much more data were incorporated than the 
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NICE study which increases the reliability of the findings. Once again, this comparison 
highlights the need for a large pragmatic clinical trial that considers all interventions for 
treating menorrhagia to be carried out.  
 
4.5.1 Strengths and Limitations 
The strength of this review is that a comprehensive update of the literature on all of the 
economic evaluations and cost studies, which report QoL, in menorrhagia is provided. 
Second, the quality of the identified studies, including the NICE guidelines, is assessed using 
a recommended checklist which, to current knowledge, has not been done before. A 
limitation of the search is the inability to obtain and review the search terms and search 
methodology used in the NICE guidelines. Although best efforts were made to acquire the 
search terms from the authors of the NICE report a response was not received. However, it is 
believed that the search terms used are appropriate as the disease-specific search terms are 
similar to other systematic reviews, that have not reviewed economic evaluations in 
menorrhagia, and the economic search terms are similar to those used by Roberts et al (2002). 
 
4.5.2 Comparison with Other Studies  
It was not deemed necessary, by the research team, to conduct a systematic review of the 
literature prior to 2006 because it is expected that the review as part of the NICE guidelines 
had comprehensively assessed all studies prior to this time point in order to compose the 
guidelines. Hence an update of the literature was required to determine whether any new 
articles of economic evidence within menorrhagia had emerged.  
Further, as mentioned in the methods, two systematic reviews were published previously. 
One was carried out by Blumenthal et al (2011) and the other by Gemzell-Danielsson et al 
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(2013). Neither review appeared to be a comprehensive systematic review of the studies that 
have assessed cost-effectiveness in menorrhagia. Both reviews focussed on LNG-IUS. The 
review by Gemzell-Danielsson et al (2013) is a more general review of LNG-IUS for all 
requirements (i.e. contraception) and in a paragraph dedicated to menorrhagia, the authors 
simply report which intervention is the most cost-effective in previous studies, referring to 
Blumenthal et al (2011). Whilst the review by Blumenthal et al (2011) is more specific 
reporting on the cost-effectiveness, and effectiveness, of LNG-IUS related to menorrhagia, a 
critical appraisal of the studies using the recommended checklists for economic evaluations 
was not provided to assess the quality of the included studies. Additionally, several more 
relevant databases, such as NHS EED and the Social Science Index, were searched to ensure 
that all studies were identified. A further three additional studies, which reported on the cost-
effectiveness of LNG-IUS for menorrhagia, were identified in the review reported in this 
chapter. 
 
4.5.3 Further Research 
The findings from the review reported in this chapter have shown that there is a need for a 
good quality economic evaluation using primary data to be conducted in the UK. This will 
ensure that robust information on the cost-effectiveness of alternative non-surgical 
interventions for menorrhagia is presented to decision-makers and that meaningful results can 
inform clinical practice. The need for more reliable evidence should be met when the CUA 
alongside the UK ECLIPSE randomised controlled trial, reported in Chapter 6, is published 
as the methods used address the issues identified here to provide a robust measure of cost-
effectiveness of non-surgical interventions for menorrhagia. 
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4.6  Conclusion 
In this chapter a systematic review of economic evaluations in menorrhagia is reported. It is 
found that there are mixed results on which treatment is most cost-effective and there is very 
little reliable data available to date on the cost-effectiveness and effectiveness, in terms of 
QoL, of pharmaceutical interventions for menorrhagia. Only one primary study, since the 
2006 is identified but a small sample size is used which limits the generalisability of the 
findings. Further, this one primary study does not carry out a full CUA as the results from 
SF-36 are not mapped onto SF-6D to generate QALYs. All of the other studies identified use 
secondary data that are taken from a different country or combined different utility valuation 
methods in the same analysis. The findings reported in this chapter indicate a need for a 
robust randomised trial with a large sample size to determine the clinical and cost-
effectiveness of LNG-IUS compared to pharmaceutical treatment. In the next chapter a 
systematic review on the use and psychometric assessment of economic outcome measures in 
menorrhagia is reported. 
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CHAPTER 5. AN ASSESSMENT OF ECONOMIC MEASURES USED IN 
MENORRHAGIA: A SYSTEMATIC REVIEW 
 
5.1 Introduction 
In this chapter, a systematic review of the economic measures (utility-based quality of life 
(QoL)) and contingent valuation) used in menorrhagia is presented. This systematic review 
has been accepted for publication (see Sanghera et al., 2013). The aim of such a systematic 
review is to assess the appropriateness and relative success of these measures in studies of 
menorrhagia. It is necessary to conduct this systematic review because (i) it has been recently 
formally recognised that QoL is the key indicator of treatment success in menorrhagia (NICE, 
2007). Therefore, it is important to identify which QoL measures have been used and whether 
they are deemed to be adequate based on the literature. (ii) A recent study by Roberts et al 
(2011) has suggested that QoL or utility values available for menorrhagia are inadequate and 
need to be reassessed because the utility values associated with treatments were the main 
cause of uncertainty in an economic evaluation. Until the evidence on the utility values 
associated with menorrhagia is strengthened, robust recommendations of economic evidence 
cannot be provided to decision-makers.  
To strengthen evidence, it is necessary to ensure that the valuation approach accurately 
reflects women’s experiences and preferences. Consequently, this systematic review provides 
a narrative review of all economic measures (utility-based QoL and contingent valuation) that 
have been used in the valuation of outcomes associated with menorrhagia, and evaluates their 
psychometric properties and clinical utility. First, the methods for the literature search and 
study selection are described. Second, the results are presented according to the instrument 
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under assessment and finally the chapter ends with conclusions on the use of QoL measures 
in menorrhagia and prospects for further work.  
 
5.2 Methods 
An initial scoping search was conducted in December 2011 to identify previous systematic 
reviews and the most appropriate search terms. Two relevant reviews were identified 
(Blumenthal et al., 2011; Clark et al., 2002). Details on the objectives of these previous 
reviews are discussed later in section 5.4.2. As neither of these reviews answered the question 
of the research reported here, it was necessary to conduct a full systematic review.  
The guidelines by the Centre for Review and Dissemination and Cochrane Collaboration for 
reviews were followed using a narrative synthesis (CRD, 2009; Higgins & Green, 2009).  
 
5.2.1 Eligibility Criteria 
Since the objective of the review was to assess the appropriateness and relative success of the 
use of economic measures in menorrhagia, studies were included in the review if they met the 
following criteria:  
 Either: 
i. Use economic measures (such as EQ-5D, SF-36, SF-6D, disease-specific 
utility based measures, willingness-to-pay (WTP)) in relation to menorrhagia 
in a clinical trial or observational study or 
ii. Discuss the development/ describe economic measures used in women with 
menorrhagia or assess economic measures used in menorrhagia.   
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The term, economic measures, refers to utility-based QoL instruments that have the potential 
to be used in an economic evaluation in order to report the results in terms of incremental 
quality adjusted life year (QALYs). These include EQ-5D, SF-36, TTO, SF-6D, and also any 
disease specific utility-based measures and visual analogue scale (VAS) in order to be 
comprehensive. Additionally, contingent valuation measures such as WTP which are used in 
cost-benefit analyses are also considered under the term ‘economic measures’. The following 
should be noted: 
 The population of interest was women with menorrhagia undergoing assessment of 
QoL 
 Studies that focused on adolescents (less than 15 years old) were not included. If 
menorrhagia is experienced in adolescents it is likely that it will subside after puberty 
and the typical population of sufferers are predominantly women approaching 
menopause. (Duckitt & Shaw, 1998)   
 Studies involving patients with adenomyosis and endometriosis were excluded 
because menorrhagia is typically secondary to another symptom 
 Studies including women with bleeding disorders such as Von Willebrand disease 
were excluded because the relationship between the impact of this on QoL compared 
to the impact of menorrhagia alone on QoL has yet to be established and treatment for 
the condition differs (James et al., 2005).  
In all other cases, studies were included where menorrhagia was the presenting complaint. 
Restrictions on study design were not applied as data from any study type would address the 
review question. 
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In January 2012 the following databases were electronically searched; Medline (1948 
onwards), EMBASE (1947 onwards), Social Science Citation Index, Science Citation Index, 
PsychInfo (1967 onwards), CINAHL, NHS EED, DARE and HTA. Reference lists from 
eligible studies that were selected were also reviewed. The review was updated in August 
2013.  
Search terms were identified from search filters in the databases and previous systematic 
reviews (Blumenthal et al., 2011; Clark et al. 2002). The search terms included were heavy 
menstrual bleeding or menorrhagia and questionnaires or quality of life or outcome 
assessment or psychometry or psychological tests or psychometrics or interview or 
instrument (see Appendix 2.1). The search was limited to female and human studies. Index 
terms and free text were combined where possible. The results were managed using 
Reference Manager Software (version 12).  
 
5.2.2 Study Selection 
The review was conducted using a two stage process which followed the method of Mugford 
(1996) and has subsequently been established and described elsewhere (Bricker et al., 2000). 
The title and abstract of studies were screened according to the eligibility criteria and the full 
paper was obtained if appropriate. Where no abstract and no full text was available, the study 
was excluded. Where no abstract was available, the full paper was obtained. All studies were 
reviewed in both stages by this author. To validate this process, 20% of the titles and 
abstracts were independently reviewed by two other investigators (Tracy Roberts and Emma 
Frew). All of the investigators were blind to the categorisation decisions.  
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Stage 1 – Initial Categorisation of studies 
The following criteria were used to assess the relevance of each study in the first stage of the 
review: 
A) Primary research is reported and includes an economic measure (utility-based QoL or 
contingent valuation), which is used in an economic evaluation or cost-study 
B) The study uses an economic measure in a clinical trial or observational study 
C) The study may have useful information  but does not obviously fall into (A) or (B) 
D) The study has no relevance 
Studies in category (A) and (B) were considered relevant to the systematic review, those 
studies in category (C) and (D) were not reviewed any further. 10% of the studies in category 
(C) were reviewed for relevance. 
 
Stage 2 – Further categorisation 
After reading the full article, the studies categorised in (A) and (B) were further categorised 
into the following categories: 
1. An economic measure is assessed or used in an economic evaluation/ cost study 
2a. Effectiveness study – An economic measure is used as a primary outcome 
2b. Effectiveness study – An economic measure is used as a secondary outcome 
3. The study discusses and/or describes QoL instruments 
4. Review article  
5. The study has no relevance 
94 
 
5.2.3 Data Extraction and Management 
It was not deemed appropriate to use a strict quality criterion where articles can pass or fail 
since the objective was to determine which instruments have been used and consider how 
they have been used from a health economics viewpoint. Data were extracted and discussed 
based on the criteria outlined in Table 5.1. A narrative synthesis of data was taken, as a meta-
analysis was not appropriate given the nature of the study question (CRD, 2009; Pirkis et al., 
2005). Thus a discussion regarding the instrument’s use is provided.  
Included studies are broadly categorised into two groups; those that assessed the 
psychometric properties and the feasibility of economic outcome measures and those that 
used the measures. The full criteria used to judge the psychometric properties of the 
instruments are presented in Table 5.1. These criteria were considered to include all key 
psychometric properties and were based on a previously published study (Pirkis et al, 2005). 
Briefly, the instruments were assessed according to the validity, whether the instrument 
measures what it is designed to measure, reliability, defined as the ability to provide 
consistent scores and sensitivity, the extent to which the measure captures clinical changes. 
The extracted data were handled in Microsoft Excel (version 2007). The data extraction 
process was completed by this author. Two investigators (Tracy Roberts and Emma Frew) 
verified the data extraction process by extracting data from 10% of the above-classified 
studies. Disagreements for all stages were resolved by discussion.  
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Table 5.1 Criteria for data extraction 
Criteria Justification 
Are details regarding the type of instrument(s) 
used provided? Is justification provided.  
Is the suitability of the instrument considered in 
detail? Or used just because it is typically used. 
Is the instrument used as secondary or primary 
outcome? Is justification provided for not using 
it as a primary outcome?  
 
It has long been recognised that QoL is most 
important and thus discussion about primary or 
secondary outcome would be valuable information. 
Validity 
 
Face validity: whether upon inspection the 
instrument measures what it claims to measure 
(Bannigan & Watson, 2009). 
Construct validity: determines whether an 
underlying relationship exists between questions in 
the instrument and an attribute that is measured 
(Streiner & Norman, 1995). 
Content validity: whether all relevant aspects of 
the condition are considered in the 
instrument.(Bannigan & Watson, 2009). 
Sensitivity/ responsiveness to change  
The extent to which the measure captures changes 
in comparison to the other measures used. 
Reliability 
 
Ability to provide consistent scores in the same 
respondent or across items in a test. 
Feasibility/ utility   
Having used the measures and assessed results the 
authors opinions on the instrument will provide 
valuable information on the utility. If the 
instrument is thought to be unacceptable then 
perhaps the measure should not be used. 
Is the completion rate stated or discussed? Are 
difficulties in completing the instrument 
discussed?  
 
This information will help to assess the 
appropriateness as a low completion rate may 
indicate difficulties with completion or highlight 
irrelevant information. 
Is a significant difference in QoL identified?  
 
If a significant difference in disease-specific 
measures is seen, is this reflected at all as a change 
in QoL? 
Are non-economic measures used? In terms of 
changes, is there a relationship between 
economic and non-economic measures? 
 
This will provide some insight into the suitability of 
economic measures. If several measures need to be 
used then it would suggest there is no consensus. 
Are health and non-health outcome measures 
used? 
 
Non-health outcomes are thought to be as the 
typically used health outcomes in this condition. 
QoL; quality of life 
 
5.3 Results 
A full break down of the number of studies identified and included in the review is provided 
in Figure 5.1. Fifty-nine papers were included in the review. Twelve papers assessed the 
psychometric properties of the outcome measures, twelve papers applied the measures in an 
economic evaluation or a cost study, eight and twenty-seven effectiveness studies used the 
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measures as a primary and secondary outcome, respectively. The results are described 
according to the type of instrument assessed. Particular psychometric properties are not 
reported for all instruments if there were no relevant studies. Table 5.2 summarises the main 
findings and presents those studies that assessed psychometric properties and feasibility. 
Remaining studies are discussed in the text. (See Appendix A2.2, Table 1 for further details 
of the studies identified).  
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Articles identified from 
electronic searches 
(n=2383) 
Duplicate studies 
 (n=926) 
Excluded studies following 
screening of title and abstracts 
(n=1323) 
Not relevant (n=1193) 
Maybe useful (n=130) 
Excluded: no abstract and no full 
text 
  (n=27) 
Potentially relevant full text articles retrieved for 
more detailed evaluation 
(n=110) 
Studies excluded following detailed 
evaluation 
Not relevant (n=22) 
Unobtainable 
(n=29) 
Studies included in the review 
(n=59) 
Articles identified from other 
sources 
(n=3) 
Articles screened  
(n=1460) 
Figure 5.1 Flow of papers through study. 
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5.3.1 EQ-5D 
Where EQ-5D was used as the single outcome measure, there were no studies reporting on 
the psychometric properties of the instrument. Some psychometric properties were reported 
when it was used alongside the menorrhagia multi-attribute utility scale (MMAS) instrument 
- the disease-specific measure which has been shown to be reliable and valid in menorrhagia 
(Pattison et al., 2011; Shaw et al., 1998). With respect to the construct validity, one case was 
identified where the overall score for EQ-5D had a poor correlation with MMAS (Pattison et 
al., 2011) which led to the authors suggesting that EQ-5D is unsuitable for patients with 
menorrhagia. A second study compared the sensitivity of EQ-5D and MMAS to changes in 
satisfaction post treatment, and found MMAS to be statistically associated with satisfaction 
whilst EQ-5D was not (Clark & Gupta, 2004). This result suggests that EQ-5D is not 
sensitive to important changes to women, such as their satisfaction with treatment outcome. 
However, in this particular study it is important to note that unconventionally, median QoL 
values were assessed and not mean QoL. The lack of sensitivity of the instrument to changes 
in QoL was also reported in another economic evaluation of treatment for menorrhagia 
(Kilonzo et al., 2010). With respect to rate of use of the instrument, EQ-5D was used in four 
of the economic evaluations identified and was the only economic measure used in two of the 
effectiveness studies (Dickersin et al., 2007; Frick et al., 2009; Hurskainen et al., 2001; 
Kennedy et al., 2003; Kilonzo et al., 2010; Sambrook et al., 2009b).  
 
5.3.2 SF-36 
Overall, more evidence was found on the psychometric properties of the SF-36 instrument 
compared to the EQ-5D. Three studies found SF-36 to be unreliable for individual decision-
making (Jenkinson et al., 1996; Ruta et al., 1994) but reliable for group decision-making 
(Garratt et al., 1993; Ruta et al., 1994). In two of these studies (Garratt et al., 1993; Ruta et 
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al., 1994), the patient group included not only patients with menorrhagia but also those with 
lower back pain, varicose veins and peptic ulcers.  
The lack of face validity of SF-36 was identified in one study (Jenkinson et al., 1996) where, 
in interviews, women expressed difficulty completing the general health and mental health 
questions because the time frame is unspecified or inappropriate (refers to the past month). 
The authors argued that the ambiguity associated with these questions is due to the cyclical 
episodic nature of menorrhagia symptoms. This is evident in one participants response where 
she considered her health, which was ‘fine’, to be separate from her periods, which affected 
her greatly (Jenkinson et al., 1996).  
The relevance of all of the SF-36 scales was confirmed by Garratt et al (1993) in a patient 
group consisting of four common conditions, including menorrhagia, lower back pain, 
varicose veins and peptic ulcers. Physical functioning was found to be the most relevant 
attribute (Garratt et al., 1993). However, when the subgroup results of the different conditions 
were assessed for menorrhagia, physical functioning was the only attribute that was not 
significantly different to the SF-36 scores of the general population, indicating that it may not 
be the most relevant attribute for the condition (Garratt et al., 1993). This finding was also 
observed in other studies identified in this review, as physical functioning is the least 
responsive domain in patients with menorrhagia and this finding has been observed in five 
studies (Cooper et al., 1997a; Cooper et al., 2005; Garratt et al., 1993; Hurskainen et al., 
2004; Sambrook et al., 2009a). Indeed, Pattison et al (2011) found a lower correlation 
between the disease-specific MMAS and the physical functioning and general health 
subscales of the SF-36. The authors state that physical functioning is greatly influenced by 
mobility and self-care, which are not impacted by menorrhagia, and these findings suggest 
SF-36 may be unsuitable for measuring QoL in these women (Pattison et al., 2011). One 
Turkish study did show that all of the SF-36 domains in a population with menorrhagia were 
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significantly different to a population without any specific condition, but the authors did 
adapt the SF-36 scale with very little explanation (Gokyildiz et al., 2013).  
The SF-36 was shown to be sensitive to changes in the social impact score (Coulter et al., 
1994), and the transition question which asks whether the condition has changed since the 
last point of measurement (Garratt et al., 1994). Discrepancies were seen between results, 
where SF-36 failed to reflect large changes that occurred in other questionnaires (Coulter et 
al., 1994). In Garratt et al (1994) when the response to the transition question was ‘my health 
is somewhat worse’, the SF-36 scores on the general health domain showed a moderate 
positive increase in general health rather than a negative change. One study also 
demonstrated that when compared to SF-36, MMAS is able to better predict the need for 
surgery (Habiba et al., 2010). This same study separated the Mental Composite Scale (MCS) 
and Physical Composite Scale (PCS) of the SF-36 to determine the impact of menorrhagia on 
specific aspects of life and concluded that the scoring procedure for these composite scales is 
inadequate and does not reflect changes seen on individual domains of the SF-36 (Habiba et 
al., 2010). The SF-36 MCS has been found to be more sensitive than the PCS as it was 
significantly associated with patient satisfaction, whilst the PCS was not (Hehenkamp et al., 
2008). 
Finally Habiba et al (2010) assessed the appropriateness of the use of SF-36 by examining 
score ranges, ceiling effects and standard deviations to identify whether the range of 
disability in the sample is similar to the range of disability covered in the measurement scale. 
At baseline, three domains, social functioning, role physical and role emotional, had a high 
ceiling effect indicating that the range of disability measured in the scale is less than the 
range of disability in the study sample, implying SF-36 had limited ability to distinguish 
between subjects.  
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SF-36 and SF-12 were the most commonly used outcome measures in effectiveness studies 
and the only outcome measure used in two of the identified economic evaluations but a lack 
of sensitivity in SF-36 is typically reported. Brown et al (2006) and Bongers et al (2005) feel 
that SF-36 fails to capture the concerns and experiences of patients. Brown et al (2006) 
observed small differences in SF-36 scores, but larger differences between treatments for 
women which fail and they therefore argue that the change in SF-36 does not correlate with 
failing treatment. The authors also highlight that sexual functioning is not addressed by SF-36 
(an important factor identified in (de Souza et al., 2010)) and that the pain and discomfort 
attributes are too broad to detect changes in menorrhagia-related pain. Bongers et al (2005) 
assert that SF-36 is difficult to answer for patients with menorrhagia and Brown et al (2006) 
suggest that WTP should be investigated.  
 
5.3.3 Willingness-to-Pay (WTP) 
The WTP measure was evaluated for reliability in one study that assessed the consistency of 
responses from women with menorrhagia. WTP was elicited directly using a payment card in 
a questionnaire based format to compare hysterectomy against conservative treatment from 
an ex-ante perspective. Women’s preference for treatments and WTP for treatments were 
elicited (Ryan & San Miguel, 2000) and in 30% (44/146 women) of cases, the greatest WTP 
and preferred treatment did not correspond, indicating that WTP lacks external reliability. 
The authors felt that the respondents were providing responses based on their knowledge of 
the cost of treatments and not their strength of preference for treatment (Ryan & San Miguel, 
2000). The implications are argued to be particularly important in menorrhagia because 
treatment costs differ drastically thus the WTP values do not reflect maximum WTP, and 
WTP for a cheaper treatment would be underestimated (Ryan & San Miguel, 2000).  
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5.3.4 General Experience of Feasibility/Utility of Measures 
Several authors (Bongers et al., 2005; Habiba et al., 2010; Kilonzo et al., 2010; Sculpher, 
1998) commented on the difficulties in answering questions in any generic instrument, 
particularly questions on general health and mental health, and obtaining utility values in a 
chronic non-life threatening cyclical condition which has acute episodes of symptoms. 
Specifically, Sculpher (1998) explains that it is difficult to value health states of a chronic 
condition, where symptoms are episodic (Sculpher, 1998). As the EQ-5D instrument refers to 
health today, a high utility value may be assigned on the day of completion but a low utility 
thereafter. The generic QoL results are influenced by the timing of assessment and as it is 
difficult to identify the ideal timing, it may be difficult to elicit an accurate response from 
patients regardless of the generic instrument used (Sculpher, 1998).  
Shaw et al (1998) and Jenkinson et al (1996) demonstrate that typically women do not 
consider menorrhagia to strictly be a health-related condition and they show that the 
condition could be considered separate to health. SF-36 and EQ-5D do not refer to non-health 
attributes which has resulted in their limited validity. Unlike SF-36 and EQ-5D the questions 
in the disease-specific MMAS mostly refer to the woman’s state during her cycle, which is 
the first day of one period to the first day of the next period. This may overcome the 
problems of timing of assessment associated with SF-36 and EQ-5D (Pattison et al 2011). In 
the case of WTP, there is insufficient evidence available that has discussed the feasibility or 
utility of this measure in menorrhagia. Brown et al (2006) suggest WTP may be more suitable 
than extra-welfarist measures as it may be more sensitive to changes in utility following 
treatment and WTP captures more than general health related QoL. Only one study (Ryan & 
San Miguel, 2000) assessed WTP in menorrhagia. 
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5.3.5 Economic Measures in an Economic Evaluation/ Cost study  
Twelve papers collected QoL data using economic measures in a study that either used 
primary data to conduct an economic evaluation or a cost study that had all of the relevant 
information to conduct an economic evaluation, but did not do so. Two papers were follow-
up studies (Hurskainen et al., 2004; Sculpher et al., 1996). Time trade off (TTO), EQ-5D and 
15D were the only measures (economic or non-economic) used alone in three studies 
(Kilonzo et al., 2010; Sculpher, 1998; Taipale et al., 2009). In addition to these studies, three 
studies that did use non-economic measures only used one economic measure, either SF-36 
or the EQ-VAS (Brown et al., 2006; Sculpher, 1993; Van der Wilt et al., 2005). The 
remaining studies combined multiple economic measures as well as using non-utility based 
disease-specific measures. These non-utility based disease-specific measures include; 
menstrual loss, satisfaction, anxiety, Health and Depression Scale and effect on sexual 
activity. In seven of the twelve studies that used economic measures in an economic 
evaluation, justification for the measure used (EQ-5D, TTO, SF-36) is provided with the most 
common reason being due to the measure being validated and/or universally accepted. See 
Appendix A2.2, Table 2 for details of the studies identified. 
 
5.3.6 Economic Measures in Effectiveness Studies  
Eight papers collected QoL data to determine the effectiveness of an intervention using a 
utility-based instrument as a primary outcome. Twenty-seven studies used QoL instruments 
as secondary outcomes, and seven of these were follow-up articles. The details of these 
studies can be found in Appendix 2.2 (see Tables 3 and 4). The large number of studies using 
QoL instruments as a secondary outcome could indicate that the importance of using QoL in 
menorrhagia is either not yet accepted or is difficult to implement with the currently available 
instruments. Where QoL instruments are used as secondary measures, the primary measure is 
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typically the degree of satisfaction and impact on sexual activity. Other than effect on sexual 
activity, non-health outcomes were considered in two studies (Dickersin et al., 2007; Malak 
& Shawki, 2006). These non-health outcomes included daily life, effect on employment, 
leisure activities and housework.  
SF-36/ SF-12 was the most commonly used instrument (19/27 studies). It was also the most 
common economic measure to be used alone (13/27 studies). Several economic measures 
were used in six out of twenty-seven studies and in five of these studies three or more 
measures were used. Given that the economic measures were secondary outcomes, they were 
combined with non-utility based disease-specific measures. The use of multiple economic 
measures may reflect that the most appropriate measure to use is unclear and the use of many 
non-utility based measures may be due to the inability of the economic measures to 
completely capture patient’s concerns. It was argued by one author that economic measures 
could complement disease-specific measures and the two should be combined to overcome 
their aforementioned problems (Bongers et al., 2005).   
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Table 5.2 Judgement on properties of instruments 
Instrument n Validity Reliability Sensitivity Feasibility/ 
utility 
Content Face  Construct 
EQ-5D 3 None None Pattison et 
al 2011 
None (Clark & 
Gupta, 
2004) 
Kilonzo et 
al 2010 
Judgement  Insufficient 
evidence 
Poor
a
 Poor Insufficient 
evidence 
Insufficient 
evidence 
Mixed 
SF-36 9 None Jenkinson 
et al 1996 
Garratt et 
al 1993 
Jenkinson 
et al 1996; 
Garratt et al 
1993; Ruta 
et al 1994 
Coulter et al 
1994;Garratt 
et al 1994; 
Habiba et al 
2010; 
Hehenkamp 
et al 2008 
Brown et al 
2006; 
Bongers et 
al 2005 
Judgement  Insufficient 
evidence 
Poor Mixed Mixed Mixed Mixed 
WTP 1 None None None Ryan et al 
2000 
None Ryan et al 
2000 
Judgement  Insufficient 
evidence 
Insufficient 
evidence 
N/A Poor Insufficient 
evidence 
Insufficient 
evidence 
a
 Comments on the face validity of SF-36 can be applied to EQ-5D 
 
5.4 Discussion 
The findings suggest that there is no consensus on the most appropriate economic measure to 
use when valuing outcomes in menorrhagia. The fundamental problem with using the generic 
measures SF-36 and EQ-5D to value QoL in menorrhagia is poor face validity due to the 
cyclical nature of the condition. As these have a standard recall component (i.e how is your 
health today (EQ-5D); during the past 4 weeks (SF-36)), any results achieved from using 
them are critically affected by the timing of assessment. The evidence suggests that women 
do not consider menorrhagia to be solely a health-related condition, as practical difficulties 
related to carrying extra sanitary protection and clothes, in addition to impact on social life 
and daily routine are found to be important (Shaw et al., 1998). This begs the question 
whether health-related QoL measures are suitable for measuring outcomes associated with 
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this condition. Furthermore, the findings from the economic evaluation suggest that 
researchers in this field do not feel they can rely on a single economic measure and have used 
several available instruments to allow an estimation of QALYs, in addition to disease-
specific measures in order to strengthen their evidence.  
The psychometric properties of EQ-5D and WTP in menorrhagia are under researched. Little 
evidence was found for the use of EQ-5D. Only one study assessed the reliability of WTP. 
Although the MMAS appears to be the most suitable measure due to the condition-specific 
nature, it cannot produce QALYs. One alternative would be to use mapping methodology 
whereby the outcome measured using the MMAS scale is mapped onto a 0-1 utility scale. 
However, this is not a perfect resolution as it requires a mapping algorithm to be generated 
based on the relationship between EQ-5D and MMAS. The limitations of mapping are 
described in section 3.3.2 under the subheading ‘Mapping’. 
 
5.4.1 Strengths and Limitations 
Based on a systematic search of the available evidence, this is the first systematic review that 
has sought to identify and review 1) the economic instruments that have been assessed in the 
menorrhagia patient population, 2) the instruments that have been used in economic 
evaluations and 3) those that have been used in effectiveness studies. The search 
methodology was robust and in line with others in the field (Blumenthal et al., 2011; Clark et 
al., 2002). The review has identified a limited set of studies that have assessed the 
psychometric properties of economic outcome measures within menorrhagia.  
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5.4.2 Comparison with Other Studies 
Two previous reviews have aimed to assess the quality of QoL instruments used in 
menorrhagia and to review economic and health related QoL outcomes data associated with 
Levonorgestrel-releasing intrauterine system (LNG-IUS) (Blumenthal et al., 2011; Clark et 
al., 2002). The present review differs to previous reviews as it assesses economic instruments 
used in any menorrhagia treatments and in studies of any design. Unlike Blumenthal et al 
(2011), who used only studies related to LNG-IUS, this review included any study using an 
economic measure in menorrhagia. The review reported here also incorporated both studies 
that used economic measures in clinical trials and observational studies to compare 
treatments, in addition to identifying evidence on the psychometric properties and feasibility 
of these measures in menorrhagia. Additionally, several more databases were searched to 
ensure all studies have been identified. In comparison to Clark et al (2002), the current 
review considers economic measures in terms of their appropriateness or use in economic 
evaluations, rather than assessing the performance of any non-utility based QoL instruments 
according to the psychometric measurement properties. Furthermore, the search terms used in 
the review by Clark et al (2002) were adapted in order to ensure all relevant articles were 
identified. In particular, the key additional search term included in the review reported in this 
chapter was ‘heavy menstrual bleeding’, as this term and menorrhagia are commonly and 
increasingly used interchangeably in clinical practice and in the literature. Hence the review 
reported in this chapter comprehensively assesses the relative success of any economic 
measure used in any study in menorrhagia, which has not been done before. 
 
5.4.3 Further Research 
It has been demonstrated that there is a case for combining QoL instruments in menorrhagia. 
However, the limitations of the instruments outlined in this review, which primarily relate to 
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the cyclical episodic nature of the condition, may not be unique to menorrhagia. The findings 
may be relevant to other conditions where symptoms occur in episodes such as migraines, 
exacerbations of chronic obstructive pulmonary disease and asthma amongst others. 
Nevertheless, the implications of our findings are particularly important for menorrhagia 
because treatment is driven by the women’s perception of the impact of the condition on their 
QoL.  
Mixed results in support of using SF-36 and EQ-5D to value health states in menorrhagia 
have been identified. Both the validity and reliability of these instruments are affected by the 
cyclical nature of the condition. WTP considers a broader range of QoL and overcomes the 
issue of timing of assessment but there is currently insufficient evidence for its use. Therefore 
the use of this outcome measure should be further explored. Many studies have successfully 
elicited WTP values in other disease areas (Frew et al., 2001; Haefeli et al., 2008), so perhaps 
WTP could prove to be the most suitable economic outcome measure in menorrhagia. 
 
5.5 Conclusion 
In this chapter a systematic review of economic outcome measures used in menorrhagia is 
reported. It is found that there is no consensus on the most appropriate measure to use in 
menorrhagia. The currently used extra-welfarist measures are shown to be limited due to their 
focus on health related QoL and the standard recall periods used meaning that the results are 
affected by the timing of assessment. The welfarist WTP, which enables a broader 
assessment of wellbeing and may overcome the issue of timing of assessment, has not been 
thoroughly explored in menorrhagia. Therefore there is scope for assessing the feasibility of 
WTP in menorrhagia. In the next chapter, the economic evaluation alongside the ECLIPSE 
trial, comparing LNG-IUS and usual medical treatment is reported. A comparison of the cost-
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effectiveness results provided by the two extra-welfarist measures, EQ-5D and SF-6D, will 
be drawn to determine the extent to which the findings from these measures differ.  
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CHAPTER 6. ECONOMIC EVALUATION ALONGSIDE ECLIPSE 
TRIAL 
 
6.1 Introduction 
In this chapter the economic evaluation alongside the NIHR HTA funded ECLIPSE 
randomised controlled trial is reported. The objective of the ECLIPSE trial is to compare the 
clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine 
system (LNG-IUS) versus usual medical treatment. As discussed in Chapter 2, following the 
recommendations of the National Institute for Health and Care Excellence (NICE), that 
surgical intervention should be the last course of treatment for patients with menorrhagia, the 
clinical and cost-effectiveness of non-surgical interventions has become the primary focus of 
clinicians and decision-makers alike.  
As discussed in Chapter 4, in 2007 NICE introduced guidelines (NICE, 2007) for the LNG-
IUS to be used for treatment of menorrhagia based on limited evidence of cost-effectiveness 
(Stewart et al., 2001). Nine other small trials compared LNG-IUS to non-hormonal and 
hormonal treatments, showing reduction in menstrual blood loss
 
but they did not consider 
cost-effectiveness (Endrikat et al., 2012; Shapley et al., 2002). The findings of the systematic 
review, in Chapter 4, on economic evaluations, further demonstrated that the existing 
economic evaluations have predominantly compared non-surgical interventions (either LNG-
IUS or usual medical treatment) to surgery, and non-surgical interventions have rarely been 
directly compared.  
The aim of this chapter, therefore, is to conduct an economic evaluation alongside the 
ECLIPSE trial to provide robust evidence on the cost-effectiveness of LNG-IUS compared to 
usual medical treatment. Further, as impact on quality of life (QoL) is the primary outcome 
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measure in menorrhagia, the outcome was measured using a number of different instruments 
including EQ-5D, SF-6D and the menorrhagia multi-attribute scale (MMAS). While MMAS 
is disease-specific, EQ-5D and SF-6D are both instruments that represent the extra-welfarist 
approach to measure outcomes. The influence on the cost-effectiveness results of using these 
extra-welfarist measures is explored. As the ECLIPSE trial has been described in detail in 
Chapter 2, a brief overview of the trial is provided here as part of the methods. The remaining 
section of the methods describes the model, the derivation of transition probabilities and 
utility values using the trial data, and resource use. The analysis and results then follow. The 
results are separated into two parts; Part 1 refers to EQ-5D and Part 2 to SF-6D. Finally, the 
discussion and implications for further research are reported. The reporting of this economic 
evaluation follows CHEERS guidelines and the checklist is presented in Appendix 3.1. 
 
6.2 Methods 
A model-based economic evaluation in the form of a cost-utility analysis (CUA) based on an 
outcome of cost per quality adjusted life year (QALY) was carried out alongside the 
ECLIPSE trial (Gupta et al., 2013). The analysis took a UK National Health Service (NHS) 
perspective in a primary care setting and provides an assessment of the difference in costs 
and QALYs between interventions over a 24 month time horizon. As the economic 
evaluation was carried out alongside a trial, an intention to treat analysis was adopted. A 
second analysis will be carried out at the 5 year time point, but falls outside the remit of this 
thesis. A societal perspective to include private costs to women was considered but deemed 
not to be feasible given the resource constraints for data collection. 
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6.2.1 Participants and Trial Design  
The ECLIPSE trial, which found LNG-IUS to be more effective than usual treatment, is 
reported in detail elsewhere (Gupta et al., 2013). Briefly, 571 women with menorrhagia from 
63 UK centres were randomised between February 2005 and July 2009. Women between 25 
and 50 years of age presenting to their general practitioner (GP) with menorrhagia, occurring 
over at least three consecutive cycles, provided written informed consent to participate. 
Women were randomised to having a LNG-IUS fitted, or usual medical treatment, chosen by 
the GP and the woman based on contraceptive needs or desire to avoid hormonal treatment. 
Usual medical treatment options included mefenamic acid, tranexamic acid, norethisterone, a 
combined oestrogen/progestogen or progestogen only oral contraceptive pill (any 
formulation), or methoxyprogesterone acetate injection (NCCWCH, 2007; RCOG, 1998). 
The particular medical treatment was specified prior to randomisation. Treatment reviews by 
GPs were carried out at 6 weeks and 3 months. Subsequently, treatments could be changed or 
discontinued due to perceived lack of benefit, side effects, change in contraception 
requirements, referral for endometrial ablation or hysterectomy as per usual practice 
(NCCWCH, 2007; RCOG, 1998). Treatment changes reported by patients were confirmed 
with the GP. 
The study was approved by the South West England multicentre research ethics committee 
and all relevant local ethics committees.   
 
6.2.2 Model 
A model-based analysis was used as a vehicle for the within trial economic analysis to 
comprehensively account for the changes in QoL that occurred whilst the women were taking 
these treatments. The model was completed alongside the trial. 
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The trial data showed that, due to its non-curative nature, women were changing their 
treatment to identify the best method for managing menorrhagia, and this process had an 
influence on their QoL. The most suitable method to capture changes in QoL, occurring 
throughout the trial, and provide a robust CUA, was to represent these experiences as health 
states in a decision model, which follows the process of management of menorrhagia used in 
the ECLIPSE trial. The analysis does not lend itself to a regression framework because 
patients change between different health states on a monthly basis and QoL was not measured 
at that frequency. Therefore, the optimal method is to attach a QoL value to the health states. 
As patient level QALYs are not available on a monthly basis, it would be inappropriate to 
infer them from QoL scores at the time they happen to be taken in the trial. Hence, a measure 
of change in utility from baseline and the endpoint of the trial, as in a typical trial-based 
analysis which does not use a decision model, would not accurately capture the health states 
that women had experienced throughout the time span of the trial. Furthermore, a trial-based 
analysis, without a decision model, would not capture the time spent in health states or the 
associated repetitive costs and resource use. In this case, a decision model based on trial data 
provides a more realistic explanation of the utility pathway, providing information that can be 
synthesised with other data and projected forward. 
A state transition (Markov) model was developed using Microsoft Excel. A Markov model 
was used because the treatment of menorrhagia has a complex prognosis that cannot be 
captured in a decision tree, again in part due to the repeated events. First, each time cycle of 
the menorrhagia model requires recurring events, which cannot be modelled in decision trees. 
Secondly, the elapse of time, i.e. monthly cycle, would also need to be made explicit which is 
only possible in Markov models (Briggs et al., 2006). Finally, as there are several possible 
consequences, or pathways, from each health state a decision tree would become overly 
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complicated and may lead to the exclusion of such data, which are likely to have resource 
implications and may affect cost-effectiveness recommendations. 
 
Model Structure 
Existing model structures from published studies, which were identified in Chapter 4, were 
not deemed relevant to this analysis. The findings of the systematic review on economic 
evaluations in menorrhagia, presented in Chapter 4, revealed that previous decision models 
have predominantly compared surgical interventions to LNG-IUS (Brown et al., 2006; Clegg 
et al., 2007; Roberts et al., 2011). When women have surgical interventions, it is unlikely that 
they will cross-over to a non-surgical treatment, thus these previous model pathways do not 
allow for cross-over, which is required for this analysis, and were therefore not used to 
inform the model structure. Furthermore, the previous models are not sufficiently 
comprehensive to include all changes in treatments and health status that are relevant here. 
Since previous model structures were not used, the structure was developed using 
information from several sources which are outlined below. 
To begin constructing the model, a map of the patient clinical pathway was drawn. The 
structure was informed by clinical input and by reviewing the ECLIPSE trial data to identify 
the pathway that women followed in the trial. Whilst the structure was not informed by 
literature, the health states for the model were developed using the pathways in the trial data 
and by adapting those used previously (NICE; 2007; Roberts et al., 2011). Several iterations 
of the structure were made as the model was continuously modified to ensure that it most 
closely reflected the trial data. The trial team, which included clinical experts, were 
extensively involved in the process of developing the model structure. Whilst the inclusion of 
menopause as a health state was considered, the 2 year time horizon of the analysis and the 
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age of the patients, between 25-50, meant very few, if any, women would be reaching 
menopause within 2 years. For similar reasons, ‘death’ was not included as a health state. 
That is, the interventions do not cause death, and the age of the women meant that the 
likelihood of death due to natural causes was minimal. As models are a simplification of 
reality, it is only necessary to include transitions between health states that commonly occur 
for the majority of patients, and this was not the case for ‘death’ and ‘menopause’. 
Figure 6.1 presents the clinical pathways and the progress of the two cohorts of women in the 
ECLIPSE trial who were randomised to either LNG-IUS or usual medical treatment. It can be 
seen that the pathway for each treatment can be represented in the same structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allocated 
treatment 
No 
treatment 
Menorrhagia 
Well with other 
treatment 
Symptomatic 
with allocated 
Well with 
allocated 
Post Surgery 
Change to other 
treatment 
Surgery 
Figure 6.1 Clinical pathway for LNG-IUS and usual medical treatment 
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Definition of Health States for LNG-IUS Pathway 
 Menorrhagia: Every woman in the ECLIPSE trial cohort suffers from excessive 
menstrual bleeding 
 LNG-IUS: All women have LNG-IUS inserted  
 Well with LNG-IUS: following the insertion of ‘LNG-IUS’ women are satisfied with 
treatment and remain in this health state  
 Symptomatic with LNG-IUS: following the insertion of ‘LNG-IUS’, adverse effects 
may arise and women may feel unsettled with their current treatment. From this state 
women may remain in the state or change to an alternative treatment i.e. usual 
treatment, surgery, or no treatment  
 Surgery: Women may choose to have surgery, which includes endometrial ablation 
or hysterectomy, which is determined from the data. Women can move to surgery 
from ‘symptomatic with LNG-IUS’, ‘change to usual medical treatment’, or ‘no 
treatment’ 
 Post-Surgery: following ‘surgery’, women will then remain in the ‘post-surgery’ 
state 
 Change to usual medical treatment: if women have chosen ‘no treatment’ or are 
‘symptomatic with LNG-IUS’ they may choose to begin usual medical treatment. 
Women may immediately become ‘well with usual medical treatment’ or may 
experience adverse effects and feel unsettled with usual medical treatment and then 
eventually become ‘well with usual medical treatment’. Alternatively, women may 
choose to have ‘surgery’ or ‘no treatment’. If women are in this state at 3 months the 
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cost of a GP review will be incurred. Women can change to usual medical treatment 
from LNG-IUS in the first cycle. (See model assumptions for further details) 
 Well with usual medical treatment: following ‘change to usual medical treatment’ 
women are satisfied with this treatment and remain in this health state  
 No treatment: Following LNG-IUS, ‘symptomatic with LNG-IUS’ and ‘change to 
usual medical treatment’, women may choose to discontinue treatment altogether. 
Following this, women may decide to ‘change to usual medical treatment’ or have 
‘Surgery’. 
 
Definition of Health States for Usual Medical Treatment Pathway 
 Menorrhagia: Every woman in the ECLIPSE trial cohort suffers from excessive 
menstrual bleeding 
 Usual medical treatment: All women have usual medical treatment 
 Well with usual medical treatment: following ‘usual medical treatment’ women are 
satisfied and remain in this health state  
 Symptomatic: following usual medical treatment, adverse effects may arise and 
women may feel unsettled. From this state women may have an alternative treatment 
i.e. ‘change to LNG-IUS’,’ surgery’, or ‘no treatment’ 
 Surgery: Women may choose to have surgery, which includes endometrial ablation 
or hysterectomy, which is determined from the data. Women can move to surgery 
from ‘symptomatic with usual medical treatment’, ‘change to LNG-IUS’, or ‘no 
treatment’ 
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 Post-Surgery: following ‘surgery’, women will then remain in the ‘post-surgery’ 
state 
 Change to LNG-IUS: if women have chosen ‘no treatment’ or are ‘symptomatic with 
usual medical treatment’ they may choose to begin treatment with LNG-IUS. Women 
may immediately become ‘well with LNG-IUS’ or may experience adverse effects 
and feel unsettled with LNG-IUS and then eventually become ‘well with LNG-IUS’. 
Alternatively women may choose to have ‘surgery’ or ‘no treatment’. Women can 
change to LNG-IUS from usual medical treatment in the first cycle. (See model 
assumptions for further details) 
 Well with LNG-IUS: following ‘change to LNG-IUS’ women are satisfied with 
treatment and remain in that health state 
 No treatment: Following ‘usual medical treatment’, ‘symptomatic with usual medical 
treatment’ and ‘change to LNG-IUS’ women may choose to discontinue treatment 
altogether. Following this, women may decide to ‘change to LNG-IUS’ or have 
‘Surgery’. 
 
Time Cycle 
A monthly time cycle was used in the analysis as this represented the clinically meaningful 
changes observed in treatment and resource use. The results of the systematic review in 
Chapter 4, on economic evaluations in menorrhagia, showed that there is no agreement on 
which time cycle should be used. A time cycle of either 1 year (You et al., 2006), 3 months 
(NICE, 2007; Ganz et al., 2013), 6 months (Lete et al., 2011) or 1 month was used previously 
(Clegg et al., 2007; Roberts et al., 2011). The NICE guidelines reported a 3 month time cycle, 
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because it was constrained by available evidence (NICE, 2007). The ECLIPSE data showed 
that in many cases treatments had been altered and women had visited their GP within a 
month of treatment administration. Thus treatment changes were occurring more frequently 
than every 3 months. A monthly time cycle was therefore required to reflect the data and 
incorporate the associated costs and treatment changes into the CUA. A half-cycle correction 
was not used to allow for transitions to occur in the middle of the cycle (instead of the 
beginning or the end of the cycle) because the time cycle is small relative to the time horizon. 
On this basis a correction would not have made a substantial difference to the costs and 
outcomes (Briggs et al., 2006). The following assumptions were developed with clinical 
expertise from the ECLIPSE trial, which included a GP and a gynaecologist.  
 
Model Assumptions 
 A woman is ‘well’ with the allocated treatment if she does not change or stop 
treatment. Some of these women may not be ‘well’ but are coping with treatment, and 
the utility values for the ‘well’ with allocated treatment state reflect this  
 A woman who is ‘well with LNG-IUS’ or ‘well with usual medical treatment’ cannot 
spontaneously become ‘symptomatic’  
 Based on the data, if in the first cycle, women move from the allocated treatment to an 
alternative state other than ‘well’, it is assumed they either move to the ‘change to 
alternative treatment’ or ‘no treatment’ state. It is assumed that they do not move to 
the ‘symptomatic’ state in the first cycle because insufficient time has elapsed for this 
to be established and so it is assumed they changed for other reasons 
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 From the second cycle onwards, if women change from their allocated treatment they 
do not go to ‘well’ but to the ‘symptomatic’ state and move on from there 
 For the transition to ‘surgery’, data were collected on whether a woman had ablation 
or hysterectomy, but not the precise technique (e.g. thermal balloon endometrial 
ablation or microwave endometrial ablation). Data on the weighted likelihood of 
surgery undertaken were taken from a previous study (Roberts et al., 2011). It is 
assumed that if a woman in the trial has endometrial ablation, then it will be for her 
first ablation and we apply the cost for first line endometrial ablation techniques  
 Once a woman has changed from the allocated treatment, it is not possible for the 
woman to move back to the allocated treatment 
 It is assumed that if a woman changes to the other treatment’, she must spend at least 
one cycle in ‘change to other treatment’ before she can move to ‘well with other 
treatment’. This is assumed as it will take at least one menstrual cycle for any effect to 
become apparent. 
 
Calculating Transition Probabilities 
To use the trial data in the model, it was necessary first to generate the ‘Markov trace’ by 
hand to identify the distribution of women in the states at any time and the transition 
probabilities between health states (Briggs et al., 2006).  
First, for every patient, the time in months from randomisation to every event was calculated. 
For example, the number of months from randomisation to ‘change to usual medical 
treatment’ was calculated, and similarly for any other changes to states. 
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Using Microsoft EXCEL, two spreadsheets were constructed, one for LNG-IUS and the other 
for usual medical treatment. In each spreadsheet, all of the possible transitions from one state 
to another were outlined in the columns of a table and the rows of the table represented each 
patient. For every patient, the treatment allocated was identified and the time in months at 
which the patient moved from each state was entered into the appropriate column of the 
relevant spreadsheet, as shown in Appendix 3.2. 
For each column that represents a change in state, the number of women who made the 
transition was summed according to the month at which the move was made. For example, all 
the women who stopped treatment in cycle 1 were summed, and those who stopped in cycle 2 
were summed and so on. This was repeated for every cycle and every change in state. 
To generate the Markov trace and obtain probabilities, the movements of all patients leaving 
and entering all of the states in each cycle of the model were tracked. The usual medical 
treatment arm is used to provide an example of how the Markov trace was conducted, but the 
method also applies to LNG-IUS. 
In the model, it is assumed that patients who move to an alternative treatment (‘surgery’, ‘no 
treatment’, ‘change to LNG-IUS’) should not move to ‘well with usual medical treatment’ 
but should be moved to the ‘symptomatic’ state. Therefore the probability of moving from 
‘usual medical treatment’ to ‘well with usual medical treatment’ was the total number of 
women who made no moves divided by the total number of women who were randomised to 
usual medical treatment. 
From ‘usual medical treatment’ to ‘symptomatic with usual medical treatment’ the 
number of women who did not move to symptomatic was counted and deducted from the 
total number of women randomised to usual medical treatment. To obtain the transition 
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probability, this number of women entering symptomatic was divided by the total number of 
women randomised to usual medical treatment.   
In cases where women made moves that were not possible in the model, for example, 
returning to allocated treatment after changing to another state, these women were censored 
at the last point a move was possible. This change only occurred in 4 cases and is advised 
against clinically. Therefore this transition was not considered to be a typical pathway and 
does not represent the population. As the point in the cycle at which the women moved back 
to ‘usual medical treatment’ is unknown, the women were censored at one cycle prior to the 
return to randomised treatment.  
From ‘usual medical treatment’ to ‘change to LNG-IUS’ to be consistent and prevent 
biasing any data, the two patients that changed to LNG-IUS within the first month of 
treatment allocation were moved directly to this state without spending any time in 
symptomatic as reflected in the data. These women were identified by referring to the number 
of women who move in cycle 1. The total number who made the transition was divided by 
the total number of women who were randomised to usual medical treatment. The same 
method was used for movements from ‘usual medical treatment’ to ‘no treatment’ in the 
first cycle. In the majority of the cases, the usual medical treatment was never taken and so 
considering these patients as symptomatic with usual medical treatment would not be 
accurate. 
For the transition of remaining in symptomatic, it was necessary to calculate the total 
number of occasions that a woman starts in the symptomatic state to obtain the denominator 
for the probability of remaining in and leaving the symptomatic state. To calculate the 
number of occasions that a patient starts in the symptomatic state, the total number who 
moved into symptomatic in the first cycle was deducted from the number of women who 
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move out of symptomatic i.e. to ‘no treatment’, ‘change to LNG-IUS’ or ‘surgery’, in cycle 1. 
This value was zero for the first cycle as all symptomatic women move into this state in the 
first cycle. For the next cycle, the number of women leaving symptomatic was deducted from 
the number of women remaining in symptomatic from cycle 1, as previously. This calculation 
was continued for every cycle. The number of occasions that women start in the symptomatic 
state was then summed for every cycle to give the total number of occasions someone starts 
in the state. The total number of times someone remains in the symptomatic state was then 
calculated by subtracting the total number of times a woman leaves the symptomatic state 
from the total number of occasions a woman starts in the symptomatic state. The probability 
of remaining in symptomatic was then this value divided by the total number of occasions 
someone starts in symptomatic.  
The method is similar for remaining in ‘change to LNG-IUS’ and remaining in ‘no 
treatment’, to that of ‘remaining in symptomatic’. The difference between these transitions 
and ‘remaining in symptomatic’ is that women enter ‘change to LNG-IUS’ and ‘no 
treatment’ from more than one state, and at any given cycle. Therefore when counting the 
number of women who start in the state and the number of women who leave in each cycle, 
the number of women entering from all states in each cycle must also be accounted for.  
Transition probabilities for ‘symptomatic with usual medical treatment’ to ‘change to 
LNG-IUS’ or ‘symptomatic’ to ‘no treatment’ or ‘symptomatic’ to ‘surgery’ were 
calculated by dividing the total number of women that leave symptomatic for the respective 
states, by the total number of occasions a woman starts in the symptomatic state.  
For the explanation of the transition probability for ‘change to LNG-IUS’ to ‘well with 
LNG-IUS’, one of the model assumptions set out above should again be highlighted. That is, 
women must spend at least one cycle in ‘change to LNG-IUS’ to then enter the ‘well with 
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LNG-IUS’ state. When a patient moves to ‘change to LNG-IUS’ and would theoretically be 
classed as ‘well with LNG-IUS’ because she did not make any subsequent moves, she is 
placed into ‘well with LNG-IUS’ in the next cycle. Therefore if a woman ‘changes to LNG-
IUS’ in cycle 4, she would be entered into the ‘well with LNG-IUS’ at cycle 5. To obtain the 
transition probability, the total number of women that move from ‘change to LNG-IUS’ to 
‘well with LNG-IUS’ was summed and divided by the total number in ‘change to LNG-IUS’.  
The probability of moving from ‘no treatment’ to ‘surgery’ or ‘change to LNG-IUS’ to 
‘surgery’ was calculated by dividing the total number of women who enter surgery, from 
each of the respective states, by the total number of women in the prior respective states. As 
women cannot stay in surgery, it is constructed as a transition state and therefore 100% of the 
women in ‘surgery’ move to ‘post-surgery’ after one cycle.  
Remaining in ‘post-surgery’ and remaining in ‘well with usual medical treatment’ are 
both absorbing states. This means women cannot leave the state once they have entered and 
therefore the probability of remaining in these states is 100%.  
The calculation of the utility values assigned to each health state will be described in the next 
section following a description of the outcome measures collected in the trial.  
 
6.2.3 Outcome Measures 
Outcome measures were collected using both EuroQol-5D (EQ-5D) and Short-Form-36 (SF-
36) at baseline prior to randomisation, then by post at 6 months, 1 year and 2 years post-
randomisation. The booklet questionnaire, given to women in the trial, contained the generic 
EQ-5D-3L questionnaire which measures the impact of treatment on broader aspects of 
health related QoL (Brooks, 1996). SF-36 was converted into SF-6D using the algorithm by 
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Brazier et al (2002). [Provided by John Brazier’s team at Sheffield University Personal 
Communication]. A complete case analysis is presented due to the nature of the analysis 
(further discussion is provided in section 6.5.1 of the discussion).  
 
Calculating Utility Values 
EQ-5D is reported as this is used for the base case; SF-6D is also reported, but in parentheses. 
The utility values for the health states were collated separately for each treatment arm. That 
is, the utilities for health states in the LNG-IUS treatment arm are taken only from women 
that were randomised to LNG-IUS. Utility values for the individual states were calculated by 
averaging the EQ-5D (SF-6D) values obtained by each woman in the given state at any given 
time. For example if a woman is randomised to LNG-IUS and then does not change treatment 
she is considered to be in the ‘well’ state for the remainder of the analysis, as outlined in the 
model assumptions previously. Therefore all of the woman’s utility values collected at 6 
months, 1 year and 2 years will be assigned to the ‘well’ health state in the model. Similarly 
if a woman is initially ‘symptomatic with LNG-IUS’ and then moves to ‘no treatment’ at 2 
years, the utility values for 6 months and 1 year will be assigned to ‘symptomatic’ and the 
utilities for 2 years assigned to the ‘no treatment’ health state. This method was used to 
derive the utility values because the utility for the state is important, not the values associated 
with the individual woman’s journey, as decision models are a reflection of the typical 
population. 
The time from randomisation to the date of completion of EQ-5D (SF-6D) for each time 
point was also calculated and converted into the monthly time cycle. This was necessary to 
ensure that the correct EQ-5D (SF-6D) value was taken for the correct health state. The 
patient’s state was then checked against the date when EQ-5D (SF-6D) was completed, and 
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the EQ-5D (SF-6D) value was assigned correspondingly for all relevant time points. Where a 
patient was shown to have changed treatment on the same cycle that the EQ-5D (SF-6D) was 
completed, the exact EQ-5D (SF-6D) completion date and treatment change date was 
checked and dealt with accordingly. If the completion date and treatment change date were 
identical, the EQ-5D (SF-6D) value was assigned to the treatment change. This assumption 
will be tested in the sensitivity analysis, where the EQ-5D (SF-6D) value will belong to the 
state prior to the change.  
Patients’ EQ-5D (SF-6D) values were classed as ‘symptomatic’ up until a treatment change 
occurred. Where no change was made, the patient did not enter ‘symptomatic’, and the EQ-
5D (SF-6D) values were all classed as ‘Well’. Where the EQ-5D (SF-6D) was completed 
beyond 24 months for the 2 year follow-up, the date of completion and patient data were 
checked. If the patient had not made any subsequent moves between states and remained in 
the last known state the ‘2 year’ EQ-5D (SF-6D) data were included. If a patient moved after 
2 years and the EQ-5D (SF-6D) was completed prior to the move, but beyond 24 months, the 
EQ-5D (SF-6D) value was included. However, the EQ-5D (SF-6D) value would not be 
included if EQ-5D (SF-6D) was completed after the move, which occurred beyond 24 
months. EQ-5D (SF-6D) data from patients who were censored from the follow-up, because 
they made a move in the model that was not possible, were excluded after the last point a 
move was possible.  
For the utility values for patients who crossed over to the other arm of the trial and became 
well, the usual medical treatment arm will be used to provide the example explanation of how 
the utility values were derived. In the usual medical treatment arm, for the ‘change to LNG-
IUS’ and ‘well with LNG-IUS’ states, the EQ-5D (SF-6D) value was classed as ‘change to 
LNG-IUS’ if EQ-5D (SF-6D) was completed in the same cycle as the ‘change to LNG-IUS’. 
If the patient subsequently moved to ‘well with LNG-IUS’ in the next cycle, the next EQ-5D 
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(SF-6D) value and subsequent values were classed as ‘well with LNG-IUS’. Where a patient 
‘changes to LNG-IUS’ and then did not move to ‘well with LNG-IUS’, but moved to another 
state, the EQ-5D (SF-6D) values in between the ‘change to LNG-IUS’ and the next move 
were classed as ‘change to LNG-IUS’. A similar method was used for changes from the 
LNG-IUS arm to the usual medical treatment arm.  
In the case of the utility values for surgery and post-surgery, as utility data were collected at 6 
months, 1 year and 2 years the utility value obtained would be for any time point after 
surgery. The utility values given could not be considered the same as the utility value at the 
time of surgery because data on the exact date of surgery were not available. Therefore, the 
utility value collected after surgery was assigned to the ‘post-surgery’ state and the ‘surgery’ 
utility value was ¾ of the post-surgery utility. This was assigned because the patient was 
likely to be most severely affected by surgery during the first week of the month after 
surgery.  
 
Significance tests for counterintuitive EQ-5D utility values 
A series of significance tests were conducted to identify whether a statistically significant 
difference was observed between states where the utility values were counterintuitive. 
In the LNG-IUS arm of the trial the EQ-5D utility values for the ‘change to usual medical 
treatment’ state and ‘well with usual medical treatment’ states were counterintuitive. This 
was because the utility value for ‘change to usual medical treatment’ was higher than the 
value for ‘well with usual medical treatment’. The histograms for the utility data for each 
health state illustrate that the data were found to be negatively skewed (Figure 6.2). To 
account for the non-normality, a Wilcoxon rank sum test was conducted using STATA 
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(v11.0). The null hypothesis for the test was that there is no statistically significant difference 
in utility values between the states.  
Figure 6.2 Histograms for EQ-5D utility data 
 
 
0; change to usual medical treatment, 1; well with usual medical treatment 
The p-value of 0.3580 is greater than 0.05 and therefore the null hypothesis cannot be 
rejected as there is no statistically significant difference between the utility values for ‘change 
to usual medical treatment’ and ‘well with usual medical treatment’ in the LNG-IUS arm.  
In the usual medical treatment arm of the trial, the utility value for ‘well with usual medical 
treatment’ is unexpectedly lower than the utility value for ‘symptomatic with usual 
medical treatment’. The utility data were found to be negatively skewed for both states 
(Figure 6.3) and a Wilcoxon rank sum test was conducted with a null hypothesis that there is 
no statistically significant difference in utility values across states.  
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Figure 6.3 Histograms for EQ-5D utility data (2) 
 
 
0; well with usual medical treatment, 1; symptomatic with usual medical treatment 
From the test it can be seen that the p-value is 0.3999 which is greater than 0.05. Therefore 
the null hypothesis cannot be rejected as there is no statistically significant difference 
between the utility values for ‘well with usual medical treatment’ and ‘symptomatic with 
usual medical treatment’ in the usual medical treatment arm.  
 
Significance tests for counterintuitive SF-6D utility values 
In the LNG-IUS arm of the trial, when SF-6D is used, the utility value for ‘change to usual 
medical treatment’ is greater than the utility value for ‘well with usual medical treatment’. 
The utility data for ‘change to usual medical treatment’ were found to be slightly negatively 
skewed (Figure 6.4). So, a Wilcoxon rank sum test was conducted with a null hypothesis that 
there is no statistically significant difference in utility values across states. 
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Figure 6.4 Histograms for SF-6D utility data 
 
 
0; change to usual medical treatment, 1; well with usual medical treatment 
The p-value is 0.9761 which is greater than 0.05 therefore the null hypothesis cannot be 
rejected and it can be said that the difference between the states is not statistically significant. 
In the usual medical treatment arm of the trial, the utility value for ‘symptomatic with usual 
medical treatment’ is greater than the utility value for ‘well with usual medical treatment’. 
The utility data for ‘symptomatic’ were found to be slightly negatively skewed (Figure 6.5), 
so a Wilcoxon rank sum test was conducted with a null hypothesis that there is no statistically 
significant difference in utility values across states. 
0
2
4
6
8
1
0
D
e
n
s
it
y
.5 .55 .6 .65
SF-6D change to oral
0
2
4
6
8
D
e
n
s
it
y
.5 .55 .6 .65 .7 .75
SF-6D well with oral
    Prob > |z| =   0.9761
             z =   0.030
Ho: chang~al(grpcha~a==0) = chang~al(grpcha~a==1)
adjusted variance       2505.69
                               
adjustment for ties       -2.31
unadjusted variance     2508.00
    combined         56        1596        1596
                                               
           1         44      1252.5        1254
           0         12       343.5         342
                                               
grpchangeo~a        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
131 
 
Figure 6.5 Histograms for SF-6D utility data (2) 
 
 
0; well with usual medical treatment, 1; symptomatic with usual medical treatment 
As the p-value of 0.0462 is very close to the arbitrary value of 0.05, it could be argued that it 
is likely that this statistical significance has occurred by chance due to the number of 
statistical significance tests conducted. 
Also in the usual medical treatment arm, the utility value for ‘change to LNG-IUS’ is greater 
than the utility value for ‘well with LNG-IUS’. The utility data for ‘well with LNG-IUS’ 
were found to be negatively skewed (Figure 6.6), so a Wilcoxon rank sum test was conducted 
with a null hypothesis that there is no statistically significant difference in utility values 
across states. 
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Figure 6.6 Histograms for SF-6D utility data (3) 
 
 
0; well with LNG-IUS, 1; change to LNG-IUS 
The p-value is 0.0238 which suggests that there is a statistically significant difference 
between the two states. It should be noted that this difference has arisen when SF-6D utility 
values are used and not EQ-5D. Perhaps this difference reflects that the measures are 
detecting different aspects of QoL and LNG-IUS may be impacting on areas that are captured 
by EQ-5D. Alternatively, the utility values may reflect that women were hopeful in the 
‘change to LNG-IUS’ state that, after having tried usual medical treatment, the effect of 
LNG-IUS would be greater than it was.  
 
6.2.4 Costs and Resource Use  
Costs were collected from a UK NHS perspective. Data on healthcare resource use, including 
GP or gynaecologist consultations, were collected from women alongside other outcome 
measures. Similar to the utility values, data on costs and resource use from the trial were 
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collated and analysed according to the randomised treatment arm. The general healthcare 
costs for both groups included healthcare staff costs and the cost of the interventions. An 
LNG-IUS fitting was estimated to take 20 minutes (informed by clinical experts within trial 
team), require both a GP and nurse to be present and also require disposable consumables. 
Treatment review by the GP was assumed to last 10 minutes (informed by clinical experts 
within trial team). Staff costs were calculated using nationally recognised reference costs 
(Curtis, 2011). The costs of standard medical treatment and LNG-IUS were estimated from 
the British National Formulary (BNF, 2011). Cost data on surgical interventions were taken 
from a previously published study and inflated to 2011 prices (Curtis, 2011; Roberts et al., 
2011). As recommended by NICE a discount rate of 3.5% was applied to both costs and 
utilities as the model time horizon is beyond 1 year (NICE, 2008). All costs are reported in 
2011 prices in UK (£) sterling using the UK hospital and community health services index 
(Curtis, 2011). Tables 6.1-6.3 present the data used in the analysis.  
In cases where women were prescribed a combination of usual medical treatments, a 
weighted average of the cost was taken. When a patient was randomised to usual medical 
treatment, precise data on the type of usual medical treatment administered were not 
available. As these data were available in the change to usual medical treatment state in the 
LNG-IUS arm, the weighted average cost of the usual medical treatment in the LNG-IUS arm 
of the trial was used as a proxy for the usual medical treatment arm. Similarly, repeat 
prescription costs were calculated based on the average weighted cost of repeat prescriptions 
in the ‘change to usual medical treatment’ state of the LNG-IUS arm. As the most commonly 
prescribed usual medical treatments involved GP review for effectiveness at 3 months, it was 
assumed that GP review occurs at 3 months.  
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Where one-off costs were incurred and were not repetitive monthly costs, such as the cost of 
LNG-IUS removal, these costs were assigned to the transition arrow rather than the state as is 
typically done when costs are not repetitive. 
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Table 6.1 Cost data used in the analysis 
 Unit cost Source 
LNG-IUS   
Consultation (GP 10 mins) £26.67 Curtis 2011/ expert opinion 
Insertion  
GP (20 mins) 
Practice nurse (20 mins) 
Device cost 
Sterile pack (insertion) 
 
£53.33 
£17.00 
£88.00 
£21.63 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
BNF 62 
NICE (inflated to 2011) 
Discontinuation 
GP (10 mins) 
Practice nurse (10mins) 
Sterile pack (removal) 
 
£26.67 
£8.50 
£3.77 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
NICE (Inflated to 2011) 
Follow-up 
6 week review: (GP 10 mins) 
3 month: (GP 10 mins) 
 
£26.67 
£26.67 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
Usual medical treatment 
Progestogen (Cerazette) 
Tranexamic acid (cyclokapron) 
Mefenamic acid (Ponstan) 
Norethisterone 
Combined oral contraceptive 
(microgynon) 
Methoxyprogesterone acetate 
injections (Depo-provera) 
Consultation: (GP 10 mins) 
3 or 6 month review (GP 10 mins) 
Discontinuation (GP 10 mins) 
 
£8.68 
£14.30 
£15.72 
£2.18 
£2.82 
 
£6.01 
 
£26.67 
£26.67 
£26.67 
 
BNF 62 
BNF 62 
BNF 62 
BNF 62 
BNF 62 
 
BNF 62 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
Surgery £1720.18 Weighted cost from trial 
All costs are presented in 2011 (£) sterling 
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Table 6.2 Health state utility data used in the model 
Health State EQ-5D 
value 
PSA Distribution 
(EQ-5D) 
SF-6D 
Value
#
 
PSA Distribution 
(SF-6D)
#
 
Source 
LNG-IUS      
LNG-IUS 0.756 Beta (653, 211) 0.597 Beta (10204, 6883) ECLIPSE trial 
Well with LNG-IUS 0.98 Beta (1169, 297) 0.598 Beta (17912, 12061) ECLIPSE trial 
Symptomatic with LNG-
IUS 
0.744 Beta (130, 45) 0.589 Beta (3464, 2418) ECLIPSE trial 
Change to usual medical 
treatment 
0.817 Beta (20, 5) 0.596 Beta (1066, 723) ECLIPSE trial 
Well with usual medical 
treatment 
0.714 Beta (66, 26) 0.594 Beta (2032, 1390) ECLIPSE trial 
No treatment 0.785 Beta (70, 19) 0.604 Beta (2108, 1380) ECLIPSE trial 
Surgery 0.620 Linked to post 
surgery 
0.430 Linked to post 
surgery 
ECLIPSE trial 
Post-surgery 0.827 Beta (59, 12) 0.574 Beta (330, 245) ECLIPSE trial 
Usual medical treatment      
Usual medical treatment 0.714 Beta (514, 206) 0.603 Beta (9892, 6519) ECLIPSE trial 
Well with usual medical 
treatment 
0.728 Beta (528, 197) 0.592 Beta (9664, 6647) ECLIPSE trial 
Symptomatic with usual 
medical treatment 
0.756 Beta (311, 100) 0.606 Beta (5168, 3359) ECLIPSE trial 
Change to LNG-IUS 0.694 Beta (49, 21) 0.627 Beta (2494, 1484) ECLIPSE trial 
Well with LNG-IUS 0.801 Beta (282, 70) 0.595 Beta (4069, 2766) ECLIPSE trial 
No treatment 0.766 Beta (223, 68) 0.586 Beta (3548, 2509) ECLIPSE trial 
Surgery  0.619 Linked to post-
surgery 
0.454 Linked to post 
surgery 
ECLIPSE trial 
Post-surgery 0.825 Beta (64, 14) 0.606 Beta (2136, 1391) ECLIPSE trial 
Utility values are rounded to 3 decimal places. α and β values for the PSA distribution are rounded to the nearest 
whole number. LNG-IUS; levonorgestrel-releasing intrauterine system, PSA; probabilistic sensitivity analysis.   
#
Values used in sensitivity analysis 4.  
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Table 6.3 Probability parameters used in the analysis 
Probability Parameters Probability  PSA distribution 
LNG-IUS   
LNG-IUS to well with LNG-IUS 0.639 (182, 103) 
(72, 213) 
(19, 266)  Dirichlet 
(12, 73) 
LNG-IUS to symptomatic with LNG-IUS 0.253 
LNG-IUS to change to usual medical treatment 0.067 
LNG-IUS to no treatment 0.042 
Remain Well with LNG-IUS 1 Fixed 
Symptomatic with LNG-IUS to well with LNG-IUS 0 Fixed 
Remain symptomatic with LNG-IUS 0.907 (700, 72) 
(27, 745) 
(32, 740)  Dirichlet 
(13, 759) 
Symptomatic with LNG-IUS to change to usual medical treatment 0.035 
Symptomatic with LNG-IUS to no treatment 0.041 
Symptomatic with LNG-IUS to surgery 0.017 
Remain change to usual medical treatment 0.708 (109, 45) 
(32, 122) 
(7, 147)   Dirichlet 
(6, 148) 
Change to usual medical treatment to well with usual medical treatment 0.208 
Change to usual medical treatment to no treatment 0.045 
Change to usual medical treatment to surgery 0.039 
Remain well with usual medical treatment 1 Fixed 
No treatment to change to usual medical treatment 0 (1, 547) 
(540, 8)    Dirichlet 
(10, 538) 
Remain no treatment  0.984 
No treatment to surgery 0.016 
Surgery to post surgery 1 Fixed  
Remain post surgery 1 Fixed 
Usual medical treatment   
Usual medical treatment to well with usual medical treatment 0.402 (115, 171) 
(162, 124) 
(2, 284)    Dirichlet 
(7, 279) 
Usual medical treatment to symptomatic with usual medical treatment 0.566 
Usual medical treatment to change to LNG-IUS 0.007 
Usual medical treatment to no treatment 0.024 
Remain Well with usual medical treatment 1 Fixed 
Symptomatic with usual medical treatment to well with usual medical 
treatment 
0 Fixed 
Remain symptomatic with usual medical treatment 0.901 (1474, 162) 
(80, 1556) 
(65, 1571)Dirichlet 
(17, 1619) 
Symptomatic with usual medical treatment to change to LNG-IUS 0.049 
Symptomatic to no treatment 0.040 
Symptomatic to surgery 0.010 
Remain change to LNG-IUS 0.603 (120, 79) 
(62, 137) 
(9, 190)    Dirichlet 
(8, 191) 
Change to LNG-IUS to well with LNG-IUS 0.312 
Change to LNG-IUS to no treatment 0.045 
Change to LNG-IUS to surgery 0.040 
Remain well with LNG-IUS  1 Fixed 
No treatment to change to LNG-IUS 0.001 (1, 852) 
(846, 7)    Dirichlet 
(6, 847) 
Remain no treatment  0.992 
No treatment to surgery 0.007 
Surgery to post surgery 1 Fixed  
Post surgery to post surgery 1 Fixed 
 α and β values for the PSA distribution are rounded to the nearest whole number. LNG-IUS; levonorgestrel-
releasing intrauterine system, PSA; probabilistic sensitivity analysis. 
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6.3 Analysis 
An incremental CUA which provides information on the difference in costs and QALYs 
between LNG-IUS and usual medical treatment is reported as an incremental cost-
effectiveness ratio (ICER), in terms of cost per QALY gained. If a treatment is less costly and 
generates a greater number of QALYs, dominance is said to occur. Analysis was by intention-
to-treat to provide a pragmatic estimate of ICERs. The base case analysis and sensitivity 
analyses will be first carried out using EQ-5D and then using SF-6D.  
Uncertainty in the model was assessed by conducting both deterministic and probabilistic 
sensitivity analysis (PSA). Population heterogeneity was not considered by assessing the cost-
effectiveness according to population subgroups because the randomised nature of the trial 
should mean that there are no systematic differences between women in each treatment arm.   
Deterministic sensitivity analyses were carried out where three individual model parameters 
were changed as set out below.  
1. In the first, the mean utility values for each state were replaced by the median utility 
value. Previously some published studies used the median and not the mean value, 
which greatly impacts the cost-effectiveness results and is argued to be inappropriate 
(Roberts et al., 2011). The current analysis assesses the impact of using such values 
when primary data are collected.  
2. In sensitivity analysis 2, the assumptions used in the UK national guidelines costing 
template which include a practice nurse for only 10 minutes for the initial consultation 
and insertion, treatment review by a nurse at 6 weeks only for those with a LNG-IUS 
fitted and annual follow-up for both treatment groups thereafter were incorporated 
(NICE, 2007).  
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3. Finally, in the base case, it was assumed that when an EQ-5D (SF-6D) completion 
date and notification of change of treatment coincide, the EQ-5D (SF-6D) value will 
belong to the subsequent state. In sensitivity analysis 3, the EQ-5D (SF-6D) value to 
the state prior to the change was assigned.   
The PSA simultaneously changes all relevant parameters in the model. For each parameter, a 
distribution is assigned and a value for each parameter is randomly drawn from the assigned 
distribution. This is repeated 1000 times and the range of incremental cost and QALY results 
for LNG-IUS and usual medical treatment are presented on the cost-effectiveness plane. 
These 1000 values were used to construct a cost-effectiveness acceptability curve (CEAC) to 
illustrate the probability of LNG-IUS being more cost-effective than usual medical treatment, 
across a range of monetary values that decision-makers may be willing to pay for an 
additional QALY.  
 
6.3.1 Distributions for the Probabilistic Sensitivity Analysis 
A Dirichlet distribution was used for the transition probabilities because this distribution 
allows for a possible movement to more than two states. Where a transition between states is 
possible but did not occur in the trial data, a value of one is added to all such transitions to 
enable the Dirichlet distribution to be assigned and to compensate for not observing the 
transition in the data (Briggs et al., 2003).  
In Table 6.3 it can be seen that some distributions are fixed at the given value. This is because 
these transitions are not dependent on the data and logically it would not be appropriate for 
the transition to be made probabilistic. For example, the transitions for remaining in well 
states should remain at 100% because these are absorbing states and women cannot leave 
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them. Fixed distributions are also assigned for the transition to ‘symptomatic’ to ‘well’ 
because given the assumptions of this model, that once a woman changes treatment and 
moves elsewhere she is classed as symptomatic, this transition to well from symptomatic is 
not possible.  
Costs are not assigned distributions because they are primarily unit costs, which are variable 
but not uncertain. Where costs are uncertain, the PSA on utilities and transitions will be 
sufficient to account for this uncertainty. Furthermore, as distributions for these costs, and 
transitions, would be particularly complex, the small number of uncertain costs and very 
small cost values are unlikely to affect the results in a manner sufficient to warrant using a 
separate distribution.  
Utility parameters are assigned a beta distribution using the method of moments. This is 
thought to be most suitable because event data are not used. In this case average values are 
used for each state and the method of moments is most suitable (Briggs et al., 2006). As the 
utility value for surgery is ¾ of the value for post-surgery, the distribution for surgery is 
linked to that of post-surgery. It would not be appropriate to sample for an individual 
distribution for ‘surgery’ because the value was taken from post-surgery and so this state does 
not have individual values to sample from. 
 
6.4 Results 
The results of the base case analysis and sensitivity analyses are presented in two parts. Part 1 
depicts the results using EQ-5D and Part 2, the results using SF-6D.  
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6.4.1 Part 1: EQ-5D 
At the 2-year time point 93 women had withdrawn from trial or were lost to follow-up (55 in 
the usual treatment arm, with 16 lost to follow-up and 38 in LNG-IUS, with 13 lost to follow-
up). In line with the trial findings, missing follow-up questionnaires were assumed to be 
missing at random. Complete EQ-5D data were available at all time points for 367 patients 
(64%). LNG-IUS had a slightly higher completion rate (66%) than the usual medical 
treatment arm (63%). However, as a decision model was employed and utility data at any time 
point were used for the health states, it was not necessary to have complete EQ-5D data at all 
three time-points to include it in the analysis. Therefore, 75% complete EQ-5D data were 
available at 6 months (76% in LNG-IUS and 73% in usual treatment), 77% at 1 year (77% in 
LNG-IUS and 77% in usual treatment) and 84% at 2 years (87% in LNG-IUS and 81% in 
usual treatment). A complete case analysis is used and is discussed further in section 6.5.1. 
Table 6.4 presents a summary of the base case and the deterministic sensitivity analysis 
results using EQ-5D.  
The base case results show that LNG-IUS costs £100 more than usual medical treatment, as it 
costs £430 whilst usual medical treatment costs £330. However, LNG-IUS also generated 
0.067 more QALYs than usual medical treatment as LNG-IUS generated 1.580 QALYs and 
usual medical treatment 1.513 QALYs. The ICER for the base case analysis shows that LNG-
IUS generates £1600 per additional QALY when compared to usual medical treatment. 
In all three of the deterministic sensitivity analyses, the findings supported the base case 
results. However, the ICER in each analysis did differ. Sensitivity analysis 1 and 2 had a 
slightly less favourable effect, increasing the ICER to £2030 and £1640 per QALY gained 
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respectively, whilst sensitivity analysis 3 resulted in a more favourable effect on the ICER 
with a reduction to £1560 per additional QALY.  
 
Table 6.4 Base case and deterministic sensitivity analysis results using EQ-5D 
 
Total mean costs 
per intervention 
(£) 
Total mean 
QALYs per 
intervention 
Incremental cost 
effectiveness ratio 
(ICER) (v usual 
medical treatment) 
Summary of base case deterministic 
results 
   
Usual medical treatment 330 1.513 1600 
LNG-IUS 430 1.580  
Mean Difference 100 0.067  
Deterministic sensitivity analysis 1* 
   
Usual medical treatment 330 1.590 2030 
LNG-IUS 430 1.643  
Mean Difference 100 0.053  
Deterministic sensitivity analysis 2
#
 
   
Usual medical treatment 340 1.513 1640 
LNG-IUS 450 1.580  
Mean Difference 110 0.067  
Deterministic sensitivity analysis 3° 
   
Usual medical treatment 330 1.514 1560 
LNG-IUS 430 1.582  
Mean Difference 100 0.068  
Cost are rounded to nearest 10. QALYs are rounded to 3 decimal places QALYS; quality adjusted life year, 
LNG-IUS; levonorgestrel-releasing intrauterine system, ICER; incremental cost-effectiveness ratio.  
*Deterministic sensitivity analysis 1 = Use median utility values 
#
Deterministic sensitivity analysis 2 = Use NICE assumptions 
°Deterministic sensitivity analysis 3 = Assigning EQ-5D completion date utility for change treatment, if change 
treatment date is the same as EQ-5D completion date. 
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The results of the PSA (Figure 6.7) illustrate the distribution of the incremental costs and 
effects from 1000 Monte Carlo simulations. It is shown that the majority of the incremental 
costs and effects lie in the upper right hand quadrant of the cost-effectiveness plane. This 
indicates that LNG-IUS is both more costly and more effective than usual medical treatment. 
The uncertainty is then summarised in relation to the changes in the decision-makers 
threshold for considering an intervention cost-effective in Figure 6.8. It depicts the CEAC, 
which shows that from £2000 per QALY, LNG-IUS has a greater probability of being the 
more cost-effective intervention. This probability increases to over 90% at approximately 
£4000 per QALY.  
 
Figure 6.7 Results of the probabilistic sensitivity analysis (EQ-5D)  
 
-£100.00
-£50.00
£0.00
£50.00
£100.00
£150.00
£200.00
£250.00
£300.00
-0.04 -0.02 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18
D
if
fe
re
n
c
e
 i
n
 C
o
s
t 
(£
) 
Difference in QALYs 
144 
 
Figure 6.8 Cost-effectiveness acceptability curves for usual medical treatment and LNG-IUS using EQ-5D 
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Table 6.5 presents the base case and deterministic sensitivity analysis results for SF-6D.  
The base case results show that LNG-IUS costs £100 more than usual medical treatment as it 
costs £430 whilst usual medical treatment costs £330. However, when SF-6D is used, usual 
medical treatment is shown to generate 0.002 more QALYs than LNG-IUS, as usual medical 
treatment generated 1.200 QALYs and LNG-IUS 1.198 QALYs. Therefore, it is shown that 
usual medical treatment dominates LNG-IUS. 
In two of the three deterministic sensitivity analyses, the findings supported the base case 
results. In sensitivity analysis 1 and 2 usual medical treatment dominated LNG-IUS. Whilst in 
sensitivity analysis 3, usual medical treatment does not dominate LNG-IUS. LNG-IUS was 
shown to be more effective than usual medical treatment and more expensive, generating an 
ICER of £112,340.  
The results of the PSA in Figure 6.9 are presented on the cost-effectiveness plane, as 
previously, and show the distribution of the incremental costs and effects from the 1000 
Monte Carlo simulations. In this case when SF-6D is used to generate the effectiveness 
outcome, it can be seen that the incremental costs and effects are spread between the upper 
right hand and upper left hand quadrant of the cost-effectiveness plane, indicating that LNG-
IUS is either more costly and more effective, or more costly and less effective. This is then 
summarised in the CEAC in Figure 6.10 to show that for any threshold willingness-to-pay per 
QALY, usual medical treatment has the greater probability of being the more cost-effective 
intervention. This probability is 100% at £0 per QALY and decreases to 90% at 
approximately £20,000 per QALY.  
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Table 6.5 Base case and deterministic sensitivity analysis results using SF-6D 
 
Total mean costs 
per intervention 
(£) 
Total mean 
QALYs per 
intervention 
Incremental cost 
effectiveness ratio 
(ICER) (v usual 
medical treatment) 
Summary of base case deterministic 
results 
   
Usual medical treatment 330 1.200 Dominates 
LNG-IUS 430 1.198  
Mean Difference 100 -0.002  
Deterministic sensitivity analysis 1* 
   
Usual medical treatment 330 1.215 Dominates 
LNG-IUS 430 1.215  
Mean Difference 100 0  
Deterministic sensitivity analysis 2
#
 
   
Usual medical treatment 340 1.200 Dominates 
LNG-IUS 450 1.198  
Mean Difference 110 -0.002  
Deterministic sensitivity analysis 3° 
   
Usual medical treatment 330 1.198 112,340 
LNG-IUS 430 1.199  
Mean Difference 100 0.001  
Cost are rounded to nearest 10. QALYs are rounded to 3 decimal places. QALYS; quality adjusted life year, 
LNG-IUS; levonorgestrel-releasing intrauterine system, ICER; incremental cost-effectiveness ratio. 
*Deterministic sensitivity analysis 1 = Use median utility values 
#
Deterministic sensitivity analysis 2 = Use NICE assumptions 
°Deterministic sensitivity analysis 3 = Assigning SF-6D completion date utility for change treatment if change 
treatment date is the same as SF-6D completion date. 
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Figure 6.9 Results of the probabilistic sensitivity analysis (SF-6D)  
 
 
Figure 6.10 Cost-effectiveness acceptability curves for usual medical treatment and LNG-IUS using SF-6D 
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6.5 Discussion 
In this chapter, the economic evaluation comparing LNG-IUS against usual medical treatment 
has been presented. The economic evaluation was first conducted using the EQ-5D to 
generate QALYs and then re-estimated using SF-6D to assess the impact of the alternative 
extra-welfarist measures on the cost-effectiveness results.  
Using EQ-5D, treating menorrhagia using LNG-IUS costs more but is also more effective 
than usual medical treatment. The relative cost-effectiveness of LNG-IUS compared to usual 
medical treatment is £1600 per QALY. This means every additional QALY costs an extra 
£1600. The deterministic sensitivity analyses showed the uncertainty in this ICER to be in the 
range of £1,560-£2,030 for an additional QALY gained. As the NICE guidelines recommend 
new interventions into practice if the ICER is below £20,000 per QALY, LNG-IUS would be 
considered cost-effective and recommended as the primary choice for patients who: require 
treatment, have no preference against contraception or intrauterine insertion, and no 
contraindication to LNG-IUS insertion. 
However, the importance of selecting the most appropriate QoL instrument is highlighted 
when the measure used to assess QoL is changed from EQ-5D to SF-6D. In the second 
analysis, Part 2, where utility values from SF-6D are used rather than EQ-5D, the cost-
effectiveness results differ. In contrast to the findings using EQ-5D, usual medical treatment 
is the more cost-effective intervention. Usual medical treatment was found to dominate LNG-
IUS in the base case and the two deterministic sensitivity analyses. In the third deterministic 
analysis, the ICER for LNG-IUS was £112,340 per QALY which is evidently greater than the 
£20,000 decision-maker willingness-to-pay threshold currently set by NICE, therefore usual 
medical treatment would be recommended for implementation in clinical practice.  
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The difference in the cost-effectiveness results derived by using the alternative extra-welfarist 
measures to value utilities has a considerable impact on the cost-effectiveness decision. The 
different measures did not just change the strength of cost-effectiveness of the same 
treatment, but the most cost-effective treatment itself changed. Therefore the recommendation 
to decision-makers would differ depending on the QoL instrument used.  
 
6.5.1 Strengths and Limitations 
The main strength of this CUA is that it is based on data from the largest multi-centre 
randomised trial undertaken for menorrhagia. Since the treatment is aimed at managing the 
condition, the changes in both QoL and costs throughout the woman’s treatment journey are 
critical to the analysis and these are most appropriately captured by using the trial data to 
populate a model. The model structure was developed based on the patient pathway data from 
the trial and supported by the advice of expert clinicians. All assumptions were agreed by the 
team in the model development stage prior to analysis.  
There are a number of limitations based on some of the assumptions. For instance it was 
assumed that women are well if they do not change treatment. However, if women enter the 
‘well’ state in the model but are not actually well it will be reflected in the overall utility value 
for ‘well’.  
A further potential limitation is that baseline differences in QoL data at the outset of the trial 
were not adjusted to be the same. The initial EQ-5D score in the LNG-IUS group was 0.042 
higher at the outset of the trial than in usual medical treatment and the difference is significant 
(p<0.05). These data are based on individuals who have been randomised, so it is assumed 
that this difference occurred by chance and it does not follow that this initial difference 
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between groups would be sustained over the 2 year time horizon in the absence of treatment. 
Adjustment for baseline therefore risks imposing a difference at every point in time over the 
time period of analysis.  
If a full adjustment was made for the difference in baseline, LNG-IUS would be shown to be 
less effective and potentially less cost-effective than usual medical treatment, but in so doing, 
the difference would be maintained over the time horizon and the probability of regression to 
the mean over time would be ignored. Therefore, it is acknowledged that the base case results 
might be over optimistic, but it is not clear how much of an adjustment, if any, would be 
appropriate.  
A final limitation is the inability to handle missing data using conventional methods such as 
multiple imputation due to the nature of the analysis, as a result a complete case analysis was 
used. Missing values can be considered as a potential source of bias, particularly if the 
complete data differ from the missing data and if there is a chance that the reason for 
missingness is due to the intervention (as is the case for this evaluation as data are considered 
to be missing at random). Whilst it is not possible to establish the relationship between the 
missingness and the unobserved values with certainty it is suggested that approaches for 
handling missing data be considered (Carpenter & Kenward, 2007). Therefore, as missing 
cases are deleted in a complete case analysis potentially revealing data are excluded and the 
analysis could be subject to bias. The use of a complete case analysis also means that 
conclusions are drawn from a smaller sample size than initially stated which can potentially 
limit the generalisability of the findings to the wider population with menorrhagia (Briggs et 
al, 2003). Therefore the most appropriate method to handling missing data for this study 
would have typically been multiple imputation, where the observed values are used to 
generate predicted values for the missing data in order to create a full dataset, this imputation 
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minimises the potential for bias. However, as the trial data are used in a decision model, it 
would be necessary to impute missing data at the individual level rather than overall at the 
QALY level for each time point. As this has not been attempted before and is not yet a 
recommended method it did not seem appropriate. Despite this limitation, the results are not 
unduly affected. The PSA (described in section 6.3) produces a range of iterations using the 
distributions assigned for the utilities to handle any uncertainty around the results and will to 
an extent compensate for not handling missing data. 
 
6.5.2 Comparison with Other Studies 
To current knowledge, this is the first study to conduct a CUA using prospectively collected 
primary data from a trial to compare LNG-IUS and usual medical treatment for menorrhagia. 
Whilst another primary study has shown LNG-IUS to be cost-effective (Hurskainen et al., 
2004), the comparator was hysterectomy, and the study is considered to have methodological 
flaws (Roberts et al., 2011). As shown in Chapter 4, other studies have compared these 
alternative treatments using model based analyses and secondary data from reviews 
(Blumenthal et al., 2006; NICE, 2007; You et al., 2006). But the studies typically compared 
various surgical techniques, LNG-IUS and various oral treatments against one another. Two 
of these showed LNG-IUS to be the most cost-effective intervention (Blumenthal et al., 2006; 
NICE, 2007). The remaining study suggested that hysterectomy was the optimal intervention 
but the authors acknowledged that insufficient published data on the effectiveness of LNG-
IUS were available at the time (You et al., 2006). Thus, the results reported in this chapter are 
new and based on the largest randomised controlled trial comparing LNG-IUS and usual 
medical treatment. When using the decision-maker recommended EQ-5D measure, the results 
concur with some of the studies which are based on secondary evidence.  
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As EQ-5D is recommended by NICE for use in economic evaluation, this study has 
determined that LNG-IUS is a cost-effective treatment at 2 years of follow up but as the 
condition is chronic and continues until menopause, further economic evaluation with a 
longer term follow-up is needed, and planned to include all relevant costs and outcomes 
(Blumenthal et al., 2006; NICE, 2007; You et al., 2006). 
 
6.5.3 Implications and Further Research 
The results, based on the decision-maker recommended EQ-5D, provide clear evidence in 
support of the NICE guidelines that recommend LNG-IUS be considered the primary 
treatment for menorrhagia. As the findings presented here are based on data from the largest 
multi-centre randomised controlled trial conducted for menorrhagia, this study provides 
robust evidence in favour of LNG-IUS over usual medical treatment. As the study was carried 
out to provide evidence to decision-makers on the cost-effectiveness of these two treatments 
for menorrhagia the primary results which are taken from this study are based on EQ-5D. 
However, as SF-6D data were also collected, the use of this measure was deemed worthy of 
exploration.  
In contrast to the EQ-5D finding, when SF-6D is used to generate QALYs usual medical 
treatment is the more cost-effective intervention. As the results are based on data from a large 
randomised controlled trial they indicate that the measures may be capturing different aspects 
of QoL, which clearly has a great impact on the results. The reasons for the differences in 
results will be explored elsewhere as it is beyond the remit of the thesis and has been observed 
in several other disease areas (Davis et al., 2012; Sach et al., 2009). The main difference 
between the instruments has already been explained by Brazier et al (2004) and Whitehurst 
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and Bryan (2011). Since QoL is the key indicator of success in menorrhagia and the woman’s 
own assessment of this determines treatment choice, it must be determined which measure is 
most suitable given that the instrument used has such a significant impact on the results. 
Furthermore, as the results of the systematic review on QoL instruments in Chapter 4 showed 
that these generic extra-welfarist measures might not be appropriate, further research should 
explore the use of alternative measures, such as the welfarist willingness-to-pay (WTP), to 
estimate the appropriateness of alternative instruments and alternative ways of capturing and 
measuring this outcome.  
 
6.6 Conclusion 
In this chapter an economic evaluation alongside the ECLIPSE trial, comparing LNG-IUS and 
usual medical treatment is reported. The economic evaluation was first estimated using the 
decision-maker recommended EQ-5D-3L and then re-estimated using SF-6D. The findings 
from the economic evaluation using EQ-5D showed that LNG-IUS is the most cost-effective 
treatment. Therefore, the recommendation to decision-makers would be that LNG-IUS be 
used as the first line treatment for menorrhagia in clinical practice. However, when SF-6D 
was used to generate QALYs, usual medical treatment was shown to be the most cost-
effective intervention. These conflicting findings show that the recommendation to decision-
makers would differ depending on the measure used. This illustrates the importance of 
ensuring that the most suitable measure is used to value outcomes in menorrhagia. Given the 
conflicting findings presented in this chapter, and that the systematic review on economic 
outcome measures illustrated that there are concerns with the use of extra-welfarist measures, 
in the next chapter the use of WTP will be explored. Specifically, the methodology used for 
the WTP empirical work is reported next.  
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CHAPTER 7. WILLINGNESS TO PAY STUDY – METHODOLOGY 
 
7.1 Introduction 
In this chapter the methodology associated with the willingness-to-pay (WTP) research is 
described. It has been suggested in Chapters 5 and 6 that the routinely used health related 
quality of life (QoL) measures (SF-36 and EQ-5D) may not be entirely suitable for use in 
menorrhagia. It is important to ensure that an appropriate measure of benefit is used because 
impact on QoL is the sole measure of benefit in this condition. Thus the aim of this empirical 
research is to explore the suitability of using the WTP measure, which enables the respondent 
to take into consideration both health and non-health outcomes and may overcome the issue 
of timing of assessment. In this feasibility study, WTP is elicited from both an ex-ante and an 
ex-post perspective. In this chapter, the methodology for the study design and data collection 
are outlined in the following order: (1) the WTP study from an ex-ante perspective, 
comparing LNG-IUS against usual medical treatment; (2) the WTP study from the ex-post 
perspective, comparing LNG-IUS against usual medical treatment; and (3) the interviews with 
a sub-group of the respondents who completed the WTP questionnaire from the ex-ante 
perspective. These sections are then followed by details of the data analysis and a discussion 
of the methodology used. In the next chapter the results of each of the analyses are presented, 
in turn, along with conclusions on the implications of the findings and the prospects for future 
work. 
 
155 
 
7.2 Method 
A substantial amendment to the ECLIPSE trial ethics was required, because the exploratory 
research, related to WTP, was a sub-study of the overall funded project. A self-complete 
questionnaire for the ex-ante and ex-post perspective was created based on previously 
successfully completed questionnaires (Donaldson et al., 1997b; Frew et al., 2001). The 
content of each questionnaire was reviewed and commented on by several experts, including a 
consultant who specialises in the area, a general practitioner (GP), psychologists, social 
scientists and external health economists. The questionnaires were subsequently revised 
according to their suggestions.  
The study protocol was then submitted and received favourable approval from the ethics 
committee and the research and development department of the hospital. 
 
7.2.1 Methodology of Ex-ante Perspective 
As explained in Chapter 2 in the discussion of the ex-ante perspective, the WTP value reflects 
the level of expected change in utility from having the treatment available. The assumption is 
that treatment will improve utility therefore a WTP value, and not a willingness-to-accept 
(WTA) value, was elicited. This section details the methods used to elicit WTP from an ex-
ante perspective using respondents from the general population. 
 
1) Design of Questionnaire for Ex-ante WTP Elicitation  
A booklet questionnaire was designed for completion without supervision to capture data on 
WTP, patient socio-demographic details and EQ-5D. First, in the questionnaire a description 
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of menorrhagia and its treatments was required, since respondents may not have had any 
experience of either menorrhagia or the treatment. Therefore data from the ECLIPSE trial, 
(described in Chapter 6), were used to develop the scenarios for the ex-ante perspective as the 
trial data are related to women with experience of menorrhagia and its treatments.   
 
1a) Scenario description development 
First, a scenario description of the impact of menorrhagia on sufferer’s lives was outlined. 
The description of menorrhagia was based on the domains of the menorrhagia multi-attribute 
scale (MMAS) QoL instrument because this measure incorporates both the health and non-
health outcomes associated with menorrhagia, which are known to be affected by the 
condition. Generic extra-welfarist measures (EQ-5D and SF-6D) were not used due to their 
narrower focus on health-related QoL. The scenario was based on the average value for each 
MMAS domain that was observed at baseline in the ECLIPSE trial. In other words, the trial 
results were used to generate a description of the expected average ‘outcome’ for 
menorrhagia, and this outcome contained both health and non-health variables. Data on 
MMAS from the ECLIPSE trial were used because this was thought to be the most reliable 
and practical source of data on how menorrhagia and its treatments impact women’s lives.  
The ‘practical difficulties’ attribute of the MMAS is presented below to provide an example 
of the calculation. Table 7.1 below shows the number of responses for each of the four levels 
of the practical difficulties attribute at baseline. Box 7.1 shows the weighting for the levels of 
the practical difficulties attribute. 
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Table 7.1 Frequency of responses for the practical difficulties attribute 
 
Box 7.1 Weightings for MMAS attribute 
 
The following formula, which was deemed the most intuitive, was applied to calculate the 
average value for each attribute of the MMAS. 
 [(fa×wa) +(fb×wb)+(fc×wc)+(fd×wd)]/ Tf  [1] 
For each level of the attribute w is the weighting, f is the frequency, and Tf is the total 
frequency for the attribute. The subscript letters (a, b, c, d) represent the different levels of the 
attribute, as notated in Table 7.1. Shaw et al (1998) had previously determined the weighting 
for the levels of all the attributes, which has been described in section 2.5.1 of Chapter 2 (see 
Appendix 4.1 for MMAS questionnaire and weightings). 
Using the formula, the average value for the ‘practical difficulties’ attribute was calculated as 
follows: the frequency of (a)- no practical difficulties (13) was multiplied by the weighting for 
the level (14) which equals 182. This calculation was then carried out for every level of the 
‘practical difficulties’ attribute. To obtain the average value for the attribute, the total for each 
level was then summed and divided by the total frequency (549). In this case the average 
value is 2500.8 divided by 549 which gives 4.56. From Box 7.1 it can be seen that the nearest 
level weighting to 4.56 is 3.1. Therefore the average baseline value for practical difficulties is 
                              Total          549      100.00
                                                                        
                d - Severe problems          166       30.24      100.00
                  c - Carry clothes          184       33.52       69.76
b - Carry extra sanitary protection          186       33.88       36.25
      a - No practical difficulties           13        2.37        2.37
                                                                        
             Practical Difficulties        Freq.     Percent        Cum.
1. Practical difficulties                Weighting 
a. I have no practical difficulties, bleed no more than I expect and take no extra precautions.   14.0 
b. I have to carry extra sanitary protection with me but take no other precautions.    9.4 
c. I have to carry extra sanitary protection and clothes because of the risk of flooding.  3.1 
d. I have severe problems with flooding, soil the bedding and need to be close to a toilet.   0 
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(c). This method was then repeated for every attribute of the MMAS at baseline to present a 
full scenario description of the impact of menorrhagia on women’s lives.  
The scenario description of menorrhagia was then followed by a description of the outcomes 
for the treatments, LNG-IUS (termed ‘Mirena’ in the questionnaire) and usual medical 
treatment (termed Oral treatment in the questionnaire). The outcomes associated with Mirena 
and Oral treatment were similarly based on the MMAS data from the ECLIPSE trial to 
capture changes in health and non-health outcomes associated with menorrhagia. However, in 
this case the 6 month data on the average MMAS score for each treatment were used. The 6 
month follow-up was the next data collection time point in the ECLIPSE trial after baseline, 
as after 6 months it is more than likely that the benefits of both treatments will begin to be 
seen. For each treatment, the average outcomes (expressed as health and non-health 
outcomes) were described using the domains within the disease-specific MMAS questionnaire 
and the results for each treatment arm within the ECLIPSE trial. At 6 months, for each 
treatment, the same process and formula [1] for the menorrhagia description was used to 
calculate the average outcome for each attribute. Similarly, the closest level weighting to the 
value derived for each attribute was then chosen as the average scenario for that attribute. 
This meant that the scenario descriptions were kept consistent to make it easier for 
respondents to identify potential benefits of treatment in terms of the impact on health and 
non-health outcomes and process utility. 
 
 1b) Scenario description presentation 
Bullet points were used to present the scenario for menorrhagia, as is typically done in health 
economics for EQ-5D and SF-6D to generate a quality adjusted life year (QALY) (Smith, 
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2008). For the scenario description of Mirena and Oral treatment, the outcomes associated 
with treatments are presented as bullet points and the process utility derived from the 
intervention is presented using a concise narrative (Smith, 2006; Smith, 2007). The process 
utility is based on the method of administration of the treatment, its burden on the patient, the 
most likely side effects and the length of time it takes for the treatment to begin working 
successfully. Information on the process utility of the two treatments was primarily obtained 
from the literature (CKS, 2012) and was checked against data from the ECLIPSE trial and by 
relevant professionals (Consultant gynaecologist, Professor Janesh Gupta, and GP, Professor 
Joe Kai).  
The health and non-health outcomes (MMAS) achieved from the intervention in addition to 
the process utility derived from the intervention itself were included to provide a 
comprehensive description of the impact of the treatments on menorrhagia and in turn on 
QoL. This approach was used because the impact of treatment on QoL is the primary measure 
of success in menorrhagia. The use of outcomes as well as the process associated with each 
intervention ensured that the WTP measure was not constrained to the time-point of 
measurement and that the measure could be applied for any treatment of menorrhagia.  
At the end of the scenarios for both Mirena and Oral treatment, three tick boxes were 
presented to determine the respondents’ preference for treatment: Mirena, Oral treatment or 
no preference. 
 
1c) Choice of elicitation method used 
Next, a maximum monthly out of pocket WTP value up from the current point in time until 
menopause was elicited for both Oral treatment and Mirena. The time frame of payment of 
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‘up until menopause’ was explicitly stated to ensure that: WTP values were not 
overestimated, individuals were aware of their budget constraint and recognised that spending 
money on the commodities measured would mean money could not be spent elsewhere 
(Smith, 2003). The time frame was selected intuitively given the nature of the condition, as 
menorrhagia would cease when menopause begins. 
The payment scale elicitation format was used to elicit WTP values because it has a higher 
completion rate than other self-completion methods that can be used in a postal questionnaire 
(Whynes et al., 2003). Although the payment scale format can be prone to range bias where 
respondents WTP values may be influenced by the range presented, this issue can be 
minimised by piloting the questionnaire to determine the most suitable range. Alternatively, 
the use of several ranges of payment scales could be used and randomly allocated to 
respondents. However, the latter approach would require a large sample size (McIntosh et al., 
2010).  
A payment scale range of £0-£500 was considered to be most suitable, given that the 
questionnaire asked respondents to provide a monthly WTP value and this estimate is line 
with likely levels of ability to pay. For example, it may be unrealistic to expect women to pay 
values greater than £500 on a monthly basis, but an option to pay more than £500 was 
presented in an open-ended question. The scale began with £0-£20 in increasing increments of 
£2, from £20-£50 in increments of £5 and £50-£100 increments of £10. The payment scale 
was immediately followed by an open-ended question to state a WTP value if greater than 
£500. Two vertical payment scales were presented alongside each other for each treatment. 
The questionnaire asked respondents to circle a maximum monthly WTP for Mirena and then 
Oral treatment. This payment scale structure was chosen as it is similar to previously 
published scales (Frew et al., 2001). The questionnaire included a reminder to respondents to 
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consider the amount that they can afford to pay to ensure that the responses obtained were 
realistic and within the respondents means (Smith, 2006). The monthly payment time frame 
was used because women generally pay monthly (or every three months) for prescriptions for 
menorrhagia and for sanitary protection. The out of pocket payment vehicle was deemed to be 
most appropriate for this context because there is some form of private payment for 
prescriptions for the Oral treatment. Although this private payment does not exist for Mirena 
it is argued that the existence of private payment within this context would minimise the issue 
of hypothetical bias.  
Following the WTP question, an open-ended question was presented to the respondent to 
outline reasons for their WTP values. The next question was a yes or no tick box, which asked 
the respondent to indicate whether they found the WTP question difficult to answer. This tick 
box was then followed by an open-ended question which asked for the reason they found the 
question difficult. The format used follows that of a previously published study (Donaldson et 
al., 1997b). As the aim of the research was to assess the suitability of the measure in 
menorrhagia it was necessary to identify if respondents found the question difficult to answer. 
The subsequent questions were related to socio-demographic details such as age, marital 
status, employment status, household income (eight income ranges, starting from less than 
10,000 to more than 70,000), whether they have experienced heavy periods, reason for 
visiting the clinic, satisfaction with life overall (five tick boxes starting from ‘very 
unsatisfied’ to ‘very satisfied’), EQ-5D and an invitation for a follow-up interview within 1 to 
2 months.  
If the women agreed to the interview, consent was taken for the patient to be contacted for 
interview and for the interviews to be recorded. The women either gave their email or home 
address details. The full ex-ante questionnaire is presented in Appendix 4.2.  
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2) Population Sampled 
Women visiting the fertility and general outpatient clinics at the Birmingham Women’s 
Hospital were invited to complete the questionnaire. This convenience sample of women 
attending the Birmingham Women’s Hospital was recruited for practical reasons. Firstly, a 
group of women who are menstruating were easily accessible through this route and, 
secondly, the use of women visiting a clinic would ensure a higher response rate than a cold 
mail out. The women were approached prior to their appointment, which may have been 
routine or one-off, and given a patient information sheet to read, which explained the study 
and what would be required. The consenting women were asked to complete the questionnaire 
in the clinic either prior to or after their appointment. This author then collected the completed 
questionnaires from the women. Where women requested to complete the questionnaire at 
home a pre-paid stamped addressed envelope was provided.  
Questionnaires were administered over a 2 month period (December 2012-January 2013). 
Due to the nature of the study the aim was to recruit between 50-100 respondents. It was the 
opinion of the research team that this size would be sufficient and pragmatic for an 
exploratory WTP study given the time constraints of the research.   
The next section outlines the methodology behind the questionnaire design, elicitation method 
and population for the ex-post perspective. 
 
7.2.2 Methodology of Ex-post Perspective 
As explained in Chapter 3 from the ex-post perspective WTP, the WTP value reflects the 
level of actual change in utility from having the treatment available. This section details the 
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methods used to elicit WTP from an ex-post perspective, thus WTP was elicited from 
respondents who were suffering with the condition and have experience of treatment. 
 
1) Design of Questionnaire for Ex-post WTP Elicitation 
A booklet questionnaire was designed for self-completion without supervision to capture data 
on disease-specific QoL (MMAS), WTP, patient socio-demographic details and EQ-5D (See 
Appendix A4.3). The design of the questionnaire was based on the standard questionnaire 
booklet sent to the ECLIPSE trial women as part of the trial follow-up. As the ex-post 
perspective requires respondents who are experiencing menorrhagia and its treatments it was 
not necessary to present scenario descriptions of menorrhagia and the treatments. 
 
1a) Choice of elicitation method used 
To assess the disease-specific QoL, the MMAS was first presented in the questionnaire. The 
MMAS questionnaire was followed by questions to identify which treatment was currently 
taken and which have previously been taken as part of the ECLIPSE trial. Following these 
questions the WTP value for the respondent’s current treatment was elicited. 
Similar to the ex-ante study, a maximum monthly out of pocket WTP value up until 
menopause was elicited, the time frame of payment of ‘up until menopause’ was explicitly 
stated and the payment scale elicitation format with the same range and increments as 
outlined in 7.2.1 was used for reasons explained previously. However, due to the nature of the 
ex-post study the questionnaire only required respondents to circle their maximum monthly 
WTP for their current treatment. Thus only one vertical payment scale was presented in the 
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questionnaire. This was immediately followed by an open-ended question which asked the 
respondent to state the WTP value if it was greater than £500, as in the ex-ante study.  
To be consistent with the ex-ante study, following the WTP question an open-ended question 
was presented to the respondent to outline reasons for their WTP values. The next question 
was a yes or no tick box, which asked the respondent to indicate whether they found the WTP 
question difficult to answer. This tick box was then followed by an open-ended question 
which asked for the reason why the respondent found the question difficult or not. The 
subsequent questions were related to socio-demographic details such as age, marital status, 
employment status, household income (eight income ranges, starting from less than 10,000 to 
more than 70,000), length of time experienced menorrhagia, impact of bleeding on work, 
daily activities, pain scale using VAS (0 no pain at all to 10 worst imaginable pain), regularity 
of cycle, perceived impact of bleeding on QoL (four tick boxes starting from ‘not at all 
affected’ to ‘extremely affected’), satisfaction with life overall (five tick boxes starting from 
‘very unsatisfied’ to ‘very satisfied’), EQ-5D, amended EQ-5D (with the order randomly 
changed) and number of visits to the GP or hospital as a result of the condition since an 
ECLIPSE trial form was last completed.  
The amended EQ-5D asked women to complete the questionnaire with reference to their 
health during their cycle. The phrase ‘during your cycle’ was used as an alternative to ‘health 
today’ because this wording is used in the validated disease-specific MMAS questionnaire. 
As the results of the systematic review on QoL measures in Chapter 5 showed the recall 
period to be an issue for EQ-5D, it was amended, with approval from EuroQoL, to assess 
whether this change altered the sensitivity of the measure.  
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2) Population sampled 
Women who were currently enrolled in the ECLIPSE trial and were receiving either Mirena 
or Oral treatment were recruited for this WTP ex-post study. As women who were currently 
using either Mirena or Oral treatment were required, the ECLIPSE trial patients seemed most 
suitable. These women are part of an established trial and were already routinely posting back 
follow-up questionnaires for the trial analysis, which would presumably result in a high 
completion rate. Questionnaires were posted out in August 2012 to all ECLIPSE patients, 
with the exception of those women who had asked to be withdrawn from the trial.  
By post, women received the following information: (1) a letter from the principal 
investigator of the ECLIPSE trial explaining that the woman’s assistance in the study would 
be appreciated and that the WTP questionnaire booklet was different to the ECLIPSE trial 
follow-up; (2) a patient information sheet outlining the purpose of the work and what is 
required; (3) an ex-post questionnaire; and (4) a pre-paid stamped addressed envelope to 
return the completed questionnaire.  
Similar to the ex-ante perspective, due to the nature of the study, the aim was to recruit 
between 50-100 respondents, as this was believed, by the current research team, to be 
sufficient for an exploratory WTP study. 
 
3) Further Considerations for the Ex-post Perspective  
In the case of the ex-post perspective additional data from the ECLIPSE trial were available. 
The ECLIPSE trial has been described in Chapter 6. Before the analysis of the WTP study is 
outlined it is necessary to provide details of the data that have already been collected as part 
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of the ECLIPSE trial, as the ex-post perspective results which use this ECLIPSE data are 
presented in the next chapter.  
Women were recruited to the ECLIPSE trial over a 3 year time period. At the time the 
exploratory work was conducted, women were at various time points in trial follow-up (either 
2 years or 5 years). Thus data on MMAS, EQ-5D and resource use are available at baseline, 6 
months, 1 year, 2 years, and 5 years where appropriate. This additional data allowed the 
association between the WTP for the change in outcome (from baseline to current time point) 
as measured by MMAS and EQ-5D to be assessed.  
In the next section the methods for the interviews using women from the ex-ante perspective 
study are described. 
 
7.2.3 Interview Methodology 
The interviews were designed to consider the women’s understanding of the question, to 
delve deeper into their WTP answers and to explore whether these women were completing 
the questionnaire according to WTP theory, as required by WTP analysts. The aim was to 
conduct 5-10 interviews. It is accepted that interview sample sizes are small and that they are 
typically conducted until saturation is observed, i.e. where little new evidence is observed 
(Ritchie & Lewis, 2003). As the interviews were designed to supplement the questionnaire 
data, in addition to the time constraints and the resource intensive nature of the interviews it 
was considered to be feasible to conduct between 5-10 interviews, which is likely to 
demonstrate saturation.  
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1a) Population sampled 
As the ex-ante perspective is recommended by decision-makers for extra-welfarist measures 
and women from the ex-ante perspective were asked to imagine the scenarios and apply WTP 
values, they were thought to be a suitable group to assess the WTP questionnaire. Therefore 
the women who completed the ex-ante questionnaire were sought for interview.  
The 30 women who were eligible and agreed to be interviewed were contacted according to 
their preferred contact method. Eligibility was assessed according to whether the patient met 
the strict definition of ex-ante, i.e. could potentially be in the menorrhagia state. Thus women 
who completed the ex-ante questionnaire and were going through the menopause or surgery, 
such as hysterectomy, which would mean they could not experience menorrhagia, were not 
selected first for interview.  
 
1b) Population recruitment process  
In late January 2013, women were initially contacted by email to attend an interview at the 
Birmingham Women’s Hospital at a date and time that suited them in February or March 
2013. If they did not respond within 1 week they then received the interview invitation by 
post.  
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1c) Interview details 
On the interview day, women were met in the main reception of the Women’s hospital and 
taken to a designated interview room in the hospital. The interviews were semi-structured, 
lasted up to 30 minutes and were recorded. The topic guide can be found in the Appendix 4.4.  
In the next section, the methods of data analysis for all three studies (ex-ante, ex-post and 
interviews) are briefly described. 
 
7.3 Analysis 
The results of the analysis are presented in three parts. Part 1 refers to the ex-ante perspective, 
Part 2 refers to the ex-post perspective and Part 3 relates to the interviews. For both the ex-
ante and the ex-post studies (Part 1 and Part 2) the mean WTP for the treatments are reported.  
 
7.3.1 Data Preparation 
For Part 1 and 2 all data from the questionnaires were entered into STATA (v 11.0) by this 
author. All of the data were checked twice on different occasions to avoid double entry. This 
author carried out all data analysis in STATA (v11.0) and Microsoft Excel. In places where a 
respondent ticked two boxes, as in the case of the ‘level of satisfaction with life’ variable and 
EQ-5D, two variables were created named variableBEST and variableWORST. As the name 
suggests, in one variable the highest score was used and in the other variable the lowest score 
was used. These were not coded as missing data, as these data were not missing and it was 
believed to be the most suitable method to ensure as much data as possible were kept in the 
analysis.  
169 
 
Appropriate variables were re-coded as dummy variables and re-categorised where necessary, 
i.e. income had eight categories and was reduced to five where each of the five income 
variables formed a dummy variable; Marital status was re-coded to a dummy variable as 
married or not and employment was re-coded to a dummy variable as employed or not. In 
each case when conducting the regression models, discussed next, the most common category 
formed the reference case for the analysis.  
There were four types of responses for the WTP question: 
1. Positive WTP values for either treatment 
2. Zero values for either treatment, which is not a protest.  
3. Non-response 
4. Protest response: zero value or non-response 
Categories 1 and 2 were the primary WTP values used in the base case analyses for Parts 1 
and 2. Category 4 refers to protest responses, which relate to the respondent misunderstanding 
the exercise and refusing to provide a WTP value. It is generally accepted in the literature that 
protest zeros should not be included in the primary analysis, however some authors do 
express concerns regarding the exclusion of such data (Halstead et al., 1992; Jorgensen et al., 
1999; Mitchell & Carson, 1989; Whitehead et al., 1993) so the effect of including category 4 
(protest responses) responses on the mean WTP were considered in a sensitivity analysis. 
Where provided, the qualitative reasons behind category 3 and category 4 were also explored.  
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7.3.2 Econometric Analysis 
The maximum mean WTP values were reported with 95% bootstrapped confidence intervals. 
The bootstrapped confidence intervals were generated in STATA (v11.0) and enable an 
assessment of uncertainty in the mean value. 1000 bootstrapped datasets were generated by 
randomly sampling values, with replacement from the observed values. Descriptive statistics 
were carried out to understand the distribution of the data. WTP data were found to be non-
normal and were log transformed to normalise the data. Each WTP value had a constant of 1 
added to it to ensure that zero values were incorporated when the data were log transformed, 
as applied in other WTP studies (Shackley & Donaldson, 2002).  
A paired t-test (Part 1 – ex-ante) or two-sample t-test (Part 2 – ex-post) was carried out on the 
log transformed data to determine the statistical significance of the difference between the two 
WTP values for each treatment. A test of statistical significance for the difference observed 
between the socio-demographic details of those who preferred (Part 1), or gave a WTP value 
(Part 2) for Mirena and those who preferred (Part 1), or gave a WTP value (Part 2) for Oral 
treatment was carried out using the Chi-squared test for categorical variables and either the 
two-sample/ paired t-test or the Wilcoxon Rank Sum test for continuous variables, depending 
on the perspective and the normality of the distribution. 
In Parts 1 and 2, an econometric analysis including the collected exploratory variables was 
carried out to identify predictors of WTP for Mirena and Oral treatment. The sample included 
zero and positive WTP values, but not protest answers. The regression analyses were 
backward selection stepwise analyses where all appropriate independent variables were 
entered into the model and rejected or selected at a p<0.1 (Draper & Smith, 1998). 
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The type of regression model used is dependent on the type of variable that the WTP value is 
considered to be. Payment scale data can be considered to be discrete in that the respondent’s 
true WTP value lies within the intervals provided in the payment scale. Alternatively, the 
payment scale data could also be considered as continuous and the circled WTP value would 
be the maximum WTP and is not considered to lie within an interval. As there appears to be 
no consensus on the most suitable model to use and in practice a range of regression models 
are estimated, the two most theoretically suitable approaches that were appropriate for the 
data were applied. In the two models explored, the WTP variable was treated as either a 
discrete variable or a continuous variable according to the model specification.  
It was expected that a two-part model would be used where the positive WTP values and zero 
values are assessed separately in two stages. Where the first part is used to identify predictors 
of (positive) WTP for Mirena and Oral treatment using ordinary least squares (OLS) linear 
regression and the second part of the model is a logistic regression model used to identify the 
characteristics of respondents who provide zero WTP values. However the proportion of 
respondents who provided zero values was very small so it was not appropriate to conduct the 
two-part model, due to limited variation in the sample. Two-part models are only 
recommended when the proportion of zero values is high (Donaldson et al., 1998). 
In Parts 1 and 2 the base case analysis therefore took the form of a linear OLS model which 
included both positive WTP values and zero values. The link test and Ramsey RESET were 
used to assess the model specification and the model form. Where appropriate, to explore any 
potential relationships between those that provided zero values and those that did not, a 
univariable analysis with descriptive statistics and significance tests was carried out to explore 
the relationship between each individual exploratory variable and the WTP outcome. 
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The sensitivity analysis took the form of an interval regression or grouped data regression to 
analyse the predictors for WTP. An interval regression analysis has also been recommended 
for use when payment scale data are available (Donaldson et al., 1998). The log likelihood 
ratios and the significance of the model compared to the constant only model were assessed to 
determine the model fit. 
Further as few respondents gave a protest or non-response in both Parts 1 and 2, it was not 
possible to conduct an analysis to identify the characteristics of the women who either gave a 
protest answer or did not respond to the WTP question. 
 
7.3.3 Analysis of WTP and the Alternative Perspectives 
Women’s understanding of the WTP elicitation technique, the reasons given for WTP values, 
and whether they found the question difficult to answer were compared across the ex-ante and 
ex-post perspective. The findings of the qualitative responses were also used to assess overall 
whether WTP can be considered for use in menorrhagia. The number of protest responses and 
non-response to the WTP question was also compared, and whether the predictors of WTP, as 
measured in the econometric analysis, differ across perspectives. 
In the ex-post perspective (Part 2) associations between WTP, EQ-5D and MMAS measures 
were assessed by Spearman’s correlation analysis. The change in health state from baseline to 
current value (as measured by MMAS) was assessed against WTP for the change in health 
state and change in EQ-5D.  The correlation coefficient was then compared to that of change 
in EQ-5D and change in MMAS. As discussed in Chapter 2, MMAS is scored on a 0-100 
scale, where each level of each question dimension is given a weighting (Shaw et al., 1998). 
These weightings are then summed, according to the levels ticked by the respondent, to 
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provide an overall score between 0-100. This was calculated for the baseline MMAS score, 
obtained from the ECLIPSE trial, and the current MMAS score. Similarly, the EQ-5D tariff 
was calculated using the relevant algorithm (Brooks, 1996). The change in scores from 
baseline to current value for both EQ-5D and MMAS was calculated by subtracting the 
current score from the baseline score.  
 
7.3.4 Interview Analysis 
In Part 3 the analysis of the interview findings is explored. The interviews were transcribed 
and analysed according to thematic analysis using Nvivo. The way in which the themes were 
derived follows the commonly used framework analysis method presented by Ritchie and 
Lewis (2003). First, descriptive themes that emerged in each interview were determined and 
used to generate the coding framework. Second, these multiple themes were placed into more 
general themes to generate an index. Each main theme and subtheme was denoted a number 
and these numbers were assigned to all of the text in the interview transcripts to indicate the 
theme discussed. In other words the interview transcripts were coded. The themes were 
collated and presented as descriptive accounts in the results chapter next.  
 
7.3.5 The Development of Coding Reasons 
In both the ex-ante and the ex-post questionnaire there were two qualitative questions. The 
first asked the respondent for reasons behind their WTP value and the second was related to 
why they did or did not find the WTP question difficult to answer. In both cases the data were 
analysed using content analysis (Bryman, 2012). For the first qualitative question, the 
qualitative reasons for the WTP value for both the ex-ante and the ex-post perspective were 
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analysed by this author and categories generated based on a previous published WTP study 
(McIntosh et al., 2010). These codes were thought to be appropriate to apply to both the ex-
ante and the ex-post perspective and the decision was verified by two other researchers (Tracy 
Roberts and Emma Frew).  
The codes for the second qualitative question, regarding difficulty, were derived by a two-
stage process. First, all three study researchers were given all of the ex-post qualitative 
responses for the question and were asked to independently identify themes. Second, the three 
sets of themes were brought together and discussed to produce one coherent list of themes. 
These themes were then applied, by all three researchers, to code the difficulty question 
within both the ex-ante and ex-post study, with only one additional theme within the ex-post 
study. 
In the next section, a discussion regarding the reasons behind the methods chosen is provided.  
 
7.4 Discussion of Methodology Used 
This chapter reports the methodology behind the elicitation of WTP for the from the ex-ante 
and the ex-post perspective. As the most appropriate method to use to elicit WTP is not 
entirely clear, this section focuses on the discussion and justification of the methodology used 
in this research. 
Overall, an out of pocket maximum monthly WTP for treatment was elicited in a 
questionnaire format using the payment scale. The ex-ante perspective recruited women who 
were attending any appointment at any Birmingham Women’s Hospital outpatient clinic. The 
ex-post perspective involved women who were already a part of the ECLIPSE trial and had 
experience of menorrhagia and its treatments. The questionnaire was designed to be self-
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completed. Women from the ex-ante perspective were then asked if they would be willing to 
take part in an interview to gain a more in-depth understanding of their WTP answers.  
 
7.4.1 Strengths and Limitations 
The strength of the methodology used is that WTP is elicited from both the ex-ante and ex-
post perspective to enable comparisons of the WTP results to be drawn across the two 
perspectives. As reported in Chapter 3, the ex-ante perspective is arguably preferred 
theoretically, and the ex-post perspective, is the most commonly used. Therefore, a 
comparison of the findings will determine the degree of difference in the results depending on 
the perspective. Also, the questionnaires were reviewed by experts in several relevant health 
related fields to determine their suitability for the respondents. Further, the inclusion of the 
qualitative questions regarding reasons behind WTP and whether the respondent had any 
difficulty with the WTP question does not only provide additional data to enable comparisons 
to be drawn between the two perspectives, but also provides an assessment of the validity of 
the WTP responses. Hence evidence is provided in favour or against the use of WTP and the 
questionnaire format in general in menorrhagia, and also provides evidence as to whether this 
format is more suitable for one perspective over the other, for valuing outcomes associated 
with menorrhagia and its treatments.  
As this research is aimed at exploring whether WTP can be readily applied to value the 
interventions used for the treatment of menorrhagia, and a convenience sample of the ex-ante 
group could be obtained from the Birmingham Women’s Hospital, it was decided that only 
women should be approached for WTP values. It would be difficult to recruit a sufficient 
number of men from this source. However, difficulties would also be expected when 
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attempting to capture WTP values from men of the general public due to the nature of the 
condition, which may arguably be difficult for men to understand. Furthermore, the 
appropriateness of eliciting men’s WTP values for such a sensitive area could be questioned 
as men are not at risk of the condition or at risk of consuming treatment, which are both 
requirements for eliciting ex-ante WTP values. There may be some cases where men are 
affected by partners with the condition. WTP values could have been elicited based on caring 
externalities, but this did not seem appropriate for this work. It could be argued that caring 
externalities have been accounted for to some degree as women that were approached knew 
family members and friends with the condition. Also, it may have been beneficial to pilot the 
questionnaire to identify the most suitable range of bid levels for the payment scale to 
minimise bias as the respondents WTP values may be influenced by the scale presented, but 
given the time constraints and the focus of the research to assess the feasibility of eliciting 
WTP the payment scale used was considered to be most suitable as the range is in line with 
likely levels of ability to pay. 
Further, in the case of the ex-ante perspective, as menorrhagia is a subjective condition and 
women were recruited from the Birmingham Women’s Hospital clinic, it was likely that 
women who: may have experienced menorrhagia in the past, have experienced the treatments 
but not menorrhagia, or have had a hysterectomy, were recruited into the sample, which does 
not strictly meet the ex-ante perspective definition as outlined in Chapter 3. However it is 
more representative of the female general population.  
For the analysis of the ex-post perspective, it is recognised that due to the nature of the 
condition and its non-curative treatments that women in the ECLIPSE trial may have crossed-
over and experienced both Mirena and Oral treatment, the numbers of which are reported in 
the results. It is recognised that there are limitations to the approach used of eliciting WTP for 
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current treatment but this was deemed to be the most suitable method. Alternative methods 
such as eliciting WTP for the originally randomised treatment were considered. However, this 
would not be intuitive as women would be asked to reveal WTP for a less preferred treatment. 
It is important to take women who have crossed-over into account to ensure that WTP values 
do not solely reflect women who are happy with the treatment.  
Finally, although calculations of sample size are typically conducted in studies assessing the 
effectiveness of treatments, i.e. in clinical trials, this is not always suitable in health 
economics. A method of obtaining the largest sample possible is often adopted, but much 
research in this area is currently being conducted. It is believed that, for the research carried 
out here, it is not readily possible to calculate a sample size as a-priori data on the distribution 
of WTP values for the Mirena or Oral treatment are not available (Donaldson et al., 1997b). 
That is, there are no data available to base the power calculation upon. It is necessary to 
identify the number and range of responses given to determine how many respondents are 
required to detect a certain difference in WTP across treatments. Furthermore, assumptions 
around the possible WTP range would also be unfeasible given the paucity of evidence on 
WTP effect sizes. Whilst information on what WTP value constitutes a meaningful difference 
in improvements from baseline or between treatments was not available for this research, this 
study could be used for future studies to calculate the required sample size.  
 
7.4.2 Comparison with Other Research 
While an interview environment is argued to be the recommended method to elicit WTP 
(Arrow et al., 1993), current recommendations for using interviews are taken from 
environmental economics where scenario descriptions are thought to require further 
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clarification because respondents are not as knowledgeable of the goods. However, it has been 
argued that within healthcare the public may be more familiar with the goods and do not need 
such a rich context of the programme and the market to elicit meaningful WTP values as 
private payment is also taken for some interventions (Smith, 2003; Smith, 2006). Thus, as the 
healthcare interventions (Mirena and Oral treatment) and health outcomes are not complex 
and can be easily explained in a written scenario, a questionnaire was thought to be most 
suitable. There are also issues of the interviewing situation influencing the respondent, 
resulting in real WTP values not being elicited due to interviewer bias (McIntosh et al., 2010). 
Furthermore, interviews were deemed to be too resource intensive and costly, and difficult to 
recommend on a wider scale if WTP was found to be a suitable measure for menorrhagia. 
Although the best method for eliciting WTP has not yet been established, the payment scale 
method was used because it has a higher completion rate than other methods that can be used 
in questionnaires, such as the open-ended questions (Whynes et al., 2003). Further the closed-
ended question requires a-priori distribution of WTP and a large sample size (Frew et al., 
2003). Research has shown that in the open-ended format protest responses and zero 
responses are more likely (Donaldson., 1997b; Frew et al., 2003; Reaves et al., 1999). 
Respondents are also more likely to try to estimate the cost of treatment when providing a 
WTP value because the format provides little guidance (Arrow et al., 1993; Donaldson, 
1997b). The closed-ended format is prone to yea-saying and requires a-priori distribution of 
WTP in addition to a large sample size to obtain a good distribution of WTP answers (Diener 
et al., 1998).  
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7.5 Conclusion 
In this chapter the methodology of the WTP feasibility study is reported. WTP was elicited in 
the form of a payment scale, presented in a questionnaire, from the ex-post and ex-ante 
perspective. WTP was elicited as an out of pocket monthly cost for LNG-IUS (Mirena) and 
usual medical treatment (Oral treatment). The methodology of the interviews using the ex-
ante perspective respondents is also outlined. In the next chapter, the results of the three parts 
of research, the ex-ante perspective, the ex-post perspective, and the interviews are presented.  
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CHAPTER 8. WILLINGNESS TO PAY STUDY – RESULTS 
 
8.1 Introduction 
In this chapter the findings for the willingness-to-pay (WTP) empirical research, described in 
the previous chapter, are reported. The results are separated into three parts. Parts 1 and 2 
refer to the study perspective, that is Part 1 (8.2) refers to the WTP feasibility study from the 
ex-ante perspective and Part 2 (8.3), the WTP feasibility study from the ex-post perspective. 
Part 3 (8.4), refers to the interviews which were carried out to identify patients understanding 
of WTP and its ease of use. Each part is followed by a discussion related to the more technical 
and specific issues related to the research presented. Parts 1 and 2 largely follow the same 
structure and report the following; questionnaire response, WTP for treatment, qualitative 
findings, the econometric analysis and demand curves. 
 
8.2 Part 1: The Ex-ante Perspective 
The results in this section refer to the ex-ante perspective and the analysis explained in the 
previous chapter (subsection 7.2.1). First the questionnaire response is reported, followed by 
the WTP for Mirena and Oral treatment and the qualitative findings related to reasons for the 
WTP values and whether the respondent found the questionnaire difficult to answer. The 
predictors of WTP for each treatment are then explored in an econometric analysis, the 
demand curves presented for WTP for each treatment, the intensity of respondents’ 
preferences for treatment are assessed according to WTP values, and a summary of WTP with 
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values using different subgroups is presented. Finally, a discussion of the findings from the 
ex-ante perspective is provided.  
 
8.2.1 Questionnaire Response 
As outlined in the methodology chapter (Chapter 7), in the ex-ante study, the WTP question 
was included in a self-complete questionnaire which was administered to women visiting the 
Birmingham Women’s Hospital clinics. In this section, the response to the questionnaire, and 
specifically the WTP questions, is detailed. The questionnaire was administered over a 2 
month period (Dec 2012 – Jan 2013). Overall 110 women completed and returned the 
questionnaire. The overall response rate for the ex-ante perspective was difficult to measure 
as every woman visiting the clinics, which were situated in different areas, was approached. 
Multiple women were given a patient information sheet followed by a questionnaire at the 
same time, by this author. Some women left the clinic after their appointment without 
completing the questionnaire or taking a stamped addressed return envelope. Approximately 
142 questionnaires were given out to women who agreed to take part and 110 were returned, 
giving a 77% return rate. The number of women approached and given a patient information 
sheet can be calculated but with limited accuracy. Approximately 174 patient information 
sheets were handed out resulting in an estimated response rate of (110/174) 63%. However, it 
should be noted that this is an overestimation of the response rate as some women returned 
the patient information sheet when refusing to take part in the study and that information sheet 
was likely to have then been given to another potential respondent.  
WTP values and corresponding qualitative answers were checked to identify non-response to 
the WTP question and protest answers (a breakdown of the qualitative information is 
182 
 
provided in section 8.2.3). Out of the 110 women who completed the questionnaire, 3 (3%) 
women did not provide a WTP value for either Mirena or Oral treatment. Two additional 
women provided a WTP for one of the treatments only. One woman did not provide a WTP 
value for Mirena and another did not provide a WTP value for Oral treatment. Thus both 
Mirena and Oral treatment received the same number of non-response (4 in each). 7 protest 
answers, which relate to the individual misunderstanding the exercise and refusing to provide 
a WTP value, were identified from the qualitative explanations offered for the WTP value. 
These 7 protest answers and 4 non-responses to WTP questions were removed from the 
analysis. After these exclusions 99 respondents provided a WTP for each treatment, and in 
total 100 respondents provided a WTP for at least one treatment. A sensitivity analysis was 
carried out which included the protest answers.  
 
Participants 
The characteristics of the sample, excluding those who gave a protest answer or non-response, 
are presented in Table 8.1. The average expected age of menopause was slightly lower than 
the typically suggested average age of menopause for the population. Many of the women 
(80%) stated that they had experience of heavy menstrual bleeding. In some cases a 
respondent may have ticked that she experienced heavy menstrual bleeding but stated in her 
qualitative explanations that she had “no experience of heavy periods”. The reason for this 
may be that at some time in their lives they may have had heavy periods but these periods 
may not have been consistently heavy over consecutive cycles. Whilst in other cases, where 
the respondent ticked that she did have experience of heavy periods, the respondent may have 
perceived that her bleeding was heavy through consecutive cycles and that it interfered with 
her quality of life (QoL), which would reflect experience of menorrhagia (heavy menstrual 
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bleeding). The responses to the income categories showed that one half of the sample lie at 
the extremes of the income categories. One quarter have a household income of less than 
£20,000 and the other quarter have a household income greater than £50,000. The average 
household income in the UK lies between £20,000-£30,000, at £26,572 and approximately 
65% of households have an income below the national average (Cribb et al., 2012). In this 
study reported here, a higher overall proportion (60%) of women have a household income of 
less than £30,000, which would suggest that the sample is fairly representative of the UK 
population in this respect. 
Table 8.1 Sample characteristic (ex-ante) 
Variable Sample analysed 
(n=100) 
Expected age of menopause (yrs) [SD] 52.1 [5.53] 
Age [SD] 36.6 [9.29] 
Marital status   
Married or living with partner 63  
Not  37  
Wanted children in future?)  
Yes  55  
No 34  
Employment status   
Employed (FT)/(PT) 74  
Not  26  
Household income   
Less than 20,000 24  
20,001-30,000 22  
30,001-40,000 14  
40,001-50,000 12  
More than 50,000 23  
Main earner   
Yes 45  
No 53  
Satisfaction with life overall [best (worst)]   
Very unsatisfied 13 /13  
Slightly unsatisfied 15 /16  
Neither satisfied nor dissatisfied 10 /11  
Slightly satisfied 22 /21  
Very satisfied 39 /38  
Experience of menorrhagia  
Yes 80 
No 20  
EQ-5D best [SD] 0.766 [0.257] 
EQ-5D worst [SD] 0.743 [0.283] 
FT; full time, PT; part time 
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Preferred treatment group 
Out of the 100 women who provided a WTP value for at least one treatment, Mirena was 
most preferred (47), followed by Oral treatment (39) and then no preference (11). Three 
women did not answer this question. The percentage of women preferring each treatment is 
presented in Figure 8.1.  
Figure 8.1 Percentage of respondents preferring each treatment 
3 women did not state whether they had a preference for treatment.  
 
The socio-demographic characteristics of the study respondents were assessed to identify if 
there was a statistically significant difference between those who preferred Mirena to those 
who preferred Oral treatment. The Chi-squared test was used for categorical variables and 
either the two sample t-test or the Wilcoxon Rank Sum test for continuous variables, 
depending on the normality of the distribution. The results are presented in Table 8.2 and 
demonstrate that the only variable that does show a statistically significant difference between 
preference groups is ‘children in future’ (p<0.05). More people who preferred Oral treatment 
wanted children in the future. Oral treatment may have been preferred by women who wanted 
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children in the future because the cessation of Oral treatment does not require a general 
practitioner (GP) appointment for removal. Unlike in the case of Mirena, women can just 
simply stop taking the Oral treatment when they please. However, as several significance tests 
were conducted, the possibility that this result may have occurred by chance cannot be 
excluded. 
Table 8.2 Descriptive statistics according to preferred treatment 
Variable Prefer Mirena 
(n=47) 
Prefer Oral 
(n=39) 
p-value 
Expected age of menopause (yrs) [SD] 52.43 [4.63] 51.5 [6.10] 0.564 
Age [SD] 38.3 [9.49] 35 [9.54] 0.130 
Marital status (%)   0.075 
Married /living with partner 34 (72%) 21 (54%)  
Not  13(28%) 18 (46%)  
Wanted children in future? (%)    
Yes  17 (45%) 29 (76%)  
No 21 (55%) 9 (24%)  
Difference across preferred treatment   0.005* 
Employment status (%)    
Employed (FT)/(PT) 33 (70%) 30 (77%)  
Not 14 (30%) 9 (23%)  
Difference across preferred treatment   0.484 
Household income (%)    
Less than 20,000 7 (16%) 12 (32%) 0.077 
20,001-30,000 10 (23%) 8 (22%) 0.931 
30,001-40,000 7 (16%) 5 (14%) 0.782 
40,001-50,000 8 (18%) 4 (11%) 0.367 
More than 50,000 12 (27%) 8 (22%) 0.583 
Main earner (%)    
Yes 21(47%) 17 (44%)  
No 24 (53%) 22 (56%)  
Difference across preferred treatment   0.778 
Satisfaction with life [best (worst)] (%)   0.783 [0.841] 
Very unsatisfied 8 (17%) 4 (11%) 0.367 [0.637] 
Slightly unsatisfied 9 (19%) 6 (16%) 0.647 [0.887] 
Neither satisfied nor dissatisfied 3 (6%) 4 (11%) 0.513 [0.513] 
Slightly satisfied 9 (19%) 6 (16%) 0.647 [0.647] 
Very satisfied 18 (38%) 18 (47%) 0.462 [0.619] 
Experience of menorrhagia (%)    
Yes 34 (72%) 32 (82%)  
No 13 (28%) 7 (18%)  
Difference across preferred treatment   0.289 
EQ-5D best [SD] 0.745 [0.285] 0.771 [0.229] 0.821 
EQ-5D worst [SD} 0.734 [0.293] 0.740 [0.270] 0.727 
*significant difference between preference groups (p<0.05) 
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8.2.2 WTP Mirena and Oral Treatment 
The mean WTP for each treatment was calculated from the respondents who provided a WTP 
for at least one treatment. The maximum average WTP for Mirena along with the 
bootstrapped confidence intervals (CI) was £15.11 (95% CI £10.22-20) and for Oral treatment 
was £15.38 (95% CI 10.92-19.85). The results, presented in Table 8.3, show the descriptive 
statistics for WTP for Mirena and Oral treatment. It can be seen that the minimum and 
maximum values are the same for both treatments. For Mirena, 19 people were not willing to 
pay anything and two people were willing to pay £150. Whilst for Oral treatment, seven 
people were not willing to pay for Oral and one person was willing to pay £150. In both 
treatments the WTP data were found to be skewed and thus the WTP data for both Mirena and 
Oral treatment were log transformed. As detailed in Chapter 7, each WTP value has a constant 
of 1 added to it to ensure that zero values would still be taken into consideration when the 
data are log transformed. 
 
Table 8.3 Descriptive statistics for WTP (ex-ante) 
 WTP Mirena (n=99) WTP Oral treatment (n=99) 
Mean  £15.11 £15.38  
Standard deviation (SD) £24.50 £22.40 
Min-Max £0-£150 £0-£150 
Inter-quartile range (IQR) £4-£20 £6-£16 
Group difference (paired t-test) p=0.1247 
WTP; willingness-to-pay 
 
To test for a statistical significance between the two log transformed WTP values for each 
treatment, a paired t-test was conducted. The results show that there is no statistically 
significant difference in mean WTP (p=0.1247) between the two treatments. Table 8.4 shows 
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the results of mean WTP according to income which is often recommended when analysing 
WTP data as a theoretical validity check (Donaldson, 1999). It can be seen that generally the 
mean WTP increases as household income increases. However, this relationship is not 
monotonic as the mean WTP does decrease at some points as income increases (£30,001-
£40,000). Hence WTP is not necessarily related to ability to pay as is required to confirm 
theoretical validity.  
 
Table 8.4 Mean WTP against household income (ex-ante) 
Household Income WTP Mirena (n) WTP Oral treatment (n) 
Less than £20,000 £12.42 (24) £12.52 (23) 
£20,001 - £30,000 £14.90 (21) £17.59 (22) 
£30,001 - £40,000 £12.36 (14) £14.43 (14) 
£40,001 - £50,000 £24.17 (12) £20.17 (12) 
More than £50,000 £10.43 (23) £10.26 (23) 
WTP; willingness-to-pay 
 
In Table 8.5 the WTP values for each treatment are presented against the number of 
respondents who chose that WTP value to explore the influence of prominent numbers on the 
WTP value. Prominent numbers are those that are typically selected by respondents and 
include 0, 1, 2, 5, 10, 20, 50, 100, 200, 500 and so on (Whynes et al., 2007).    
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Table 8.5 Frequency of WTP value (ex-ante) 
WTP Mirena (n) Oral treatment (n) 
£0 19 7 
£2 3 5 
£4 3 11 
£6 8 8 
£8 8 11 
£10 22 23 
£12 1 3 
£14 1 3 
£16 3 4 
£18 4 2 
£20 18 9 
£25 2 2 
£30 3 5 
£45 0 1 
£50 0 1 
£100 2 3 
£150 2 1 
Total 99 99 
The underlined numbers are the prominent numbers that were present in the payment scale 
 
It can be seen that in the case of Mirena, the majority of the respondents have selected 
prominent numbers (£10 and £20). However, for Oral treatment a WTP value of £10 was 
selected the most number of times but there is a greater spread of values amongst non-
prominent numbers compared to Mirena. The reasons for this difference in findings may be 
related to the nature of the two treatments and is explored further in the discussion (section 
8.2.9).  
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As the question order of WTP for treatment was not randomly changed, Mirena was always 
asked first followed by Oral treatment. The effect on the WTP values of not randomly 
changing the order of the treatment payment scale first presented to respondents was also 
investigated. Hence the effect on the mean WTP of those who preferred Oral treatment 
providing a WTP for Mirena first, their least preferred treatment, is explored. Table 8.6 shows 
the mean WTP values for Mirena and Oral treatment according to preferred treatment.  
 
Table 8.6 Assessment of ordering effects 
Preferred treatment WTP Mirena 
(mean) 
WTP Oral 
(mean) 
Prefer Mirena (n=47) £20.30 £15.83 
Prefer Oral treatment (n=39) £10.39 £17.26 
 
It can be seen from Table 8.6 that those who prefer Mirena are willing to pay more for Mirena 
than Oral treatment and vice versa for those who prefer Oral treatment. It also shows that 
despite those who prefer Oral treatment being presented with their least preferred treatment 
option first, the mean WTP value for their preferred option (Oral treatment) is greater. 
However, a greater difference between WTP values for the two treatments is produced for 
those who prefer Oral treatment, compared to those who were asked the WTP value for their 
most preferred treatment (Mirena) first. This finding could be due to the lack of randomisation 
of the question order, or that those who prefer Oral treatment placed a greater value on it 
compared to the value placed on Mirena, by those that prefer Mirena. 
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8.2.3 Qualitative Findings  
Following the WTP questions for Mirena and Oral treatment, the women were asked to 
answer two qualitative questions. The first, related to the reason behind their WTP value and 
the second, asked women to explain why they did, or did not, find the WTP question difficult 
to answer. As outlined in the methodology Chapter (7), categories or ‘themes’ were generated 
using content analysis. 
 
Reason for WTP 
Nine categories of reasons for a WTP value were generated from the qualitative information 
from the full sample of women, which included protests and non-response. In total, 107 
respondents offered an explanation for the WTP value. Only one code was required to 
categorise the written explanation in 61 cases. In 46 cases, two or more categories of 
explanations were required. The categories of reasons for the full sample and for the sample 
used in the analysis are presented in Table 8.7. 
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Table 8.7 Explanation given for WTP value (ex-ante) 
Category Explanation Full sample 
n (%) 
One WTP 
n (%) 
R1 Subject expressed difficulty estimating WTP owing to: 
- Difficult to answer 
- Cannot put a price on healthcare 
3 (2%) 1 (0.7%) 
R2 WTP based on nominal amount 
- Arbitrary sum/ guess/ out of thin air 
5 (3%) 5 (3%) 
R3 WTP reflects ability to pay (affordability) 
- Maximum affordable amount given current 
situation  
39 (24%) 39 (26%) 
R4 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
11 (7%) 11 (7%) 
R5 WTP reflects cost of treatment 
- Attempted to estimate cost 
- Used a comparator such as prescription costs 
30 (19%) 30 (20%) 
R6 WTP reflects effects of treatment 
- In terms of effectiveness outcomes 
- In terms of process utility 
54 (34%) 54 (36%) 
R7 Protest expressed at idea of payment 
- Paid National Insurance and taxes/ NHS should 
pay 
- Women cannot help the condition/ treatment 
should be free 
6 (4%) 0 (0%) 
R8 Related to cost of sanitary wear 
- Washing clothes/wipes/painkillers 
9 (6%) 9 (6%) 
R9 Misunderstood exercise but provided WTP value 3 (2%) 3 (2%) 
Total  160 152 
NHS; National Health Service, WTP; willingness-to-pay 
 
Among the respondents that offered at least one WTP value, all but one offered a reason. The 
most commonly cited reason for a WTP value for both the full sample and the sample 
analysed was ‘R6 where WTP reflects the effect of treatment’, followed by ‘R3: 
affordability’. Three respondents misunderstood (R9) the WTP question. As it could be 
argued that these WTP values are not valid, a sensitivity analysis was conducted and is 
reported in section 8.2.8 to estimate the mean WTP excluding these three respondents. 
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Difficulty with WTP explanation 
Over 60% of women who completed at least one WTP question said that the question was not 
difficult to answer (Figure 8.2).  
 
Figure 8.2 Proportion of women who did and did not find WTP difficult to answer 
 
 
Respondents were then asked to provide a written explanation for their answer. One 
respondent did not complete the previous question on whether she found WTP difficult to 
answer but did provide an explanation for whether she found the question difficult to answer. 
Nine categories of explanation were generated from the qualitative information from the 
entire sample of women, including protests and non-response. Out of the 110 women, 92 
provided a reason for their answer and 16 of these reasons were coded as one category. 76 
provided an explanation that was coded into two or more categories. Among the 98 women 
who provided a WTP value for both Mirena and Oral treatment, or a WTP for at least one 
treatment, 86 provided an explanation as to why they did or did not find the question difficult 
to answer. The categories of explanations for the sample analysed (which excludes those who 
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did not provide a protest answer) are presented according to whether the question was 
difficult to answer in Table 8.8 below. 
 
Table 8.8 Explanation given for difficulty question (sample analysed, ex-ante) 
Category Explanation  Difficult   
n (%) 
Not 
difficult 
n(%) 
Total    
n (%) 
D1 Found valuation difficult 
- Not used to it/ difficult to quantify/WTP out of 
thin air 
- Not aware of cost implications 
19 (44%)* 1 (2%) 20 (20%) 
D2 Used prescription costs as a proxy 
- “I know the cost of prescription...” 
1 (2%) 5 (8%) 6 (6%) 
D3 Benefits of treatment – reasonable amount for expected 
outcomes 
- Due to way menorrhagia impacts lives 
- Due to nature of treatment effects  
8 (19%) 23 (39%) 31 (30%) 
D4 Ability to pay dictated amount 4 (9%) 8 (14%) 12 (12%) 
D5 Difficulty with hypothetical nature of WTP question 
- No personal experience of menorrhagia 
7 (16%) 0 (0%) 7 (7%) 
D6 Balance of impact on QoL and affordability  
- Explicitly explained WTP not difficult to 
answer 
2 (5%) 
 
20 (34%) 22 (22%) 
D7 Protest – I would not pay 0 (0%) 0 (0%)* 0 (0%) 
D8 Misunderstood exercise but provided WTP value 2 (5%) 1 (2%) 3 (3%) 
D9 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
0 (0%) 1 (2%) 1 (1%) 
Total  43 59 102 
*5 additional reasons were cited in the entire sample (protests and non-response were considered). Three 
protested again (D7) to the WTP question and considered the question not to be difficult, two were ‘D1: not used 
to valuing healthcare’ and said the question was difficult.  
 
In the case where the respondents completed one WTP question it can be seen that for those 
who did find the question difficult to answer, the most common reason was related to ‘D1: not 
being used to valuing healthcare’. For those who did not find the valuation difficult the most 
commonly cited reason was ‘D3: a reasonable amount to pay for the expected benefits’. There 
were two cases where inconsistent responses were observed between the answer provided for 
the WTP question and the explanation given. That is, one respondent stated that the question 
was not difficult to answer and then in the difficulty reason stated that it was difficult. The 
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other respondent ticked that it was difficult and explicitly stated that it was not difficult in the 
qualitative explanation. This inconsistency in responses will be discussed further in section 
8.2.10.  
 
8.2.4 Econometric Analysis 
It was outlined in the analysis section of the methodology chapter that a two-part model could 
not be used to assess WTP as the proportion of respondents who provided zero values was 
quite small (details next). To explore any potential relationships between those that provided 
zero values and those that did not, a univariable analysis was carried out. Further, as the 
number of respondents who gave a protest (n=7) or non-response (n=4 in each arm) was too 
few, it was also not appropriate to conduct an analysis to identify the characteristics of the 
women who either gave a protest answer or did not respond to the WTP question. 
In the following section, the results of the analysis on the zero values is reported first and is 
followed by the OLS linear regression on the sample, which includes the zero values, but not 
protests and non-response. The exclusion of these respondents is further explored in a 
sensitivity analysis. As part of a sensitivity analysis, an interval regression was also run on 
Mirena and Oral treatment (See Appendix A5.1).  
 
Analysis of Zero WTP values 
As there is insufficient variation in the sample, a regression analysis of the 19% and 7% of 
respondents who provided a zero WTP value for both Mirena and Oral treatment respectively 
cannot be conducted to identify predictors for providing a zero value. Only 3 respondents 
gave a zero value for Oral treatment alone, and 15 respondents gave a zero value for Mirena 
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alone (4 gave zero values for both treatments). Table 8.9 presents the descriptive statistics of 
the respondents who provided a zero value for each treatment. Significance tests using Chi-
squared test for categorical variables and Wilcoxon Rank Sum for continuous variables were 
carried out to identify if there were any significant differences between those who provided 
zero values for either treatment and those that did not. The significance tests showed that 
respondents who provided zero values are significantly less likely to have experience of 
menorrhagia (p=0.040), earn £20,000-30,000 (p=0.015), earn £40,000-50,000 (p=0.050) and a 
lower EQ-5Dbest score (p=0.050). There are insufficient numbers in each treatment group to 
obtain any robust significance test results between those who provided zero values for each 
treatment, and those that did not.  
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Table 8.9 Descriptive statistics for zero WTP values (ex-ante) 
Variable Mirena Zero 
(n=19) 
Oral Zero 
(n=7) 
Expected age of menopause (yrs)[SD] 53.3 [3.56] 54 [2.94] 
Age (%) 35.4 [6.98] 33.3 [8.81] 
Marital status (%)   
Married or living with partner 13 (68%) 5 (71%) 
Not  6 (32%) 2 (29%) 
Wanted children in future? (%)   
Yes  13 (72%) 5 (83%) 
No 5 (28%) 1 (17%) 
Employment status (%)   
Employed (FT)/(PT) 13 (68%) 5 (71%) 
Not 6 (32%) 2 (29%) 
Household income (%)   
Less than 20,000 7 (39%) 2 (33%) 
20,001-30,000 6 (33%) 3 (50%) 
30,001-40,000 2 (11%) 0 (0%) 
40,001-50,000 0 (0%) 0 (0%) 
More than 50,000 3 (17%) 1 (17%) 
Main earner (%)   
Yes 9 (47%) 2 (29%) 
No 10 (53%) 5 (71%) 
Satisfaction with life overall [best 
(worst)] (%) 
  
Very unsatisfied 4 (21%) / 4 (21%) 1 (14%) / 1 (14%) 
Slightly unsatisfied 3 (16%) / 4 (21%) 2 (29%) / 2 (29%) 
Neither satisfied nor dissatisfied 4 (21%) / 4 (21%) 1 (14%) / 1 (14%) 
Slightly satisfied 4 (21%) / 4 (21%) 1 (14%) / 1 (14%) 
Very satisfied 4 (21%) / 3 (16%) 2 (29%) / 2 (29%) 
Experience of menorrhagia (%)   
Yes 19 (100%) 6 (86%) 
No 0 (0%) 1 (14%) 
EQ-5D best [SD] 0.693 [0.236] 0.642 [0.317] 
EQ-5D worst [SD] 0.665 [0.274] 0.642 [0.317] 
SD; standard deviation 
 
Figure 8.3 presents the preference groups against the percentage of zero values. The figure 
shows that in the case of zero values for Mirena, intuitively, the respondents who were most 
likely to provide a zero value for Mirena preferred the Oral treatment (78%). However, for the 
women who preferred Mirena, they were not more likely to provide a zero value for Oral 
treatment, as one would expect. It was observed that it was still the Oral treatment preference 
group that provided the most zero values for Oral treatment (43%). 
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Figure 8.3 Zero values provided against preferred treatment 
 
 
Figure 8.4 illustrates that out of those who found the WTP question difficult to answer, a 
higher percentage of respondents provided a zero value for Oral treatment. Conversely out of 
those who did not find the question difficult to answer, a higher percentage of respondents 
provided a zero value for Mirena.  
 
Figure 8.4 Difficulty with WTP according to zero value 
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To explore the reason for these zero values Figure 8.5 illustrates the reason codes cited by 
those who provided a zero WTP value for Mirena or Oral treatment. 
 
Figure 8.5 Explanation given for zero value 
 
R1: difficulty ; R2: nominal amount; R3: ability to pay; R4: reasonable value; R5: cost fo treatment; R6: effects 
of treatment; R7: protest; R8: cost of sanitary wear; R9: misunderstood 
 
It can be seen that for those who provided a zero value for Mirena, the most commonly cited 
reason was ‘R6: the effect of the treatment’. As all 19 women who gave a zero value for 
Mirena had experience of heavy periods (Table 8.9), it is likely that they have experience of 
Mirena and therefore that these women did not think that the effect of Mirena was worth any 
monetary amount. The second most common reason for providing a zero value for Mirena 
was ‘R3: affordability’. For those that provided a zero value for Oral treatment, similarly to 
Mirena, ‘R6: effect of treatment’ was the most commonly cited reason for providing a zero 
value followed by both ‘R3: affordability’ and ‘R4: A reasonable value but the NHS should 
pay’. Similarly, as all but one of the respondents who provided a zero value for Oral treatment 
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had experience of menorrhagia and by extension was likely to have experience of Oral 
treatment, they may not have believed that Oral treatment was worth any monetary amount.  
 
OLS linear regression 
The results of the stepwise OLS linear regression on the log transformed data are presented in 
Table 8.10. Two variables were excluded - one was excluded to preserve the sample size, the 
variable ‘children in future’ was dropped from the analysis as this variable contained 10% 
missing data. Due to the nature of the stepwise analysis to keep the sample size constant 
throughout the analysis even if ‘children in future’ was not significant in the final model, the 
sample size would remain at the reduced level. Thus a univariable analysis was conducted 
using ‘children in future’ for both treatment options and in both cases it was found that this 
variable was not significant at the 30% level. A flexible value of p<0.3 was used at the 
univariable stage to ensure that the variable was not excluded unnecessarily. The ‘satisfaction 
with life’ variables were dropped to prevent collinearity. ‘Satisfaction’ was also assessed in a 
univariable analysis and was not found to be significant at p<0.3. 
It can be seen that in the case of Mirena that WTP is positively influenced by income. Whilst 
the WTP responses from the lower income categories are not significant, the ranges of the 
confidence intervals show that there is a tendency for an increasing positive association with 
WTP as income increases. However, this relationship is not monotonic as there is a reduction 
in the association with WTP at the highest income, but this also did not reach significance. 
The only significant income category was £40,001-£50,000 thus compared to those in the 
lowest household income bracket, those earning £40,001-£50,000 are willing to pay 
significantly more for Mirena (p=0.005; p<0.05). It can be seen in Table 8.10 that ‘R9: 
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misunderstanding the exercise’ (p=0.020), ‘preferring Oral treatment’ (p=0.002), having 
‘experience of heavy menstrual bleeding’ (p=0.019) and being ‘married’ (p=0.008) all have a 
significantly negative impact on WTP (p<0.05). It could be intuitively expected that 
preferring Oral treatment would lead to a negative impact on WTP for Mirena. It is also 
possible that women who suffer from menorrhagia may have already experienced Mirena and 
would not pay for the treatment effects. Further as Mirena causes temporary negative effects 
on women for the first 6 months, as described in the treatment scenario, it could be that 
women who are married would prefer a more immediate effect to minimise the strain on the 
relationship. In contrast ‘R3: affordability’ (p=0.010), ‘R5: the cost of treatment’ (p=0.023), 
and current ‘EQ-5Dbest’ (p=0.004) have a significantly positive effect on WTP for Mirena 
(p<0.05). The reason code ‘R1: finding the valuation difficult’ had a tendency towards 
significance (p=0.063) but the confidence intervals suggest there could be either a positive or 
negative relationship with WTP.  
The link test, used to assess the model form and model specification, revealed that the model 
is correctly specified (p=0.095). Thus the null hypothesis, that an important variable has not 
been excluded, cannot be rejected. Despite the significant p-value observed in the Ramsey 
RESET test (p=0.0483), indicating that variables were omitted, as the p-value is only 
bordering on significance and the link test revealed that the model is correctly specified it is 
possible that this result has occurred by chance.  
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Table 8.10 OLS linear regression for Mirena WTP values (ex-ante) 
Variable Coefficient 95% CI P-value 
Expected age of menopause -0.0626 -0.100,  -0.026 0.001 
R3: affordability  0.598  0.148,  1.047 0.010 
R5: cost of treatment 0.563 0.081,  1.044 0.023 
R9: Misunderstanding exercise -1.381 -2.536, -0.226 0.020 
Experience of menorrhagia -0.623 -1.142, -0.104 0.019 
Preferred treatment    
Prefer Oral treatment -0.718 -1.153, -0.283 0.002 
No preference 0.0546 -0.653,  0.762 0.878 
Income    
£20,001-£30,000 -0.114 -0.674,  0.446 0.687 
£30,001 -£40,000 0.254 -0.456,  0.964 0.479 
£40,001-£50,000 1.041 0.320,  1.762 0.005 
More than £50,000 0.0803 -0.505,  0.666 0.785 
Married -0.606 -1.064, -0.165 0.008 
EQ-5Dbest 1.286 0.427,  2.145 0.004 
R1: Found valuation difficult 1.999 -0.155,  4.113 0.063 
Constant 5.015 2.898,  7.133 0.000 
Adjusted R
2
=0.394, n=93 
In the case of the linear regression model for Oral treatment (Table 8.11) it can be seen that 
none of the variables for Mirena arose as significant predictors for WTP for Oral treatment. 
Overall, finding the question ‘difficult to answer’ (p=0.003) has a significantly negative 
impact on WTP for Oral treatment (p<0.05), but having ‘D5: difficulty with the hypothetical 
nature’ (p=0.015), ‘D1: not being used to valuing healthcare’ (p=0.002) and using ‘R8: cost of 
sanitary wear’ (p=0.044) as a proxy for WTP were positively associated with WTP (p<0.05). 
The following variables had a tendency towards significance; ‘D3: reasonable amount for the 
expected outcomes’ (p=0.06), ‘R9: misunderstanding the exercise’ (p=0.062) and ‘R3: 
affordability’ (p=0.078) but the confidence intervals include both negative and positive 
associations. Similar to the Mirena model, the link test revealed that the model is correctly 
specified (p=0.688). Thus it is not possible to reject the null hypothesis that an important 
variable has not been excluded and the Ramsey RESET test also shows that there are no 
omitted variables (p=0.8164). However since the R
2
 for this regression is low (R
2
=0.111), this 
could indicate that WTP is also predicted by something else that is not captured by any of the 
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explanatory variables in this model. However, caution of interpretation of these models is 
necessary given the relatively small sample size. 
 
Table 8.11 OLS linear regression for Oral treatment WTP values (ex-ante) 
Variable Coefficient 95% CI P-value 
R9: Misunderstood exercise 1.039 -0.0535,  2.132 0.062 
Difficult to answer -0.860 -1.430, -0.291 0.003 
D5: Difficulty with hypothetical  1.111 0.217, -2.005 0.015 
R3: affordability  0.364 -0.0412,  0.769 0.078 
D1: Not used to valuing 1.021 0.378,  1.664 0.002 
D3: Reasonable amount for treatment 
effects  0.399 -0.016,  0.814 0.06 
R8: Cost of sanitary wear 0.682 0.018,  1.345 0.044 
Constant 1.947 1.615,  2.279 0.000 
Adjusted R
2
=0.111, n=93 
 
The results of the sensitivity analysis using interval regression for both Mirena and Oral 
treatment can be found in the Appendix 5.1. The model for Mirena is similar to the OLS 
model except ‘R9: Misunderstanding the exercise’ is included as a significant variable in the 
linear OLS model and is not in the interval regression. Also ‘R5: cost of treatment’ is not 
significant in the interval regression but is in the OLS model. The signs of the coefficients for 
the variables are the same in both the OLS and interval regression models and the size of the 
coefficients differ only slightly. The results of the interval regression for Oral treatment differ 
from the OLS model in that ‘income’, ‘D3: reasonable amount for expected outcomes’ and 
‘R3: affordability’ are significant for interval regression but ‘D3: reasonable amount for 
expected outcomes’ and ‘R3: affordability’ only have a tendency towards significance in the 
OLS model. The signs of the coefficients of the OLS and interval regression models are the 
same, and the coefficients vary slightly. The interval regression model for both Mirena and 
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Oral treatment was shown to be statistically significant compared to the constant only model 
(likelihood ratio 48.64, p=0.000) (likelihood ratio 31.92, p=0.008). 
 
8.2.5 Demand Curves 
Figure 8.6 shows the demand curves for Mirena and Oral treatment. A demand curve 
represents the quantity demanded of a good according to changes in price. In a competitive 
market it is expected that as the price of the good decreases, the demand increases, thus 
producing a downward sloping curve (Sloman & Wride, 2009). When using contingent 
valuation, a hypothetical market is created which is contingent on the scenario provided. Thus 
it is expected that the demand curves in this WTP study behave as those in competitive 
markets. The demand curves for Mirena and Oral treatment resemble a ‘typical’ demand 
curve. It can be seen that from £60 upwards the demand curves for both treatments are 
inelastic as great changes in price (£150-£60) result in very small changes in quantity 
demanded. However, at lower prices, below £20, both treatments are elastic, as below the £20 
price demand changes greatly from 5% to 80% of the respondents. 
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Figure 8.6 Demand curves for Mirena and Oral treatment 
 
8.2.6 Preference Reversals and Inconsistent Responses 
Table 8.12 presents the preferred treatment against the greater WTP value. It shows that in 
39% of cases, the respondent has stated that they have a preferred treatment but gave an equal 
WTP to both treatments. Nine respondents who preferred Oral treatment gave a greater WTP 
value to Mirena. One respondent who preferred Mirena gave a WTP that was higher for Oral 
treatment. Seven respondents who had no preference did not give equal WTP values, but gave 
a greater value to Mirena or Oral treatment.  
Table 8.12 Preferred treatment against greatest WTP value provided 
Preferred treatment  Is WTP Oral > WTP Mirena  
No (%) Equal (%) Yes (%) Total 
Oral  9 (9%) 13 (13%) 17 (18%) 39 (40%) 
Mirena 21 (22%) 25 (26%) 1 (1%) 47 (48%) 
No preference 5 (5%) 4 (4%) 2 (2%) 11 (11%) 
Total 35 (36%) 42 (43%) 20 (21%) 97 
WTP; willingness-to-pay 
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The qualitative reasons for the respondents who provided equal WTP values even though a 
preference for treatment is stated are displayed in Figure 8.7. The figure shows that the two 
most commonly cited reasons for equal WTP values are related to ‘R6: the effect of 
treatment’ and ‘R3: affordability’ for both Oral treatment and Mirena. However, it should also 
be noted that it is possible that the respondent has a preference for treatment, but this 
preference may not be particularly strong, which could result in equal WTP values (Ryan & 
San Miguel, 2000). Therefore these 39% of cases do not need to be treated as inconsistent 
responses and are therefore included in the sample. 
 
Figure 8.7 Reason for equal WTP value according to preferred treatment 
 
R1: difficulty ; R2: nominal amount; R3: ability to pay; R4: reasonable value; R5: cost of treatment; R6: effects 
of treatment; R7: protest; R8: cost of sanitary wear; R9: misunderstood 
 
The qualitative reasons for preference reversals, where a respondent has stated that they prefer 
one treatment but provide a greater WTP value for the other treatment, were also checked to 
identify why these individuals provided inconsistent responses. It can be seen from Table 8.13 
that the most commonly cited reason that respondents who preferred Oral treatment gave a 
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greater WTP value for Mirena was related to ‘R5: the cost of the treatment’. Thus, these 
respondents expected the Mirena to cost more than Oral treatment and therefore gave a 
greater WTP. Similarly, the only reasons given why respondents who preferred Mirena gave a 
greater WTP for Oral treatment includes ‘R5: the cost of treatment’ and ‘R4 providing a 
reasonable WTP value for treatment’.  
 
Table 8.13 Reasons for inconsistent WTP values 
Category Explanation Prefer Oral, > 
Mirena WTP 
Prefer Mirena 
> Oral WTP 
R1 Subject expressed difficulty estimating WTP owing to: 
- Difficult to answer 
- Cannot put a price on healthcare 
0 (0%) 0 (0%) 
R2 WTP based on nominal amount 
- Arbitrary sum/ guess/ out of thin air 
0 (0%) 0 (0%) 
R3 WTP reflects ability to pay (affordability) 
- Maximum affordable amount given current situation  
3 (30%) 0 (0%) 
R4 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
2 (20%) 1 (50%) 
R5 WTP reflects cost of treatment 
- Attempted to estimate cost 
- Used a comparator such as prescription costs 
4 (40%) 1 (50%) 
R6 WTP reflects effects of treatment 
- In terms of effectiveness outcomes 
- In terms of process utility 
0 (0%) 0 (0%) 
R7 Protest expressed at idea of payment 
- Paid National Insurance and taxes/ NHS should pay 
- Women cannot help the condition/ treatment should 
be free 
0 (0%) 0 (0%) 
R8 Related to cost of sanitary wear 
- Washing clothes/wipes/painkillers 
1 (10%) 0 (0%) 
R9 Misunderstood exercise but provided WTP value 0 (0%) 0 (0%) 
Total  10 2 
NHS; National Health Service, WTP; willingness-to-pay. 
 
8.2.7 Intensity of Preferences 
The intensity of the preferences were assessed to identify why the WTP for Mirena (£15.11) 
was not greater than the WTP for Oral treatment (£15.38) given that Mirena was the most 
preferred treatment in the sample (48%). 
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The findings in Table 8.14 show that overall the WTP for Oral treatment is 2% greater than 
the WTP for Mirena. This finding contradicts the results of the most preferred treatment as 
Mirena was the most preferred in the sample (48%). Those that preferred Mirena were willing 
to pay 28% more for Mirena than Oral treatment, which is as theory would predict. Those that 
preferred Oral treatment were willing to pay 66% more for Oral treatment. This finding could 
indicate that those who preferred Oral treatment had a stronger preference for Oral treatment 
than Mirena, which may explain the greater overall WTP value for Oral treatment.  
 
Table 8.14 Intensity of preferences 
Preferred treatment  WTP ratio 
All cases  WTP Oral/ WTP Mirena = 1.02 
Mirena  WTP Mirena/ WTP Oral = 1.28
a
 
Oral treatment  WTP Oral/ WTP Mirena= 1.66 
No preference  WTP Mirena/ WTP Oral = 1.19
a
 
a 
To identify the intensity of preferences for Mirena and No preference it is more appropriate to divide Mirena by 
Oral treatment, rather than the reverse (‘Mirena’ -WTP Oral/ WTP Mirena =0.78/ ‘No preference’ WTP 
Oral/WTP Mirena = 0.86) 
 
However, those respondents that had no preference for treatment were willing to pay 19% 
more for Mirena than Oral treatment. The results of the qualitative reasons for WTP values 
were checked to determine the reason for providing a greater WTP for Mirena. All 5 
respondents who stated that they had no preference but gave a greater WTP value for Mirena 
provided at least one reason for their WTP values. ‘R4: WTP reflects a reasonable value but 
the NHS should pay’, ‘R5: WTP reflects the cost of treatment’ and ‘R6: WTP reflects effects 
of treatments’ were each cited twice and ‘R3: affordability’ was cited once. The effects of 
treatments impacting on WTP may be related to Mirena having better long-term effects than 
Oral treatment. The perceived greater cost of Mirena has also led to greater WTP values for 
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Mirena and it seems from R4 that a ‘Reasonable value for treatment, but the NHS should pay’ 
may also be related to the outcomes for the two treatments presented in the scenario 
description.  
 
8.2.8 Summary of WTP with Excluded Subgroups 
Table 8.15 details the WTP results according to the individual subgroups that were excluded, 
to identify the impact of excluding these responses on WTP.  
Table 8.15 WTP according to excluded subgroups (ex-ante) 
Analysis Mean [SD] Median No. of Obs 
Mirena    
Sample analysed £15.11 [24.54] £10 99 
Without misunderstood £15.60 [25.03] £10 94 
Without equal WTP £15.49 [25.32] £10 92 
Preference reversals £15.27 [24.62] £10 98 
Full sample £14.11 [24.00] £10 106 
Oral treatment    
Sample analysed £15.38 [22.39] £10 99 
Without misunderstood £14.69 [21.17] £10 94 
Without equal WTP £15.99 [23.06] £10 92 
Preference reversals £16.01 [23.36] £10 90 
Full sample £14.37 [21.97] £10 106 
SD; standard deviation, WTP; willingness-to-pay.  
It can be seen from Table 8.15 that the only subgroup that alters the findings, that Oral 
treatment generates a greater WTP than Mirena, is the exclusion of those who misunderstood 
the exercise. The exclusion of protests, preference reversal, those who provided equal WTP 
values despite having a preferred treatment changes the mean WTP very slightly. In the case 
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of the 5 respondents who misunderstood the exercise the mean WTP for Mirena is 91 pence 
greater than Oral treatment.  
 
8.2.9 Discussion 
In this first part of the chapter the results of the WTP feasibility study from an ex-ante 
perspective were presented.  
The results showed that Mirena was the preferred treatment but that the mean WTP for Oral 
treatment (£15.38) was slightly greater than the mean WTP for Mirena (£15.11). However 
this difference was not statistically significant. The reasons for the wide confidence intervals 
for both treatments and the subsequent lack of statistical significance are likely to be related to 
the nature of the payment scale. As a full numerical scale is not used and it was shown that 
respondents tended to value treatments within the £10-£20 range, there are very few numbers 
that respondents can select between those values, which could have then led to overlap in 
confidence intervals. Furthermore, women may see the two treatments as something they may 
want to try at different times in their life, or may consider the other treatment as the next 
option if the first did not improve QoL. Therefore they could be more indifferent about the 
treatments.  
Those women who preferred Oral treatment were willing to pay 66% more for Oral treatment 
than Mirena, compared to those who preferred Mirena, who were willing to pay 28% more for 
Mirena than Oral treatment. Thus it is possible that Mirena did not generate a greater mean 
WTP because those who preferred Oral treatment had a stronger preference for Oral treatment 
than those who preferred Mirena. Alternatively, it could be argued that an embedding effect 
may have been observed, where the respondents may have failed to distinguish between the 
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two treatments and were simply providing a WTP for any treatment (Kahnemann & Knetsch, 
1992). 
The two most commonly cited reasons for WTP values were related to the ‘effects of the 
treatments’ and ‘affordability’. Therefore in this study, most respondents valued the 
treatments according to their associated process utility and outcomes, as is required to elicit 
valid WTP values. It is expected that ‘affordability’, i.e. ability to pay, would be a commonly 
cited consideration for providing a WTP value (Donaldson, 1999). The mean WTP results 
presented against income groups demonstrated that generally mean WTP does increase as 
income increases but that the relationship is not monotonic. Thus, this study shows that it may 
not necessarily be the case that those who have a higher household income will be willing to 
pay more for treatment. This would suggest that in this case, resource allocation would not be 
skewed towards the rich, as is commonly suggested in the literature as a downfall of the 
welfarist approach (Coast, 2004; Gold et al., 1996). However, the lack of a monotonic 
relationship between income and WTP is said to suggest that theoretical validity is not 
demonstrated. 
Overall women did not consider the WTP question to be difficult to answer. The reasons 
provided by those respondents that did not find the question difficult to answer were related to 
providing a reasonable value for the expected outcomes. Whilst those who did find the 
question difficult cited not being used to valuing healthcare, which is not an unexpected 
finding given that generally UK citizens do not pay at the point of consumption of healthcare.  
The qualitative reasons were found to be important predictors of WTP for Oral treatment, but 
not the socio-demographic variables, whilst predictors of WTP for Mirena included both 
qualitative reasons and socio-demographic factors. The results of the sensitivity analysis using 
211 
 
interval regression varied only slightly. The removal of various subgroups of WTP values; 
including protests and inconsistent responses did not lead to a difference in which treatment 
generates the greatest WTP, except in the case of misunderstanding the exercise as Mirena 
had a slightly higher mean WTP than Oral treatment. However as the difference was so small, 
the results would not change the findings of a cost-benefit analysis (CBA) (presented in 
Chapter 9).  
 
Strengths and Limitations 
This is the first study to elicit WTP for Mirena and Oral treatment from an ex-ante perspective 
in menorrhagia. A potential limitation is that patients with experience of the condition and the 
treatments were included in the sample, which does not strictly meet the ex-ante perspective 
criteria (described in Chapter 3) but it does represent the female general population who could 
need the treatment. However, the number of women with experience of the treatment was not 
determined. It is possible that the inclusion of these respondents in the ex-ante perspective is 
likely to affect the validity of the WTP results as it is not clear whether these respondents 
based their WTP values on their own experience of the treatments or the descriptions 
provided. Further, despite the WTP questions for Mirena and Oral treatment not being 
randomly ordered, as WTP for Oral treatment always followed WTP for Mirena, the findings 
suggest that the results were not impacted by ordering. Mirena did not receive the highest 
mean WTP value, even when the respondent preferred Oral treatment, which is expected to 
occur due to the ordering effect (Stewart et al., 2002). This finding also suggests that the 
respondents did consider the two treatment scenarios as two separate elicitations tasks. 
According to economic theory, if respondents considered the two treatments as one elicitation 
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task, the respondent’s value would be expected to be greater for the first treatment than the 
second. As this was not the case in the WTP study presented in this chapter, the findings 
suggest that the respondents did not apply the same budget to both treatments. However, it is 
unclear whether an anchoring effect occurred where the respondent ‘anchored’ their second 
WTP value for Oral treatment, on the value provided for Mirena.  
 
Comparison with Other Studies 
In comparison to other WTP studies, the number of protest answers (n=6) and non-response 
to the WTP question (n=4 in each treatment arm) was relatively low. It is often observed that 
a large proportion of the sample report protest answers (Dalmou-Matarrodona, 2001). 
Similarly, there were few genuine zero WTP values (n= 3 for Oral treatment and n=15 for 
Mirena) which eliminated the need to use one of the commonly used methods, a two-part 
model, which accounts for zero values (Donaldson, 1998). Inconsistent responses and 
preference reversals were observed in this study where individuals had a preference for a 
treatment but either gave a greater WTP to another treatment or gave equal WTP values to 
both treatments. As mentioned in the QoL review chapter, Ryan and San Miguel (2000) 
carried out research to determine the reliability of WTP. In their ex-ante study on treatments 
for menorrhagia, they found that 30% of respondents provided inconsistent responses. In 
which case, a respondent reported a preferred treatment and gave a greater WTP value to 
another treatment. In contrast to Ryan and San Miguel’s findings, the percentage of 
inconsistent responses was much lower in this study, as only 10% of responses were 
considered to be inconsistent. Furthermore, the exclusion of preference reversals (inconsistent 
responses), in this study, did not change which treatment had the greatest mean WTP value. 
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Ryan and San Miguel (2000) also found the cost of treatment to impact the mean WTP 
values, whilst in the study reported in this chapter, affordability and effect of treatment were 
the most commonly cited reasons for inconsistent responses and not cost of treatment. 
However, as noted previously, the reason for any inconsistent responses observed within the 
study may be related to random error as explained by Harless and Camerer (1994). Hence it is 
possible that these inconsistent responses occurred by chance due to a lapse in concentration 
by the individual (McIntosh et al., 2006). 
It has been also shown in the literature that respondents tend to select prominent numbers, 
such as £5, £10, £20 and so on, and that the selection of prominent numbers can be related to 
the respondent’s perception of the difficulty of the task (Hertwigg et al., 1999). That is 
respondents are likely to provide less precise WTP values when they do not believe that they 
have an adequate knowledge of the good, in this case Mirena and Oral treatment (Whynes et 
al., 2007). The WTP values elicited were taken from the ex-ante perspective where 
respondents may have experience of menorrhagia but not necessarily both treatments. It was 
shown that a greater proportion of respondents selected prominent numbers for the WTP for 
Mirena compared to Oral treatment. It is possible that this result is due to respondents finding 
it easier to imagine having an Oral treatment, as they are likely to have been prescribed one in 
the past, than it is to imagine the intrauterine device, Mirena.  
Finally, as a significant different between WTP for the two treatments was not observed an 
alternative method has been suggested for eliciting WTP to improve its ability to differentiate 
between treatments. That is, the marginal WTP approach, where the respondent is asked to 
state which treatment they prefer and are then asked to provide a WTP value to have their 
preferred treatment rather than their least preferred (Donaldson et al 1997). It has been 
suggested that this approach may improve discrimination between treatments because, instead 
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of eliciting WTP for both treatments, WTP for the respondent’s first choice treatment is 
elicited. Hence, as respondents are more aware of the choice between treatments this approach 
is expected to lead to more discriminate answers (Shackley and Donaldson, 2000), which 
might result in significant differences in WTP values for the alternative treatments.  
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8.3 Part 2: Ex-post Perspective 
The results in this section refer to the ex-post perspective and the methods explained in the 
previous chapter (subsection 7.2.2). The structure for the ex-post perspective largely follows 
the structure of the ex-ante perspective. That is, the questionnaire response, WTP for current 
treatment (either Mirena or Oral treatment), the qualitative findings for reasons for WTP 
values and finding the WTP question difficult, the econometric analysis to identify predictors 
for current treatment and demand curves are reported. These sub-sections are followed by a 
summary of WTP values for various subgroups of responses, an assessment of the association 
of WTP against the condition-specific measures and EQ-5D, and finally a discussion related 
to the findings from the ex-post perspective. 
 
8.3.1 Questionnaire Response 
As outlined in Chapter 7, in the ex-post study, the WTP question was included in a self-
complete questionnaire which was posted to women who were already part of the ECLIPSE 
trial. In this section, the response to the questionnaire and specifically the WTP questions are 
detailed.  
Questionnaires were posted out in August 2012 to all 506 ECLIPSE patients, excluding those 
women who had withdrawn from the trial (n=165). The initial response rate to the 
questionnaire was (117/506) 23%. In November 2012, a reminder letter in addition to a 
second copy of the questionnaire and a pre-paid envelope was posted to women who had not 
responded. The findings of the ECLIPSE trial subsequently revealed that many women had 
stopped treatment, had surgery or experienced menopause at the 2 year time point (Box 8.1 
below). Thus in an effort to increase response rates, the reminder letter asked women who 
were experiencing menopause to complete the questionnaire.  
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Box 8.1 Findings from the ECLIPSE trial 
  
After the reminder letter was posted out to the remaining women the overall response rate 
increased to 32%. Whilst this response could be considered to be low for a clinical trial there 
are several factors that must be taken into consideration. Firstly, the 5 year time point of the 
trial must be taken into account as the trial response rate has also decreased to 80%. Secondly, 
Box 8.1 shows that at the 2 year time point, there are fewer numbers of women who are still 
taking either of the randomised treatments. As some of these women were at the 5 year 
follow-up at the time the exploratory work was undertaken, these numbers in Box 8.1 are 
likely to be an underestimation. However, accurate data at the current time point were not 
available.  
Out of the 163 respondents that replied, 50 responses were excluded as the women either 
stated that they would not pay because they were no longer taking any treatment or they were 
no longer contactable as they were not living at the address provided to the ECLIPSE trial. A 
further 19 provided a WTP value for no treatment or surgery as WTP for current treatment 
was elicited. As surgery is not one of the two treatments researched in this exploratory work 
and it would be invalid to use WTP values for no treatment, these 19 responses were 
excluded. Finally 9 women who were not taking either of the randomised treatments protested 
and were therefore excluded. These responses will be considered in the discussion (8.3.8). 
The information available from the ECLIPSE trial stated that at 2 years: 
 Out of the 286 women randomised to oral treatment, 105 women were still taking oral 
treatment.  
 Out of the 285 women randomised to Mirena, 167 women still had the Mirena inserted.  
It is known that before the 2 year time point: 
 80 women crossed-over from the Oral treatment arm to the Mirena arm 
 29 women crossed-over from the Mirena arm to Oral treatment arm 
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The WTP values and corresponding qualitative answers were also checked to identify non-
response to the WTP question and protest answers. A breakdown of the qualitative 
information is provided in section 8.3.3. Out of the remaining 85 women who returned the 
questionnaire and were currently taking one of the randomised treatments, 3 (4%) women did 
not provide a WTP value for their current treatment and 11 (13%) protest answers were 
identified from the qualitative explanations offered for the WTP value. These 14 non-
responses and protest answers were also removed from the analysis for reasons explained 
previously. Therefore the total number on which the analysis was conducted was 71 
respondents. Two of the returned questionnaires were completed retrospectively as these 
women were no longer taking any treatment due to menopause.  
 
Participants 
The characteristics of the sample, excluding those who gave a protest answer or non-response, 
are presented in Table 8.16. It can be seen that 51 respondents gave a WTP value for Mirena, 
and 20 respondents gave a WTP value for Oral treatment. The average expected age of 
menopause was 54 years old for both treatments which is close to the typically suggested 
average age of menopause (55 years old) for the population. Many of the women, 76% and 
85% in Mirena and Oral treatment respectively, stated that they had experienced menorrhagia 
for more than a year. The employment status of 78% and 80% for Mirena and Oral treatment 
is slightly higher than observed in the ex-ante study. Similar to the ex-ante study the 
household income categories show that one half of the sample lie at the extremes of the 
income categories. The proportion of respondents that have a household income of less than 
£30,000 is approximately 50% for Mirena and 55% for Oral treatment, which is slightly lower 
than the national average where 65% are below approximately £27,000 (Cribb et al., 2012).  
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Table 8.16 Sample characteristics (ex-post) 
Variable Mirena 
(n=51) 
Oral treatment 
(n=20) 
p-value 
Expected age of menopause (yrs) [SD] 53.8 [2.59] 53.8 [2.24] 0.857 
Age [SD] 47.7 [3.73] 49.5 [4.44] 0.043* 
Marital status (%)    
Married or living with partner 40 (78%) 14 (70%)  
Not  11 (22%) 6 (30%)  
Difference across treatment   0.454 
Visits to GP (%)    
Yes 4 (8%) 9 (45%)  
No 47 (92%) 11 (55)  
Difference across treatment   0.001* 
Employment status (%)    
Employed (FT)/(PT) 40 (78%) 16 (80%)  
Not 11 (22%) 4 (20%)  
Difference across treatment   1.000 
Household income (%)    
Less than 20,000 16 (33%) 6 (30%) 0.910 
20,001-30,000 9 (18%) 5 (25%) 0.517 
30,001-40,000 9 (18%) 1 (5%) 0.263 
40,001-50,000 5 (10%) 4 (20%) 0.258 
More than 50,000 10 (20%) 4 (20%) 1 
Main earner (%)    
Yes 23 (46%) 9 (45%)  
No 27 (54%) 11 (55%)  
Difference across treatment   0.940 
Prevented from daily activities (%)    
Yes 4 (8%) 7 (35%)  
No 47 (92%) 13 (65%)  
Difference across treatment   0.009* 
Drugs for pain relief (%)    
Yes 12 (24%) 12 (60%)  
No 39 (76%) 8 (40%)  
Difference across treatment   0.005* 
Time off work (%)    
Yes 1 (80%) 2 (10%)  
No 50 (20%) 18 (90%)  
Difference across treatment   0.189 
Number on pain scale [SD] 1.85 [2.554] 5.03 [2.92]  
Satisfied with life (%)    
Very unsatisfied 5 (10%) 1 (5%)  
Slightly unsatisfied 4 (8%) 4 (20%)  
Neither satisfied nor dissatisfied  6 (12%) 4 (20%)  
Slightly satisfied 10 (20%) 2 (10%)  
Very satisfied 24 (49%) 9 (45%)  
Difference across treatment   0.484 
How is QoL affected (%)    
Not at all affected 34 (72%) 3 (16%)  
Slightly affected 8 (17%) 7 (37%)  
Affected  4 (9%) 7 (37%)  
Extremely affected 1 (2%) 2 (11%)  
Difference across treatment   0.000* 
Time with HMB (%)    
Less than a year 12 (24%) 3 (15%)  
More than year 39 (76%) 17 (85%)  
Difference across treatment   0.531 
*p<0.05. SD; standard deviation, QoL; quality of life, GP; general practitioner, HMB; heavy menstrual bleeding  
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The socio-demographic characteristics of the study respondents were assessed to identify if 
there is a statistically significant difference between those who provided a WTP value for 
Mirena to those who provided a WTP value for Oral treatment. The Chi-squared test was used 
for categorical variables where the number of respondents in each group is greater than 5, and 
the Fisher’s exact test was used for categorical variables where the number of respondents in 
each group has a value less than 5. Continuous data were non-normal and were tested using 
the non-parametric Wilcoxon Rank Sum test. The respondents who are currently taking 
Mirena are significantly less likely to visit the GP (p=0.001), be prevented from daily 
activities (p=0.009), to take drugs for pain relief (p=0.005) and have their Qol affected 
(p=0.000). These findings suggest that these respondents find Mirena to be a more effective 
treatment than Oral treatment. Further, the average age of those valuing Mirena is 
significantly lower than those valuing Oral treatment (p=0.043).  
 
8.3.2 WTP Mirena and Oral Treatment 
The mean WTP for each treatment was calculated and is presented in Table 8.17. The 
maximum average WTP for Mirena along with bootstrapped confidence intervals was £31.08 
(95% CI £11.26-£55.31) and for Oral treatment was £17.45 (95% CI £9.89-£25.02). It can be 
seen from the table that the minimum and maximum values differ between the two treatments, 
with Mirena ranging from £0-500 and Oral treatment ranging from £0-50. In the case of 
Mirena two respondents were not willing to pay for Mirena and one was willing to pay the 
maximum on the payment scale (£500). Whilst for Oral treatment two respondents were not 
willing to pay for Oral treatment and three were willing to pay £50. As the WTP data are 
skewed the WTP values for both Mirena and Oral treatment were log transformed. As detailed 
in the methods chapter (7), each WTP value has a constant of 1 added to it to ensure that zero 
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values would still be taken into consideration when the data are log transformed. A two 
sample t-test was carried out and determined that the difference between the two WTP values 
is not statistically significant (p=0.257) as the confidence intervals for the WTP values for the 
two treatments overlap.  
Table 8.17 Descriptive statistics for WTP (ex-post) 
Max WTP Mirena Oral treatment Overall 
Valid numbers 51 20 71 
Mean £31.08 £17.45 £27.24 
Min -Max £0-£500 £0-£50 £0-£500 
SD £70.24 £16.92 £60.33 
Median £16 £10 £10 
Two sample t-test p=0.257  
Min/Max; Minimum/Maximum, SD; standard deviation; WTP; willingness-to-pay 
 
The mean WTP for both treatments is presented according to income (Table 8.18) and it can 
be seen that generally mean WTP increases with household income but that in some cases, 
with the small numbers, i.e. £40,001-£50,000, the mean WTP reduces from the previous 
household income category. Thus WTP does not necessarily increase with household income 
in the ex-post study.  
Table 8.18 Mean WTP against household income (ex-post) 
Household income groups WTP Mirena 
Mean (n) 
WTP Oral treatment 
Mean (n) 
Less than £20,000 £49.44 (16) £9.67 (6) 
£20,001-£30,000 £12.33 (9) £8.40 (5) 
£30,001 - £40,000 £25.44 (9) £50.00 (1) 
£40,001- £50,000 £19.20 (5) £20.75 (4) 
More than £50,000 £33.80 (10) £30.75 (4) 
WTP; willingness-to-pay 
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In Table 8.19 the WTP values for each treatment are presented against the number of 
respondents who chose that WTP value, to explore the influence of prominent numbers on the 
WTP value. 
 
Table 8.19 Frequency of WTP value (ex-post) 
WTP Mirena (n) Oral treatment (n) 
£0 2 (4%) 2 (10%) 
£2 3 (6%) 0 
£4 1 (2%) 1 (5%) 
£6 1 (2%) 1 (5%) 
£8 2 (4%) 2 (10%) 
£10 15 (29%) 7 (35%) 
£12 1 (2%) 0 
£16 1 (2%) 0 
£18 0 1 (5%) 
£20 9 (18%) 2 (10%) 
£25 3 (6%) 0 
£30 3 (6%) 0 
£40 2 (4%) 0 
£45 0 1 (5%) 
£50 5 (10%) 3 (15%) 
£100 2 (4%) 0 
£500 1 (2%) 0 
Total 51 20 
WTP; willingness-to-pay. Underlined values are the prominent numbers in the payment scale 
 
In the case of Mirena, the most common WTP values selected were prominent numbers; those 
are £10 and £20. For Oral treatment £10 was the most common number selected, which again 
is a prominent number. However, the small sample size means that even when a prominent 
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number is selected only three times, as in the case of £50 for Oral treatment, it would be the 
second most common WTP value selected on the payment scale. Therefore the emphasis on 
selecting prominent numbers is difficult to judge from this ex-post perspective. 
 
8.3.3 Qualitative Findings 
Following the WTP questions for current treatment, the women were asked to answer two 
qualitative questions. The first, related to the reason behind their WTP value and the second, 
asked women to explain why they did, or did not, find the WTP question difficult to answer. 
Similar to the ex-ante study, the themes were generated by content analysis.  
 
Reason for WTP 
In total, 138 respondents offered an explanation for their response to the WTP value. Only 
one code was required to categorise the written explanation in 102 cases. In 36 cases two or 
more category explanations were required. Ten categories of reasons for a WTP value were 
generated from the qualitative information from the entire sample of women, including 
protests and non-response. The categories of reasons for the entire sample and for the sample 
used in the analysis are presented in Tables 8.20 and 8.21. 
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Table 8.20 Explanation given for WTP value (full sample, ex-post) 
Category Explanation Total n (%) 
R1 Question deemed inapplicable on grounds of: 
- No longer taking treatment 
- Patient has had surgery 
31 (17%) 
R2 Subject expressed difficulty estimating WTP owing to: 
- Difficult to answer 
- Cannot put a price on healthcare 
8 (4%) 
R3 WTP based on nominal amount 
- Arbitrary sum/ guess/ out of thin air 
1 (0.5%) 
R4 WTP reflects ability to pay (affordability) 
- Maximum affordable amount given current situation  
48 (26%) 
R5 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
12 (7%) 
R6 WTP reflects cost of treatment 
- Attempted to estimate cost 
- Used a comparator such as prescription costs 
5 (3%) 
R7 WTP reflects effects of treatment 
- In terms of effectiveness outcomes 
- In terms of process utility 
36 (20%) 
R8 Protest expressed at idea of payment 
- Paid National Insurance and taxes/ NHS should pay 
- Women cannot help the condition/ treatment should be free 
20 (11%) 
R9 Related to cost of sanitary wear 
- Washing clothes/wipes/painkillers 
17 (9%) 
R10 Misunderstood exercise but provided WTP value 6 (3%) 
Total  184 
NHS; National Health Service, WTP; willingness-to-pay. 
 
Among the 71 women who provided a WTP value for current treatment, 69 provided a reason 
for the value. Out of the 20 women who provided a WTP value for Oral treatment, 19 
provided a reason for their answer. Out of the 51 respondents who provided a WTP for 
Mirena, 50 provided a reason for the WTP value. It can be seen from Table 8.21, which 
describes the sample that are used in the analysis, that for both Mirena and Oral treatment 
‘R3: affordability’ and ‘R7: effects of treatment’ are the most commonly cited reason for a 
WTP value. It can also be seen that there are five cases where a respondent has misunderstood 
the WTP question. As it could be argued that these WTP values are not valid, a sensitivity 
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analysis is conducted to estimate the mean WTP excluding these five respondents who 
misunderstood the WTP question, and is reported in section 8.2.6.  
 
Table 8.21 Explanation given for WTP value (sample analysed, ex-post) 
Category Explanation Total  
n (%) 
Mirena 
n (%) 
Oral 
n (%) 
R1 Question deemed inapplicable on grounds of: 
- No longer taking treatment 
- Patient has had surgery 
0 (0%) 0 (0%) 0 (0%) 
R2 Subject expressed difficulty estimating WTP owing to: 
- Difficult to answer 
- Cannot put a price on healthcare 
8 (7%) 8 (10%) 0 (0%) 
R3 WTP based on nominal amount 
- Arbitrary sum/ guess/ out of thin air 
1 (0.9%) 1 (1%) 0 (0%) 
R4 WTP reflects ability to pay (affordability) 
- Maximum affordable amount given current 
situation  
37 (35%) 27 (33%) 10 (38%) 
R5 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
8 (7%) 4 (5%) 4 (15%) 
R6 WTP reflects cost of treatment 
- Attempted to estimate cost 
- Used a comparator such as prescription costs 
5 (5%) 3 (4%) 2 (7%) 
R7 WTP reflects effect of treatment 
- In terms of effectiveness outcomes 
- In terms of process utility 
30 (28%) 24 (30%) 6 (23%) 
R8 Protest expressed at idea of payment 
- Paid National Insurance and taxes/ NHS should 
pay 
- Women cannot help the condition/ treatment 
should be free 
0 (0%) 0 (0%) 0 (0%) 
R9 Related to cost of sanitary wear 
- Washing clothes/wipes/painkillers 
13 (12%) 10 (12%) 3 (12%) 
R10 Misunderstood exercise but provided WTP value 5 (5%) 4 (5%) 1 (4%) 
Total  107 81 26 
NHS; National Health Service, WTP; willingness-to-pay 
 
Difficulty with WTP explanation 
Overall, when responses from all the women who provided a WTP value for either Mirena or 
Oral treatment are considered, it can be seen from Figure 8.8, that approximately half of the 
women found the WTP question difficult to answer and the remaining half did not. 74% of 
the Oral treatment group did not find the question difficult, whilst more respondents (56%) 
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who had Mirena, did find the question difficult to answer and this difference is statistically 
significant (p=0.027).  
 
Figure 8.8 Percentage of respondents that found WTP difficult to answer 
 
 
Respondents were then asked to provide a written explanation for their answer. In total 79 
respondents offered an explanation for the WTP value. Only one code was required to 
categorise the written explanation in 48 cases. In 31 cases two or more category explanations 
were required. Ten categories of explanation for their response to the difficulty question were 
generated using the qualitative information from the entire sample of women, including 
protests and non-response. The categories of explanations for the entire sample are presented 
according to whether the question was difficult to answer in Table 8.22. 
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Table 8.22 Explanation given for difficulty question (full sample, ex-post) 
Category Explanation Difficult 
n (%) 
Not 
difficult 
n (%) 
Total    
n (%) 
D1 Found valuation difficult 
- Not used to it/ difficult to quantify/Figure out of 
thin air 
- Not aware of cost implications 
23 (34%) 1 (2%) 24 
(21%) 
D2 Consideration of actual costs 
Used prescription costs as a proxy 
- “I know the cost of prescription...” 
2 (3%) 1 (2%) 3 (3%) 
D3 Benefits of treatment – reasonable amount for expected 
outcomes 
- Due to way menorrhagia impacts lives 
- Due to nature of treatment effects  
14 (21%) 12 (25%) 26 
(23%) 
D4 Ability to pay dictated amount 16 (24%) 9 (19%) 25 
(22%) 
D5 Based on cost of sanitary products 1 (1%) 3 (6%) 4 (3%) 
D6 Explicitly explained WTP not difficult to answer 
- Balance of impact on QoL and affordability  
0 (0%) 7 (15%) 7 (6%) 
D7 Protest – I would not pay 2 (3%) 9 (19%) 11(10%) 
D8 Recall issue to duration of satisfaction 3 (4%) 0 (0%) 3 (3%) 
D9 Misunderstood exercise but provided WTP value 5 (7%) 3 (6%) 8 (7%) 
D10 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
1 (1%) 3 (6%) 4 (3%) 
Total  67 48 115 
NHS; National Health Service, WTP; willingness-to-pay 
The most common explanation for those who did find the WTP question difficult was related 
to ‘D1: Not used to valuing healthcare’. The most common explanation for those who did not 
find the WTP question difficult was ‘D3: A reasonable amount to pay for expected outcomes’ 
followed jointly by ‘D4: ability to pay’ and ‘D7: protest’. 
Among the 71 women who provided a WTP value for either Mirena or Oral treatment, 51 
provided an explanation as to why they did or did not find the question difficult to answer. 
The categories for difficulty reasons were separated according to those who provided a WTP 
value for Mirena and those who provided a value for Oral treatment. Figure 8.9 shows that for 
those who found the question difficult to answer ‘D1: not used to valuing healthcare’ was the 
most common reason for both Oral treatment and Mirena followed by ‘D3: a reasonable 
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amount for the expected outcomes’ and ‘D4: ability to pay’ for both Mirena and Oral. In 
addition to ‘D2: consideration of actual treatment costs for Oral treatment’.  
 
Figure 8.9 Reasons given from respondents who found the question difficult 
 
D1: Not used to valuing; D2: actual costs; D3: reasonable amount for expected outcomes; D4: ability to pay; D5: 
cost of sanitary products; D6: not difficult explicitly stated; D7: protest; D8: Recall issue; D9: misunderstood; 
D10: reasonable value but NHS should pay  
 
Figure 8.10 shows that for those who did not find the question difficult to answer for Mirena 
‘D3: reasonable amount for expected outcomes’ and ‘D6: explicitly explained the question is 
not difficult as it is a balance of impact on QoL and affordability’ were the most commonly 
cited reasons, whilst the most common explanation for Oral treatment was ‘D4: ability to pay’ 
followed by ‘D3: reasonable amount for expected outcomes’. 
0
2
4
6
8
10
12
14
16
18
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10
N
o
. o
f 
ti
m
e
s 
ci
te
d
 
Difficulty reasons 
Oral treatment Difficult
Mirena Difficult
228 
 
Figure 8.10 Reasons given for not finding the question difficult 
D1: Not used to valuing; D2: actual costs; D3: reasonable amount for expected outcomes; D4: ability to pay; D5: 
cost of sanitary products; D6: not difficult explicitly stated; D7: protest; D8: Recall issue; D9: misunderstood; 
D10: reasonable value but NHS should pay  
 
It can be seen from both Figures (8.9 and 8.10) that 6 respondents misunderstood the exercise 
(D9) but provided a WTP value. As it could be argued that these WTP values are not valid, a 
sensitivity analysis is conducted to estimate the mean WTP excluding these 6 respondents 
who misunderstood the WTP question (see section 8.2.6). 
 
8.3.4 Econometric Analysis 
Similar to the ex-ante perspective, it is not appropriate to conduct a two-part model due to the 
low proportion of zero WTP values in the sample. However, in this case, as there are only 4 
respondents who provided a zero WTP across the sample, it is also inappropriate to carry out 
significance tests and present descriptive statistics in a univariable analysis. Nevertheless, the 
qualitative responses for those who provided zero values can be explored.  
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An OLS model, using the sample that includes the zero values, is used to identify predictors 
for WTP. As the number of respondents who provided WTP values for Oral treatment is small 
(n=20) an OLS linear regression cannot be run to identify predictors of WTP for Oral 
treatment. In order to explore the relationship between WTP for Oral treatment and other 
variables, a univariable analysis is conducted. An OLS model is run to identify predictors of 
WTP for Mirena and then a second OLS model is run to identify predictors of WTP for any 
treatment, i.e. Mirena and Oral combined.  
Further, as there are very few respondents that did not respond to the question (n=3) and 11 
protest answers (n=8 for Mirena and n=3 for Oral treatment), it would not be appropriate to 
conduct a regression model or univariable analysis to identify predictors for non-response or 
protest answers either. 
In the following section the qualitative responses related to zero values is reported first and is 
followed by the univariable analysis for Oral treatment, the OLS linear regression for Mirena 
and the OLS linear regression on WTP for treatment, including Mirena and Oral treatment. As 
part of the sensitivity analysis, an interval regression model is run on WTP for Mirena and 
overall treatment. 
 
Analysis of Zero WTP values 
Overall, for both treatments, Mirena and Oral treatment, all 4 respondents who gave a zero 
value offered a reason for their WTP value, with 1 respondent providing a reason that was 
coded into two categories. ‘R2: difficulty completing the question’ was cited twice and ‘R4: 
affordability’, ‘R7: effect of the treatment’, and ‘R10: misunderstanding the exercise’ were 
each cited once.  
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Univariable analysis for Oral treatment 
As an OLS model could not be run for Oral treatment due to the limited variation in the 
sample, a univariable analysis was conducted. The univariable analysis showed that those 
with a household income of more than £50,000 were willing to pay significantly more than 
those earning less than £20,000 (p=0.038; p<0.05). The amended EQ-5D score, with the 
amended wording of ‘health during your cycle’, was positively associated with WTP for Oral 
treatment (p=0.000); p<0.05). Hence those with a higher amended EQ-5D score were willing 
to pay significantly more for Oral treatment. However, the original EQ-5D, referring to 
‘health today’, was not found to be a significant predictor for WTP.  
 
OLS Linear Regression 
The results of the OLS linear regression on the log transformed data for Mirena are presented 
in Table 8.23. As is typical for stepwise analysis all appropriate variables have been entered 
into the model and rejected or selected at a p<0.1. Similar to the ex-ante, to preserve a large 
sample size, the variables ‘number on pain scale’ and ‘How is QoL affected’ were dropped 
from the analysis as these variables contain 7% missing data. The same missing data are 
observed in both variables and do not occur as missing in any other variable. Two univariable 
analyses were conducted including ‘number on pain scale’ and ‘How is QoL affected’ to 
ensure that these omitted variables are not significant predictors of WTP for Mirena. In both 
cases, it was found that these variables are not significant at the 30% level, generating p-
values of p=0.625 and p=0.7150 respectively. Similar to the ex-ante study, a flexible value of 
p<0.3 was used to determine significance at the univariable stage to ensure that the variables 
were not excluded unnecessarily.  
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In Table 8.23 it can be seen that WTP is significantly positively influenced by ‘R7: effects of 
treatment’ (p=0.01) and ‘D1: not used to valuing healthcare’ (p=0.008). Whilst ‘R10: 
misunderstanding the exercise’ (p=0.037), ‘expected age of menopause’ (p=0.015), and ‘R2: 
finding the valuation difficult’ (p=0.043) all have a significantly negative impact on WTP 
(p<0.05). However, in contrast to the ex-ante findings, income was not found to be a 
significant predictor of WTP for Mirena. Similarities between predictors of WTP for Mirena 
across the models include ‘expected age of menopause’ leading to a negative impact on WTP. 
Whilst the reason code related to ‘R1: having difficulty completing the question’ only had a 
tendency towards significance (p=0.063) in the ex-ante study. The link test revealed that the 
model type is correct and that the model is correctly specified (p=0.109). Thus it is not 
possible to reject the null hypothesis that an important variable has not been excluded. The 
Ramsey RESET test also shows that there are no omitted variables in the model (p=0.4453). 
 
Table 8.23 OLS linear regression for Mirena WTP values (ex-post) 
Variable Coefficient 95% CI p-value 
Current MMAS 0.0144 -0.002,  0.031 0.087 
R2: Found valuation difficult -0.760 -1.494, -0.260 0.043 
Expected age of menopause -0.167 -2.30, -0.033 0.015 
R7: effect of treatment 0.721 0.180,  1.262 0.01 
R10: Misunderstanding the exercise -1.094 -2.121, -0.067 0.037 
D1: Not used to valuing 0.838 0.235, 1.441  0.008 
Constant 10.064 3.219, 16.909 0.005 
Adjusted R
2
= 0.3142, n=49. MMAS; menorrhagia multi-attribute scale 
In the case of the linear regression model for both treatments (Table 8.24) it can be seen that 
overall ‘D9: misunderstanding the exercise’ (p=0.031) has a significantly negative impact on 
WTP for both treatments (p<0.05), but having ‘difficulty with the question’ (p=0.009), ‘R7: 
effects of treatment’ (p=0.04) and the ‘amended EQ-5D’ (p=0.000) were positively associated 
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with WTP (p<0.05). ‘R2: found valuation difficult’ (p=0.055), ‘R3: based on a nominal 
amount’ (p=0.08) and EQ-5D (p=0.064) had a tendency towards significance but the 
confidence intervals include both negative and positive coefficients. The link test again 
revealed that the form of the model is appropriate and that the model is correctly specified 
(p=0.436). Thus it is not possible to reject the null hypothesis that an important variable has 
not been excluded. The Ramsey RESET test also shows that there are no omitted variables 
(p=0.6761). 
Compared to both the Mirena and Oral treatment models from the ex-ante perspective the 
only two variables that have appeared in this ex-post model, for overall treatment, that appear 
in either of the ex-ante models are ‘misunderstanding the exercise’, which has a significantly 
negative effect on WTP and in the regression overall treatment ‘difficult to answer’ had a 
positive effect on WTP whilst in the ex-ante model for Oral treatment ‘difficult to answer’ 
had a negative effect. Other possible variables that did not reach significance in this model, 
but did in the ex-ante models, include ‘cost of treatment’, ‘affordability’, and being ‘married’.   
 
Table 8.24 OLS linear regression for overall treatment WTP values (ex-post) 
Variable Coefficient 95% CI p-value 
R7: effect of treatment 0.496 0.023,  0.968 0.04 
D9: Misunderstood the exercise -0.978 -1.861, -0.095 0.031 
R3: Nominal amount 1.753 -0.216,  3.721 0.08 
Difficult to answer 0.653 0.170,  1.136 0.009 
R2: Found valuation difficult -0.705 -1.427,  0.016 0.055 
EQ5Damended 1.947 1.014,  2.880 0.000 
EQ5D -0.978 -2.016,  0.060 0.064 
Constant 1.536 0.403,  2.670 0.009 
Adjusted R
2
=0.3247, n=67 
The results of the sensitivity analysis using interval regression for both Mirena and overall 
treatment can be found in the Appendix 5.2. The OLS and interval regression models for 
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Mirena differ vastly in that only the variables ‘misunderstanding the exercise’ and ‘R7: effects 
of treatment’ are included in both models. Current MMAS has a tendency towards 
significance in the OLS model but is significant in the interval regression. The remaining 
variables (R3: WTP based on a nominal amount’, ‘time off work’, ‘D5: ability pay’, and 
‘income’) that were found to significantly predict WTP for Mirena in the interval model are 
not identified as predictors in the OLS model.  
Similarly OLS and interval regression models for the overall treatment also differ. The 
interval regression model does not include ‘D9: misunderstanding the exercise’ and ‘Difficult 
to answer’ as significant predictors of WTP for overall treatment but does include the 
remaining variables for the OLS model. Variables that have a tendency towards significance 
in the OLS model are significant in the interval regression (‘R2: Finding the valuation 
difficult’, ‘R3: WTP based on a nominal amount’). The interval regression model for overall 
treatment also includes ‘R10: misunderstanding the exercise’, ‘expected age of menopause’, 
‘D1: not used to valuing healthcare’ and ‘prevented from daily activities’ as significant 
predictors of WTP for overall treatment (Mirena and Oral treatment). The interval regression 
model for Mirena and overall treatment was shown to be statistically significant compared to 
the constant only model (likelihood ratio 36.01, p=0.002) and (likelihood ratio 40.36, 
p=0.000). 
 
8.3.5 Demand Curves 
Figure 8.11 shows the demand curves for Mirena and overall treatment. Similar to the ex-ante 
demand curves it can be seen that the curves for Mirena and Oral treatment resemble a 
‘typical’ demand curve. It can be seen that from £100 upwards the demand curves for both 
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treatments are inelastic as great changes in price (£500-£100) result in very small changes in 
quantity demanded, but at lower prices, below £50, both treatments are elastic, because when 
prices are below £50 demand changes from 5% to 100% of the respondents. This is a similar 
result to the ex-ante study. 
 
Figure 8.11 Demand curves for overall treatment and Mirena. 
 
 
8.3.6  Summary of WTP Values for Excluded Groups 
Table 8.25 presents the WTP results according to the individual subgroups that were 
excluded, to identify the impact of excluding these responses on WTP. The full sample group 
refers to the sample that was analysed in addition to the protest answers.  
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Table 8.25 WTP according to excluded subgroups (ex-post) 
Analysis Mean [SD] Median No. of Obs 
Mirena    
Sample analysed £31.08 [70.24] £16 51 
Without misunderstood £34.53 [75.13] £20 44 
Full sample £26.86 [66.01] £10 59 
Oral treatment    
Sample analysed £17.45 [16.92] £10 20 
Without misunderstood £18.38 [16.86] £10 19 
Full sample £15.17 [16.83] £10 23 
Overall treatment    
Sample analysed £27.24 [60.33] £10 71 
Without misunderstood £29.65 [63.67] £16 63 
Full sample £21.62 [56.86] £10 89 
SD; standard deviation 
 
It can be seen from the table that, in every subgroup, mean WTP for Mirena is still greater 
than mean WTP for Oral treatment, but that mean and median values differ. Hence in this 
case, the inclusion or exclusion of protest answers and those who misunderstood the exercise 
made no difference to the results. However, as only 11 respondents gave zero protest values 
and 8 misunderstood the exercise if the numbers in each of these subgroups were greater the 
findings may differ.  
 
8.3.7 Associations between Measures 
This section reports the findings of the association between WTP, EQ-5D and MMAS as data 
were available at baseline on EQ-5D and MMAS from the ECLIPSE trial. In this case MMAS 
is considered to be the gold standard in menorrhagia as it has been shown to be valid (Pattison 
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et al; 2011). The following section relates to WTP for both Mirena and Oral treatment 
combined (overall treatment).  
As outlined in the methodology chapter (7), the association between the measures was 
assessed using Spearman’s correlations analysis. The results are presented in Table 8.26 and 
show that WTP has a significantly positive relationship with change in MMAS. Thus, the 
greater the change in health state, as measured by changes in MMAS, the greater the WTP 
value. When compared to the association between change in EQ-5D and change in MMAS it 
can be seen that this association is not statistically significant. Thus WTP has a significant 
correlation with change in MMAS, whilst change in EQ-5D does not.  
 
Table 8.26 Associations between measures 
 Change in MMAS 
(rho) 
WTP  
(rho) 
Change in EQ-5D  
(rho) 
Change in MMAS 1.0000   
WTP 0.2674* 1.000  
Change in EQ-5D 0.2265 -0.0158 1.000 
*p<0.05. MMAS; menorrhagia multi-attribute scale, WTP; willingness-to-pay 
 
The correlation values which compare the current MMAS with current EQ-5D and the 
amended EQ-5D are reported in Appendix 5.3 as this is not the focus of the thesis.  
The percentage improvement in MMAS from baseline to current time point was also 
calculated. The percentage change was differentiated according to arbitrary categories to 
establish the extent of the improvement in disease-specific QoL from baseline. The 
categories, the number of respondents that fall into the categories and the mean WTP values 
for respondents in each category were then calculated and are detailed in Table 8.27. 
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Table 8.27 Mean WTP against percentage improvement in MMAS 
% change in MMAS Number of observations Mean WTP 
<25% 21 £16.29 
26% - 50% 14 £20.86 
51% - 75% 24 £23.38 
>75% 11 £63.09 
MMAS; menorrhagia multi-attribute scale, WTP; willingness-to-pay 
 
Figure 8.12 graphically presents the relationship between mean WTP and percentage change 
in MMAS. It can be seen from the figure that as the percentage improvement in MMAS 
increases, the mean WTP for treatment also increases. A Kruskal Wallis test was carried out 
to identify if the differences between the WTP values for each percentage change category are 
significant. Only the WTP values between ‘<25%’ and ‘51%-75%’ are found to be 
significantly increased as percentage change in MMAS increases (p= 0.035; p<0.05). Given 
that the significant difference was observed between the two groups with the greatest number 
of observations, it is likely that the remaining categories were not found to be significant due 
to the limited sample size for the groups ‘26-50%’ and ‘>75%’. Thus there may not have been 
sufficient power to detect a significant difference between these groups.  
Figure 8.12 Percentage change in MMAS against mean WTP 
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Overall, the results show that WTP behaves as would be expected. The greater the 
improvement in health state, the greater the WTP.  
 
8.3.8 Discussion 
In the second part of the chapter the results of the WTP feasibility study from the ex-post 
perspective were presented.  
The results showed that WTP for Mirena (£31.08) was approximately twice as large as the 
WTP for Oral treatment (£17.45) but the difference was not statistically significant. The 
reasons for the lack of statistical significance may again be related to the nature of the 
payment scale and the use of prominent numbers, but also the small sample size which is 
discussed in ‘Strengths and Limitations’. When the mean WTP values were presented against 
income it was shown that generally mean WTP increases with income but that the relationship 
is not monotonic. Out of those respondents who provided a WTP value for Mirena or Oral 
treatment the most commonly cited reason for WTP values were ‘affordability’ and ‘effects of 
treatment’. Hence from the ex-post perspective, respondents valued the treatments and 
provided WTP as is expected by analysts. In the case of the ex-post perspective, 
approximately half of the sample found the WTP question difficult to answer (52%) and half 
did not (48%). The most commonly cited reason for finding the WTP question difficult was 
related to ‘not being used to valuing healthcare’ and for those who did find the question 
difficult to answer, the most commonly cited reason was ‘a reasonable amount to pay for the 
expected outcomes’.  
Predictors for WTP for Mirena and overall treatment using the OLS linear regression model 
primarily included qualitative reasons with fewer socio-demographic factors. However, in the 
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interval regression sensitivity analysis, the results differed considerably to those using the 
OLS linear regression, particular for Mirena. The interval regression for Mirena included 
more qualitative reasons. As it is not possible to use the same test to assess the model fit, due 
to the nature of the models, it is difficult to establish which model is ‘correct’. The reasons for 
this stark difference in models may be related to the limited sample size.   
The results show that the inclusion and exclusion of subgroups such as those who 
misunderstood the question and those respondents that provided zero protest values did not 
change the mean WTP values. The mean WTP for Mirena was still greater than the mean 
WTP for Oral treatment in all cases. The findings from the tests of associations between 
change in measures from baseline showed that WTP is significantly associated with change in 
MMAS score. These findings suggest that the greater the improvement in the condition, the 
greater the WTP. Interestingly, change in EQ-5D was not shown to be significantly associated 
with change in MMAS, thus suggesting that WTP is more sensitive to changes in 
menorrhagia, which is likely to be due to WTP encompassing both health and non-health 
benefits.  
Finally, a comment must be made on the number of respondents who provided WTP values 
for their current treatment when they stated that they were not currently taking any treatment. 
The responses where women provided WTP values for no treatment were excluded because it 
would be invalid to use WTP values for no treatment. 16 respondents provided a WTP value 
for no treatment, some of which were zero due to affordability. It is possible that these women 
may have been referring to a prior treatment or surgery, or perhaps placing a value on any 
treatment to alleviate menorrhagia. This misunderstanding may have possibly arisen due to 
the lack of clarity in the questionnaire due to the reference to ‘current treatment’ or perhaps 
the respondent may not have read the question as intended. 
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Strengths and Limitations 
This is the first study to elicit WTP for Mirena and Oral treatment from an ex-post perspective 
in menorrhagia. Further, this is the first study to assess the correlation of WTP against change 
in MMAS, compared to the correlation of change in MMAS and change in EQ-5D.  
A limitation of the study is the small sample size for WTP, in particular for Oral treatment. 
The small sample size, and subsequent insufficient power to detect a difference, is likely to 
have been the reason that a significant difference in mean WTP between Oral treatment and 
Mirena was not detected, despite the large apparent difference in values. However, it should 
also be noted that there were statistically significant differences in socio-demographic 
variables for those who provided a WTP for Oral treatment and those that provided a WTP 
value for Mirena, which could also be related to the lack of significance. The limited sample 
size for Oral treatment also meant that a regression model could not be run to identify 
predictors of WTP for Oral treatment. Finally, it is likely that the small sample size, will have 
also led to the lack of statistical significance between the different change in WTP and the 
MMAS percentage change groups. The two groups (<25% and 51-75%) that demonstrated the 
change were the two with the greatest sample size.  
A further limitation of the ex-post perspective, that is unrelated to sample size, is the 
completion of the questionnaire by some respondents who were going through menopause. It 
is unclear to what WTP time frame these respondents were providing their WTP value for as 
the questionnaire states until menopause. Fortunately, the number of women who completed 
the questionnaire whilst experiencing menopause was very few (n=2) and this number is 
unlikely to affect the results.  
241 
 
A final limitation is that it may have been necessary to assess whether the respondents were 
experiencing any symptoms when providing a WTP value. Despite the advantage of eliciting 
WTP over extra-welfarist measures, being due to a specific recall period not being used, in 
order to truly determine whether the results are at all affected by the timing of assessment, the 
WTP values of women experiencing symptoms and those that were not could be compared. 
 
Comparisons with Other Studies 
The number of protest responses and non-response was low. Furthermore, few zero values 
(n=4) were observed which again is unexpected for a WTP study and eliminated the need to 
use one of the commonly used methods, a two-part model, which accounts for zero values 
(Donaldson, 1998). Whilst no other study has directly elicited WTP from an ex-post 
perspective in menorrhagia, San Miguel et al (2000) have indirectly elicited WTP in 
menorrhagia using conjoint analysis to compare conservative surgery against hysterectomy. 
Conjoint analysis is a method of assessing the importance of various attributes of a treatment 
(Ryan, 1999). However, the purpose of the study by San Miguel et al (2000) was to test the 
conjoint analysis method rather than to consider its use in menorrhagia. However, it was 
demonstrated that conjoint analysis could be used to assess WTP indirectly in the condition. 
In the next part of this chapter the findings of the interviews with women from the ex-ante 
perspective are reported.  
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8.4 Part 3: Interviews 
30 women, from the ex-ante perspective, who agreed to be interviewed whilst completing the 
questionnaire were approached. 
 
8.4.1 Interview Response 
7 of the 30 women (23%) responded to email and postal invitations. Two had recently had a 
hysterectomy and therefore could not attend within the specified time frame. Five agreed to 
attend an interview. One did not turn up to the interview, one agreed a date but could not 
subsequently attend due to changes in work commitments and therefore could not attend at 
all. Consequently three (10%) women attended an interview in February or March 2013. The 
interviews lasted between 20 and 60 minutes, with an average of 36 minutes. As outlined in 
Table 8.28, all of the interviewees had experience of menorrhagia, were white and were aged 
between 29-46 years old. As is typical in the qualitative literature, in the next section the 
interviews will be described according to the key themes identified from the thematic 
framework.  
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Table 8.28 Interview sample characteristics 
Variable Sample 
characteristics (n=3) 
Experience of menorrhagia 3 
Average age (yrs) 37 
Preferred treatment 
 Mirena 
 Oral 
 
1 
2 
WTP Mirena 
WTP Oral 
5 [0-10] 
39 [8-100] 
Marital status 
 Married/ living with partner 
 Single 
 
2 
1 
Main income earner 
 Yes 
 No 
 
2 
1 
Income 
 <20,000 
 20,001-30,000 
 
2 
1 
Employment 
 Employed FT 
 Employed PT 
 
1 
2 
Children in future 
 Yes  
 No  
 
1 
2 
FT; full-time, PT; part-time, WTP; willingness-to-pay 
 
8.4.2 Descriptive Accounts of Interviews 
The following themes were identified from the interviews and are described in this section, 
‘experience of menorrhagia’, ‘considerations related to treatments’, ‘reasons for WTP values’, 
‘opportunity cost and the effect on the budget’, and ‘suitability of EQ-5D and WTP’. 
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1) Experience of menorrhagia 
As all the women interviewed had experience of menorrhagia it was clear that they were 
relating their own experiences of the condition to the questions presented in the questionnaire. 
For example, when asked about their thoughts on the scenario description of menorrhagia, 
unsurprisingly the interviewees assessed whether the description reflected their own 
experience of menorrhagia.  
I3: “I don’t really have to imagine it because I know how it is […] I have to do a lot of that 
anyway” 
I2: “yeah, I’ve been through all that” 
I2: “I can relate to all that yeah I mean that I used to have to carry, not just extra sanitary 
protection but extra underwear as well…” 
I1: “yeah it’s true about the protection cause I only ever used tampax. I was using tampax 
and towels and socially like absolutely I wouldn’t go out you know…” 
But one respondent did attempt to separate her own experiences from the scenario presented 
on the treatments available, Mirena and Oral treatment. 
I1 “…From my case I’d been told that I can’t have the Mirena coil […] but putting that aside 
if I could have either [treatment] I would find it a lot easier to take tablets than I would the 
coil” 
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2) Considerations related to treatments 
When deciding between the two treatments, the benefits and disadvantages of each treatment 
appeared to be primarily related to the process of care associated with each treatment. But the 
longer term benefits of Mirena were noted.  
I1: “the thing that put me off with that Mirena was erm if there was any concerns… if …there 
was a side effect or it wasn’t suitable the Oral treatment would discontinue because that’s 
[the Mirena] fitted, that’s what put me off…” 
I2: “the idea of having something inserted into me for that long I don’t like the sound of… 
having the thought of that in there as well makes me cringe…” 
I2: “I’m no good at taking tablets I always forget so that one [Oral treatment] would 
probably be out the window…” 
I2: “yeah, I’d rather have less bleeding and anxiety… I like the Mirena that there’s no 
practical difficulties and bleed no more…. You could get on with what you normally do… 
whereas the Oral treatment you’re still gonna get your periods” 
I3: “… I would find it a lot easier to take tablets than I would the coil for practical issues…” 
I3: “erm, I suppose with the coil probably it can take up to 6 months to have the effects of it 
when periods are bad you want the effects straight away…” 
 
3) Reasons for WTP values 
When providing reasons for WTP values, in addition to the points mentioned relating to the 
process and outcomes of treatment in the previous section, it became clear that some of the 
respondents based their WTP values on their perceived cost of production in addition to using 
prescription costs as a proxy, amongst other things. 
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I2: “ummh, I suppose because I dunno probably wouldn’t make as many as the coils as you 
think Oral treatment would be bulk made you’d have to take quite a lot of them so it’d be 
cheaper” 
I3: “yes, I think you would have indeed lots of repeat prescriptions of the tablets whereas the 
coil would be one fitted bit whereas the tablets there would be 28 tablets in the pack” 
I3: “I suppose I wouldn’t go [pay] more than a couple times more than normal prescription 
costs…” 
Whilst other reasons for WTP values were unclear.  
I2: “difficult err dunno anything over £10 just seems a lot of money” 
I1: “I really don’t know [laughter is heard] off the head and erm, I was trying, I did try to 
calculate how much my prescriptions was…” 
And one respondent also focussed on the uncertainty of the treatment outcomes in her own 
experience when providing a WTP value for treatment. 
I3: “I don’t know it would all depend on the guarantee of it actually working, if it would work 
then there’s pretty much no limit to what I’d pay…but there is no guarantee”  
When the notion of WTP was explained and the respondent had the opportunity to reflect 
back on what was discussed in the interview, it was clear that they had not incorporated all 
relevant factors into their valuation for the WTP study. All of the women changed their WTP 
values upon reflection after taking into consideration all factors, such as the true value of 
treatment to them, costs aside. One woman also stated that upon reflection her opinion of the 
ease of completion of the WTP exercise had changed.   
247 
 
I3: “I’d find it a bit more difficult I think than I did yeah when I was initially filling it in 
because I just went with a low amount thinking what would I pay for prescriptions roughly 
that valuing the tablets a bit more to be willing to pay a bit more for them so I was kind of 
either side of prescription costs but thinking about it now bringing in other factors yeah, a bit 
harder to answer “ 
I3: I suppose it would be more difficult now justifying it a bit more I kind of put those amounts 
almost on instinct, what I felt right then at the time, now comparing the two different amounts 
yeah maybe I’m not quite as certain as I was, as I was back then.” 
 
4) Opportunity cost and the effect on the budget 
When asked if they had considered the opportunity cost of not being able to spend the money 
on other things, it was observed that the women were not providing WTP values that would 
cause them to make any sacrifices in spending, which could be related to the amount of value 
they place on the treatments. In some cases, they misunderstood the exercise by then stating 
that in reality they would minimise the amount they paid through the use of pre-paid 
prescription cards. 
I3: “If that was all the treatment I had to take, probably not much because that’s not much 
difference to what I pay now either prescription costs or extra bits. I buy heat pads to stop the 
cramps and all other things like that, so it would probably balance itself out. If I’m still 
paying that on top of everything else, it would be a factor, it wouldn’t make me immediately 
go into my overdraft but it would be a consideration to know that’s another bill in effect every 
month that has to go out” 
I1: “erm yeah I suppose it would be feasible you know because I do, I do I would probably 
get one of them prescription cards [laughter is heard] because they do help like [with the 
cost] they do give me 2 months’ worth of you know when I go for my prescriptions so it 
doesn’t cost so much erm but yeah, yeah I would”   
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 I2: “probably the amount I could afford comfortably…so I’d not have to sacrifice anything”  
 
5) Suitability of EQ-5D  
When the respondents were asked what they thought about the EQ-5D questionnaire, many 
drew from their own experience of the condition to assess whether EQ-5D captured what is 
important to them.  
I2: “I would be confined to bed, I wouldn’t I’d still have no problems with self-care but I’d be 
unable to perform my usual activities and I’d be in extreme pain or discomfort and I’d be 
extremely anxious or depressed “ 
I1: “ok, erm I suppose in regards of like mobility erm when you’re walking about and you’ve 
got heavy periods I don’t know, ….erm I’d be less likely to do erm any usual activities. Only if 
the housework doesn’t get done by me then nobody would do it erm pain/discomfort yeah 
absolutely yeah erm yeah you would be anxious and depressed you see …because of the way 
that it changes your moods then yeah, I would say I would be erm anxious and depressed 
yeah I’d go for moderately there…”  
I3: “I suppose it touches a bit on the social activities that there might be, these are quite 
practical issues but sometimes you might not have problems with the activities but you don’t 
want to do them because you’re forcing yourself to do things that affect you rather than, it’s 
not that you’re not physically able to get out and go to work or whatever it’s harder to do so 
and mentally the extra effort for it um I think they cover a good amount …” 
One respondent discussed the issues with EQ-5D’s recall period for assessing the condition 
stating that;  
I3: “um, it can vary day by day even the week or 4 and a half weeks when I’m on my period. 
Some days you’re fine, yes it’s a bit more awkward as you have to go to the toilet more often, 
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you don’t feel depressed, you still feel active enough, and the next day can be utterly 
exhausted, because you don’t want to get out of bed at all. So it can work fine as a measure if 
it’s your health today, but it isn’t necessarily an average or good representative of the whole 
of the month or the whole week with your periods….. ”  
 
8.4.3 Discussion 
The interviews were carried out in an attempt to supplement the findings from the ex-ante 
WTP questionnaire to gain an in-depth knowledge of respondents understanding of the WTP 
question and their reasons for the WTP values. It can be seen from the small numbers of 
interview respondents and from the profile of the sample that the respondents who more 
closely reflected the criteria of an ex-ante perspective were not willing to attend an interview. 
Hence, only those respondents that have experience of menorrhagia were willing to attend the 
interview, which does not entirely meet the aim of the interviews of understanding ex-ante 
respondents’ answers. But it does provide some insight into the respondents thought 
processes. Therefore the interpretation of these interview findings and their generalisability is 
limited. 
However, whilst the findings from these particular women, with experience of menorrhagia, 
cannot be generalised to all respondents it was observed that the use of an interview based 
elicitation format may have improved the quality of the valuations provided by these 
particular women. The interviews showed that the women did not entirely understand the 
WTP question, perhaps because they themselves have the condition and were asked to 
imagine it. Two of the respondents were not able to explain why they chose the WTP value 
and also one stated that in reality she would use a prescription card to reduce the cost. Despite 
this finding, the respondents did discuss some of the limitations associated with EQ-5D, 
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stating that some of the dimensions are not entirely suitable and that there are issues with the 
recall period used in the questionnaire.  
  
Strengths and Limitations 
The main strength of the interviews is that an understanding was gained of how respondents 
who have the condition provide WTP values when a scenario of the condition and the 
treatments are presented to them. However, a significant limitation of these findings is related 
to the small sample size and the sample characteristics of the respondents which have resulted 
in a lack of generalisability of the findings and a limited contribution to the literature.  
 
Comparison with Other Research 
To current knowledge, no other study has attempted to specifically identify respondents 
understanding of the WTP exercise in menorrhagia. However, previous studies have been 
carried out to assess the methodology of WTP through the use of such interviews. Smith 
(2007) carried out a thinkaloud study which suggests that higher WTP values are more stable 
than lower WTP values because respondents are likely to think about the values more than 
they would for lower WTP values. Baker et al (2008) carried out a systematic review of the 
qualitative research for WTP and found that there is a paucity of evidence in this area. They 
identified studies that showed, similar to the findings observed in this chapter, that 
respondents provide WTP values that would not sufficiently impact their budget to cause 
changes in spending habits. 
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Further Research 
Additional interviews should be carried out to not only validate the WTP values provided in a 
questionnaire based format, but also to validate the responses provided in the qualitative 
component of WTP questionnaires. This would gain a more in-depth understanding of the 
suitability of WTP in menorrhagia in terms of respondents understanding of the exercise and 
their reasoning for WTP values. As ex-ante perspectives are currently recommended by the 
UK government, particular research should be focussed on the understanding of ex-ante WTP 
values in menorrhagia. 
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8.5 Overall Discussion of WTP Study 
WTP was elicited from both the ex-ante and the ex-post perspective to explore the impact on 
the results of the theoretically preferred ex-ante perspective and the most commonly practiced 
ex-post perspective.  
In the case of the ex-ante perspective, the difference between WTP for the two treatments was 
very small, with Oral treatment receiving a slightly greater WTP value than Mirena. Whilst 
the ex-post perspective showed that WTP for Mirena (£31.08) was approximately twice as 
large as the WTP for Oral treatment (£17.45), the difference was not significant in either case. 
It is possible that the larger difference in the ex-post group arose because the respondents 
were largely focussing on the benefits of their current treatment, whilst the embedding effect 
may have been observed in the ex-ante group as respondents may have been providing values 
for treatment in general. However, the stronger preference for Oral treatment may have also 
led to the ex-ante finding.  
The wide confidence intervals and the lack of statistical significance in the ex-ante 
perspective are likely to be related to the nature of the payment scale, as most respondents 
appeared to provide values between £10-£20 and there are very few numbers in between these 
values for respondents to choose. Furthermore, the findings may suggest that the respondents 
are indifferent about the two treatments as at some point in their lives, they might want to try 
both treatments according to their needs, which may lead to more equal valuations. Whilst in 
the case of the ex-post perspective, despite the large difference observed in mean WTP, the 
small sample size is likely to have limited the ability to detect a statistically significant 
difference between WTP values.  
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Further, it can be seen that the confidence intervals for WTP values for both treatments in the 
ex-post perspective overlap with the confidence intervals of the ex-ante perspective, which is 
likely to be due to some women, in the ex-ante perspective, having experience of the 
condition and potentially the treatments. It could also be interpreted that as the confidence 
intervals for Oral treatment are fairly similar between the two perspectives (£10-£25 for ex-
post and £11-£20 in the ex-ante), it is easier to imagine Oral treatment than it is Mirena. The 
confidence intervals between the ex-ante and the ex-post perspectives for Mirena are much 
more varied than those for Oral treatment, (£10-£20 for ex-ante and £11-£55 for ex-post) 
which could indicate that having experienced menorrhagia, as the ex-post women have, the 
benefits of Mirena weigh out the negative effects associated with initial treatment. 
Alternatively, as the ex-post women are providing WTP values after much longer than 6 
months of treatment, typically 5 years, the beneficial effect of Mirena of causing bleeding to 
cease will have occurred for several years. Whilst, in the ex-ante perspective, the scenario for 
Mirena describes the side effects of causing bleeding to become worse during the first 6 
months and then eventually the cessation of bleeding. Hence the respondents from the ex-ante 
perspective are accounting for these side effects when providing a WTP value, which the ex-
post perspective women may not remember vividly or incorporate into their WTP value.  
In both the ex-ante and the ex-post perspective studies it was shown that generally mean WTP 
does increase as income increases but that the relationship is not monotonic. The lack of a 
monotonic relationship between income and WTP is said to suggest that theoretical validity is 
not demonstrated. It is likely that, in both perspectives, the small number of respondents that 
fall into each of the five income categories is the reason for the lack of a relationship. A larger 
sample size may prove to be a better indicator of the relationship between WTP and income. 
A possible solution could be to collapse the income categories into smaller groups to reduce 
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the spread of responses. However, the categories used are those that are typically used in other 
published studies and therefore enable comparability with other studies.     
The two most commonly cited reasons for WTP values for both the ex-post and the ex-ante 
perspective were related to the ‘effects of the treatments’ and ‘affordability’. Therefore, in this 
study, most respondents valued the treatments according to their associated process utility and 
outcomes, as is required to elicit valid WTP values. It is expected that ‘affordability’, i.e. 
ability to pay, would be a commonly cited consideration for providing a WTP value.  
Unexpectedly, the majority of women did not consider the WTP question difficult to answer 
from the ex-ante perspective, whilst there was an approximately equal number of those who 
did and did not find the question difficult in the ex-post perspective. The most commonly 
cited reasons for those who did and those who did not find the question difficult were the 
same for both perspectives. The reasons provided by those respondents that did not find the 
question difficult to answer were related to providing a reasonable value for the expected 
outcomes. Those who did find the question difficult cited not being used to valuing 
healthcare, which is not an unexpected finding given that generally UK citizens do not pay at 
the point of consumption of healthcare.  
Predictors for WTP from both perspectives primarily included qualitative reasons with fewer 
socio-demographic factors. This finding suggests that the inclusion of qualitative reasons in 
the WTP elicitation process is important. A higher proportion of protest responses were 
observed in the ex-post perspective (13%) compared to the ex-ante perspective (6%). It is 
possible that those who have the condition and immediately require the treatments are more 
prone to strategic bias, where the respondents do value the treatment but fear they may have 
to pay for it in the future and therefore state that somebody else should pay (i.e. NHS).  
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The results of the associations between measures also showed that WTP is significantly 
associated with change in MMAS score, whilst change in EQ-5D was not. These findings 
suggest that the greater the improvement in health state, the greater the WTP. Thus WTP is 
more sensitive to changes in menorrhagia, which is likely to be due to WTP encompassing 
both health and non-health benefits.  
Very little can be drawn from the interview findings, as the sample interviewed does not meet 
the typical definition of an ex-ante perspective respondent. All three women interviewed had 
experience of menorrhagia. However, it was observed that some of the women did not fully 
understand the WTP exercise, but it cannot be unreservedly stated that this is due to the WTP 
exercise itself as it could also be related to the women having experience of the condition and 
being asked to imagine the scenarios and the treatments.   
 
8.5.1 Strengths and Limitations 
This is the first study to elicit WTP for Mirena and Oral treatment from both the ex-ante and 
the ex-post perspective, and it is the first to compare the findings from the two perspectives in 
menorrhagia. Another strength is that once the questionnaires were developed, they were 
checked by clinical experts in menorrhagia, by psychologists and health economists to assess 
their face and content validity. Further, rather than basing the ex-ante questionnaire scenarios, 
for menorrhagia and treatment effectiveness, on expert opinion alone or expected outcomes, 
they were based on observed evidence from the ECLIPSE trial, which increases the reliability 
of the findings.  
Although it should be noted that it was difficult to draw comprehensive comparisons between 
the ex-ante and ex-post perspectives because of the small sample size in the ex-post 
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perspective. The OLS linear regression could not be carried out in the ex-post perspective for 
Oral treatment therefore a comparison could not be drawn between the predictors of WTP for 
Oral treatment across the two perspectives.  
A limitation of the study is that some variables were not forced into the stepwise regression 
models. Variables such as income can be thought to relate to the theoretical validity of WTP 
and their inclusion in the regression model could increase the explanatory power of the model. 
However, variables are not always forced into regression models in WTP studies and in this 
case as WTP has not necessarily been shown to increase monotonically with income it was 
decided that forcing income into the regression model would be of limited value, particularly 
in cases where the stepwise model did not consider income to improve the explanatory power 
of the model.  
A final limitation is the inability to assess respondents understanding of the WTP exercise, 
along with the inability to supplement the information on reasons for WTP values given in the 
questionnaires through interviews. Very few women attended an interview, all three women 
gave WTP values from an ex-ante perspective but had experience of menorrhagia, which 
meant that the findings could not be generalised to the wider ex-ante population. Therefore, 
very little can be drawn from the findings of the interviews.  
 
8.5.2 Comparison with Other Studies 
In comparison to other WTP studies, the number of protest answers and non-response to the 
WTP question in both perspectives were relatively low. It is often observed that a large 
proportion of the sample report protest answers (Dalmou-Matarrodona, 2001). Similarly, there 
were few genuine zero WTP values in both perspectives which eliminated the need to use one 
257 
 
of the commonly used methods, a two-part model, which accounts for zero values 
(Donaldson, 1998).  
The value for Oral treatment is 12% higher in the ex-post perspective compared to the ex-ante 
perspective value. The value for Mirena is 51% greater in the ex-post perspective than the ex-
ante perspective. It is often reported that values provided from patients (ex-post perspective) 
are greater than those observed by the general population (Brazier & Rowen, 2011), and this 
was also observed in the WTP study reported here. These differences in values amongst 
perspectives are often observed and the reasons not to use patient values relate to issues 
around adaptation, which is explored further in section 9.5 of the next chapter (Brazier & 
Rowen, 2011).    
Other studies have used welfarist measures in menorrhagia. The study by Ryan and San 
Miguel (2000) similarly elicited WTP in menorrhagia using a payment scale approach. 
However, WTP was elicited to compare hysterectomy against conservative treatment to assess 
the reliability of WTP in general, rather than to assess outcomes in menorrhagia. Finally 
another study has used a welfarist method in menorrhagia to compare conservative surgery 
against hysterectomy (San Miguel et al., 2000). However, a conjoint analysis was carried out 
and WTP was elicited indirectly in the choice experiment. Similar to the study by Ryan and 
San Miguel (2000), the aim of the study was to assess the use of conjoint analysis rather than 
assessing outcomes in menorrhagia.   
 
8.6 Conclusion  
In this chapter the results of Part 1: the ex-ante perspective, Part 2: the ex-post perspective and 
Part 3: the interviews are reported. It was found that the treatment with the greatest WTP 
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differed according to the perspective used. From the ex-ante perspective Oral treatment had 
the greatest WTP value and from the ex-post perspective Mirena had the greatest WTP value. 
Respondents completed the WTP exercise by focussing on the benefits of treatment and 
affordability. A higher percentage of respondents in the ex-post perspective found the WTP 
questions difficult to answer than in the ex-ante perspective, and WTP was found to have a 
greater correlation with change in MMAS than change in EQ-5D did in the ex-post 
perspective. The number of women who agreed to attend an interview was too small to obtain 
any generalisable findings. 
The next chapter reports the CBA comparing Mirena and Oral treatment using the WTP data 
reported here from the ex-ante perspective.  
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CHAPTER 9. COST-BENEFIT ANALYSIS 
 
9.1 Introduction 
In this chapter a cost-benefit analysis (CBA) comparing Mirena against Oral treatment is 
reported. It has been discussed in the previous chapters that there are concerns with the use of 
current extra-welfarist outcome measures based on EQ-5D and SF-6D in menorrhagia. 
Further in Chapter 6, where the economic evaluation alongside the ECLIPSE trial was 
reported, it was observed that when used in an economic evaluation the different measures 
provide different recommendations regarding which treatment is most cost-effective.  
Now that the benefits, in terms of willingness-to-pay (WTP), for both Mirena and Oral 
treatment have been elicited using the welfarist framework (reported in Chapter 8), the WTP 
outcomes are combined with the costs associated with each treatment in a welfarist economic 
evaluation. The CBA will use the WTP data from the ex-ante perspective only and the 
justification for this will be explained in the discussion (section 9.5). The objective of this 
chapter is therefore to report an economic evaluation from the welfarist perspective to 
establish the cost-benefit of Mirena compared to Oral treatment. These findings can then be 
compared to those using the extra-welfarist (cost-utility) analysis reported previously 
(Chapter 6). 
The reporting of this economic evaluation follows CHEERS guidelines (the checklist is 
presented in Appendix 3.2) (Husereau et al., 2013).  
Firstly, the methods of CBA are presented. As the methods related to the WTP elicitation 
exercise and resource use have been reported in detail in Chapters 6 and 7, in this chapter 
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these methods will be only briefly described. The analysis and results sections follow and 
finally a discussion on the findings is reported. 
 
9.2 Methods 
A CBA was carried out based on an outcome of WTP, from an ex-ante perspective. The 
analysis is related to the primary care setting and provides an assessment of the difference in 
costs and WTP between interventions over a 24-month time horizon. A 24-month time 
horizon and a National Health Service (NHS) perspective for costs were taken to enable 
comparisons to be drawn between the findings from the CBA and the findings of the cost-
utility analysis (CUA) reported in Chapter 6. The societal perspective for costs was not used 
in this evaluation and the explanation for this will be considered in the discussion, section 9.5. 
 
9.2.1 Participants and Study Design 
The participants and study design is reported in detail in Chapter 7, section 7.2.1. Briefly, 110 
women were recruited from any gynaecological outpatient clinic in the Birmingham Women’s 
Hospital between December 2012 and January 2013. Women who did not necessarily have 
experience of menorrhagia or its treatments were sought, so all women attending an 
appointment were approached to complete a booklet questionnaire, either in the clinic or at 
home. Those respondents who took the questionnaire home to complete were given a stamped 
addressed envelope. Women were asked to value two treatments Mirena and Oral treatment 
which are described in detail in section 2.5 of Chapter 2.  
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The South West England research ethics committee and all relevant local committees 
approved the study.  
 
9.2.2 Outcome Measures 
As described in Chapter 7, section 7.2.1, data on the monetary outcome measure were 
collected in terms of WTP for both Mirena and Oral treatment. As women were not expected 
to have experience of menorrhagia, the questionnaire included a scenario description of 
menorrhagia, and its two alternative treatments, Mirena and Oral treatment (section 7.2.1). 
WTP was elicited for both treatments as a maximum monthly, out of pocket cost, in the 
payment scale format. The booklet questionnaire also collected information on socio-
demographic details. The average WTP value for each treatment was calculated.  
 
9.2.3 Cost and Resource Use 
As the majority of women were not taking either Mirena or Oral treatment, primary data were 
not available for these women, so cost data from the economic evaluation of the ECLIPSE 
trial, reported in Chapter 6, were used as the best available source and were considered an 
appropriate proxy for the costs. Resource use was collected as part of the ECLIPSE trial and 
the unit costs were applied, as described in section 6.2.4 of Chapter 6. Briefly, costs were 
collected from a UK NHS perspective and the general healthcare costs for both treatments 
included healthcare staff costs and the cost of the treatments. The costs of Mirena and Oral 
treatment were estimated from the British National Formulary (BNF, 2011). Staff costs were 
calculated using the nationally recognised reference costs (Curtis, 2011). The overall costs for 
both Mirena and Oral treatment at the 2 year time point in the ECLIPSE trial included 
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crossover between treatment arms, as the analysis within the trial was intention to treat. Table 
6.4 of Chapter 6, section 6.4, reports the average cost of Mirena and Oral treatment per person 
to be £430 and £330 respectively. These costs are used to enable comparability between the 
CBA and the CUA results. The strengths and limitations of using these costs are explored in 
the discussion.  
 
9.3 Analysis 
The net benefit (NB: WTP minus the cost of treatment) of each treatment along with the 
bootstrapped 95% confidence intervals around the mean values are presented. Bootstrapping 
enables an assessment of uncertainty in the mean value, by randomly sampling values, with 
replacement from the observed values. Multiple samples are drawn, as 1000 bootstrap 
datasets are generated using STATA (v11.0), and each dataset is considered to be a reiteration 
of the trial (Glick et al., 2007). The distribution of the bootstrapped values is then presented 
graphically. 
If the NB of the treatment is positive a welfare gain is said to occur and the intervention 
should be implemented. If the NB for the treatment is negative there is a welfare loss and the 
intervention should not be implemented. The treatment with the greatest NB should be 
recommended as the first line treatment. For completeness the incremental NB is also 
presented which shows the difference between the NB’s. (i.e. Mirena NB – Oral NB). In this 
case if the incremental NB exceeds zero, Mirena would be considered the most cost-beneficial 
intervention. Similar to the economic evaluation reported in Chapter 6, the recommended 
discount rate of 3.5% was also applied to both the costs and outcomes as the evaluation time 
horizon was beyond 1 year (NICE, 2008). The WTP values derived for both Mirena and Oral 
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treatment were based on a monthly amount, to obtain the present value the WTP value was 
discounted for every month up to and including 24 months. All costs are reported in 2011 
prices in UK (£) sterling using the UK hospital and community health services index (Curtis, 
2011). 
The base case analysis is presented using the cost data described above, which relates to the 
outcome of the economic evaluation alongside ECLIPSE, reported in Chapter 6, and is based 
on an intention to treat analysis. 
A deterministic sensitivity analysis using alternative cost data, which were not related to the 
model or based on intention to treat analysis, was carried out to identify the impact of the use 
of different types of cost data. In this sensitivity analysis the primary resource use and cost 
data related to the exclusive use of either Mirena or Oral treatment for 2 years were applied, 
thus treatment cross-over and movement to other treatment types was not considered. Table 
9.1 outlines the cost data used in the sensitivity analysis. As Oral treatment comprises a range 
of pharmaceutical treatments the average cost of Oral treatment was weighted according to 
the frequency with which each treatment is prescribed, similar to the evaluation alongside the 
ECLIPSE trial. For this sensitivity analysis it should also be noted that the WTP scenario 
description refers to Oral treatment, but one treatment, Depo-provera, is an injection and not 
an oral tablet. This medication was only prescribed twice in the trial data so the weight given 
is very small and its effect on the overall cost data is as little as 20 pence. As the difference 
was very small and the inclusion of this medication provides a strict comparison between the 
CBA and CUA, Depo-provera was included in the calculation to form the average cost of 
Oral treatment. Similar to the economic evaluation reported in Chapter 6, the cost of repeat 
prescriptions was calculated as a weighted average, as described in section 6.2.4.  
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Table 9.1 Cost data used in sensitivity analysis 
 Unit cost Source 
LNG-IUS   
Consultation (GP 10 mins) £26.67 Curtis 2011/ expert opinion 
Insertion  
GP (20 mins) 
Practice nurse (20 mins) 
Device cost 
Sterile pack (insertion) 
 
£53.33 
£17.00 
£88.00 
£21.63 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
BNF 62 
NICE (inflated to 2011) 
Follow-up 
6 week review: (GP 10 mins) 
3 month: (GP 10 mins) 
 
£26.67 
£26.67 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
Oral treatment 
Progestogen (Cerazette) 
Tranexamic acid (Cyclokapron) 
Mefenamic acid (Ponstan) 
Norethisterone 
Combined oral contraceptive 
(Microgynon) 
Methoxyprogesterone acetate 
injections (Depo-provera) 
Consultation: (GP 10 mins) 
Review of medication (GP 10 mins) 
 
£8.68 
£14.30 
£15.72 
£2.18 
£2.82 
 
£6.01 
 
£26.67 
£26.67 
 
BNF 62 
BNF 62 
BNF 62 
BNF 62 
BNF 62 
 
BNF 62 
 
Curtis 2011/ expert opinion 
Curtis 2011/ expert opinion 
Cost data are reported in UK £ sterling. The cost year is 2011. GP; general practitioner, LNG-IUS; 
levonorgestrel-releasing intrauterine system 
 
 
9.4 Results 
The response rate, socio-demographic details, and reasons for WTP answers are reported in 
detail in Chapter 8. Briefly, 99 women provided a WTP value for Mirena and Oral treatment, 
their average age was 37 years old and 80% of women said they had experience of heavy 
periods at one time in their lives, but this may not necessarily mean experience of heavy 
periods over consecutive cycles as defined by menorrhagia (see Chapter 8, section 8.2.1). 
Typically women did not consider the WTP question to be difficult to answer and the two 
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most commonly cited reasons for a WTP value were related to the effect of the treatment and 
affordability. 
The base case results using cost data from the ECLIPSE trial are reported below, followed by 
the results from the sensitivity analysis.  
 
9.4.1 Base Case Results 
When using cost data from the ECLIPSE decision model it can be seen in Table 9.2 that the 
maximum average WTP for Oral treatment was 13% higher than the cost of the intervention, 
whilst the maximum average WTP for Mirena was 15% lower than the cost of treatment over 
2 years.  
 
Table 9.2 Base case results: mean WTP and cost of treatment 
Intervention WTP [95% CI] Cost Source of costs 
Mirena £365.08 [£247.02-£483.14] £430 ECLIPSE trial 
Oral treatment £371.67 [£267.00-£476.33] £330 ECLIPSE trial 
Mean difference £-6.59 £100  
Cost data are reported in UK £ sterling and refers to 2011. Costs are rounded to the nearest 10. 
 
The NB (WTP minus cost of treatment) for each treatment along with the bootstrapped 95% 
confidence intervals around the mean value is reported in Table 9.3. These base case results 
show that Oral treatment provides a positive NB of £45, resulting in a welfare gain, and 
Mirena produces a negative NB of £-68, leading to a welfare loss. The incremental NB 
exceeds zero suggesting that Oral treatment is cost-beneficial compared to Mirena. However, 
the confidence intervals between the NB’s for both treatments do overlap, suggesting that the 
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difference is not statistically significant and that there is an indifference between which 
treatment is most cost-beneficial. However based on the mean values Oral treatment would be 
considered the most cost-beneficial intervention.  
 
Table 9.3 Base case net benefit results 
Intervention Net benefit 95% CI Incremental Net Benefit 
Mirena £-67.94 £-186.16 – £50.28  
Oral treatment £45.29 £-55.14 – £145.72 £113.23 
CI; confidence interval 
A clear illustration of the welfare gain and welfare loss produced by these treatments can be 
seen in Figures 9.1 and 9.2 where the bootstrapped NB’s for Mirena and Oral treatments are 
presented. Each point on the x-axis represents one bootstrapped plot. It can be seen in Figure 
9.1, that in the majority of cases Oral treatment produces a positive NB, as a greater 
proportion of the bootstrapped NB values lie above £0, whilst Figure 9.2 for Mirena is the 
inverse of that for Oral treatment, showing that in the majority of cases Mirena would produce 
a negative NB, as a greater proportion of the bootstrapped NB values lie below £0. Despite 
the confidence intervals overlapping, this distribution plot of bootstrapped values suggests 
that Oral treatment is more likely to be cost-beneficial relative to Mirena.  
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Figure 9.1 Base case results: bootstrapped net benefits - Oral treatment 
 
Figure 9.2 Base case results: bootstrapped net benefits - Mirena 
 
9.4.2 Sensitivity Analysis 
In the sensitivity analysis where the cost data are based on the primary costs incurred by using 
Mirena and Oral treatment alone, it can be seen from Table 9.4 that mean WTP for Mirena is 
41% greater than the cost of Mirena. Whilst the mean WTP for Oral treatment is 280% greater 
than the cost of Oral treatment. 
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Table 9.4 Sensitivity analysis: mean WTP and cost of treatment  
Intervention WTP [95% CI] Cost Source of costs 
Mirena £365.08 [£247.02-£483.14] £260 See methodology 
Oral treatment £371.67 [£267.00-£476.33] £100 See methodology 
Mean difference £-6.59 £160  
Cost data are reported in UK (£) sterling and the year is 2011. Costs are rounded to the nearest 10. 
 
The NB and the 95% bootstrapped confidence intervals are presented in Table 9.5, both 
treatments result in a welfare gain. The NB’s for Mirena and Oral treatment are £105 and 
£274 respectively. Oral treatment generates a greater welfare gain than Mirena. The 
incremental NB exceeds zero suggesting that Oral treatment is the most cost-beneficial 
compared to Mirena. However, similar to the base case results the NB confidence intervals for 
both treatments overlap, suggesting that the difference between treatments is not statistically 
significant, but based on the mean values Oral treatment would be considered the most cost-
beneficial intervention. 
Table 9.5 Sensitivity analysis net benefit results  
Intervention Net benefit 95% CI Incremental Net Benefit 
Mirena £105.48 £-10.11 – £221.07  
Oral treatment £273.83 £168.01– £379.65 £168.35 
CI; confidence interval 
The bootstrapped NB’s for each treatment are plotted in Figures 9.3 and 9.4 to illustrate the 
range of values. The plots show that in the case of Oral treatment (Figure 9.3) the entire range 
of values generate a welfare gain, as the NB’s are all above £0. Whilst in the case of Mirena 
(Figure 9.4) some of the values do produce a welfare loss which is represented by the values 
below a NB of £0. Overall, the NB for Mirena is not as great as that for Oral treatment, as the 
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positive NB values for Mirena lie between £0 and £250 and the NB values for Oral treatment 
lie between £0 and £450. Hence these bootstrapped plots would suggest that despite the 
overlap between the confidence intervals of the treatment, Oral treatment is likely to be 
considered the more cost-beneficial intervention.  
Figure 9.3 Sensitivity analysis results: bootstrapped net benefits for Oral treatment  
 
Figure 9.4 Sensitivity analysis results: bootstrapped net benefits for Mirena 
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9.5 Discussion 
In this chapter an economic evaluation, using CBA to compare Mirena against Oral treatment 
is reported. The results show that Oral treatment is both less costly, as it costs £100 less than 
Mirena, and generates on average £6.60 more benefits than Mirena, but this difference in 
benefits is greater by a non-significant amount. The overall NB of Oral treatment was £42 and 
generated a welfare gain as it has a greater mean WTP relative to the mean treatment cost. 
Mirena generates a welfare loss of £-68 as the mean WTP for Mirena is less than the cost of 
the treatment. The incremental NB was £113 in favour of Oral treatment. Hence based on the 
mean NB and mean incremental NB values, Oral treatment would be recommended as the 
first line treatment for menorrhagia. 
The findings from the sensitivity analysis show that whilst both Oral treatment and Mirena 
generated a welfare gain of £274 and £106 respectively, Oral treatment generated a greater 
welfare gain as the NB was 61% greater than the NB for Mirena. Similar to the base case 
findings, despite the lack of statistical significance between the NBs of the two treatments, 
based on the mean NB values and the mean incremental NB values (£168 in favour of Oral 
treatment), Oral treatment is considered the most cost-beneficial intervention.  
Therefore the base case analysis and sensitivity analysis both support the finding that based 
on the mean NB values, Oral treatment would be considered the most cost-beneficial 
treatment and recommended as the first choice treatment in clinical practice, when a CBA is 
used.   
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9.5.1 Strengths and Limitations 
This is the first study, to current knowledge, that applies a CBA from an ex-ante perspective 
to compare Mirena against Oral treatment in menorrhagia.  
It could be argued that the study did not strictly use an ex-ante perspective as some women 
with experience of menorrhagia and its treatments were used. However, it could also be 
argued that the sample does to some extent reflect the at risk population group, which would 
be made up of both women who have and do not have the condition. This research is a 
feasibility study carried out to compare the cost-benefit of two treatments for menorrhagia and 
to demonstrate the merits of using a CBA when comparing Mirena against Oral treatment.  
It was not deemed appropriate to carry out a CBA from the ex-post perspective for several 
reasons. First the limited data available (20 for Oral treatment and 51 for Mirena) meant that 
any conclusions drawn from the findings would not be particularly meaningful and could not 
be generalised to the wider population. Second, it would also be unsuitable to carry out a 
CBA from the ex-post perspective because the women used to elicit WTP were several years 
beyond immediate treatment. Hence the beneficial effects of the treatments will have occurred 
for several years and these women may not account for the initial side effects and difficulties 
with treatments when providing a WTP value. Third, decision-makers do not recommend the 
use of an ex-post perspective because in a publicly financed healthcare system society funds 
healthcare, therefore, all of society’s views should be taken into consideration when valuing 
outcomes. Societal values are also recommended due to issues of adaptation, that is, 
individuals with a condition may not be able to desire properly because they have adapted to 
the condition, therefore society should value outcomes on their behalf. Finally, theoretically 
the ex-ante CBA is recommended for a publicly funded healthcare system (O’Brien & Gafni, 
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1996) so for all these reasons outlined above the CBA from the ex-ante perspective is 
considered the most suitable. 
In the ex-post perspective a low response rate was observed as only 20 WTP values were 
elicited for Oral treatment and 51 were elicited for Mirena. However, a greater difference 
between the average WTP values for treatment was observed in the ex-post perspective than 
in the ex-ante perspective. These differences were likely to arise due to the ex-post women 
having current experience of the treatments, hence these women are fully informed about the 
condition and the treatment as they have first-hand experience of both. A discussion around 
the difference in results between the two perspectives is provided by Brazier et al (2005) and 
they state that there is potential for patient values to be taken into account to some degree. If 
this is the case then the ex-ante perspective WTP values which have been used in the CBA 
analysis reported here, are reasonably informed, since some women do have experience of 
menorrhagia and in some cases, its treatments. This is not unexpected given that women were 
recruited from gynaecological outpatient clinics. However, the proportion of patients with 
these experiences may not be representative of the female general population.  
The costs used in the base case were taken from the average overall results of the model-
based economic evaluation reported in Chapter 6. These cost data were used to enable 
comparability between the CUA and CBA as they reflect changes that women in each 
treatment arm are likely to experience. However a limitation of this approach is that the 
probabilities of moving to different states (i.e. stopping treatment, moving to the other 
treatment and having surgery) were not presented in the WTP scenario and hence women did 
not consider this when providing a WTP value. Incorporating these probabilities and other 
states into the WTP scenario would have made the elicitation exercise cognitively 
burdensome. However, when using cost data that are only related to the WTP scenario the 
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same treatment was found to be superior. In this case although the overall cost-benefit 
decision did not differ, the extent of the welfare gain produced by Oral treatment compared to 
Mirena did vary, and was dependent on the cost data used in the CBA.  
Whilst this study was the first to carry out a contingent valuation and CBA of two non-
surgical treatments for menorrhagia, it was not possible to conduct a comprehensive CBA as 
societal costs were not available. As mentioned in the introduction of section 9.2 only the 
costs from an NHS perspective were considered in this evaluation. The potentially relevant 
costs to healthcare and society are outlined below.  
NHS (healthcare) costs include; treatment cost and consumables, healthcare providers time 
(Clinician and Nurse) for administration of treatment, initial consultations and follow-up 
appointments.  
Societal costs include; lost productivity which is related to time off work or reduced 
productivity at work, travel time and travel costs, out of pocket prescription costs and over the 
counter medication 
Of these societal costs, it is hypothesised that the two most likely to have an impact are lost 
productivity and out of pocket prescription costs. Incorporating these costs however is not 
straightforward as it is possible that the WTP outcome already incorporates the relevant 
societal costs as women were presented with a scenario that took into consideration the effect 
of menorrhagia and its treatments on work/daily routine. This notion of potential ‘double-
counting’ has been reported extensively in the literature (Drummond et al., 2005). Hence the 
increase in productivity as a result of treatment will be captured by the benefits and by 
incorporating changes in productivity into the cost side of the equation, it is possible that the 
benefits of treatment are double counted. The only other more relevant societal cost that may 
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not be captured is the cost of prescriptions. The qualitative findings, reported in Chapter 8, 
showed that many women used the cost of prescriptions as an anchor for their WTP value and 
so these prescription costs may to some extent be taken into consideration with the benefits. 
Given that these out of pocket prescription costs are only incurred in the Oral treatment arm, 
for some of the treatments, it could be considered as bias in favour of Oral treatment not to 
consider this cost. However, on average, across all the Oral treatments, this cost is likely to be 
incurred eight times over 2 years, and as the standard UK cost of a prescription is £7 the 
exclusion of this societal cost is unlikely to change the overall recommendation of the most 
cost-beneficial treatment.  
 
9.5.2 Comparison with Other Studies 
To current knowledge, this is the first study to carry out a CBA comparing Mirena against 
Oral treatment. A recent CBA has been carried out but in the area of spinal surgery in 
Switzerland, where WTP was elicited from the ex-post perspective using patient values 
(Haefaeli et al., 2008). The authors elicited the ex-post WTP and conducted the CBA but 
suggested that further methodological work be carried out on the use of ex-ante WTP values, 
as this perspective is recommended for publicly funded healthcare systems.  
As reported in Chapter 6, other studies have carried out CUAs but none have directly 
compared Mirena against Oral treatment. When compared to the findings of the CUA carried 
out in Chapter 6, it can be seen that the recommendations for first line treatment in the CBA 
are the same as those of the CUA using SF-6D. Both analyses show indifference between 
treatments, with Oral treatment being recommended as first line treatment for menorrhagia. 
However, when the CUA was estimated using EQ-5D it can be seen that these results and 
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those of the CBA reported in this chapter do not concur. As decision-makers currently 
recommend EQ-5D for the valuation of outcomes, Mirena would be considered the most cost-
effective treatment, despite other measures demonstrating that Mirena is not the most cost-
effective intervention. These findings have significant implications for decision-makers which 
will be explored further in the next chapter.    
 
9.5.3 Implications and Further Research 
The results of the CBA provide evidence that would be seen to question the recommendations 
of the NICE guidelines which suggest that Mirena (LNG-IUS) should be used as the first line 
treatment for menorrhagia. The results reported in this chapter show that there is somewhat of 
an indifference about which treatment is most cost-beneficial, with the results tending to 
favour Oral treatment as the most cost-beneficial intervention. The characteristics of the study 
population did not completely reflect the ex-ante criteria as a high proportion (80%) of the 
sample had experience of menorrhagia or its treatments. In order to provide generalisable and 
robust evidence to decision-makers it would be beneficial to conduct the economic evaluation 
using a study population, with a larger sample size, but with fewer women who have 
experienced menorrhagia and its treatments to more closely reflect a general population and 
an ex-ante perspective.   
 
9.6 Conclusion 
In this chapter the CBA comparing Mirena against Oral treatment was reported. The results 
suggest that Oral treatment was the most cost-beneficial intervention in both the base case and 
sensitivity analysis, and would be most likely recommended as the first line treatment for 
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menorrhagia. In the final chapter of the thesis the overall discussion is reported, summarising 
the entire thesis and providing reflections of welfarist and extra-welfarist approaches to 
valuing outcomes.  
  
277 
 
CHAPTER 10. DISCUSSION AND CONCLUSION 
 
10.1 Introduction 
The objective of this research was to: 
1) Determine the value of levonorgestrel-releasing intrauterine system (LNG-IUS) 
compared to usual medical treatment in menorrhagia, and 
2) Consider the suitability of current measures available for assessing the value of 
outcomes and interventions in menorrhagia. 
In essence, to meet these objectives, a comparison was drawn between welfarist and extra-
welfarist approaches to valuing outcomes in menorrhagia.  
In the clinical condition of menorrhagia, an assessment of quality of life (QoL) is the primary 
indicator of treatment success. So it is particularly important to ensure that a suitable measure 
that accurately captures patients concerns and experiences is available for use. Menorrhagia is 
a particularly interesting condition to consider for two reasons; first the condition is chronic 
but symptoms occur in episodes and second, the condition is known to greatly impact on non-
health aspects as well as health aspects of women’s lives. These are two properties that can 
make valuing outcomes in menorrhagia more problematic than other conditions. 
In this thesis, alternative approaches to valuing the outcomes in menorrhagia have been 
assessed by exploring the use of outcome measures from the two theoretical frameworks in 
health economics, welfarism and extra-welfarism. The extra-welfarist outcome measure, the 
quality adjusted life year (QALY), is currently recommended by decision-makers such as the 
National Institute of Health and Care Excellence (NICE). In contrast, the willingness-to-pay 
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(WTP) approach to valuing outcomes which is based on a welfarist framework is not 
currently recommended but has potential advantages compared to extra-welfarist measures 
and these may be potentially beneficial to conditions such as menorrhagia. 
To compare the alternative frameworks for valuing outcomes in menorrhagia, data were 
collected using the extra-welfarist instruments of EQ-5D and SF-6D, and the welfarist 
approach of WTP was also used. An economic evaluation comparing LNG-IUS against usual 
medical treatment was carried out using measures from each framework to compare the cost-
effectiveness decision. 
In this chapter a summary of the key findings from the entire thesis is presented. This is 
followed by reflections on welfarist and extra-welfarist measures in menorrhagia, strengths 
and limitations, main findings in relation to other research, implications for policy, further 
research recommendations and finally a conclusion of the thesis. 
 
10.2 Summary of the Findings 
The conclusions from the systematic review in Chapter 4 of economic evaluations comparing 
LNG-IUS and usual medical treatment were that there was no reliable evidence on the cost-
effectiveness of these treatments. Furthermore, this conclusion was drawn from all the 
available published evidence to date which was typically based on secondary data, with the 
exception of one small study that used primary data but was not carried out in the UK (Brown 
et al., 2006). This suggested there was a clear need to carry out a UK based economic 
evaluation alongside a trial that directly compared LNG-IUS and usual treatment to inform 
clinical practice. Further, when exploring the use and assessment of outcome measures in 
menorrhagia, the findings from the previous literature, reported in Chapter 5, showed that 
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there is no consensus on the most suitable measure. There is concern that extra-welfarist 
measures, such as EQ-5D and SF-6D, may be unsuitable for this particular medical condition 
because of their narrow health-related focus. Evidence suggested that women do not consider 
menorrhagia to be solely a health related condition, as impact on social life, daily activities 
and family life/relationships were shown to be important to women with menorrhagia (Shaw 
et al., 1998). Hence these measures were purported to have poor face validity and women 
were found to be unsure whether the instruments should be completed with reference to 
general health or menorrhagia. The condition’s periodic nature and the standard recall periods 
of these extra-welfarist measures also meant that the results would be dependent on the timing 
of assessment.  
The first part of the empirical work was carried out, (and is reported in Chapter 6) to 
determine whether the use of the different extra-welfarist measures, EQ-5D and SF-6D, leads 
to the same recommendation regarding the most cost-effective treatment for menorrhagia. A 
model-based economic evaluation alongside the ECLIPSE trial was carried out from a 
National Health Service (NHS) perspective with a 2 year time horizon. A Markov model was 
developed using patient level data to accurately capture the associated changes in QoL and 
repetitive resource use associated with the pathways of the non-curative trial treatments, 
LNG-IUS and usual medical treatment. The results of the economic evaluation, which was 
first estimated using EQ-5D, and then re-estimated using SF-6D, showed that the most cost-
effective treatment differed depending on the outcome measure used. Hence these measures 
were shown to capture different aspects of QoL and these findings highlighted the importance 
of using the most appropriate measure. Using EQ-5D, LNG-IUS was shown to cost more but 
was also more effective than usual medical treatment, generating an ICER of £1600 per 
QALY. This is within the NICE guidelines threshold of £20,000 per QALY for 
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recommending new interventions into practice. Hence using EQ-5D, LNG-IUS was 
recommended as the first line treatment for menorrhagia and this recommendation was 
supported in all sensitivity analyses.  
In contrast, the utilities derived from SF-6D presented results that suggested usual treatment 
dominated LNG-IUS, thus implying that usual treatment should be recommended as the first 
line treatment for menorrhagia. This result was again supported by all relevant sensitivity 
analyses. Therefore the recommendation to decision-makers was shown to differ depending 
on the instrument used. These findings coupled with those of the systematic review in Chapter 
5, illustrated that there are concerns about the use of these extra-welfarist measures in 
menorrhagia, which therefore presented a case for the exploration of a measure from the 
alternative welfarist framework, namely WTP, which enables a broader assessment of 
wellbeing and may overcome the issue of timing of assessment.  
The second part of the empirical work, (reported in Chapters 7 and 8) involved eliciting WTP 
for LNG-IUS (termed Mirena in the questionnaire) and usual medical treatment (termed Oral 
treatment in the questionnaire) to consider the use of WTP in menorrhagia in a feasibility 
study. The methodology is reported in Chapter 7 and explains that WTP was elicited from the 
theoretically preferred ex-ante perspective, where expected utility for the change is elicited, 
and also from the most commonly practiced ex-post perspective, where WTP for actual utility 
after the change is elicited. This was with the intention of drawing comparisons between the 
two perspectives. A questionnaire was developed for each perspective to elicit information on 
WTP, socio-demographic details and other information on QoL. A payment scale format was 
used and maximum WTP was elicited as a monthly out of pocket cost up until menopause. 
When WTP was elicited from the ex-ante perspective, women were presented with a scenario 
of menorrhagia and its treatments and were asked to provide a WTP value for both Mirena 
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and Oral treatment. The scenario for menorrhagia and the expected outcomes of treatment 
were based on the disease-specific menorrhagia multi-attribute scale (MMAS) outcomes of 
the ECLIPSE trial data. Process utility was also included in the scenario for the relevant 
treatments, (Mirena and Oral treatment), to ensure that the results were not constrained to the 
time point of assessment. Hence the respondents were presented with information on the 
initial process of care in addition to the longer-term outcomes, therefore when future 
alternative treatments become available and if a similar scenario was presented, these WTP 
values could be compared against those presented in Chapter 7. The WTP values from the ex-
post perspective were elicited from women who were enrolled in the ECLIPSE trial and had 
experience of menorrhagia and its treatment. Therefore, the WTP was for current treatment. 
The analyses of WTP were reported in Chapter 8. Part 1 referred to the analyses of the ex-ante 
perspective, and Part 2 referred to the analysis of the ex-post perspective. In Part 1, Mirena 
was the preferred treatment but despite this, the mean WTP for Oral treatment (£15.38) was 
slightly greater than the mean WTP for Mirena (£15.11). It appeared that women who 
preferred Oral treatment were willing to pay 66% more for Oral treatment than Mirena, 
whereas women who preferred Mirena were willing to pay 28% more for Mirena than Oral 
treatment – a smaller difference in WTP. In Part 2 when WTP was elicited from the ex-post 
perspective, the women from the ECLIPSE trial who had experience of menorrhagia and 
either Mirena or Oral treatment were asked to complete a postal questionnaire and provide a 
WTP value for their current treatment. In contrast to the ex-ante perspective Mirena had the 
highest average WTP value with the WTP for Mirena (£31.08) being approximately twice as 
large as the WTP for Oral treatment (£17.45). 
In both perspectives it was shown that respondents who provided WTP values were 
completing the questionnaire as is expected and required by analysts. The most commonly 
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cited reason for WTP was related to the effects of treatment, hence respondents were focusing 
on the effects and value of the treatments to themselves, providing support for the use of WTP 
as a suitable measure of outcome for menorrhagia. In the regression analyses, reasons for 
WTP values, rather than socio-demographic information, were shown to be more important 
predictors of WTP in both the ex-ante and ex-post perspective. When WTP was presented 
against income it was shown that generally mean WTP increases with income but the 
relationship was not shown to be monotonic, which according to previous research would 
suggest that theoretical validity has not been demonstrated. However, the sample size and 
number of respondents in each income category could be the reason for this finding.  
In Part 2 with the ex-post perspective, the association between measures was investigated. As 
baseline data from the ECLIPSE trial were available it was possible to assess the association 
between the ex-post perspective WTP and the change in EQ-5D against the change in disease-
specific MMAS from baseline. The associations were assessed by Spearman’s correlation and 
showed that there was a significant correlation between WTP and change in MMAS. 
However, a significant correlation was not observed between MMAS and EQ-5D, which 
would suggest that WTP is detecting certain effects, most likely the non-health effects, which 
EQ-5D does not capture.  
Finally, in Chapter 9 a cost-benefit analysis (CBA) using ex-ante WTP comparing Mirena and 
Oral treatment was reported. This analysis helped to determine whether the most cost-
beneficial intervention differs between the welfarist approach when WTP is used and the 
extra-welfarist approach when EQ-5D and SF-6D is used. To enable comparisons between the 
welfarist and extra-welfarist approaches, both economic evaluations were undertaken using a 
2 year time horizon. As the opportunity to collect ex-post WTP data was available it was 
initially decided that an attempt should be made to compare the CBA results across 
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perspectives. However upon reflection it was realised that a CBA from the ex-post 
perspective would not be theoretically recommended for a publicly funded healthcare system, 
in addition to the lack of sufficient data available. As decision-makers recommend societal 
values in a publicly funded healthcare system, because society contributes to funding the 
provision of healthcare, and theoretically the ex-ante perspective would be most suitable for a 
publicly funded healthcare system, the findings from the ex-ante CBA are likely to be more 
acceptable to decision-makers than those of the ex-post perspective. In both the base case and 
the sensitivity analysis, it was found that Oral treatment was the most cost-beneficial 
intervention as it was both less costly and resulted in a greater WTP value, hence producing 
the greatest welfare gain. The results of the CBA recommend Oral treatment as the first line 
treatment for women with menorrhagia. This finding of Oral treatment being the most cost-
beneficial intervention concurred with the findings of the extra-welfarist SF-6D, but not the 
decision-maker recommended EQ-5D. The meaning of the findings is explored in more detail 
in section 10.5, but the findings across the measures demonstrate that both the SF-6D and 
WTP do not support the findings of the currently recommended EQ-5D measure. 
 
10.3 Strengths and Limitations of Research  
10.3.1 Strengths 
The main strength of this research is that empirical primary data on the alternative instruments 
were collected and used throughout to value the outcomes in menorrhagia.  
First, a comprehensive systematic review was carried out to determine which measures have 
been used and assessed in menorrhagia. The review illustrated the lack of consensus on the 
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most suitable measure to use in menorrhagia and highlighted the issues associated with the 
currently used EQ-5D and SF-6D. 
Second, to current knowledge, this study is the first to comprehensively assess all the existing 
evidence on outcomes for menorrhagia and carry out two contrasting economic analyses to 
encompass both a welfarist and extra-welfarist perspective. The conflicting findings observed 
from the comparison of the economic evaluation using alternative extra-welfarist measures 
EQ-5D and SF-6D in menorrhagia were based on primary data taken directly from the largest 
multi-centre randomised controlled trial carried out to date in the UK for menorrhagia. 
Further, the economic evaluation was carried out using a Markov model based on trial data 
and expert opinion, and developed using sophisticated methods. Hence the findings from a 
robust data set and analysis have illustrated that the selection of instruments to measure QoL 
in menorrhagia is very important as different decisions on cost-effectiveness were observed. 
This could potentially lead to policy-makers making decisions on interventions for clinical 
practice based on ambiguous data. 
Third, the questionnaires eliciting WTP were developed and subsequently assessed by clinical 
experts in menorrhagia, by psychologists and health economists, increasing the content and 
face validity of the questionnaires. The scenarios presented to respondents in the 
questionnaire on menorrhagia and the effectiveness of the interventions were based on 
tangible evidence from the ECLIPSE trial, rather than expert opinion alone or expected 
outcomes as these may not actually be observed in practice. From this respect, providing 
WTP for actual observed outcomes increases the reliability of the findings. Further, the initial 
protocol for the empirical work for the WTP research was assessed by an international expert 
in the field of applying WTP in practice.  
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Finally, the research reported here is the first to: elicit WTP from an ex-ante and ex-post 
perspective; carry out a CBA from the ex-ante perspective comparing LNG-IUS to usual 
treatment in menorrhagia; compare SF-6D and EQ-5D in menorrhagia; and draw a 
comparison between the cost-effectiveness decision of the cost-utility analyses (CUA) and the 
CBA.  
 
10.3.2 Limitations 
The main limitations of this thesis are outlined in this section. 
First, in the economic evaluation alongside the ECLIPSE trial, reported in Chapter 6, missing 
data in EQ-5D and SF-6D were not imputed using conventional methods such as multiple 
imputation due to the nature of the analysis. As the trial data are used in a decision model, it 
would be necessary to impute missing data at the individual level rather than overall at the 
QALY level for each time point. As this has not been attempted before and is not yet a 
recommended method, it did not seem appropriate. To some extent the probabilistic 
sensitivity analysis would compensate for not handling missing data.   
Second, it was not possible to calculate a suitable sample size required for the WTP work, in 
Chapters 7-9, because a prior study in the area has not been carried out, therefore a value for 
what constitutes a meaningful change or difference in WTP has not been identified to be able 
to base the calculation upon. This meant that the study was not sufficiently powered to test for 
the statistical significance of the difference in WTP values. However, as the a-priori 
distribution of WTP values has been presented in this thesis, it can now be used to determine 
the required sample size in future studies. 
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Third, insufficient WTP data were available from the ex-post perspective to enable a 
comparison to be drawn between the WTP values of the ex-ante and ex-post perspectives. 
This also meant that a CBA from the ex-post perspective could not be carried out but it is 
likely that this may not have been entirely suitable as explained in the discussion of Chapter 
9. Further, it could be argued that the ex-ante perspective WTP values and subsequent CBA 
do not entirely meet the criteria for an ex-ante perspective because men’s values were not 
considered and women who do have experience of menorrhagia were also included. Therefore 
caution to these limitations must be considered, when drawing conclusions from this research.  
Finally, there was a difficulty in recruiting women to attend interviews to more 
comprehensively assess reasons for WTP values and their understanding of the question. As 
outlined in Chapter 8, there are likely to be a multitude of reasons for respondents to not have 
attended the interviews. Some respondents stated that they had recently had a hysterectomy 
making attending an interview within the stated timeframe difficult. For others, the timing of 
the interviews (Easter holiday period) or unexpected inclement weather (multiple heavy snow 
days) could have represented insurmountable difficulties. Furthermore, attending an interview 
would have meant that women were required to take time off work which could expectedly 
lead to the poor response rate. In hindsight, a telephone interview may have been more 
appropriate.  
 
10.4 Main Findings in Relation to Other Research 
10.4.1 Comparison of EQ-5D and SF-6D  
A difference in utilities observed between SF-6D and EQ-5D was observed in Chapter 6 and 
this led to the different cost-effectiveness decisions. Previous studies have similarly observed 
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that SF-6D and EQ-5D generate different utilities for the same patient in seven other 
conditions (Brazier et al., 2004; Whitehurst & Bryan, 2011; Whitehurst et al., 2011). Brazier 
et al (2004) also observed these differences and found that one of the reasons for these 
differences is likely to be due to the ceiling effects associated with EQ-5D, as SF-6D is able 
to discriminate between health at the top end of the utility scale, which is anchored by 0 and 
1. It was suggested that when full health is observed on EQ-5D but not SF-6D it is likely that 
the dimensions affected are those that are not comprehensively captured by EQ-5D such as 
vitality, mental health and physical functioning (Brazier et al., 2004). These additional SF-6D 
attributes are more likely to be those impacted by menorrhagia. Whilst the differences 
observed in this thesis are likely to be similar, there are likely to be additional specific reasons 
associated with the nature of menorrhagia, as discussed previously, but these reasons were not 
explored in this thesis.  
 
10.4.2 WTP Research  
Whilst this is the first study to elicit WTP for LNG-IUS and usual medical treatment, prior 
studies have attempted to elicit WTP in menorrhagia. A conjoint analysis study has been 
carried out in menorrhagia comparing the effectiveness of conservative surgery against 
hysterectomy (San Miguel et al., 2000). Cost was used as an attribute in the choice 
experiment to indirectly elicit WTP from patients with the condition. However, the purpose of 
the study by San Miguel et al (2000) is more related to testing the conjoint analysis method 
rather than attempting to assess the suitability of the measure in menorrhagia. Nonetheless it 
was demonstrated that the method could be used to assess WTP indirectly in the condition but 
that further research is required. The study by Ryan and San Miguel (2000), discussed in the 
systematic review in Chapter 5, also used WTP in menorrhagia, however again, not with the 
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purpose of assessing outcomes in menorrhagia but instead to assess the reliability of WTP. In 
this study WTP was elicited directly using a payment card in a questionnaire based format to 
compare hysterectomy against conservative treatment from an ex-ante perspective. Hence no 
study has aimed to investigate the use of WTP in menorrhagia, instead the previous studies 
have used the data from women with menorrhagia to assess the methodology of WTP itself.  
 
10.4.3 Economic Evaluations in Menorrhagia 
The first CUA in menorrhagia was carried out by Sculpher (1998) and he compared surgical 
interventions for the condition. Given that, at the time, recommendations on the instrument to 
use were not presented by decision-makers, Sculpher considered EQ-5D but then used TTO to 
generate QALYs. Utilities were elicited for several condition-specific health state scenarios 
directly through TTO using patient values. It is not unexpected that one of the first economic 
evaluations in the area differs markedly to those carried out today. As demonstrated in the 
CUA in Chapter 6, economic evaluations are now required to use generic health state 
descriptions that are valued by society using EQ-5D.  
In Chapter 4 it was demonstrated that all prior economic evaluations in the area that had 
focused on either LNG-IUS or usual medical treatment had been carried out from the extra-
welfarist theoretical framework. As expected, given current recommendations, CUAs were 
carried out using either EQ-5D or SF-6D to generate the QALY outcome. Whilst LNG-IUS 
had been used as a comparator in these evaluations, it was often compared to surgical 
interventions and was not always found to be the most cost-effective intervention. A CBA 
was not identified. The prior evaluations were generally found to be of poor quality, based on 
secondary data and/or were conducted outside the UK, which has implications for the 
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transferability of the findings. The CUAs carried out in Chapter 6 were the first to directly 
compare LNG-IUS against usual medical treatment using data from a robust trial. It was also 
the first to carry out the economic evaluation using the recommended EQ-5D and to re-
estimate the evaluation using SF-6D to compare the cost-effectiveness results in menorrhagia. 
Other studies have assessed whether a difference in cost-effectiveness is observed in other 
conditions and similar to the findings presented in Chapter 6, they have also shown that the 
degree of cost-effectiveness, and the cost-effectiveness decision, can differ across the two 
measures (Davis et al., 2012; Sach et al., 2009).  
Finally, to current knowledge the CBA reported in Chapter 9 is the first to compare LNG-IUS 
to usual medical treatment in menorrhagia. Another recent CBA has been carried out in the 
area of spinal surgery in Switzerland (Haefaeli et al., 2008). In this spinal study, the WTP was 
elicited from the ex-post perspective using patient values. Initially the payment scale method 
was considered but was not used because issues around starting point bias were observed in 
the pilot study. Thus WTP was elicited as an open ended and closed ended question, in 
addition to willingness-to-accept. The authors were able to successfully elicit the ex-post 
WTP and conduct the CBA, but suggested that methodological work should be carried out on 
the comparison of findings across the ex-ante and ex-post perspective, because the ex-ante 
method is recommended for publicly funded healthcare systems.  
 
10.5 Reflections on Welfarist and Extra-welfarist Measures in Menorrhagia 
In summary, in the context of menorrhagia, it has been shown that there are concerns around 
the use of the extra-welfarist measures EQ-5D and SF-6D. The findings from the welfarist 
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approach demonstrate that it is feasible to elicit WTP and conduct a CBA within this 
condition.  
The focus of this thesis was to explore the differences between the welfarist and extra-
welfarist measures. The reasons behind the difference in utilities derived and cost-
effectiveness results between the extra-welfarist measures were not explored as it was 
considered to be beyond the scope of the objective. However, potential reasons for these 
differences are likely to be due to the measures capturing different aspects of QoL, and the 
different recall periods presented in the questionnaires, amongst other things. SF-6D refers to 
health ‘during the past month’ which is likely to lead to an underestimation of the QALY. 
Whilst EQ-5D could lead to an under or overestimation of the QALY due to the recall period 
used of ‘health today’. For example, if the woman is experiencing the symptoms on the day 
she completes EQ-5D, the QALY gain from treatment is likely to be overestimated, and 
underestimated if she completes the EQ-5D questionnaire when she is not experiencing 
symptoms. This is due to the calculation of the QALY, i.e. the linear interpolation of the value 
and the use of area under the curve to generate the QALYs.   
What can be drawn from the evidence presented in this thesis is that the combined focus on 
health-related QoL and the specified time-frame used in extra-welfarist measures poses 
difficulties for completion and could result in misleading decisions about which treatment is 
most cost-effective. It has been shown in Chapter 5 that these measures do not capture what is 
important to women with menorrhagia and that the questions are presented in a manner that 
women find difficult to comprehend given the chronic, but episodic nature of the condition. 
However, the primary advantage of the use of extra-welfarist measures in menorrhagia is that 
they are currently recommended to generate QALYs. A QALY is argued to be the most 
suitable outcome due to its focus on health related QoL, which is considered most appropriate 
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for decision-makers to allocate healthcare resources (NICE, 2008). Hence, decision-makers 
such as NICE have signed up to the extra-welfarist school of thought with its focus entirely on 
health and its aim to maximise health. It is increasingly recognised that this school of thought 
that focuses entirely on health is not suitable for certain conditions where benefits can 
additionally lie beyond health (McIntosh et al., 2010). However, it is important to state here 
that the findings presented in this thesis are a criticism of the current extra-welfarist measures 
EQ-5D and SF-6D and not all extra-welfarist multi-attribute utility instruments. But EQ-5D 
and SF-6D are the only recommended extra-welfarist measures in the UK to have a value set 
based on the UK adult population.  
The advantage of the use of WTP is that it is based on economic theory and captures a 
broader assessment of wellbeing than extra-welfarist measures. In menorrhagia it is known 
that benefits beyond health are important to sufferers and that these benefits are unlikely to be 
captured using the current extra-welfarist measures (Shaw et al., 1998). This would therefore 
have a negative effect on policy implications for healthcare resource use as treatments may 
not be shown to be cost-effective and would not be recommended for clinical practice because 
an inappropriate measure was used to assess the benefits. Evidence for the use of WTP in 
menorrhagia has been presented in Chapter 8 and has shown that WTP is capturing aspects of 
life that are important to women, most likely the non-health benefits, that extra-welfarist 
measures do not capture. Furthermore, WTP values from both the ex-ante and the ex-post 
perspective were elicited and women were shown to focus on the value of the treatments, as is 
required. Very few protest responses were observed and a low non-completion rate provides 
an indication of the acceptability of the method from both perspectives. Hence the potential 
for the use of WTP in menorrhagia has been demonstrated but the reasons behind the WTP 
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values and the respondents understanding of the exercise would need to be verified with the 
use of in-depth interviews.  
The way in which WTP should be used is open to debate. In keeping with theory and 
decision-makers recommendations for the use of societal values, the ex-ante perspective WTP 
should be used. A further potential benefit of using the ex-ante perspective WTP is its ability 
to overcome the issue of timing of assessment. As these women are not experiencing the 
condition, the results are unlikely to be affected by the timing of assessment, which is the case 
when patients complete the extra-welfarist measures.  
Despite these positive findings, there are obstacles against the use of WTP. As mentioned in 
Chapter 3, it is clear that the use of WTP does not currently ‘fit’ within the guidelines 
provided by decision-makers. A wide range of alternative extra-welfarist techniques are 
recommended prior to the consideration of any other information. Other methods are 
suggested in the guidelines but can only be presented as additional to information using the 
extra-welfarist approach. Decision-makers’ aversion to the welfarist method is due to the 
perception that WTP is based on ability to pay alongside on-going methodological issues 
(NICE, 2004). Practice is unlikely to change instantaneously but the gradual accumulation of 
evidence against the use of extra-welfarist measures in menorrhagia may encourage decision-
makers to consider alternative techniques.   
In relation to the findings of this thesis, it is not surprising that WTP and the change in the 
disease-specific measure MMAS from baseline are correlated. As WTP is elicited specifically 
for the treatment of the condition it will always inherently be more sensitive than EQ-5D and 
SF-6D, as these extra-welfarist measures are designed to capture general aspects of health. 
However, it is interesting that change in EQ-5D and change in MMAS did not have a 
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significant correlation. This lack of correlation suggests that the changes that occur on the 
disease-specific measure are not comprehensively captured by EQ-5D. This finding could be 
excused because these extra-welfarist measures are not designed to capture disease-specific 
health. However, as mentioned previously, the issue with the extra-welfarist measures arises 
because menorrhagia is not primarily a health related condition, but healthcare resources are 
used to treat the condition. Therefore, these extra-welfarist measures are not comprehensively 
valuing outcomes in menorrhagia because they do not sufficiently capture the impact of the 
condition. It is the extent to which these measures do not capture these aspects that is 
important and with the remit of decision-makers broadening to include health and care 
excellence, this issue of how to incorporate benefits beyond health must be resolved.  
A second issue is the episodic nature of the condition as it means that the timing of 
assessment will always arise as an issue when attempting to value outcomes in such 
conditions. Sculpher et al (1996) has previously argued that it is difficult to determine when 
the correct time would be to elicit values. Therefore the resolution to this problem is related to 
identifying which measure is considered to most comprehensively assess values in these 
episodic conditions. It is clear that the results from EQ-5D will be the most influenced by the 
timing of assessment due to its recall period. Given that decision-makers currently 
recommend extra-welfarist measures it would appear that SF-6D is less likely to be affected 
by the timing of assessment, as the measure will at least capture some information related to 
the condition. Yet it must be recognised that the extent to which it is able to detect attributes, 
i.e. non-health, relevant to the condition is limited. Whilst WTP captures the non-health 
benefits and is less likely to be affected by timing of assessment, it is argued that currently 
information from several measures should be provided to decision-makers to ensure the 
relevant information is fully captured.  
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Further, whilst in this thesis the decision-maker recommended EQ-5D shows a greater 
difference in QALYs between the two interventions, in favour of LNG-IUS, the SF-6D and 
WTP do not support this evidence. SF-6D and WTP suggest indifference between the 
treatments that is slightly more in favour of usual treatment. It is possible that the result of 
WTP and SF-6D agreeing is due to chance, or perhaps because SF-6D has a more 
comprehensive recall period than EQ-5D therefore it has captured some of what is important 
to women, as explained previously. Hence SF-6D is more sensitive and more closely follows 
the results of WTP. Although EQ-5D shows that LNG-IUS is more effective, which 
corresponds with the trial disease-specific measure, the correlation analysis showed that EQ-
5D and the disease-specific measure are not correlated significantly and therefore the reasons 
for this agreement is not clear. So as the majority of the evidence suggests that there is a 
limited difference between the effectiveness of the two treatments, perhaps there is a case to 
take into account women’s preferences rather than following a prescriptive list of 
recommendations. In menorrhagia, there may be scope for preference based treatment 
allocation as originally discussed by Sculpher (1998) and most recently mentioned by Roberts 
et al (2011). Sculpher discussed that there may be potential for a preference based treatment 
system in menorrhagia rather than assuming the ‘all or nothing’ approach to decision-making. 
Both usual treatment and LNG-IUS are already, and will be, used in clinical practice because 
LNG-IUS provides contraception, which is not required by all women. Furthermore, the 
randomised allocation of the ECLIPSE trial, and clinical practice, is based on whether women 
have a preference for contraception. This coupled with the relative indifference between 
treatments may mean that there may be scope for the use of preference-based treatment 
allocation in menorrhagia.   
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In summary, the three pieces of information provided by the three measures EQ-5D, SF-6D 
and WTP are providing decision-makers with different information and therefore the findings 
presented in this thesis would suggest that they should not be considered individually but 
rather altogether. The differences observed in the results are likely to be caused due to a 
number of factors, as all three measures have different elicitation methods, each measure 
captures different aspects of QoL and each measure refers to different recall periods. It is 
difficult to directly compare the measures for these reasons, although comparisons are often 
drawn between EQ-5D and SF-6D because they are used to generate the same QALY 
outcome. Therefore, the most suitable method of assessing the measures is by comparing the 
cost-effectiveness decisions and attempting to identify the potential reasons for these 
differences. Based on the current evidence it is difficult to categorically say which measure is 
more suitable than the other, therefore the information from the measures should be 
considered altogether, as explained further in section 10.6. WTP should currently be 
considered as a complement to these extra-welfarist measures, it cannot be recommended as 
the sole measure in menorrhagia because there is not currently sufficient evidence to support 
this. But a clear case has been presented in this thesis for WTP in menorrhagia because it 
more comprehensively overcomes the issues associated with extra-welfarist measures but 
further research exploring WTP within the area is required, particularly through the use of 
interviews.  
 
10.6 Implications for Policy 
Current recommendations from the NICE guidelines state that LNG-IUS should be 
implemented as the first line treatment for menorrhagia (NICE, 2007). The cost-effectiveness 
results of the economic evaluation carried out alongside the ECLIPSE trial using the decision-
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maker recommended EQ-5D correspond with the NICE guideline recommendations, as LNG-
IUS was shown to be cost-effective. However, the recommendations from the NICE 
guidelines were not supported when SF-6D was used to generate QALYs in the economic 
evaluation. Hence the implications for clinical practice are dependent on the measure used, 
clearly indicating a need to ensure that the most suitable measure is used. It has been shown in 
the literature that neither measure is considered to be entirely suitable for menorrhagia. It 
should be noted that there was strong support from the principle investigators of the ECLIPSE 
trial to explore the use of WTP in menorrhagia because the shortcomings of the extra-
welfarist measures in menorrhagia are recognised. This evidence suggests that there is a need 
for policy-makers to consider the findings from measures other than EQ-5D and SF-6D when 
evaluating interventions for menorrhagia. The potential for the use of WTP in menorrhagia 
has been demonstrated in this thesis, though further research is required. The findings from 
both SF-6D and WTP provide evidence against the guidelines issued in the UK that 
recommend the use of the extra-welfarist EQ-5D for use in all conditions.  
NICE recommend that measures other than EQ-5D should not be used without justification 
(NICE, 2008). Their list of recommendations for alternative methods to valuing outcomes is 
presented in Box 3.1 of Chapter 3. In this section a case against the use of EQ-5D and the 
subsequent suggested methods in the guidelines is presented, similar to the manner required 
by NICE to justify the use of an alternative method; 
1. Evidence of the limited psychometric properties and use of EQ-5D and SF-6D in 
menorrhagia have been presented in Chapter 5, suggesting that neither measure is able 
to fully capture the concerns and experiences of women with menorrhagia 
2. EQ-5D and SF-6D have provided conflicting evidence in an economic evaluation 
alongside a trial, reported in Chapter 6.  
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3. The use of an alternative generic multi-attribute utility instrument would not be 
suitable given that a value set using a UK population has not been generated. 
Furthermore, a condition-specific multi-attribute utility instrument cannot be used as 
one has not been developed for menorrhagia.  
4. Mapping from the condition-specific measure is unsuitable because the recommended 
measure that the condition-specific measure should be mapped on to is EQ-5D, which 
has been shown to have limited use in menorrhagia.  
There is a need for policy-makers to develop a standard framework for evaluating conditions 
where the benefits can lie beyond health, as EQ-5D and SF-6D are known to be problematic 
in these cases. The use of WTP in menorrhagia has been demonstrated. However, whilst the 
research in this thesis shows the feasibility of using WTP in menorrhagia, further research 
does need to be carried out within the area. Until additional evidence in support of WTP is 
available, it is recommended that a cost-consequence analysis be used as each measure is 
providing additional information that should be taken into consideration. Therefore, due to 
limited evidence, the recommended approach is neither a welfarist nor extra-welfarist 
approach, instead it is a decision-maker approach where decision-makers are presented with 
all of the relevant information that is currently available in a cost-consequence analysis, as 
shown in Table 10.1. Thereby enabling decision-makers to make decisions about resource 
allocation in menorrhagia with a more informed opinion.  
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Table 10.1 Presentation of a cost-consequence analysis 
Treatment EQ-5D SF-6D WTP  
(ex-ante) 
Cost 
LNG-IUS 1.580 1.198 365.08 430 
Usual treatment 1.513 1.200 371.67 330 
Difference 0.070 0.002 6.59 100 
Overall ICER: 1600 Dominates INB: -110 - 
Cost-effective 
treatment 
LNG-IUS Usual treatment Usual treatment - 
LNG-IUS; levonorgestrel-releasing intrauterine system, ICER; incremental cost-effectiveness ratio; WTP; 
willingness-to-pay 
 
10.7 Further Research Recommendations 
Further research is required in a number of areas to further advance the field. Whilst the 
feasibility of using WTP in menorrhagia has been shown, it is recognised that subsequent 
studies with larger sample sizes will need to be carried out to validate the findings. 
Additionally, it may be beneficial to carry out some in-depth interviews to determine the 
respondents understanding of the elicitation exercise. There are also still some methodological 
issues that need to be resolved before WTP will be implemented on a wider scale. The 
research around the methodology of WTP has shown that the WTP values are sensitive to the 
elicitation format and also to the use of an interview or questionnaire. Further, the sensitivity 
of WTP to the size of the good has also been questioned. Whilst sensitivity was shown in this 
thesis, the issue needs to be assessed on a wider scale. Even the method by which WTP 
should be assessed is debated i.e. whether it be through psychometric testing or whether 
theoretical validation is more important (O’Brien & Gafni, 1996). It is agreed amongst health 
economists that these differences exist but a framework has yet to be produced that outlines 
how to move forward within the area. For the use of WTP to progress in menorrhagia, and in 
other conditions, there first has to be in place a set of guidelines or recommendations for how 
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contingent valuation techniques should be used in health care, which analysts should follow. 
Without such guidelines, it will be difficult to convince decision-makers of the merits of WTP 
due to the methodological differences observed in studies.  
An alternative welfarist method, which is still in its infancy in health economics, could be 
considered in menorrhagia. The stated preference discrete choice experiment is gaining 
increased credibility for valuing outcomes. It appears to have so far received a more 
welcoming reception from health economists to the conventional contingent valuation method 
as WTP values can be elicited indirectly for changes in separate and in groups of attributes 
(Ryan & Gerrard, 2003). It has been argued to be able to overcome some of the shortfalls of 
direct elicitation of WTP (Hanley et al., 2001). However, methodological work does need to 
be carried out to establish this.   
Next steps for extra-welfarist measures include research into identifying the drivers behind 
the differences between the findings of SF-6D and EQ-5D. More in-depth analyses could be 
carried out to assess the sensitivity to change of EQ-5D and SF-6D compared to the disease-
specific measures MMAS. It would also be interesting to identify which domains on SF-6D 
are affected by the condition compared to the domains affected by EQ-5D by using the 
changes in response to changes in MMAS. Similarly, it will be important to assess whether a 
meaningful change in MMAS is reflected in both the extra-welfarist measures and whether 
this change is matched by the respondents’ report of general health.  
Further, as the EQ-5D-5L has now been developed (Herdman et al., 2011) to help overcome 
the issues with ceiling effects of the EQ-5D-3L, there may be scope for testing this measure 
against WTP, though the results are likely to be similar to those found here as the recall 
period remains the same and the non-health benefits are not captured. The amended EQ-5D 
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measure developed and briefly touched on in this thesis could also be more thoroughly 
assessed. Rather than using a recall period of ‘health today’, a period of ‘during your cycle is 
used’ to determine to what extent this change improves the sensitivity of the measure, as an 
amended EQ-5D is likely to be more readily accepted by decision-makers.  
 
10.8 Conclusion 
The aim of this thesis was to draw a comparison between welfarist and extra-welfarist 
approaches to valuing outcomes in menorrhagia. To meet this aim, first a CUA was carried 
out using the extra-welfarist measure EQ-5D and was re-estimated using SF-6D; second, a 
questionnaire was developed to elicit the welfarist WTP from an ex-ante and an ex-post 
perspective; and third a CBA was carried out using the WTP values from the ex-ante 
perspective. The findings between the alternative extra-welfarist measures were compared, 
and these, in turn, were compared with the CBA results. The success of the completion of 
WTP was also assessed. The key contributions of this thesis are that it has been demonstrated 
that in the case of a chronic condition, with episodic symptoms, current recommendations 
from decision-makers on which outcome measures should be used are not supported by 
evidence and this has significant implications for clinical practice. Two other measures, SF-
6D and WTP, did not support the findings of the recommended EQ-5D measure suggesting 
that it should not be used alone in this condition. A second contribution is that the potential 
for the use of the somewhat controversial welfarist WTP measure was also demonstrated, as it 
was shown to have an association with changes in the disease-specific measure whilst EQ-5D 
did not. Several concerns around the use of the EQ-5D and SF-6D extra-welfarist measures in 
menorrhagia have been shown. The feasibility of the use of the welfarist WTP also 
demonstrated. However, there is still much scope for further research to be carried out to 
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understand what aspects of QoL, if any, the current extra-welfarist measures are capturing, 
and to solidify the need to consider the use of a welfarist measure, such as WTP, in a 
condition like menorrhagia. 
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APPENDIX 1. SYSTEMATIC REVIEW OF ECONOMIC 
EVALUATIONS: SEARCH TERMS AND QUALITY ASSESSMENT 
OF STUDIES  
 
A1.1 Search Terms  
Ovid Medline  
 
1.  menorrhagia.mp. 
2.  exp Menorrhagia/  
3.  exp "cost"/  
4.  Cost$.mp.  
5.  heavy menstrual bleeding.mp.  
6.  HMB.mp.  
7.  1 or 2 or 5 or 6  
8.  economic$.mp. 
9.  exp economics/  
10.  exp "Costs and Cost Analysis"/  
11.  3 or 4 or 8 or 9 or 10  
12.  levonorgestrel releasing intrauterine system.mp.  
13.  LNG-IUS.mp.  
14.  exp tranexamic acid/  
15.  tranexamic acid.mp.  
16.  exp mefenamic acid/  
17.  mefenamic acid.mp.  
18.  exp progestogen/  
19.  norethisterone.mp.  
20.  progestogen.mp.  
21.  levonorgestrel intrauterine system.mp.  
22.  oral contraceptive.mp.  
23.  12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22  
24.  7 and 11 and 23  
25.  limit 24 to yr="2006 -Current" 
 
EMBASE 
1.  menorrhagia.mp. 
2.  exp Menorrhagia/  
3.  exp "cost"/  
4.  Cost$.mp.  
5.  heavy menstrual bleeding.mp.  
6.  HMB.mp.  
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7.  1 or 2 or 5 or 6  
8.  economic$.mp  
9.  exp economics/  
10.  exp "Costs and Cost Analysis"/  
11.  3 or 4 or 8 or 9 or 10  
12.  levonorgestrel releasing intrauterine system.mp.  
13.  LNG-IUS.mp. 
14.  exp tranexamic acid/ 
15.  tranexamic acid.mp.  
16.  exp mefenamic acid/  
17.  mefenamic acid.mp.  
18.  exp progestogen/  
19.  norethisterone.mp.  
20.  progestogen.mp.  
21.  levonorgestrel intrauterine system.mp.  
22.  oral contraceptive.mp.  
23.  12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22  
24.  7 and 11 and 23  
25.  limit 24 to yr="2006 -Current" 
 
PsychInfo 
1. menorrhagia.mp. 
2. Cost$.mp.  
3. heavy menstrual bleeding.mp.  
4. HMB.mp.  
5. 1 or 3 or 4   
6. economic$.mp  
7. exp economics/  
8. exp "Costs and Cost Analysis"/  
9. 2 or 6 or 7 or 8  
10. levonorgestrel releasing intrauterine system.mp.  
11. LNG-IUS.mp.  
12. tranexamic acid.mp.  
13. mefenamic acid.mp.  
14. norethisterone.mp.  
15. progestogen.mp.  
16. levonorgestrel intrauterine system.mp. 
17. oral contraceptive.mp.  
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17  
19. 5 and 9 and 18  
20. limit 19 to yr="2006 -Current" 
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Science Citation Index And Social Science Citation Index (Web of Science) 
1. TS= (Menorrhagia OR “heavy menstrual bleeding” OR HMB)  
2. TS= (Cost$ OR "Cost analysis" OR economic$)  
3. TS=("Levonorgestrel releasing intrauterine system" OR "Levonorgestrel intrauterine system" 
OR "LNG-IUS" OR "tranexamic acid" OR "mefenamic acid" OR "Oral contraceptive" OR 
progestogen OR norethisterone)  
4. #3 AND #2 AND #1  
 
DARE and NHS EED (Cochrane library) 
1. MeSH descriptor: [Costs and Cost Analysis] explode all trees  
2. MeSH descriptor: [Menorrhagia] explode all trees 
3. MeSH descriptor: [Economics] explode all trees 
4. MeSH descriptor: [Tranexamic Acid] explode all trees 
5. MeSH descriptor: [Mefenemaic Acid] explode all trees 
6. MeSH descriptor: [Contraceptives, Oral] explode all trees 
7. MeSH descriptor: [Progestins] explode all trees 
8. Levonorgestrel releasing intrauterine system:ti,ab.kw (Word variations have been searched) 
9. Levonorgestrel intrauterine system: ti,ab.kw (Word variations have been searched) 
10. LNG-IUS: ti,ab.kw (Word variations have been searched) 
11. Mefenamic acid or tranexamic acid or oral contraceptive$ or progestogen or norethisterone: 
ti,ab.kw (Word variations have been searched) 
12. HMB or heavy menstrual bleeding: ti,ab.kw (Word variations have been searched) 
13. Cost$ or economic$: ti,ab.kw (Word variations have been searched) 
14. (#2 or #12) and (#1 or #3 or #13) and (#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11) From 
2006-2013, in other reviews and economics evaluations  
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A1.2 Assessment of quality of studies included in systematic review of economic evaluations in menorrhagia 
Study (Country) Assessment of quality 
You et al 2006  
(Hong Kong) 
 The cycle length of one year is not suitable – does not capture all relevant changes in QoL and resource use 
 Used median utility values -  mean is deemed to be more suitable as it accounts for all individuals equally (Roberts et al., 2011) 
 Data source for utility values – Hong Kong study using UK utility values – TTO using patient values 
 Reason for using triangular distribution in the PSA instead of more typically observed distribution was not specified 
Brown et al 2006 
(New Zealand) 
 A decision tree was used – does not allow for recurrent events which are required given the chronic nature of the condition 
 No QALYs reported  
 Uncertainty not comprehensively assessed – a PSA was not carried out, particularly important given small sample size of study (n=70) 
 Data on QoL was collected at baseline and 24 months only – due to the non-curative nature of the non-surgical treatments this frequency 
is insufficient to capture changes in QoL. Despite resource use being captured at 3, 12 and 24 months there was no explanation for not 
collecting QoL  
Clegg et al 2007 
(UK) 
 Combined TTO using patient values and EQ-5D valuation methods in the same analysis – different valuation methods provide different 
results. Additionally, TTO was valued using patient values and EQ-5D was valued using general population values, the utilities are not 
comparable 
 Combined utility values from UK (TTO) and Finland (EQ-5D) in the same analysis – utility value sets are not transferable across 
countries and a combination is likely to result in a poor evaluation 
 Used a combination of mean and median utility values in the same analysis– mean is deemed to be more suitable as it accounts for all 
individuals equally. The use of both without justification indicates a poor assessment of the data sources 
 Where unavailable utility values were estimated from other states – some estimation methods are unclear 
 Used rates and outcomes for hysterectomy from Finnish study, despite acknowledging that the use of hysterectomy in UK clinical 
practice is no longer recommended or as commonly used as the time the study was carried out.  
NICE 2007 
(UK) 
 A comprehensive assessment of uncertainty of results was not carried out, which is particularly important given the poor data used. Only 
a one-way sensitivity analysis was carried out, not a PSA 
 Based on Finnish study and used these utility values for a UK population – the value sets are not transferable 
 No direct comparisons of treatments were carried out, despite the use of a decision model – incremental differences need to be assessed to 
determine which treatment is most cost-effective relative to another 
 Two treatments, oral and injected progestogen, were recommended for clinical practice without any evidence of cost-effectiveness 
Roberts et al 2011 
(UK) 
 Combined TTO using patient values and EQ-5D valuation methods in the same analysis – different valuation methods provide different 
results. Additionally, TTO was valued using patient values and EQ-5D was valued using general population values, the utilities are not 
comparable 
 Combined utility values from UK (TTO) and Finland (EQ-5D) in the same analysis – utility value sets are not transferable across 
countries and a combination does not produce a robust evaluation 
However, a comprehensive assessment of uncertainty associated with the model inputs was carried out in the PSA 
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Study (Country) Assessment of quality 
Lete et al 2011 
(Spain) 
 Claimed to use EQ-5D because it is validated, but actually used TTO from Sculpher (1998) study which was based on patient values – 
limits credibility and confidence in the analysis 
 TTO values taken from the UK population for a Spanish study – utility value sets are not transferable across countries 
 Used median utility values -  mean is deemed to be more suitable as it accounts for all individuals equally 
 Six month cycle for model  is not suitable- does not capture all associated changes in QoL and resource use 
 PSA distribution was not specified for utilities – given the utility data used was also from a different country it is particularly important to 
assess uncertainty, using a PSA, in the utility data 
 
Ganz et al 2013 
(US) 
 Utilities were taken from a Finnish study that used EQ-5D for a US population - utility value sets are not transferable across countries  
 Data comes from women who have at baseline bleeding greater than 80ml per cycle – Population group does not reflect current women 
who are treated with menorrhagia as an objective assessment of blood loss is no longer considered suitable.  
 Probabilities of treatment success of oral and LNG-IUS were taken from studies that recruited women who were bleeding in excess of  
80ml and utilities were taken from the Finnish study which did not use the objective assessment – utilities may differ between those who 
subjectively complain of menorrhagia and those who are objectively bleeding in excess of 80ml per cycle. Women who bleed in excess of 
80ml are also likely to suffer with anaemia which may impacts QoL and the probabilities of treatment success may not be the same for 
those who bleed in excess compared to those recruited due to a subjective assessment of impact on QoL 
 Applied utility for successful LNG-IUS to all treatments – LNG-IUS is likely to be associated with a higher utility value than other 
treatments because it stops bleeding whereas others only reduce bleeding hence assuming utility for successful LNG-IUS is the same for 
all treatments is not a suitable assumption 
LNG-IUS; levonorgestrel-releasing intrauterine system, PSA; probabilistic sensitivity analysis, QoL; quality of life, TTO; Time trade off.  
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APPENDIX 2. SYSTEMATIC REVIEW OF OUTCOME MEASURES: 
SEARCH TERMS AND DATA EXTRACTION TABLES 
 
A2.1 Search Terms 
Ovid Medline 
1. exp Menorrhagia/  
2. Menorrhagia.mp. 
3. Heavy menstrual bleeding.mp. 
4. HMB.mp. 
5. exp questionnaires/ 
6. questionnaire$.mp. 
7. exp quality of life/ 
8. quality of life.mp. 
9. QoL.mp. 
10. Exp Outcome assessment (Healthcare)/  
11. Outcome assessment.mp. 
12. Exp psychological test/ 
13. Psychological test$  
14. Exp Interview, Psychological/ 
15. Interview$  
16. Exp psychometrics/ 
17. Psychometric$ 
18. 1 or 2 or 3 or 4 
19. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
20. 18 and 19 
21. Limit 20 to (humans and female) 
 
Source – EMBASE Classic + EMBASE (Ovid)  
1. exp menorrhagia/  
2. menorrhagia.mp.  
3. heavy menstrual bleeding.mp. 
4. HMB.mp.  
5. exp questionnaire/  
6. questionnaire$.mp.  
7. exp "quality of life"/   
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8. quality of life.mp.  
9. QoL.mp.  
10. exp outcome assessment/  
11. outcome assessment.mp.  
12. exp psychologic test/   
13. psychological test$.mp.   
14. exp interview/   
15. interview$.mp.    
16. exp psychometry/    
17. psychometric$.mp.    
18. 1 or 2 or 3 or 4     
19. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17   
20. 18 and 19     
21. limit 20 to (human and female)   
 
CINAHL Plus Cumulative Index to Nursing, Allied Health Literature (EBSCO) 
1. (“MH “Menorrhagia”) OR Menorrhagia OR heavy menstrual bleeding OR HMB  
2. ("MH "Psychological Tests+) OR (MH "Questionnaires+") OR "questionnaire* OR (MH 
"Quality of Life+") OR (psychological test*) OR MH "Outcome Assessment") OR (outcome 
assessment) OR psychometric* OR (MH "Interviews+") OR interview* OR (MH 
"Psychometrics") OR QoL" 
3. #1 AND #2 
4. Limit 3 to Human and Female 
 
Source – PsycInfo (Ovid) 
1. Menorrhagia.mp.  
2. heavy menstrual bleeding.mp.  
3. HMB.mp.  
4. exp Questionnaires/  
5. questionnaire$.mp.  
6. exp "Quality of Life"/  
7. quality of life.mp.  
8. QoL.mp.  
9. outcome assessment.mp.  
10. exp Psychometrics/  
11. psychometric$.mp.  
12. psychological test$.mp.  
13. interview$.mp.  
14. exp interviews/  
15. 1 or 2 or 3  
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16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  
17. 15 and 16  
18. limit 17 to (human and female)  
 
Source – Science Citation Index (Web of Science) 
1. TS= (Menorrhagia OR “heavy menstrual bleeding” OR HMB) 
2. TS=(questionnaire$ OR QoL OR "quality of life" OR "outcome assessment" OR 
"psychological test$" OR interview$ OR psychometric$) 
3. 1 AND 2 
 
Source – Social Science Citation Index (Web of Science) 
1. TS= (Menorrhagia OR “heavy menstrual bleeding” OR HMB) 
2. TS=(questionnaire$ OR QoL OR "quality of life" OR "outcome assessment" OR 
"psychological test$" OR interview$ OR psychometric$) 
3. 1 AND 2 
 
NHS EED National Health Service Economic Evaluation Database (Cochrane Library –
Wiley)  
1. interview OR psychometric in Technology Assessments and Economic Evaluations  
2. questionnaire OR QoL OR quality of life OR outcome assessment OR psychological test in 
Technology Assessments and Economic Evaluations  
3. heavy menstrual bleeding OR HMB OR menorrhagia in Technology Assessments and 
Economic Evaluations  
4. MeSH descriptor Menorrhagia explode all trees  
5. MeSH descriptor Questionnaires explode all trees  
6. MeSH descriptor Quality of Life explode tree 1   
7. MeSH descriptor Outcome Assessment (Health Care) explode all trees  
8. MeSH descriptor Psychological Tests explode all trees  
9. MeSH descriptor Interviews as Topic explode all trees  
10. MeSH descriptor Psychometrics explode all trees  
11. (( #3 OR #4 ) AND ( #1 OR #2 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 ))  
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Source – HTA Health Technology Assessment (Cochrane Library –Wiley)  
1. interview OR psychometric in Technology Assessments and Economic Evaluations  
2. questionnaire OR QoL OR quality of life OR outcome assessment OR psychological test in 
Technology Assessments and Economic Evaluations  
3. heavy menstrual bleeding OR HMB OR menorrhagia in Technology Assessments and 
Economic Evaluations  
4. MeSH descriptor Menorrhagia explode all trees  
5. MeSH descriptor Questionnaires explode all trees  
6. MeSH descriptor Quality of Life explode tree 1  
7. MeSH descriptor Outcome Assessment (Health Care) explode all trees  
8. MeSH descriptor Psychological Tests explode all trees  
9. MeSH descriptor Interviews as Topic explode all trees  
10. MeSH descriptor Psychometrics explode all trees  
11. (( #3 OR #4 ) AND ( #1 OR #2 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 ))  
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A2.2 Results (Data Extraction) Tables  
Table 1. Study characteristics for economic measures that have been assessed for psychometric properties 
Study Comparator 
Measure assessed Psychometric property assessed 
Comment 
SF-36 EQ-5D MMAS WTP other Validity Sensitivity Reliability 
Clark & 
Gupta 2004 
Thermal 
balloon 
ablation  
 ✓ ✓    ✓  MMAS was statistically significantly associated with 
satisfaction (p=0.001), whilst EQ-5D was not (p=0.08). 
Coulter et al 
1994 
 
Surgery vs. 
non-surgery 
 
✓    ✓  ✓   Other measures: social impact (SI) score & satisfaction. 
 Improvement in QoL is generally reflected across all 
questionnaires.  
 Discrepancies were seen in menorrhagia specifically. SI shows 
moderate improvement for no surgery group, SF-36 shows a 
small improvement in 2 domains only 
 Those satisfied with treatment and with moderate menorrhagia, 
showed improved SI scores on social functioning and energy 
in SF-36. With Little to no influence on general health status. 
The attributes general health, role physical and physical 
functioning either showed a small change or no difference. 
Garratt et al 
1993 
 
4 conditions 
vs. general 
population 
 
✓     ✓  ✓  In a group of patients with 4 different conditions assessed 
reliability through internal consistency (cronbach’s alpha); 
validity through confirmatory factor analysis; & construct 
validity 
 For all conditions together, internal consistency of SF-36 was 
observed on all 8 scales. Factor analysis confirmed relevance 
of 8 scales: Physical functioning was most relevant in the 
group with 4 conditions. For menorrhagia specifically physical 
functioning was not statistically significantly different to the 
general population. 
Garratt et al 
1994 
 
General 
population 
vs. 4 
conditions 
 
✓      ✓   In line with responses to SF-36 transition question mean 
improvements in all health states were observed. 
 Discrepancies were seen in menorrhagia specifically.  
 For the answer my health is much better: large improvements 
were observed on SF-36 for pain, energy, role physical, social 
functioning domains, moderate responses were observed for 
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Study Comparator 
Measure assessed Psychometric property assessed 
Comment 
SF-36 EQ-5D MMAS WTP other Validity Sensitivity Reliability 
the remaining attributes except physical functioning which was 
small.  
 For the answer my health is somewhat better: the pain, energy, 
role physical, social functioning domains showed a moderate 
improvement (social and energy were borderline), the 
remaining domains showed a small improvement.  
 For the answer my health is the same: a small change was 
observed for pain, energy, role physical, social functioning 
domains 
 For the answer my health is somewhat worse: a small decrease 
was observed in for physical functioning, energy, role 
physical, social functioning domains. The general health 
attribute improved to moderate.  
 For my health is worse: a moderate reduction was observed for 
2 attributes, and the reductions were small for the remaining 
attributes. General health reduced to negative-small and pain 
improved 
Gokyildiz 
et al 2013 
Menorrhagia 
population 
vs. 
population 
without 
disease 
✓      ✓  Adapted to Turkish scale. All domains of the SF-36 are 
significantly different in the menorrhagia population compared 
to the population without a condition 
Habiba et al 
2010 
 
SF-36 (MCS 
& PCS) vs. 
MMAS 
 
✓  ✓       Many women may find SF-36 inappropriate or difficult to 
answer – face validity is questioned 
 MCS/PCS were not statistically significantly improved even 
though some dimensions of SF-36 were significant. Therefore 
authors argue PCS/MCS scoring procedure may not accurately 
summarise subscales  
 A statistically significant improvement in SF-36 was observed 
in MCS only and MMAS. At baseline statistically significant 
association in MMAS and need for surgery. This association 
was observed for the SF-36 attributes role physical, pain, 
social functioning and mental health - but not for PCS or 
MCS. 
Hehenkamp 
et al 2008 
UAE vs. 
hysterectomy 
✓ ✓   ✓    Other measure: HUI3. 
The SF-36 MCS was more sensitive than the PCS as it was 
significantly associated with patient satisfaction (p=0.01), 
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Study Comparator 
Measure assessed Psychometric property assessed 
Comment 
SF-36 EQ-5D MMAS WTP other Validity Sensitivity Reliability 
whilst the PCS was not (p=0.191). Significant differences in 
QoL between treatment groups were observed in the PCS only.  
Jenkinson 
et al 1996 
 
Results vs. 
general 
population 
 
✓     ✓  ✓  Interviews revealed that women are unsure whether to 
complete for general health or periods. Therefore issues with 
face validity. Cyclical symptoms leads to ambiguity with 
questions with time frames.  
 Mental health, general health and social functioning showed 
lower internal reliability than Oxford general population, 
especially mental health and general health 
 
Pattison et 
al 2011 
 
LNG-IUS vs. 
oral treatment 
 
✓ ✓ ✓   ✓    Overall score for EQ-5D had a poor correlation with MMAS. 
MMAS was shown to have face validity, convergent & 
discriminant validity, and test retest reliability. 
 Authors stated general health and Physical functioning 
attributes of SF-36 are heavily weighted to mobility and self-
care which are not affected by menorrhagia, which are 
inappropriate items on SF-36. General health and EQ-5D were 
argued not to be precise enough to measure differences in 
patient groups  as they refer to general condition rather than 
cycle 
Ruta et al 
1994 
 
general 
population 
vs. 4 
conditions 
✓       ✓ Assessed reliability through internal consistency using 
cronbach's alpha & test re-test. Found to be reliable for groups 
of patients only not individual patient management 
Ryan et al 
2000 
 
conservative 
vs. 
hysterectomy
: preference 
& WTP 
   ✓    ✓ Inconsistent responses (30%) between treatment preference and 
maximum WTP 
Shaw et al 
1998 
Development 
& assessment 
  ✓   ✓   Main areas of concern: physical health, psychological health, 
family, social, work life, practical difficulties. The attributes ‘ 
Family life/relationships’ and ‘Physical health and wellbeing’ 
were given the greatest weightings 
4 conditions - group of back pain, varicose veins, peptic ulcers, menorrhagia 
 
HUI3; Health Utility Index mark 3, LNG-IUS; levonorgestrel-releasing intrauterine system, MCS; mental composite scale, MMAS; menorrhagia multi-attribute scale, PCS; physical composite 
scale, QoL; quality of life, WTP; willingness-to-pay. 
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Table 2. Study characteristics for economic measures in an economic evaluation or cost study 
Study Comparator 
Economic measure Non-economic measure Comment 
SF-36 EQ-5D VAS other PBAC 
Ruta 
scale 
Satis-
faction 
Anx & 
dep 
other 
 
Brown et al 2006 LNG-IUS vs TBEA ✓    ✓     
Authors comments:SF-36 is insensitive. WTP 
should be used instead. (cost study) 
Frick et al 2009 Hysterectomy vs EA ✓ ✓ ✓   ✓    Cost study 
Hurskainen et al 
2001 
LNG-IUS vs 
Hysterectomy 
 ✓ ✓ ✓   ✓ ✓ ✓ 
EQ-5D was the primary outcome – validated 
and universally accepted.  Affect on sexual life 
was the other non-economic measure.  
5 yr follow-up:  
Hurskainen et al 2004 
          
Kennedy et al 
2003 
Decision aid: 
interview vs leaflet vs 
control 
✓ ✓    ✓ ✓ ✓  
Authors comments: All dimensions on SF-36 
were unlikely  to show a difference between 
groups, but  generic measures allow 
comparisons across studies. validated and 
universally accepted 
Kilonzo et al 
2010 
MEA vs TBEA  ✓        
Authors comments: Sensitivity of EQ-5D in 
menorrhagia is questionable 
Sculpher et al 
1993 
TCRE vs 
hysterectomy 
  ✓    ✓   
A formal economic evaluation was not carried 
out. Costs and outcomes were presented 
separately 
2 yr follow-up: 
Sculpher et al 
1996 
ER vs hysterectomy ✓  ✓    ✓   SF-36 validated and universally accepted 
Sculpher, 1998 
Hysterectomy vs 
TCRE 
   ✓      
TTO used. Authors comments: Menorrhagia is a 
chronic, episodic, condition and QoL results will 
be dependent on the timing of assessment. TTO 
widely used 
tai pale et al 
2009 
Hysterectomy vs no 
treatment  
   ✓      Utilities were derived using 15D 
Van der wilt et al 
2005 
Blood loss chart vs no 
chart 
✓    ✓    ✓ 
Menorrhagia severity index. SF-36 domains: 
physical functioning, vitality, pain, health 
perception - validated  
Vuorma et al 
2004 
Decision aid booklet   ✓ ✓   ✓ ✓ ✓ 
RAND-36: universally accepted. Other sex and 
inconvenience 
Anx & dep; anxiety and depression, EA; Endometrial ablation, ER; endometrial resection, LNG-IUS; Levonorgestrel intrauterine system, MEA; Microwave endometrial ablation, PBAC; Pictorial 
blood assessment chart, QoL; quality of life, TBEA; Thermal balloon endometrial ablation, TCRE; Transcervical resection of the endometrium, TTO; time trade off, WTP; willingness-to-pay. 
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Table 3. Study characteristics for economic measures as a primary outcome in an effectiveness study 
Study Comparator 
Economic measure Non-economic measure 
Comments 
SF-36 EQ-5D VAS other PBAC 
Satis-
faction 
Dep & 
Anx 
other 
Bongers et al 2005 
Balloon EA vs Bipolar 
EA 
✓      ✓ ✓ 
Authors comments: SF-36: insensitive to treatment 
effect & difficult to answer. Other non-economic 
measure: Structured clinical history questionnaire 
&Rotterdam Symptom Checklist 
Busfield et al: main 
study for Brown 
LNG-IUS vs TBEA ✓    ✓ ✓  ✓ 
Other non-economic measures: questions on menstrual 
symptoms 
De Souza et al 
2010 
Effect on QoL ✓    ✓   ✓ 
SF-36 Mental composite scale and physical composite 
scale considered separately. Non-economic other: 
haemoglobin levels 
Gorgen et al 2008 LNG-IUS   ✓  ✓   ✓ 
Authors comments: VAS is too simplistic. Other non-
economic measure: Daily life, libido, pain 
kupperman et al 
2004 
Hysterectomy vs 
medical treatment 
✓  ✓     ✓ 
SF-36 Mental composite scale and physical composite 
scale considered separately. Other non-economic 
measure: sexual functionings, sleep problems 
Matsumoto et al 
2007 
Combined oral 
contraceptive 
   ✓     Other economic measure: WHO-QoL 
Olah et al 2005 EA   ✓°       
Shawki et al 2009 LNG-IUS  ✓   ✓    
Authors comments: EQ-5D is appropriate – changes in 
blood loss were reflected in EQ-5D 
Dep & Anx; depression and anxiety, EA; endometrial ablation, LNG-IUS; Levonorgestrel intrauterine system, PBAC; pictorial blood assessment chart, QoL; quality of life, TBEA; thermal balloon 
endometrial ablation, VAS; visual analogue scale. 
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Table 4. Study characteristics for economic measures as secondary outcomes in effectiveness studies 
Study Comparator 
Economic measures Non-economic measures 
Comments 
SF-
36* 
EQ-5D VAS other PBAC 
Satis-
faction 
Anx & 
dep 
MMA
S 
other 
Abbott et al 2003 
TBEA vs. Bipolar 
EA 
✓ ✓ ✓  ✓ ✓   ✓ Other non economic measure: sexual life 
Chadha et al 
2000 
effectiveness of 
national guidelines 
✓        ✓ 
Authors comments: The only domains of SF-36 that are 
most likely to show a change are general health, role 
physical, mental health, social functioning. Other non-
economic: condition specific questions 
Clark et al 2011 
Bipolar EA vs. 
TBEA 
 ✓ ✓   ✓  ✓ ✓ 
Other non-economic measures: Amenorrhoea, 
acceptability, menorrhagia outcomes questions, sexual 
activity 
Cooper et al 
1997 
Med treatment vs. 
TR 
✓      ✓  ✓ 
Other non economic measures: Clinical questions, 
Bleeding and Pain Score 
2 yr follow-up: Cooper et al 1999           
5 yr follow-up: Cooper et al 2001           
Cooper et al 
1999 
MEA vs TCRE ✓     ✓   ✓ 
Authors comments: Health related QoL should be used as 
definitive indicator of treatment success. Other non-
economic measures: Acceptability (bleeding and pain) 
2 yr follow-up: Bain et al 2002 ✓     ✓   ✓  
5 yr follow-up: Cooper et al 2005 ✓     ✓   ✓  
10 yr follow-up: Sambrook et al 2009 ✓     ✓  
 
✓  
Cooper et al 
1997 
preference based vs 
non-preference 
based treatment 
✓      ✓  ✓ Other non-economic clinical questions 
Crosignani et 
al1997 
ER vs hysterectomy ✓     ✓ ✓  ✓ Other non-economic measure: impact on sexual life 
Crosignani et 
al1997 
ER vs LNG-IUS ✓    ✓ ✓     
Davis et al 2000 
Oral contraceptive 
vs placebo 
✓    ✓    ✓ 
Authors comments: SF-36: Physical health domain is most 
likely to be affected (self-care walking climbing stairs). 
Other non-economic condition-specific clinical 
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Dickersin et al 
2007 
Hysterectomy vs EA  ✓       ✓ 
Other non-economic measures: bleeding, pain, fatigue, 
sexual function, employment, housework, leisure activities 
Edwards et al 
2004 
SDM vs risk 
communication 
skills 
✓   ✓  ✓ ✓   Other economic measure: Comrade questionnaire 
Gupta et al 2013 
LNG-IUS vs usual 
medical treatment 
✓ ✓ ✓     ✓ ✓ 
Other non-economic measure: sexual activity 
questionnaire 
Hawe et al 2003 
TBEA vs YAG 
Laser 
✓ ✓ ✓   ✓   ✓ 
EQ-5D was lower at baseline in one arm compared to 
another, this was not reflected in SF-12. SF-12 or SF-36: 
MCS and PCS separately. Other non-economic measures: 
Amenorrhoea, acceptability and sexual activity 
Van der Kooji et 
al 2010 
(Hehenkamp 
follow-up) 
UAE vs 
hysterectomy 
✓    ✓ ✓  
 
 
Other non-economic measures: elimination of 
menorrhagia., sexual activity, body image,  
Helal et al 2011 TBEA   ✓   ✓   ✓ Other non-economic measures: volume of blood loss 
Henshaw et al 
2002 
MEA vs LNG-IUS ✓     ✓   ✓ Other non-economic measures: acceptability 
5 year follow up 
to Bongers: 
Kleijn et al 2007 
LNG-IUS vs ER ✓     ✓     
Malak & Shawki 
2006 
decision aid   ✓  ✓     
EQ -VAS: Well-being, work performance, physical and 
sexual activity 
Protheroe et al 
2007 
TBEA vs MEA       ✓ ✓ ✓ Other non-economic measures: decision conflict scale 
Ramazanzadeh et 
al 2012 
LNG-IUS vs copper 
IUD 
✓     ✓   ✓ Other non-economic measures: menstrual history 
Sambrook et al 
2009 
Bipolar EA vs 
Balloon EA 
✓ ✓ ✓  ✓ ✓ ✓  ✓ Other non economic measure: pain 
Samuel et al 
2009 
outpatient EA vs 
inpatient EA 
     ✓  ✓ ✓ Other non economic measure: general health 
*SF-36 or SF-12. Dep & Anx; depression and anxiety, EA; endometrial ablation, ER; endometrial resection, IUD; intrauterine device, LNG-IUS; Levonorgestrel intrauterine system, MEA; 
microwave endometrial ablation, MMAS; menorrhagia multi-attribute scale, PBAC; pictorial blood assessment chart, QoL; quality of life, SDM; shared decision making, TBEA; thermal balloon 
endometrial ablation, TCRE; Transcervical resection of the endometrium, TR; transcervical resection, UAE; uterine artery emboliszation, VAS; visual analogue scale. 
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APPENDIX 3. ECONOMIC EVALUATION ALONGSIDE ECLIPSE 
TRIAL: CHEERS GUIDELINES AND EXAMPLE OF DATA 
MANAGEMENT 
 
A3.1 CHEERS Guidelines for Reporting Economic Evaluations 
Section/item 
Item 
No Recommendation 
 Title and abstract 
Title 1 Identify the study as an economic evaluation or use more specific terms such 
as “cost-effectiveness analysis”, and describe the interventions compared. 
 
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods 
(including study design and inputs), results (including base case and 
uncertainty analyses), and conclusions. 
 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the broader context for the study.  
Present the study question and its relevance for health policy or practice 
decisions. 
 
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and subgroups analysed, 
including why they were chosen. 
 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be 
made. 
 
Study perspective 6 Describe the perspective of the study and relate this to the costs being 
evaluated. 
 
Comparators 7 Describe the interventions or strategies being compared and state why they 
were chosen. 
 
Time horizon 8 State the time horizon(s) over which costs and consequences are being 
evaluated and say why appropriate. 
 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say 
why appropriate. 
 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of benefit in the 
evaluation and their relevance for the type of analysis performed. 
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Section/item 
Item 
No Recommendation 
 Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design features of the single 
effectiveness study and why the single study was a sufficient source of 
clinical effectiveness data. 
 
11b Synthesis-based estimates: Describe fully the methods used for identification 
of included studies and synthesis of clinical effectiveness data. 
 
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used to elicit preferences 
for outcomes. 
 
Estimating resources 
and costs 
13a Single study-based economic evaluation: Describe approaches used to 
estimate resource use associated with the alternative interventions. Describe 
primary or secondary research methods for valuing each resource item in 
terms of its unit cost. Describe any adjustments made to approximate to 
opportunity costs. 
 
13b Model-based economic evaluation: Describe approaches and data sources 
used to estimate resource use associated with model health states. Describe 
primary or secondary research methods for valuing each resource item in 
terms of its unit cost. Describe any adjustments made to approximate to 
opportunity costs. 
 
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities and unit costs. Describe 
methods for adjusting estimated unit costs to the year of reported costs if 
necessary. Describe methods for converting costs into a common currency 
base and the exchange rate. 
 
Choice of model 15 Describe and give reasons for the specific type of decision-analytical model 
used. Providing a figure to show model structure is strongly recommended. 
 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-
analytical model. 
 
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include 
methods for dealing with skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to validate or make 
adjustments (such as half cycle corrections) to a model; and methods for 
handling population heterogeneity and uncertainty. 
 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions 
for all parameters. Report reasons or sources for distributions used to 
represent uncertainty where appropriate. Providing a table to show the input 
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Section/item 
Item 
No Recommendation 
 values is strongly recommended. 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main categories of 
estimated costs and outcomes of interest, as well as mean differences 
between the comparator groups. If applicable, report incremental cost-
effectiveness ratios. 
 
Characterising 
uncertainty 
20a Single study-based economic evaluation:Describe the effects of sampling 
uncertainty for the estimated incremental cost and incremental effectiveness 
parameters, together with the impact of methodological assumptions (such as 
discount rate, study perspective). 
 
20b Model-based economic evaluation: Describe the effects on the results of 
uncertainty for all input parameters, and uncertainty related to the structure of 
the model and assumptions. 
 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-effectiveness that 
can be explained by variations between subgroups of patients with different 
baseline characteristics or other observed variability in effects that are not 
reducible by more information. 
 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how they support the conclusions 
reached. Discuss limitations and the generalisability of the findings and how 
the findings fit with current knowledge. 
 
Other 
Source of funding 23 Describe how the study was funded and the role of the funder in the 
identification, design, conduct, and reporting of the analysis. Describe other 
non-monetary sources of support. 
 
Conflicts of interest 24 Describe any potential for conflict of interest of study contributors in 
accordance with journal policy. In the absence of a journal policy, we 
recommend authors comply with International Committee of Medical Journal 
Editors recommendations. 
 
For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement 
checklist 
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A3.2 – Example of Data Management 
 
 
 
For example in column F it can be seen that patient 1002 (row 3) changed to usual medical treatment during cycle 14. Then column E 
shows that the same patient stopped treatment altogether at cycle 16. 
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APPENDIX 4. WILLINGNESS TO PAY METHODS: SCENARIOS, 
QUESTIONNAIRES AND INTERVIEW TOPIC GUIDE 
 
A4.1 MMAS questionnaire weightings 
 
 
1. Practical difficulties 
1. I have no practical difficulties, bleed no more than I expect and take no extra precautions.   14.0 
3. I have to carry extra sanitary protection and clothes because of the risk of flooding.    9.4 
2. I have to carry extra sanitary protection with me but take no other precautions.    3.1 
4. I have severe problems with flooding, soil the bedding and need to be close to a toilet.    0 
 
2. Social life 
1. My social life is unaffected during my cycle. I can enjoy life as much as usual.   10.0 
2. My social life is slightly affected during my cycle. I may have to cancel or modify my plans.  6.7 
3. My social life is limited during my cycle. I rarely make any plans.     2.7 
4. My social life is devastated during my cycle. I am unable to make any plans.    0 
 
3. Psychological health 
1. During my cycle I have no worries I can cope normally.      14.0 
2. During my cycle I experience some anxiety and worry.      8.4 
3. During my cycle I often feel down and worry about how I’ll cope     2.9 
4. During my cycle I feel depressed and cannot cope.      0 
 
4. Physical health and wellbeing 
1. During my cycle I feel well and relaxed. I am not concerned about my health.   21.0 
2. During my cycle I feel well most of the time. I am a little concerned about my health.   14.9 
3. During my cycle I often feel tired and do not feel especially well. 1 am concerned about my health. 4.2 
4. During my cycle I feel very tired and do not feel well at all. I am seriously concerned about my health. 0 
 
5. Work/ daily routine 
1. There are no interruptions to my work/daily routine during my cycle.    18.0 
2. There are occasional disruptions to my workldaily routine during my cycle.    11.3 
3. There are frequent disruptions to my work/daily routine during my cycle    4.1 
4. There are severe disruptions to my WorMdaily routine during my cycle.    0 
 
6. Family life/relationships 
1. My family life/relationships are unaffected during my cycle.     23.0 
2. My family life/relationships suffer some strain during my cycle.     14.0 
3. My family life/relationships suffers quite a lot during my cycle.     5.3 
4. My family life/relationships are severely disrupted as a result of my cycle.    0 
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A4.2 Ex-ante questionnaire 
 
 
 
Currently there are two possible ways of treating heavy menstrual bleeding (heavy periods) and we 
need to decide which is better. Although you may not personally experience heavy menstrual 
bleeding it is important to identify the views of women on the value of different treatment options. 
 
We would be most grateful if you could complete the enclosed questionnaire. It should take no 
longer than 10 minutes to complete. Once completed please return the questionnaire using the 
stamped addressed envelope provided. 
 
The questionnaire has two sections. The first section presents you with a scenario of heavy menstrual 
bleeding and will ask you about how much you would value different treatments for heavy menstrual 
bleeding. The second section will ask you some general questions about yourself.  
 
There are no right or wrong answers. We are just interested in your views.  
Please answer all the questions even if some may seem repetitive or less relevant, as it is 
important to get complete information. 
 
The questionnaire is anonymous. 
Your answers will remain confidential. 
If you have any queries about completing this questionnaire do not hesitate to contact: 
Miss Sabina Sanghera 
Health Economics Unit 
Public Health Building 
University of Birmingham 
Birmingham 
B15 2TT 
 
 
 
Thank you for your participation in this study. 
Study ID      
Please check that you have answered each question 
WOMENS’ VALUES OF TREATMENT FOR 
HEAVY MENSTRUAL BLEEDING 
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Section 1: Valuing treatments for heavy menstrual bleeding 
 
TAKE YOUR TIME TO READ THE DESCRIPTIONS BELOW 
 
The descriptions explain the experience of heavy menstrual bleeding (heavy periods) and the two 
treatment options.  
 
Please imagine that you start having heavy periods from tomorrow, and what is described to you 
below is what you will experience up until the change (menopause). 
 You have to carry extra sanitary protection and clothes because of the risk of flooding 
 Your social life is slightly affected during your cycle. You may have to cancel or modify your 
plans 
 During your cycle you experience some anxiety and worry 
 During your cycle you often feel tired and do not feel especially well. You feel concerned about 
your health  
 There are frequent disruptions to your work/daily routine during your cycle 
 Your family life/relationships suffer some strain during your cycle  
 
Now, rather than continue to live with heavy periods you could either be treated with Mirena coil 
(a coil that is designed to treat heavy periods) or Oral Treatment using tablets. Each treatment 
helps you to manage the bleeding in a different way: 
 
 
Please turn over for description of treatments 
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Mirena 
Mirena is a coil that is inserted into your womb by your GP or other qualified practitioner. The 
procedure usually takes a few minutes. Mirena can last for up to 5 years but it can be removed 
before if you wish. If you were given the Mirena, during the first 6 months you may experience 
irregular periods (bleeding in between periods) and your periods may not improve . Women are 
advised to persevere as the benefit of treatment can be seen after 6 months and by 12 months most 
women will have stopped their periods.  At 6 months on average you will: 
  Have no practical difficulties, bleed no more than you expect and take no extra precautions 
 Your social life is unaffected during your cycle and you can enjoy life as much as usual 
 During your cycle you experience some anxiety and worry 
 During your cycle you feel well most of the time and are a little concerned about your health 
 There are no interruptions to your work/daily routine during your cycle 
 Your family life/relationships suffer some strain during your cycle  
 
 
Oral Treatment 
Depending on the Oral Treatment you and your GP choose, you may either have to take tablets every 
day or just during your period. You may temporarily experience headaches or nausea or changes to 
your mood. If these persist you could change to a different Oral Treatment. When taking Oral 
Treatment you will see an immediate effect where on average you will:  
 Have to carry extra sanitary protection but take no other precautions 
 Your social life is slightly affected during your cycle and you may have to cancel or modify plans  
 During your cycle you experience some anxiety and worry 
 During your cycle you feel well most of the time and are a little concerned about your health 
 There are occasional disruptions to your work/daily routine during your cycle 
 Your family life/relationships suffer some strain during your cycle 
 
 
1. Out of these two treatment options Mirena or any Oral Treatment what is your preferred 
treatment?  
 
Mirena     Oral Treatment   No preference 
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One way of measuring the value of different types of treatment for heavy menstrual bleeding is to 
ask you how much money you would be willing to pay for it. Of course, the treatments are provided 
free on the NHS and would stay free. This is simply a method of measuring the value you place on 
each treatment. So, imagine you do have to pay. 
 
We believe that you should not have to pay for healthcare, other than prescription costs where 
necessary. The information you provide us will in no way be used to set or change prices for 
healthcare, it is simply a method of measuring how strongly you feel about the different treatment 
options and how much you value them. 
 
There are no right or wrong answers. The amount you say could be large or small. Please keep in 
mind that you will need to provide values that are within your means i.e. please do not state values 
that you would not actually be able to pay. When thinking of a value assume that you would pay this 
amount every month until you reach menopause. Generally menopause occurs around 55 years of 
age.  
 
If you expect menopause to occur earlier or later than 55 years, based on your family history please 
write the age below and use this age as your basis for duration of monthly payment: 
 
My expected age of menopause is ........................................... years old 
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PLEASE ANSWER BOTH QUESTIONS 
2. What would be the maximum monthly 
amount you would be willing to pay, out 
of your own pocket, for Mirena?  
Put a circle around the maximum amount 
you would pay  
£0 
£2 
£4 
£6 
£8 
£10 
£12 
£14 
£16 
£18 
£20 
£25 
£30 
£35 
£40 
£45 
£50 
£60 
£70 
£80 
£90 
£100 
£150 
£200 
£250 
£300 
£350 
£400 
£450 
£500 
 
If more than £500 please state the exact 
amount: £______________________ 
 
3. What would be the maximum monthly 
amount you would be willing to pay, out 
of your own pocket, for Oral Treatment? 
Put a circle around the maximum amount 
you would pay  
£0 
£2 
£4 
£6 
£8 
£10 
£12 
£14 
£16 
£18 
£20 
£25 
£30 
£35 
£40 
£45 
£50 
£60 
£70 
£80 
£90 
£100 
£150 
£200 
£250 
£300 
£350 
£400 
£450 
£500 
 
If more than £500 please state the exact 
amount: £______________________ 
 
 
The information you provide us will in no way be used to set or 
change prices for healthcare, 
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4. In the space provided below could you please tell us the reasons behind your answers to 
question 2 and 3? (What did you think about when choosing a maximum monthly amount?) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please check that you have answered each question 
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5. Did you find questions 2 and 3 difficult to answer? 
      Yes    No 
6. Could you please explain your answer to question 5 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
 
 
 
Please turn over for remaining questions 
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Section 2: General information about yourself 
Could you please tell us your age?  
 
7. What is your current status? 
Single Divorced 
Married/living with partner   Separated 
Widowed 
 
8. Would you like to have children in the future? 
 Yes       No 
 
9. What is your current employment status: 
Employed (Full -time)                   Retired       Long-term sick 
Employed (Part-time)      Student       Self-employed 
Unemployed       Looking after family or home 
Other 
If other please state:____________________________________ 
If employed, what is your current occupation? ____________________________________ 
 
10. Are you the main income earner in the household? 
      Yes    No 
If No, what is the occupation of the main income earner? ____________________________ 
 
11. Could you please estimate the annual income of your household before deducting tax and 
national insurance (if you receive any benefits include them as income)?  
Less than £10,000  £40,001 - £50,000 
£10,000 - £20,000 £50,001 - £60,000 
£20,001 - £30,000 £60,001 - £70,000 
£30,001 - £40,000 More than £70,000 
 
12. Have you experienced heavy menstrual bleeding? 
 Yes   No 
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13. Could you please explain why you are visiting the Birmingham Women’s hospital today? 
 
 
14. Could you please indicate how satisfied or dissatisfied you are with your life overall: Please tick 
the box which you feel best describes how satisfied or dissatisfied you are. 
 Very unsatisfied 
 Slightly unsatisfied 
  
   
  
  
 
Please answer the questions by ticking one box in each group. Please indicate which statement 
best describes your own health today 
Mobility  
I have no problems walking about 
I have some problems walking about 
I am confined to bed 
Self care 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual activities (e.g work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
 
15. Would you be willing to take part in an interview, that would last for about 30 minutes, to 
discuss your answers? The interview will be conducted at your own convenience at the 
Birmingham Women’s Hospital. 
            No    Yes 
Thank you for completing this questionnaire  
Slightly satisfied 
Very satisfied 
Neither satisfied nor unsatisfied 
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A4.3 Ex-post Questionnaire 
 
 
 
 
We would be most grateful if you could complete the enclosed questionnaire to help us better 
understand the affect that heavy menstrual bleeding has on your life and the value you would place 
on the different treatment options. It should take no longer than 15 minutes to complete. Once 
completed please return the questionnaire using the stamped addressed envelope provided within 2 
weeks. 
 
The questionnaire has three sections. The first section will ask you about your periods. The second 
section will ask you about how much you value treatments for heavy menstrual bleeding. The third 
section will ask you some general questions about yourself.  
 
Please read through the instructions at the beginning of each section carefully. The questions are 
simple to complete. There are no right or wrong answers. We are just interested in your views.  
 
Please answer all the questions even if some may seem repetitive or less relevant, as it is 
important to get complete information. 
 
The questionnaire is anonymous. 
Your answers will remain confidential. 
 
If you have any queries about completing this questionnaire do not hesitate to contact: 
 
Miss Sabina Sanghera 
Health Economics Unit 
Public Health Building 
University of Birmingham 
Birmingham 
B15 2TT 
 
 
 
Thank you for your participation in this study. 
 
 
PATIENTS’ VALUES OF TREATMENT FOR 
HEAVY MENSTRUAL BLEEDING 
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Section 1: Questions about your periods  
In each of the following areas of health, select the statement that best applies to you and place a 
tick in the right hand side box provided.  Please tick only one statement in each area. 
 
1) Practical difficulties 
a. I have no practical difficulties, bleed no more than I expect and take no extra 
precautions. 
 
b. I have to carry extra sanitary protection with me but take no other precautions.  
c. I have to carry extra sanitary protection and clothes because of the risk of 
flooding. 
 
d. I have severe problems with flooding, soil the bedding and need to be close to a 
toilet. 
 
 
2) Social life 
a. My social life is unaffected during my cycle.  I can enjoy life as much as usual.  
b. My social life is slightly affected during my cycle.  I may have to cancel or modify 
my plans. 
 
c. My social life is limited during my cycle.  I rarely make any plans.  
d. My social life is devastated during my cycle.  I am unable to make any plans.  
 
3) Psychological health 
a. During my cycle I have no worries I can cope normally.  
b. During my cycle I experience some anxiety and worry.  
c. During my cycle I often feel down and worry about how I’ll cope.  
d. During my cycle I feel depressed and cannot cope.  
 
4) Physical health and wellbeing 
a. During my cycle I feel well and relaxed.  I am not concerned about my health.  
b. During my cycle I feel well most of the time.  I am a little concerned about my 
health 
 
c. During my cycle I often feel tired and do not feel especially well.  I am concerned 
about my health.  
 
d. During my cycle I feel very tired and do not feel well at all.  I am seriously 
concerned about my health. 
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5) Work/daily routine 
a. There are no interruptions to my work/daily routine during my cycle.  
b. There are occasional disruptions to my work/daily routine during my cycle.  
c. There are frequent disruptions to my work/daily routine during my cycle.  
d. There are severe disruptions to my work/daily routine during my cycle.  
 
6) Family life/relationships 
a. My family life/relationships are unaffected during my cycle.  
b. My family life/relationships suffer some strain during my cycle.  
c. My family life/relationships suffer quite a lot during my cycle.  
d. My family life/relationships are severely disrupted as a result of my cycle.  
 
 
Please turn over for remaining questions 
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Section 2: Valuing treatments for heavy menstrual bleeding 
 
1. What treatment(s) are you currently taking for your heavy periods? tick as many as applicable. 
Mirena coil     Copper coil 
Ponstan (mefenamic acid)   Cyklokapron (tranexamic acid) 
Contraceptive pill (any brand)   Depo-provera 
Norethisterone     Cerazette  
No treatment 
Other (Please write the name)  
 
2. Have the treatment(s) that you take for your heavy periods changed since you last completed 
an ECLIPSE questionnaire (upon entering the trial 6mth/ 1 year/ 2 years/5 years)?   
          No  Yes 
 
3. If YES, what treatment(s) were you taking before? Indicate as many as applicable 
Mirena coil     Copper coil 
Ponstan (mefenamic acid)   Cyklokapron (tranexamic acid) 
Contraceptive pill (any brand)   Depo-provera 
Norethisterone     Cerazette  
No treatment 
Other (Please write the name)  
 
 
 
Please turn over for remaining questions 
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One way of measuring the value of different types of treatment for heavy menstrual bleeding is to 
ask you what you would be prepared to give up to receive each treatment i.e. how much money 
would you be willing to pay for it.  
 
We believe that you should not have to pay for healthcare, other than prescription costs where 
necessary. The information you provide us will in no way be used to set or change prices for 
healthcare, it is simply a method of measuring how strongly you feel about the different treatment 
options and how much you value them. 
 
There are no right or wrong answers. The amount you say could be large or small. Please keep in 
mind that you will need to provide values that are within your means i.e. please do not state values 
that you would not actually be able to pay. When thinking of a value assume that you would pay this 
amount every month until you reach menopause. Generally menopause occurs around 55 years old.  
 
If you expect menopause to occur earlier or later than 55 years old based on your family history 
please write the age below and use this age as your basis for duration of monthly payment: 
 
My expected age of menopause is ........................................... years 
 
 
Please turn over for the question 
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4. What would be the maximum monthly amount you would be willing to pay, out of your own 
pocket, for your current treatment? 
Put a circle around the maximum amount you would pay  
 
£0 
£2 
£4 
£6 
£8 
£10 
£12 
£14 
£16 
£18 
£20 
£25 
£30 
£35 
£40 
£45 
£50 
£60 
£70 
£80 
£90 
£100 
£150 
£200 
£250 
£300 
£350 
£400 
£450 
£500 
 
If more than £500 please state the exact amount: £______________________ 
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5. In the space below could you please tell us the reasons behind your answers to question 4? 
(What did you think about when choosing a maximum monthly value?) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please check that you have answered each question 
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6. Did you find question 4 difficult to answer? 
      Yes    No 
7. Could you please explain your answer to question 6 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
________________________________________________________________________________ 
 
 
 
 
 
Please turn over for remaining questions 
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Section 3: General information about yourself 
8. Could you please tell us your age? 
 
9. What is your current status? 
Single     Divorced 
Married/living with partner   Separated 
Widowed 
 
10. What is your current employment status: 
Employed (Full -time)   Retired   Long-term sick 
Employed (Part-time)   Student   Self-employed 
Unemployed     Looking after family or home 
Other 
If other please state:____________________________________ 
If employed, what is your current occupation? ____________________________________ 
 
11. Are you the main income earner in the household? 
      Yes    No 
If No, what is the occupation of the main income earner? ____________________________ 
 
12. Could you please estimate the annual income of your household before deducting tax and 
national insurance (if you receive any benefits include them as income)?  
Less than £10,000  £40,001 - £50,000 
£10,000 - £20,000 £50,001 - £60,000 
£20,001 - £30,000 £60,001 - £70,000 
£30,001 - £40,000 More than £70,000 
 
13. How long have you had heavy menstrual bleeding? 
 Less than 1 year            3 - 4 years 
 1 - 2 years             4 -5 years 
2 - 3 years             More than 5 years 
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We would be grateful if you could help our research into the best treatment for heavy periods by 
answering all of the following questions by ticking the appropriate boxes and providing any 
necessary additional information. 
Thinking about the last 3 months: 
14. Have you had to visit your GP due to heavy periods?             No        Yes 
If YES, how many times did you visit your GP?   
What for?    
15. Has your GP had to visit you at home due to heavy periods?         No           Yes 
If YES, how many times did your GP visit you?   
What for?   
16. Have you had to take time off work because of your heavy periods? 
      No          Yes      Not currently working  
If YES, how many days have you taken off work in the last three months?   
17. Have your heavy periods prevented you from doing your other daily activities? 
       No          Yes   
If YES, how many days in the last three months?  
18. On average how many tampons/sanitary towels do you use during your period?   
19. How regular is your cycle? 
Regular, I know when to expect my period 
Fairly regular, my period starts within a few days of when I expect 
Irregular, I cannot predict when my period will start 
I have bleeding on and off all the time 
20. Do you take any drugs for pain relief during your periods? 
           No           Yes 
If YES, what drugs?  Ibuprofen (Neurofen)  Paracetamol  Aspirin  
Other (please write the name) 
On average how many do you take during your period? 
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21. Please tick a number shown below to indicate how much pain you experience due to your 
periods 
 
 
No pain at all       Worst imaginable pain  
22. Could you please indicate how much your quality of life is affected by your heavy menstrual 
bleeding. Please tick the box which you feel best describes how your quality of life is affected. 
 Not at all affected 
 Slightly affected 
 Affected 
 Extremely affected 
Could you please indicate how satisfied or dissatisfied you are with your life overall: Please tick the 
box which you feel best describes how satisfied or dissatisfied you are. 
 
 
 
Please answer the questions by ticking one box in each group. Please indicate which statement 
best describes your own health today 
Mobility  
I have no problems walking about 
I have some problems walking about 
I am confined to bed 
Self care 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual activities (e.g work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
Slightly unsatisfied 
0 1 2 3 4 5 6 7 8 9 0 10 
Slightly satisfied 
Very satisfied 
Neither satisfied nor unsatisfied 
Very unsatisfied 
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Please answer the questions by ticking one box in each group. Please indicate which statement 
best describes your own health during your cycle 
Mobility  
I have no problems walking about 
I have some problems walking about 
I am confined to bed 
Self care 
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual activities (e.g work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
 
 
 
Please turn over for remaining questions 
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23. Since you last completed an ECLIPSE questionnaire (upon entering the trial 6mth/1 year/2 
years/5 years) have you been to hospital due to heavy periods?   
      No       Yes  
If YES, what was this for? 
Tests or investigations: 
Laparoscopy (camera via belly)    Hysteroscopy (camera via vagina) 
Ultrasound scan    
Other (please describe)  
Treatment or surgery other than hysterectomy or endometrial ablation: 
Removal of polyps     Removal of fibroids 
Treatment of endometriosis 
Other (please describe)  
Did you have to stay in hospital for the treatment?    No  Yes 
       If YES, how many nights? 
Have you attended any follow-up clinics?    No  Yes 
       If YES, how many times? 
Surgery: 
Hysterectomy      
       Endometrial ablation (removal of lining of womb)  
How many nights did you stay in hospital? 
If you made two or more visits to hospital, please tell us about each visit – you can use the space at 
the end if necessary 
......................................................................................................................................................... 
24. Have you experienced any hot flushes/night sweats? No          Yes 
 
Thank you for completing this questionnaire 
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A4.4– Interview Topic Guide 
Research Questions 
1. Which outcome is most suitable 
2. Was process and outcome utility taken into consideration 
3. Were both health and non-health outcomes taken into consideration 
4. Did they place a greater emphasis on non-health outcomes 
5. Was WTP difficult to answer and why? 
6. What did they take into consideration when completing the WTP questionnaire 
 
Introduction 
Firstly I’d just like to thank you for taking part in this study. My name is Sabina and I am a 
researcher at the University of Birmingham. As you know, we are carrying out some research 
to identify which measures should be used to value treatments for heavy periods. So we want 
to look at some of your answers to the questionnaire and talk a bit more about them. 
The interview is very informal and completely confidential. Only my colleagues and I will see 
it and your name will not appear in anything we write. As you are already aware I will be 
recording the interview, this is so I can concentrate on what you are telling me rather than 
spending the whole time taking notes.  As soon as we have written up the study all of the 
recordings will be destroyed.  
 
To start off, I would like to find out a little bit more about you.... 
1. How is your health in general? 
1. How do you feel during your monthly periods? 
i. What makes you say that? 
ii. What affect do they have on your everyday life/ normal activities? How 
so? 
2. Have you ever been to your GP to seek advice about your periods? 
i. Could you tell me a bit more about that? 
 
If you remember, in the questionnaire we asked you to imagine you were experiencing heavy 
periods 
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Description of HMB 
 
2. After reading the text in the questionnaire about heavy periods. How did you find 
placing yourself in the position of somebody with heavy periods? 
1. Could you imagine what it would feel like? 
2. What did you think of the description provided? 
 
Description of treatments 
3. So after the description of heavy periods we then described how the two treatments 
Mirena and Oral treatment would improve your periods. When reading the scenarios 
for the two treatments, was any part of the description more important to you than the 
other or was it all important? (process or outcome utility)  
1. Why was that? 
2. What did you like and dislike about each treatment? 
 
 
WTP answers 
So if we look at your answers to the questionnaire, particularly question 3 and 4 about the 
two treatment options and how much you would pay for them. You’ve said that you would be 
WTP £… for mirena and £…. For oral.  And that your reason was… 
 
4. Could you tell me a bit more about how you came up with value for each treatment? 
1. What type of things did you take into consideration?   
i. Did you think about how the periods would affect your life? 
[PROMPT: the cost of sanitary products, time off work or impact on 
family life] 
 
2. Was the affect of the heavy periods on your health (wellbeing and anxiety) 
equally important to you as affect on everyday activity (social life and family 
relationships)?   
 
3. You said previously that certain things related to the descriptions of each 
treatment were more important to you? How did that factor in to your decision-
making here?  
i. How important was it to you when coming up with a value for the 
treatment? 
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4. Did you think about the impact on your monthly budget of having to pay the 
amounts -that you would have to sacrifice spending this money on one thing in 
order to pay for the treatment? 
i. What effect would paying this have on your monthly budget? 
 
You’re imagining you have the condition, what would be the point at which you would 
not be WTP any more? 
 
Difficulty w/ WTP 
 
5. You said in the questionnaire that you thought the WTP question was/was not difficult 
to answer.  
1. Can you tell me a bit more about why you thought that?  
i. What did you mean by…? 
 
Preference reversal  
5. You said that you prefer one treatment to the other but would be willing to pay the 
same amount for both treatments. Could you just explain your answer? (If preference 
reversal – why?) 
a. So if we set the cost of the treatments aside and think about purely how much 
you would value each treatment and how much of your monthly budget you 
would be willing to give up for this treatment, would you change the amount 
that you would be willing to pay for treatment, or keep them as they are?  
 
 
Reconsider WTP value 
 
6. Having thought about everything we have talked about so far would you like to 
change the amount that you would be willing to pay for the treatments or keep them as 
they are? 
 
Appropriateness of questionnaires 
 
7. How did you feel about the question on page 11 – EQ-5D (show questionnaire 
response)?  
a. Imagining you have heavy periods again, how would you feel answering these 
types of questions? 
i. Do you think it picks up on things that would be important to you? 
Why? 
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b. How do you think this measure compares to the WTP question? Difficult, 
easy? Why? 
 
8. As you know we are trying to find out which measure is best for heavy periods. We 
use these measures to decide which treatment is better for women. Would you say that 
these measures (WTP or EQ-5D) are equally relevant or is one more than the other? 
And why? 
 
9. Finally, in relation to heavy periods do you think there is anything missing from the 
questionnaire that we should have asked you? 
 
Thank you very much for your time and for taking part. Your answers will be kept 
confidential and the recordings will be destroyed as soon as we have written up the study. 
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APPENDIX 5. WILLINGNESS TO PAY RESULTS: INTERVAL 
REGRESSION 
A5.1: Interval Regression Results (Ex-ante) 
Mirena 
Variable Coefficient 95% CI P-value 
Age of menopause -0.0598 -0.096, -0.023 0.001 
R5: Cost of treatment 0.459 -0.028, 0.945 0.064 
R1: Found valuation difficult 1.923 -0.146, 3.995 0.068 
R3: Affordability 0.601 0.144, 1.058 0.01 
Experience of menorrhagia -0.539 -1.053, -0.026 0.04 
Preferred treatment    
Prefer Oral treatment -0.749 -1.187, -0.311 0.001 
No preference -0.104 -0.814, 0.607 0.775 
Income    
£20,001-£30,000 -0.174 -0.746, 0.397 0.55 
£30,001-£40,000 0.416 -0.297, 1.129 0.253 
£40,001-£50,000 1.156 0.440, 1.872 0.002 
More than £50,000 0.187 -0.402, 0.777 0.533 
Married -0.670 -1.117, -0.223 0.003 
EQ5Dbest 1.236 0.362, 2.110 0.006 
Constant 4.675 2.577, 6.774 0.000 
Log likelihood = -232.210, n= 93 
Oral treatment 
Variable Coefficient 95% CI P-value 
R8: Cost of sanitary wear 0.713 0.079, 1.348 0.028 
Difficult to answer -0.846 -1.407, -0.285 0.003 
R9: Misunderstanding exercise 1.040 -0.037, 2.117 0.059 
D5: Difficulty with hypothetical  1.010 0.155, 1.865 0.021 
D1: Not used to valuing 1.083 0.448, 1.717 0.001 
Preferred treatment    
Prefer Oral treatment 0.260 -0.131, 0.652 0.193 
No preference -0.481 -1.130, 0.168 0.146 
Income    
£20,001-£30,000 0.535 0.021, 1.048 0.041 
£30,001-£40,000 0.850 0.215, 1.484 0.009 
£40,001-£50,000 0.540 -0.088, 1.168 0.092 
More than £50,000 0.194 -0.322, 0.711 0.461 
D3: Benefit of treatment 0.417 0.016, 0.817 0.041 
R3: Affordability 0.511 0.104, 0.918 0.014 
Constant 1.238 0.742, 1.734 0.000 
Log likelihood = -234.95, n=93 
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A5.2 Interval Regression (Ex-post) 
Mirena  
 Coefficient 95% CI p-value 
Current MMAS 0.044 0.023, 0.064 0 
R7: effect of treatment 0.596 0.109, 1.082 0.016 
R3: Nominal amount 1.781 0.015, 3.548 0.048 
Time off work 4.309 1.949, 6.668 0 
D5: Cost of sanitary products -1.394 -2.673, -0.115 0.033 
D10: Reasonable value -1.189 -2.422, 0.044 0.059 
Income    
£20,001-£30,000 -0.454 -1.163, 0.256 0.21 
£30,001-£40,000 0.427 -0.319, 1.174 0.262 
£40,001-£50,000 -0.403 -1.340, 0.534 0.399 
More than £50,000 0.739 0.060, 1.418 0.033 
R10: Misunderstanding exercise -1.588 -2.506, -0.670 0.001 
Constant -1.666 -3.569, 0.238 0.086 
Log likelihood= -136.982, n=49 
 
Overall treatment 
Variable Coefficient 95% CI p-value 
Current MMAS 0.015 -0.001, 0.031 0.061 
R10: Misunderstanding exercise -1.241 -2.189, -0.293 0.01 
Expected age of menopause -0.110 -0.218, -0.002 0.046 
D1: Not used to valuing 0.830 0.320, 1.339 0.001 
R7: effect of treatment 0.512 0.054, 0.969 0.028 
EQ5Damended 1.856 0.797, 2.916 0.001 
EQ5D -0.961 -2.039, 0.116 0.08 
R2: Found valuation difficult -0.740 -1.470, -0.009 0.047 
R3: Nominal amount 2.019 0.096, 3.943 0.04 
Prevented daily activities 0.977 0.039, 1.915 0.041 
Constant 5.948 -0.036, 11.932 0.051 
Log likelihood=-188.115, n=67 
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A5.3: Associations with EQ-5Da 
 Current MMAS (rho) Current EQ-5Da  
(rho) 
Current EQ-5D  
(rho) 
Current MMAS 1.0000   
Current EQ-5Da 0.5392* 1.0000  
Current EQ-5D 0.0931 0.1860 1.0000 
*p<0.01 
It can be seen that the amended EQ-5D has a significant correlation with MMAS scores, 
whilst EQ-5D has a weak non-significant correlation. The rho correlation coefficient (0.5392) 
for the amended EQ-5D and MMAS is considered to be a strong correlation. 
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